dbgap_rnaseq_sample	dbgap_subject_id	dbgap_dnaseq_sample	cohort	used_manuscript_analyses	manuscript_dnaseq	manuscript_rnaseq	manuscript_inhibitor	consensus_sex	inferred_sex	reportedRace	reportedEthnicity	inferred_ethnicity	centerID	CEBPA_Biallelic	consensusAMLFusions	ageAtDiagnosis	isRelapse	isDenovo	isTransformed	specificDxAtAcquisition_MDSMPN	nonAML_MDSMPN_specificDxAtAcquisition	priorMalignancyNonMyeloid	priorMalignancyType	cumulativeChemo	priorMalignancyRadiationTx	priorMDS	priorMDSMoreThanTwoMths	priorMDSMPN	priorMDSMPNMoreThanTwoMths	priorMPN	priorMPNMoreThanTwoMths	dxAtInclusion	specificDxAtInclusion	ELN2017	dxAtSpecimenAcquisition	specificDxAtAcquisition	ageAtSpecimenAcquisition	timeOfSampleCollectionRelativeToInclusion	specimenGroups	diseaseStageAtSpecimenCollection	specimenType	rnaSeq	exomeSeq	totalDrug	analysisRnaSeq	analysisExomeSeq	analysisDrug	cumulativeTreatmentTypeCount	cumulativeTreatmentTypes	cumulativeTreatmentRegimenCount	cumulativeTreatmentRegimens	cumulativeTreatmentStageCount	cumulativeTreatmentStages	responseToInductionTx	typeInductionTx	responseDurationToInductionTx	mostRecentTreatmentType	currentRegimen	currentStage	mostRecentTreatmentDuration	vitalStatus	overallSurvival	OS.status	OS.time	causeOfDeath	%.Basophils.in.PB	%.Blasts.in.BM	%.Blasts.in.PB	%.Eosinophils.in.PB	%.Immature.Granulocytes.in.PB	%.Lymphocytes.in.PB	%.Monocytes.in.PB	%.Neutrophils.in.PB	%.Nucleated.RBCs.in.PB	ALT	AST	albumin	creatinine	fabBlastMorphology	hematocrit	hemoglobin	karyotype	LDH	MCV	otherCytogenetics	plateletCount	surfaceAntigensImmunohistochemicalStains	totalProtein	wbcCount	FLT3-ITD	allelic_ratio	NPM1	RUNX1	ASXL1	TP53	variantSummary	status	time	clusters
BA2409R	2418	NA	Waves1+2	yes	no	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	n	y	y	n	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	Refractory	Standard Chemotherapy	7	Bone Marrow Transplant	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	-1	Dead	397	1	13.04312115	Dead-Disease	0	68	NA	1	NA	30	49	3	NA	14	18	3	0.85	M5	21.9	7.6	46,XX[20]	313	102.9	Normal	125	Blast Immunphenotype: CD13, CD33, CD34, CD38, dim CD45, CD117, CD123, and HLA-DR positive; Promonocyte Immunophenotype: CD11b, CD13, CD14, CD33, CD64, and HLA-DR	5.5	14.9	negative	0	negative	NA	NA	NA	BRAF (G596R)|WT1 (2400/10000 copies)	1	13.04312115	4
BA3037R	2391	NA	Waves1+2	yes	no	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	55	FALSE	FALSE	FALSE	FALSE	FALSE	y	Hodgkin Lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	FavorableOrIntermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	55	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	n	y	y	n	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Dead	707	1	23.22792608	Dead-Disease	0	88	NA	0	NA	6	0	1	NA	19	26	3.4	0.88	M1	28.2	9.6	46,XX[20]	678	99.9	Normal	19	partial CD7, CD13, CD25, CD33, partial CD34, dim CD45, CD117, CD123, and partial HLA-DR positive	6.8	17.9	positive	NA	positive	NA	NA	NA	FLT3-ITD|NPM1|WT1 (8000/10000 copies (High))	1	23.22792608	3
BA2496R	2099	NA	Waves1+2	yes	no	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	70	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	y	y	n	n	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	Chronic myelomonocytic leukaemia	MissingMutations	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	70	34	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	n	y	y	n	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	Dasatinib|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine	4	Salvage|Experimental|Maintenance|Re-induction	NA	NA	NA	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	4	Dead	311	1	10.21765914	Dead-Disease	5	36	9	5	NA	21	38	22	NA	19	22	3.6	1.18	M4	28.7	9.7	46,XY[20]	231	99.6	Normal	47	CD11b, CD13, CD14, CD15, variable CD16, dim CD33, CD58, bright CD64, HLA-DR positive	7.1	21	positive	0.111111111	negative	NA	NA	NA	NA	1	10.21765914	4
BA2172R	2398	NA	Waves1+2	yes	no	yes	yes	Male	Male	NA	NA	AdmixedBlack	7	NA	KMT2A_re	NA	unknown	unknown	unknown	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	unknown	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	unknown	18	0	Unknown	Unknown	Peripheral Blood	y	n	y	y	n	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Unknown	0	0	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	NA	0	0	4
BA2865R	2271	NA	Waves1+2	yes	no	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	50	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	50	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	n	y	y	n	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|HiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	27	Bone Marrow Transplant	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	-1	Alive	3129	0	102.8008214	Alive	0	90	82	0	NA	1	0	2	NA	19	30	2.8	0.86	M0	26.4	9.1	46,XX,t(11;17)(q13;q21)[20]	1165	97.7	While the chromosome 17 breakpoint is clearly within band 17q21 by metaphase chromosome analysis, these results suggest that it is not within the RARA gene	8	dim CD4, CD13, dim CD15, dim CD33, CD38, CD58,CD64, CD117, CD123, dim HLA-DR, and cMPO	5.3	84.1	negative	0	positive	NA	NA	NA	FLT3 (A680V)|NPM1 (W288fs*12 )|WT1 (5000/10,000 copies)	0	102.8008214	3
BA2923R	2545	NA	Waves1+2	yes	no	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	81	FALSE	FALSE	TRUE	FALSE	FALSE	y	Anal carcinoma|Breast Cancer	y	y	n	n	y	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	81	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	n	y	y	n	y	1	Supportive/Palliative Care	1	Azacitidine	1	Supportive/Palliative Care	NA	NA	NA	Supportive/Palliative Care	Azacitidine	Supportive/Palliative Care	42	Dead	147	1	4.829568789	Dead-Disease	0	NA	NA	0	NA	12	33	7	NA	60	64	3.2	1.08	M5	26.6	8.8	46,XX,t(8;16)(p11.2;p13.3)[8]/46,XX,del(7)(q11.2q22),del(20)(q13.1q13.3)[cp3]/46,XX[12]	2700	92.4	NA	46	NA	6.3	37.1	negative	0	negative	NA	NA	NA	NA	1	4.829568789	4
BA2751R	2518	NA	Waves1+2	yes	no	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	72	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	y	n	y	y	n	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	3	1	0.098562628	Dead-Other	0	95	82.5	0	NA	3	0	1	NA	47	58	2.7	0.96	M4	16.5	5.6	46,XY[20]	697	114	Normal	51	Blast phenotype:  CD13, partial CD33, CD34, CD38, CD58, CD123, HLA-DR and TdT-positive; Monocytic phenotype:  CD11b, CD14, CD33, CD38, CD58, CD64 and HLA-DR-positive	4.9	97	positive	1	negative	NA	NA	NA	FLT3-ITD	1	0.098562628	2
BA2480R	2374	NA	Waves1+2	yes	no	yes	no	Male	Male	Asian	NON-HISPANIC	Asian	1	NA	NA	56	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	60	309	Relapse|Post-Chemotherapy	Relapse	Peripheral Blood	y	n	y	y	n	y	1	Standard Chemotherapy	8	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Azacitidine|3+3 plus Sorafenib|Clofarabine|Clofarabine, Cytarabine	4	Consolidation|Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Cytarabine	Consolidation	64	Dead	1735	1	57.00205339	Dead-Disease	0	77.5	75	1	NA	16	1	4	NA	NA	NA	NA	NA	NOS	26.3	9.3	46,XY[4]	NA	87.8	Normal	9	CD13, CD33, partial CD56, CD58, CD64, dim CD117, CD123and partial/dim cMPO positive	NA	7.9	positive	2.448275862	positive	NA	NA	NA	NA	1	57.00205339	2
BA2286R	2340	NA	Waves1+2	yes	no	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	n	y	y	n	y	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	7	Alive	33	0	1.084188912	Alive	0	46	NA	1	NA	24	5	4	NA	18	34	3.2	1.05	M2	26.4	8.8	46,XY[20]	551	89.1	Normal	72	CD13, CD33, CD34, CD117, dim CD123, HLA-DR,partial MPO (+)	7	16.5	negative	0	negative	NA	NA	NA	FLT3-D835	0	1.084188912	1
BA2922R	2269	NA	Waves1+2	yes	no	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	DEK-NUP214	11	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(6;9)(p23;q34); DEK-NUP214	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(6;9)(p23;q34); DEK-NUP214	14	950	Relapse|Post-Transplant|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	y	n	y	y	n	y	6	DLI|Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)|Intrathecal|Targeted Therapy - Other	13	Cyclophosphamide, TBI|HAM (Cytarabine, Mitoxantrone)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Cytarabine, Mitoxantrone, Sorafenib|ADE (Cytarabine, Daunorubicin & Etoposide)|Donor Lymphocyte Infusion|Cytarabine|Sorafenib|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)|Methotrexate|Etoposide, Cytarabine	8	Allogeneic - Sibling|Consolidation|Unknown|Induction|Experimental|Intensification|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	9	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	187	Dead	1655	1	54.37371663	Dead-Disease	0	80	NA	3	NA	78	3	16	NA	42	38	4.3	0.66	M2	41.6	14.3	48,X,-Y,+4,t(6;9)(p22;q34),+8,+10,del(15)(q11.2q15)[20]	NA	102.9	DEK/NUP probe set; 70/100 (70%) interphasecells scored had a 1 red/ 1 green/ 2 yellow fusion signal pattern,consistent with DEK/NUP fusion and the 6;9 translocation observed in themetaphase karyotype.	50	CD13, CD33, CD34, CD38, CD117,CD123, dim HLA-DR, partial MPO	7.6	2.2	positive	NA	NA	NA	NA	NA	FLT3-ITD	1	54.37371663	4
BA2452R	2157	BA2452D	Both	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	34	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	36	574	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation|Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	43	Dead	595	1	19.54825462	Dead-Unknown	1	90	30	0	NA	46	30	8	NA	43	11	2.8	0.92	M4	25.5	9.1	46,XY,add(17)(p13)[19]/46,XY[1]	123	85	Normal	14	partial CD7, CD13, CD33, CD38, dim CD45, dimCD58, CD117, CD123, and HLA-DR	5.8	0.6	positive	0.960784314	positive	NA	NA	NA	NA	1	19.54825462	4
BA3379R	2606	BA3379D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	34	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE	Acute undifferentiated leukaemia	Intermediate	ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE	Acute undifferentiated leukaemia	34	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Cyclophosphamide, TBI|7+3 (Cytarabine, Idarubicin)|HAM-VD (Cytarabine, Mitoxantrone, Vincristine, Dexamethasone)	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	Cyclophosphamide, TBI	Allogeneic - Sibling	-1	Alive	3022	0	99.28542094	Alive	NA	88	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[20]	231	NA	cryptic t(14;21) (54.5% of cells had three signals for AML1)	NA	CD2 , CD7 , CD13 , CD34 , dim CD45 , CD117 , HLA-DR , TdT positive	NA	31.9	positive	0.041666667	negative	NA	NA	NA	FLT3-D835|FLT3-ITD	0	99.28542094	2
BA2887R	2038	NA	Waves1+2	yes	no	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	24	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	24	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	n	y	y	n	y	4	DLI|Standard Chemotherapy|Bone Marrow Transplant|Other	8	7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Radiation|Busulfan, Cyclophosphamide	7	Consolidation|Salvage|Unknown|Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine	Maintenance	-1	Dead	2531	1	83.15400411	Dead-Disease	0	88	NA	0	NA	3	40	3	NA	13	14	2.8	0.62	M4	31.7	10.9	47,XY,+10[18]/46,XY[2]	419	86.3	Normal	89	CD11b, dim CD13, dim CD14, CD33, CD34, dim CD38, partialCD56, CD58, partial CD64, CD117, CD123, dim HLA-DR, and MPO	5.8	21.7	negative	0	negative	NA	NA	NA	NOTCH1 (p.V1578delV; MAF 50%)	1	83.15400411	2
BA2712R	2034	BA2712D	Both	no	no	no	no	Female	Female	White	NON-HISPANIC	White	2	NA	NA	61	FALSE	FALSE	FALSE	FALSE	FALSE	y	Follicular lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	61	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	16	1	0.525667351	Dead-Disease	1	50	89	1	NA	0	0	0	NA	61	NA	2.5	0.84	NA	25.3	8.4	NA	NA	102.8	NA	24	CD2(-), CD4(dim +), CD7(-), CD11b(partial +), CD13(partial +), CD14(partial +), CD15(variably and slightly bright +), CD16 (-), CD33(variably bright +), CD34(-), CD36(partial +), CD38(variably +), CD45(variably +), CD56(+), CD64(partial +), CD117(-), HLA-DR(partial dim +), MPO(+), TdT(-). (92% population of medium-sized to large cells)	4.5	53	negative	0	negative	NA	ASXL1 (p.G646Wfs*12; 28.6%)	NA	NA	1	0.525667351	4
BA2068R	2469	BA2068D	Waves1+2	yes	yes	yes	yes	Female	Female	Black	NON-HISPANIC	Black	2	NA	NA	64	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	64	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Induction	5	Alive	1112	0	36.5338809	Alive	1.4	76	0	0.1	NA	94.3	1.5	2.7	NA	22	20	3.6	0.48	NA	32.6	10.9	46,XX[14]	184	NA	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],	32	CD4(few +), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(partial +), CD16(-), CD34(-), CD36(-), CD38(+), CD45(+), CD56(few +), CD64(-), CD117(partial +), HLA-DR(-), MPO(+) and TdT (+)	7.5	1.5	negative	0	positive	NA	NA	NA	NA	0	36.5338809	3
BA2236R	2446	BA2236D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	54	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	57	349	Relapse|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	7	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	5	Consolidation|Salvage|Induction|Re-induction|Maintenance	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	Decitabine	Re-induction	160	Dead	1378	1	45.27310062	Dead-Disease	3	71	83	2	NA	5	10	4	NA	35	31	3.9	0.81	M4	33.7	11.7	47,XY,+21[17]/47,idem,t(10;22)(q22;q13)[cp3]/46,XY[1]	438	100.6	80% Trisomy 21	119	CD13, CD33, CD38, CD58, dim CD64, CD117, and CD123	7.1	33.8	negative	0	positive	NA	NA	NA	NA	1	45.27310062	4
BA2104R	2378	BA2104D	Both	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	83	FALSE	FALSE	FALSE	FALSE	FALSE	y	Colon Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	83	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	9	1	0.295687885	Dead-Disease	0	NA	90	0	NA	9	7	4	NA	242	341	1.9	2.48	M5	17.6	6.2	47,XY,+8[6]/46,XY[13] (Specimen Source: Blood)	2037	94.5	trisomy 8 (Specimen Source: Blood)	14	CD11b, CD13, dimCD14, CD15, dim CD16, CD33,     CD56,     CD58, CD64, CD123, and HLA-DR positive	3.6	82	negative	0	positive	NA	NA	NA	FLT3-D835 (bone marrow)|NPM1 (An insertion mutation is present in exon 12 (near the C-terminus) of NPM.)	1	0.295687885	4
BA3124R	2832	BA3124D	Waves3+4	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	62	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute erythroid leukaemia	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute erythroid leukaemia	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	-1	Dead	1472	1	48.3613963	Dead-Disease	1	26	NA	0	NA	26	1	64	NA	21	14	3.7	0.76	M6	32.5	10.4	46,XX,del(16)(q22q23)[8]/46,XX[12]	159	96.1	del(16q)	19	CD13, dim CD14, CD33, CD34, CD38, CD58, CD123, CD117, HLA-DR, partial cTdT and cMPO positive	7.4	2.9	negative	0	negative	NA	NA	NA	NA	1	48.3613963	1
BA3395R	2771	NA	Waves3+4	yes	no	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	68	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	68	132	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	n	y	y	n	y	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|Azacitidine|Azacitidine, Lenalidomide|Decitabine	3	Unknown|Induction|Re-induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	Decitabine	Re-induction	9	Dead	344	1	11.30184805	Dead-Unknown	18	20	occasional	4	NA	39	16	4	NA	25	14	2.5	0.8	NOS	28.4	9.5	41~46,XY,add(4)(p16),del(5)(q15q33),inv(7)(q11q34),-13,add(14)(p11.1),-16,-17,-18,add(19)(q13.1),-20,i(21)(q10),+1~4mar[cp10]/43~45,idem,-add(4)(p16),der(4)add(4)(p16)add(4)(q31)[cp10]	215	89	5q deletion (64%) | Monosomy 16 and derivative chromosome 16 (91%)	72	CD13, CD33, CD34, CD56, CD117, dim CD123, HLA-DR, partial TdT positive	6.5	1.2	NA	NA	NA	NA	NA	NA	NA	1	11.30184805	1
BA2921R	2466	BA2921D	Both	no	no	no	no	Male	Male	White	NON-HISPANIC	White	2	NA	NA	70	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	71	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	2	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Hypomethylating/Low Dose Cytarabine|Induction	Refractory	Standard Chemotherapy	-1	Supportive/Palliative Care	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Dead	194	1	6.373716632	Dead-Disease	NA	NA	78	NA	NA	12	5	3	NA	NA	NA	NA	1.12	NA	24.7	8.2	46,XY,del(7)(q22q36)[7]/47,idem,+22[cp12]/46,XY[1]	NA	89.2	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[187/200], (D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	18	NA	NA	24.4	positive	0.01010101	negative	NA	NA	NA	NA	1	6.373716632	4
BA2449R	2081	NA	Waves1+2	yes	no	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	RUNX1-RUNX1T1	7	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	7	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	n	y	y	n	y	1	Standard Chemotherapy	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	2	Induction|Re-induction	Complete Response	Standard Chemotherapy	9	Standard Chemotherapy	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Re-induction	-1	Dead	158	1	5.190965092	Dead-Treatment	0	85	30	0	NA	42	0	27	NA	18	19	3.9	0.41	M1	27.7	9.4	46,XX,t(8;21)(q22;q22)[19]/46,XX[1]	747	90.5	91.5% AML/ETO fusion, t(8;21)	71	CD13, CD33, CD34, CD56, CD71, CD117, HLA-DR, MPO-positive	7.3	4.8	negative	0	negative	NA	NA	NA	KIT (D816V; MAF 50%)	1	5.190965092	3
BA2003R	2491	BA2003D	Both	no	no	no	no	Female	Female	NA	NA	AdmixedAsian	3	NA	NA	57	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	58	215	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Unknown	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	-1	Dead	257	1	8.443531828	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX[20]	NA	NA	Normal	NA	NA	NA	NA	positive	2.125	positive	NA	NA	NA	FLT3-ITD|NPM1	1	8.443531828	4
BA2360R	2298	BA2360D	Waves1+2	yes	yes	yes	yes	Male	Female	White	NON-HISPANIC	White	1	bi	NA	78	FALSE	FALSE	FALSE	FALSE	FALSE	y	Bladder Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	79	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Induction	-1	Dead	267	1	8.772073922	Dead-Disease	0	87	72	1	NA	17	4	1	NA	19	41	3.4	0.75	NA	32.3	10.6	45,X,-Y[19]/46,XY[1]	460	103.6	Normal	15	CD7, CD13, CD33, partial CD34, CD117, CD123, HLA-DR, MPO +	6.2	8.5	negative	0	negative	NA	NA	NA	CEBPA (1031?1032 ins AAC; MAF 50%)|CEBPA (347?348 del GACCTGT; MAF 50%)|WT1 (p.R369R; MAF 50%)	1	8.772073922	2
BA2802R	2005	BA2802D	Both	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	52	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE	Mixed phenotype acute leukaemia, T/myeloid, NOS	NonInitial	ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE	Mixed phenotype acute leukaemia, T/myeloid, NOS	53	234	Post-Transplant|Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|Sunitinib|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Decitabine|Busulfan, Cyclophosphamide	5	Salvage|Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Salvage	80	Dead	404	1	13.27310062	Dead-Disease	0	50	NA	0	NA	9	2	29	NA	32	34	3.7	0.68	NA	34	11.1	45~48,XY,+5,add(5)(q11.2)x2,t(7;7)(q22;q36),+11,add(13)(q13),-22[cp9]/45~47,sl,-add(5)(q11.2),der(11)t(11;12)(p11.2;q13),-12[cp6]/46,sl,t(Y;18)(p11.2;q21),der(9)t(9;17)(p13;q11.2),-17[2]/46,XY[3]	167	102.8	Deleted 5q	152	partial CD7, CD13, CD33, CD34, partial CD56, CD58, HLA-DR, and partial MPO-positive CD117, CD123,	6.7	14	negative	0	negative	NA	NA	TP53 (p.V216M; 66.9%)	NA	1	13.27310062	1
BA2235R	2407	BA2235D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	60	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	104	Alive	2801	0	92.02464066	Alive	0	80	NA	0	NA	11	13	23	NA	32	50	2.9	0.64	M2	41.1	13.4	46,XX[20]	660	86.1	normal	228	partial CD7, partial CD11b, CD13, CD33, dim CD45, CD58,     partial CD64, partial CD117, CD123, dimHLA-DR,  MPO positive	7.4	53.9	negative	0	positive	NA	NA	NA	DNMT3A (p.Q696fs*9; MAF 40% )|IDH1 (p.R132H; MAF 40%)|NPM1 (p.W288fs*12; MAF ~40%)|PTPN11 (p.G503A; MAF 40%)	0	92.02464066	4
BA2858R	2087	BA2858D	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	70	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	73	93	Post-Chemotherapy	Remission	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction|Maintenance	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine	Maintenance	-1	Dead	1165	1	38.275154	Dead-Unknown	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[19]	NA	NA	Normal	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	NA	1	38.275154	1
BA3038R	2278	BA3038D	Waves1+2	yes	yes	yes	yes	Male	Male	Multiracial	HISPANIC	HispNative	1	NA	CBFB-MYH11	24	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	24	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine, Methotrexate|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	Alive	3041	0	99.90965092	Alive	0	50	NA	0	NA	19	52	16	NA	NA	NA	NA	NA	M4	26.3	9.2	47,XY,inv(16)(p13q22),+22[20]	NA	91.5	62.5% CBFB rearrangement|74% BCR/ABL/ASS	53	- 14% Myeloid blasts: CD13, CD34, CD38, CD58, partial CD64,     CD117, CD123,          HLA-DR, and MPO positive     - 30% Monoblasts/promonocytes: CD11b, CD13, CD14, CD38, CD58, bright CD64,     HLA-DR, and MPO	NA	13.8	negative	0	negative	NA	NA	NA	KIT (p.D816H; MAF ~50%)|WT1 (rs16754; MAF ~50%)	0	99.90965092	2
BA3006R	2239	BA3006D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	3	NA	NA	33	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	33	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone)	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	-1	Dead	439	1	14.42299795	Dead-Treatment	NA	70.8	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M2	NA	NA	46,XX[7]	NA	NA	NA	NA	increased CD117 positive, partial CD34 positive myeloblasts,   representing approximately 91% of the leukocytes, consistent with acute myeloid leukemia	NA	NA	positive	4	positive	NA	NA	NA	FLT3-ITD|NPM1	1	14.42299795	4
BA2245R	2173	BA2245D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	65	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	67	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	8	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cladribine	6	Hypomethylating/Low Dose Cytarabine|Salvage|Consolidation|Unknown|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Cladribine	Unknown	5	Dead	1020	1	33.51129363	Dead-Unknown	0	NA	77	0	NA	15	1	3	NA	18	10	3.6	1.01	M2	28.1	9.3	NA	132	93.5	NA	22	NA	6.3	19.5	negative	0	negative	NA	NA	NA	NA	1	33.51129363	2
BA2667R	2286	BA2667D	Waves1+2	yes	yes	yes	yes	Male	Male	Unknown	UNKNOWN	White	1	NA	NA	74	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	n	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	74	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	126	1	4.13963039	Dead-Unknown	0	60	NA	1	NA	26	18	24	NA	250	160	3.2	0.59	M2	22	7.1	46,XY[20]	399	87.4	NA	107	partial CD7, CD13, CD33, CD34, CD38, CD58, CD117, CD123, TdT, and HLA-DR positive	7	11.8	negative	0	negative	RUNX1 (p.A142Gfs*4; 32.2%)	NA	NA	RUNX1 (p.A142Gfs*4; MAF 30% )|SRSF2 (p.P95L; MAF 48%)	1	4.13963039	4
BA2239R	2326	BA2239D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	66	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	74	Alive	2756	0	90.54620123	Alive	0	90	NA	0	NA	14	61	1	NA	19	14	2.4	1.13	M5	23.9	7.9	46,XY[20]	387	103.6	normal	122	CD11b, dim/partial CD13, CD14, CD33, CD38, CD58, CD64,     partial CD117, dim/partial CD123, and HLA-DR positive	6.3	28	negative	0	positive	NA	NA	NA	CREBBP (p.Q2208H; MAF 50%)|DNMT3A (p.R882H; MAF 50%)|NPM1 (W288fs*>9; MAF 50%)|WT1 (rs16754; MAF 50%)	0	90.54620123	4
BA2782R	2235	BA2782D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	3	NA	NA	53	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	752	1	24.7063655	Dead-Treatment	NA	73	32	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[20]	NA	NA	Normal	NA	atypical monocytic cells expressing weaker than   normal CD13 and CD33, with increased promonocytes/monoblasts representing approximately 44% of the leukocytes, (and increased atypical CD117 positive, CD34 negative myeloblasts showing weak expression   of aberrant CD7 and representing approximately 14% of the leukocytes)	NA	22.79	negative	0	positive	NA	NA	NA	NPM1	1	24.7063655	4
BA2649R	2097	BA2649D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	PML-RARA	65	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	ATRA (Tretinoin)|3+7 (Cytarabine, Daunorubicin)	1	Induction	Unknown	Standard Chemotherapy	5	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	3	Dead	7	1	0.229979466	Dead-Other	0	72	57	0	NA	36	1	8	NA	24	33	2.9	0.6	M3	20.7	6.8	46,X,der(X)add(X)(p22.1)add(X)(q22~24),add(7)(p15),der(15)t(15;17)(q22;q21),der(17)t(15;17)(q22;q21)inv(17)(q21q21)del(17)(q21)[17]/46,XX[3] (unusual PML-RARA translocation)	398	90.2	76% Unusual t(15;17), with the fusion signal on the derivative chromosome 15	10	partial CD2, CD13, CD33, partial CD34, CD117, CD123, MPO-positive	5.6	9.8	positive	NA	negative	NA	NA	NA	FLT3-ITD (MAF 40%)|SF3B1 (p.K66N; MAF 40%)|WT1 (rs16754; MAF 50%)	1	0.229979466	3
BA2488R	2489	BA2488D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	PML-RARA	83	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	83	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	3	Ruxolitinib|ATRA, Arsenic Trioxide|Idarubicin	3	Induction|Maintenance|Symptom Control	Complete Response	Standard Chemotherapy	253	Standard Chemotherapy	Idarubicin	Symptom Control	0	Alive	2806	0	92.1889117	Alive	0	75	70	0	NA	17	2	23	NA	14	9	3.7	0.7	M3	23.4	8.1	46,XX,t(15;17)(q24;q21)[12]/46,XX,idem,del(16)(q12.1q24)[3]/46,XX[5]	367	86.2	7% 16q deletion	NA	CD13, CD33, partial CD34, CD64, CD117, CD123, and MPO-positive	6.8	6	negative	0	negative	NA	NA	NA	FLT3-D835 (D835H; MAF Unlisted)|JAK2 (p.V617F; MAF 90%)	0	92.1889117	3
BA2861R	2015	BA2861D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	mono	NA	22	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	22	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	-1	Alive	2729	0	89.65913758	Alive	0	56	55	2	NA	7	33	24	NA	67	16	2.2	0.64	M4	24	8	46,XX[24]	373	95.2	normal	34	partial CD7 ,dim/partial CD10 , CD13 , CD33 , CD34 , CD38 , CD56 , CD64 , dim CD123 , HLA-DR , and MPO positive	6.5	29.4	negative	0	negative	NA	NA	NA	CEBPA (p.D107fs*; MAF ~50%)|WT1 (p.Y385*; MAF 20%)|WT1 (rs16754; MAF ~50%)	0	89.65913758	2
BA2909R	2509	BA2909D	Waves1+2	yes	yes	yes	yes	Male	Male	Asian	NON-HISPANIC	Asian	1	NA	RUNX1-RUNX1T1	8	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	8	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	2	Induction|Intensification	Complete Response	Standard Chemotherapy	11	Standard Chemotherapy	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Intensification	62	Alive	2662	0	87.45790554	Alive	0	30	NA	0	NA	33	17	20	NA	NA	NA	NA	0.53	M2	29.3	10.3	46,XY,t(8;21)(q22;q22)[5]/46,idem,der(7)t(7;8)(q22;q11.2)[13]/46,XY[2]	NA	93.5	t(8;21) (34%) | t(8;21) and der(7)t(7;8) (56%) | Missing D7S486 signal (70%)	109	dim CD7, CD13, CD33, CD34, CD38, partial CD56,CD58, CD117, CD123, dim HLA-DR, and MPO	NA	19.5	negative	0	negative	NA	NA	NA	NA	0	87.45790554	2
BA2429R	2473	BA2429D	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	78	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	78	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	2	Azacitidine|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Maintenance	NA	NA	NA	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Dead	356	1	11.69609856	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NOS	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	NA	1	11.69609856	4
BA2653R	2191	BA2653D	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	1	mono	NA	42	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute megakaryoblastic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute megakaryoblastic leukaemia	42	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	4	Dead	273	1	8.969199179	Dead-Disease	0	70	NA	0	NA	43	6	38	NA	36	28	3.5	0.81	M7	34.8	12	NA	762	85.2	Extra signals were observed for BCR (22q11.2), PML (15q22), MLL (11q23),     RUNX1T1 (8q21.3) and RUNX1 (21q22) in roughly 45-60% of interphase cells.     These results suggest the presence of a hyperdiploid clone.	13	CD7, CD13, CD33, CD58, partial CD61, CD71, and Factor 8 positive	6.8	7.9	negative	0	negative	NA	NA	NA	CEBPA (p.V119?M120insV; MAF 30% )	1	8.969199179	1
BA2134R	2417	NA	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	72	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	72	8	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	n	y	y	n	y	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	6	Dead	176	1	5.782340862	Dead-Unknown	0	NA	NA	1	NA	3	77	8	NA	57	27	3.5	0.61	M4	26.3	8.7	46,XY,del(12)(p11.2p13)[15]/46,XY[5]	324	92.8	84% 12p deletion	19	NA	7.2	56.5	negative	0	negative	NA	ASXL1 (p.A619fs*14; MAF 50%)	NA	ASXL1 (p.A619fs*14; MAF 50%)|EZH2 (p.R583*; MAF 95%)|FLT3-D835|FLT3-D835 (MAF unavailable)|PTPN11 (p.D61H; MAF 15%)|RUNX1 ( p.P345?S356del; MAF 25%)|RUNX1 (p.P345?S356del; MAF 25%)|RUNX1 (p.V51; MAF 50%)|RUNX1 (p.V5I; MAF 50%)|TET2 (p.Y867H; MAF 50%)	1	5.782340862	4
BA2947R	2506	NA	Waves1+2	yes	no	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	RUNX1-RUNX1T1	14	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	14	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	n	y	y	n	y	1	Standard Chemotherapy	1	COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)	1	Induction	Complete Response	Standard Chemotherapy	133	Standard Chemotherapy	COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)	Induction	133	Alive	2487	0	81.70841889	Alive	0	62	64	0	NA	28	1	7	NA	15	9	4.1	0.58	M2	18.5	6.3	45,X,-Y,t(8;21)(q22;q22)[4]/45,idem,del(9)(q12q22)[13]/46,XY[3]	486	105.8	RUNX1T1/ RUNX1 fusion and t(8;21) (94%)	63	CD13, CD33, CD34, dim CD45, partial CD56, CD58, dim CD117, HLA-DR, MPO, and partial TdT-positive	7.9	13.3	negative	0	negative	NA	NA	NA	TP53 (p.S366A; MAF 50% )	0	81.70841889	3
BA2032R	2022	BA2032D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	2	NA	NA	64	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	5	Crenolanib|MEC, plexifor, GCSF|Sorafenib|7+3 (Cytarabine, Idarubicin) plus LBH|Clofarabine, Cytarabine	4	Salvage|Induction|Experimental|Re-induction	Refractory	Standard Chemotherapy	21	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	124	Dead	455	1	14.9486653	Dead-Disease	NA	81	94	NA	NA	6	NA	NA	NA	87	47	2.8	0.53	NA	27.2	9.7	46,XX,t(3;11)(q21;p11.2),t(15;15)(q15;q22)[19]/46,XX,t(2;14)(q21;q11.2)[2]	743	NA	nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2 (5'MLL con 3'MLLx2)[198],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	11	CD7(partial +), CD15(partial +), CD33(bright +), CD34(partial +), CD45(+), and CD117(variably +). (80% population of variably-sized cells)	5.2	26	positive	15.66666667	positive	NA	NA	NA	NA	1	14.9486653	3
BA2162R	2220	BA2162D	Both	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	77	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	77	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	7	Dead	129	1	4.238193018	Dead-Disease	NA	NA	47	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY,-7,+13,i(17)(q10)[20]	NA	NA	D7S486/ CEP 7:  92/100 cells (92%) had a 1 red/ 1 green signal pattern, indicating monosomy 7, consistent with the metaphase karyotype. | RARA:  79/100 cells (79%) had three signals, consistent with the isochromosome 17q observed in the metaphase karyotype and the presence of three copies of the long arm.  There was no evidence for PML/RARA fusion. | TP53:  89/100 cells (89%) had a single signal, reflecting deletion and consistent with the isochromosome 17q observed in the metaphase karyotype.	NA	CD13, CD33, CD34, CD117, dim CD123, and HLA-DR-positive	NA	25.3	negative	0	negative	NA	ASXL1 (p.W583*; 47.9%)	NA	ASXL1 (p.W583*; MAF 50%)|ETV6 (p.N384*; MAF 40%)|FBXW7 (p.T196A; MAF 50%)|SRSF2 (p.P95H; MAF 70%)	1	4.238193018	1
BA2564R	2339	BA2564D	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	1	NA	CBFB-MYH11	18	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	18	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	2	Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Re-induction	-1	Alive	540	0	17.7412731	Alive	0	50	22	0	NA	24	49	20	NA	13	15	3.6	0.77	M4	21	7.4	46,XX,inv(16)p13.1q22)[4]/47,idem,+22[15]/46,XX[1]	415	97.8	CBFB rearrangement and inv(16) (64%) | +22 (71%)	23	Blast phenotype:  CD13, CD33, CD34, CD38, CD58, dim CD123,     HLA-DR-positive               - Monocytic phenotype:  CD11b, CD13, CD14, CD33, CD58, CD64, HLA-DR-positive	7.6	8.8	negative	0	negative	NA	NA	NA	KRAS (p.G13D; MAF 10%)|NRAS (p.G13D; MAF 30%)	0	17.7412731	2
BA2597R	2290	BA2597D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	4	NA	NA	79	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	79	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine, Lenalidomide	1	Induction	Refractory	Standard Chemotherapy	137	Standard Chemotherapy	Azacitidine, Lenalidomide	Induction	137	Dead	189	1	6.209445585	Dead-Disease	NA	73	56	NA	NA	NA	1	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX,del(16)(p11.2)[3]/46,XX[2]	NA	NA	NA	NA	CD34, CD4(dim), CD7, CD11c(dim), CD13, CD33(dim),CD38, CD117, and HLA-DR	NA	8.7	negative	0	negative	NA	ASXL1 (p.G645Vfs*58; 12.5%)	NA	IDH2 (R140Q)	1	6.209445585	3
BA3243R	2683	NA	Waves3+4	yes	no	yes	yes	Male	Male	Unknown	NA	NA	2	NA	PML-RARA	51	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	n	y	y	n	y	1	Targeted Therapy - Other	1	ATRA, Arsenic Trioxide	1	Experimental	NA	NA	NA	Targeted Therapy - Other	ATRA, Arsenic Trioxide	Experimental	193	Alive	1051	0	34.52977413	Alive	NA	47	48	NA	NA	NA	NA	NA	NA	16	15	3.6	NA	M3	22.9	8.3	46,XY,t(15;17)(q24;q21.1)/46,XY	NA	NA	nuc ish(PML,RARA)x3(PML con RARAx2)[164/200] (Labs conducted twice on day of specimen collection. This is result 1 of 2 on 8/6/2013.) | nuc ish(PML,RARA)x3(PML con RARAx2)[190/200] (Labs conducted twice on day of specimen collection. This is result 2 of 2 on 8/6/2013.)	23	CD2(partial +), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(bright +), CD34(-), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(+), CD117(+), HLA-DR(-), MPO(+), TdT(-) (Labs conducted twice on day of specimen collection. This is result 1 of 2 on 8/6/2013.) | CD2(partial +), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(bright +), CD34(-), CD36(-), CD38(variably +), CD45 (variably +), CD56(-), CD64(+), CD117(+), HLA-DR(-) (Labs conducted twice on day of specimen collection. This is result 2 of 2 on 8/6/2013.)	6.4	2.8	positive	0.020408163	negative	NA	NA	NA	FLT3-D835|FLT3-ITD	0	34.52977413	4
BA2106R	2055	BA2106D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	4	NA	NA	35	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	37	1	Post-Chemotherapy|Relapse	Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cyclophosphamide, Etoposide, TBI	5	Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	53	Dead	761	1	25.00205339	Dead-Disease	NA	92	97	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5	NA	NA	46,XX[5]	NA	NA	NA	NA	CD45, DIM CD64, DIM CD13, DIM CD33, CD15, CD38, MPO, CD11C, DIM CD4, DIM PARTIAL CD19, CD117, AND HLA-DR	NA	140	negative	0	positive	NA	NA	NA	FLT3-D835|IDH1|NPM1	1	25.00205339	4
BA2427R	2559	BA2427D	Waves1+2	yes	yes	yes	no	Female	Female	NA	NA	White	4	NA	CBFB-MYH11	53	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	60	0	Post-Chemotherapy|Relapse	Relapse	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	5	7+3 (Cytarabine, Idarubicin)|3+7 (Cytarabine, Daunorubicin)|Azacitidine, Gemtuzumab|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Cytarabine	2	Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine, Gemtuzumab	Re-induction	-1	Alive	2522	0	82.85831622	Alive	NA	82	25	NA	NA	NA	19	NA	NA	NA	NA	NA	NA	M4eo	NA	NA	47,XX,t(16;16)(p13;q22),+22[20]	NA	NA	CBFB inv(16)	NA	Positive (ABNORMAL CD34+ BLAST POPULATION, 11%, EXPRESSING CD117, CD15,CD13, CD33 (DIM), AND HLA-DR, WITH ABERRANT EXPRESSION OF CD19(DIM-PARTIAL) AND CD22 (DIM-PARTIAL)ABNORMAL MONOCYTIC POPULATION EXPRESSING CD64, CD14, CD34(DIM), CD2 (DIM), CD7 (DIM), AND CD8 (DIM-PARTIAL))	NA	4.3	negative	0	negative	NA	NA	NA	FLT3-D835	0	82.85831622	2
BA2841R	2274	BA2841D	Waves1+2	yes	yes	yes	no	Male	Male	Asian	NON-HISPANIC	Asian	4	bi	NA	31	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	32	0	Relapse|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	y	y	n	y	y	n	4	DLI|Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	7	7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Fludarabine, Cyclophosphamide, TBI	6	Allogeneic - Sibling|Consolidation|Salvage|Unknown|Induction|Re-induction	Complete Response	Standard Chemotherapy	8	Supportive/Palliative Care	Decitabine	Salvage	-1	Alive	1377	0	45.24024641	Alive	NA	28	23	NA	NA	NA	6	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[20]	NA	NA	NA	NA	CD34, CD117, CD38, MPO, CD11c (dim),CD13, CD33, CD15, and HLA-DR,CD7 and CD56 (partial)	NA	4	negative	0	negative	NA	NA	NA	CEBPA (Double mutation)	0	45.24024641	2
BA2446R	2429	BA2446D	Waves1+2	yes	yes	yes	yes	Female	Female	Pacific Islander	NON-HISPANIC	Asian	1	NA	MLLT3-KMT2A	30	FALSE	FALSE	FALSE	FALSE	FALSE	y	Acute Promyelocytic Leukemia	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	30	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	4	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	6	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	31	Dead	270	1	8.87063655	Dead-Disease	0	64	65	0	NA	28.9	25.4	19.3	1.7	48	33	3.6	0.64	M1	21.8	7.5	46,XX,t(9;11)(p11;q34)[19]/46,XX[1]	NA	111.8	Disruption of MLL signal and t(9;11) (65%)	29	CD11b, CD13, CD14,  CD33, CD64, CD56, CD123 and HLA-DR positive	6.1	29.25	negative	0	negative	NA	NA	NA	CREBBP (p.A254T; MAF 50%)|CREBBP (p.T910S; MAF 40%)|FLT3-D835 (p.D835; MAF 35%)	1	8.87063655	4
BA2645R	2230	BA2645D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	Asian	4	NA	NA	73	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	73	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Decitabine|Stanford Protocol 9153 (TLI, ATG)	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Stanford Protocol 9153 (TLI, ATG)	Allogeneic - Mismatched Unrelated Donor	-1	Dead	330	1	10.84188912	Dead-Disease	NA	84	71	NA	NA	NA	6	NA	NA	NA	NA	NA	NA	M5	NA	NA	46,XY[20]	NA	NA	NA	NA	\ CD4(subset), CD11c(partial), CD13(partial), CD14(partial), CD15(partial), CD33(subset), CD34(subset), CD38, CD64(subset), CD117(subset), HLA-DR and MPO\""	NA	16.2	negative	0	negative	NA	NA	NA	NA	1	10.84188912	4
BA2525R	2543	BA2525D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	4	NA	NA	72	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	Azacitidine, Lenalidomide|Temozolomide, Vorinostat	2	Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Temozolomide, Vorinostat	Re-induction	-1	Dead	420	1	13.79876797	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX,del(5)(q31q35),inv(7)(p15q32),del(12)(q?15)[2]/45~46,idem,add(3)(q27),-9,-del(12)(q?15),+add(12)(q13),-16,-17,+mar1,+mar2x2[cp16]/46,XX[2]	NA	NA	NA	NA	NA	NA	NA	positive	0.538461538	positive	NA	NA	TP53	TP53	1	13.79876797	1
BA2876R	2198	BA2876D	Waves1+2	yes	yes	yes	no	Female	Female	NA	NA	White	4	NA	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	3	Cytarabine|Azacitidine|Stanford Protocol 9153 (TLI, ATG)	3	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	NA	NA	NA	Standard Chemotherapy	Cytarabine	Supportive/Palliative Care	9	Dead	719	1	23.62217659	Dead-Disease	NA	34	8	NA	NA	NA	15	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX,t(8;19)(q24;q13),del(11)?(q14q23)[19]/46,XX[1]	NA	NA	NA	NA	CD34, CD117, CD38, DIM CD13, CD33, HLA-DR, AND PARTIAL CD7	NA	4.2	negative	0	negative	NA	NA	NA	NA	1	23.62217659	4
BA2357R	2245	BA2357D	Waves1+2	yes	yes	yes	yes	Male	Male	Unknown	NA	HispNative	2	NA	NA	52	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	52	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	5	7+3 (Cytarabine, Idarubicin)|HiDAC|AG-221|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Fludarabine, Melphalan, ATG	5	Consolidation|Salvage|Induction|Experimental|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	15	Bone Marrow Transplant	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	-1	Dead	1237	1	40.64065708	Dead-Disease	NA	21	5	NA	NA	68	4	23	NA	17	23	3.6	0.89	NA	28.3	8.5	89<4n>,XXY,-Y,-7,-12,+13,+13,-17,-21[2]/46,XY[18]	183	NA	nuc ish(RUNX1T1x4,RUNX1x3)[33/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[41/200],(PMLx4,RARAx3~4)[31/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[27/200]	22	partialCD4, partialCD15, dimCD33, CD34, CD38, dimCD45, CD117, HLA-DR, TdT, MPO	7.5	3.42	negative	0	negative	RUNX1 (p.R201Q; 33.9%)	NA	NA	NA	1	40.64065708	2
BA2546R	2259	BA2546D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Consolidation	-1	Dead	228	1	7.490759754	Dead-Treatment	1.8	51	NA	0.9	NA	41.2	37.7	11.4	0	20	20	3.2	1.37	M4	33.7	11	42~45,XY,del(4)(q31q35),del(5)(q13q35),add(9)(q21),add(13)(p11.2),-16,-21[cp15]/40~46,sl,+9,-add(9)(q21),-15,+der(16)t(15;16)(q11.1;p13.3),-18,+mar[cp5]	NA	92.6	Extra MLL signal (5%) | 5q deletion (95%) | Abnormal 9q (33%) | Partial deletion of RUNX1 (34%)	24	CD13, CD33, CD34, CD56, CD58, dim CD64, CD117 and partial HLA-DR.	7.1	5.23	negative	0	negative	NA	NA	TP53 (p.X307_splice; 46.6%)|TP53 (p.R273S; 40.4%)	TP53 (Intron 7, 5' splice site mutation; MAF 40%)|TP53 (p.R273S; MAF 40%)	1	7.490759754	4
BA2742R	2403	BA2742D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	62	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	2	1	0.065708419	Dead-Disease	0	95	95	0	NA	9.5	1.9	4.8	0.2	93	104	3.2	1.85	M5	26.2	8.5	46,XY[20]	2941	104.8	Normal	92	CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38,      partial CD56, CD58, CD64, CD123, and HLA-DR positive	6.5	250.23	positive	15.66666667	negative	RUNX1 (p.X205_splice; 56.7%)	NA	NA	DNMT3A (p. R882C; MAF 50%)|DNMT3A (p.R882C; MAF 50%)|FLT3-ITD (MAF 90%)|RUNX1 (Intron 5, 3' splice site mutation; MAF 50%)	1	0.065708419	4
BA2316R	2403	BA2316D	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	62	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	62	1	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	2	1	0.065708419	Dead-Disease	0	95	95	0	NA	9.5	1.9	4.8	0.2	93	104	3.2	1.85	M5	26.2	8.5	46,XY[20]	2941	104.8	Normal	92	CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38, partial CD56, CD58, CD64, CD123, and HLA-DR positive	6.5	250.23	positive	NA	negative	RUNX1 (p.X205_splice; 44.3%)	NA	NA	DNMT3A (p. R882C; MAF 50%)|DNMT3A (p.R882C; MAF 50%)|FLT3-ITD (MAF 90%)|RUNX1 (Intron 5, 3' splice site mutation; MAF 50%)	1	0.065708419	4
BA2421R	2195	BA2421D	Waves1+2	yes	yes	yes	yes	Male	Male	Unknown	NA	White	2	NA	NA	75	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	75	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	5	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Consolidation|Induction|Re-induction|Maintenance	Refractory	Standard Chemotherapy	56	Standard Chemotherapy	Azacitidine	Maintenance	34	Dead	383	1	12.58316222	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	47,XY,+8,inv(9)(p11q12)c[1]/48,idem,+3[5]/49,idem,+3,+15[1]/50,idem,+3,+8,+mar(8]/46,XY,inv(9}(p11q12)c[5]	NA	NA	nuc ish (D8Z2x3~4)[134/200],(D15Z4x3)[114/200]	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	NA	1	12.58316222	4
BA2087R	2221	BA2087D	Waves1+2	yes	yes	yes	yes	Female	Female	Unknown	NA	White	2	NA	MLLT3-KMT2A	40	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	40	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	Alive	1435	0	47.14579055	Alive	NA	84	29	NA	NA	63	3	5	NA	21	23	3.7	0.65	NA	35	12	46,XX,t(9;11)(p22;q23)[20]	613	NA	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1) [179/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	34	brightCD4, partialCD11b, brightCD15, brightCD33, partialCD36, partialCD38, CD45, brightCD64, partialCD117, HLA-DR (86% population of cells)	6.5	9.1	negative	0	negative	NA	NA	NA	NA	0	47.14579055	4
BA2910R	2261	BA2910D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	2	NA	NA	79	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	79	0	Post-Chemotherapy|Relapse	Relapse	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	7+3 (Cytarabine, Idarubicin)|Crenolanib	2	Induction|Experimental	Complete Response	Standard Chemotherapy	4	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	14	Dead	124	1	4.073921971	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	positive	0.470588235	positive	NA	NA	NA	FLT3-ITD (High level (>50%))|NPM1 (Positive for insertion mutation in exon 12)	1	4.073921971	4
BA2148R	2128	BA2148D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	HispNative	2	NA	CBFB-MYH11	31	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	31	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response i	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	95	Alive	143	0	4.698151951	Alive	NA	57	45	3	NA	25	20	7	NA	NA	NA	NA	1.04	NA	22	7.4	46,XX,inv(16)(p13.1q22)[11]/47,idem,+22[4]/46,XX[5]	229	NA	nuc ish(D4Z1,D10Z1)x2[199],(SCFD2,LNX,PDGFRA/KIT)x2[200],(5'PDGFRB,3'PDGFRB)x2(5'PDGFRB con 3'PDGFRBx2)[200],(5'FGFR1,3'FGFR1)x2([200],(RUNX1T1,RUNX1)x2[200](ABL1x2,BCRx3)[63/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[197],(ETV6,RUNX1)x2[198],(PML,RARA)x2[200],(CBFBx2)(5’CBFB sep 3’CBFBx1)[147/200]	30	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(partial+), CD16(-), CD22(few +), CD33(dim + to -), CD34(+), CD36(-), CD38(variably +), CD41(-), CD45(variably +), CD56(-), CD61(-), CD64(-), CD117(variably +), HLA-DR(partial +), Gly-A(-), MPO(+), TdT(partial +)	NA	13.63	negative	0	negative	NA	NA	NA	NA	0	4.698151951	2
BA2063R	2165	BA2063D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	2	NA	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	MissingKaryo	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|BL-8040	4	Consolidation|Salvage|Induction|Experimental	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Cytarabine	Salvage	-1	Dead	973	1	31.96714579	Dead-Disease	0.5	N/A	0	2.5	NA	56.8	2.6	37.6	NA	21	27	3.9	0.93	NA	33.4	11.2	NA	195	NA	NA	89	NA	6.9	2	negative	0	negative	NA	NA	NA	NA	1	31.96714579	4
BA2329R	2186	BA2329D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	61	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	61	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	3	Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Salvage	126	Dead	370	1	12.15605749	Dead-Disease	NA	19	10	NA	NA	27.7	NA	39.2	NA	47	22	3.8	0.5	M5	25.8	8.5	47~49,XY,-21,+1~4mar[cp21]/46,XY[2]	NA	86.6	Monosomy 21 (30%)	40	Blasts (15-20%): CD11b, CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, and HLA-DR, and partial TdT positive - Aberrant monocytic population (20%): CD11b, CD13, CD14, bright CD33, dim CD56, CD64, and HLA-DR positive	7.6	5.5	negative	0	negative	NA	NA	NA	CSF3R (p. T618I; MAF: 50%)|WT1 (benign SNP rs16754 (R369R: no amino acid change); MAF: 50%)	1	12.15605749	4
BA3178R	2789	NA	Waves3+4	yes	no	yes	no	Male	Male	NA	NA	NA	3	NA	MLLT3-KMT2A	71	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	71	7	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	n	n	y	n	n	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	3	Consolidation|Induction|Re-induction	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	Re-induction	-1	Dead	179	1	5.880903491	Dead-Disease	NA	84.2	93	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5a	NA	NA	49,XY,+8,+8,t(9;11)(p22;q23),+der(9)t(9;11)	NA	NA	8q22 (RUNX1T1): gain of two copies present  11q23 (MLL): rearrangement present (95% RUNX, 91% MLL)	NA	CD4+, CD33+, CD117+, HLA-DR+ myeloblasts	NA	93.46	negative	0	negative	NA	NA	NA	NA	1	5.880903491	4
BA2072R	2115	BA2072D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	CBFB-MYH11	35	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	35	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	94	Alive	1848	0	60.71457906	Alive	0	70	27	1.8	NA	19.6	37.5	7.1	0	20	17	3.1	0.88	M4	14.3	4.8	46,XX,t(16;16)(p13.1;q22)[16]/47,idem,+22[4]	505	100.7	Trisomy 22 (16%) | t(16;16) (90%)	36	Myeloid blasts (21%): CD13, CD33, CD34, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive. Promonocytic/monocytic cells (55%): CD11b, CD13, CD14, CD33, dim/partial CD34, CD38, CD58, CD64, variable CD123, HLA-DR, and MPO-positive. (Included both populations of cells)	7.8	49.4	negative	0	negative	NA	NA	NA	CREBBP (P552S; MAF 50%)|KDM6A (K395N; MAF 50%)|KIT (D816V; MAF 1%)|NRAS (G13D; MAF 6%)	0	60.71457906	2
BA3029R	2079	BA3029D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	2	NA	NA	62	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	63	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	n	y	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	24	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	141	Dead	568	1	18.66119097	Dead-Unknown	0	81	59	0	NA	0	0	10	NA	34	15	4	NA	NA	30.2	10.7	46,XY	NA	NA	NA	17	CD2(-), CD4(dim +), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(variably +), CD16(-), CD33(bright +), CD34(-), CD36(-), CD38(+), CD45(moderately +), CD56(-), CD64 (partial +), CD117(variably +), HLA-DR(-), MPO(+), TdT(-).	6	1.8	positive	10.11111111	positive	NA	NA	NA	CCND3 (Foundation, P203S; MAF 8%)|CHEK2 (Foundation; T367fs*15; MAF 9%)|DNMT3A (Foundation, R882H; MAF 9%)|FLT3 (Foundation, Y591_V592INSVDFREYEYDLKWEFPRENLEFD; MAF 13%)|NPM1 (Foundation; W288fs*10+;MAF 8%)	1	18.66119097	3
BA2733R	2408	BA2733D	Waves1+2	yes	no	yes	no	Female	Female	NA	NA	White	2	NA	CBFB-MYH11	33	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	33	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	103	Alive	920	0	30.22587269	Alive	0	72	18	0	NA	38	26	3	NA	85	30	3.4	NA	NA	25.9	9	47,XX,inv(16)(p13.1q22),+22	NA	NA	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2x3, D20S108x2)[7/200],(RUNX1T1,RUNX1)x2[197],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[198], (CBFBx2)(5’CBFB sep 3’CBFBx1)[140/200]	18	CD2(-), CD7(-), CD11b(-), CD13(variably +), CD14(-), CD15(variably +), CD16(-), CD33(+), CD34(variably +), CD36(-), CD38(+), CD45(+), CD56(-), CD64(partial +), CD117(+), HLA-DR(+)	6.1	26.3	negative	0	negative	NA	NA	NA	NA	0	30.22587269	2
BA2995R	2281	BA2995D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	2	NA	NA	71	FALSE	FALSE	FALSE	FALSE	FALSE	y	Prostate Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	NA	NA	NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	55	Dead	156	1	5.125256674	Dead-Unknown	0	76	58	2	NA	38	6	14	NA	27	25	3.1	NA	NA	25	8.5	46,XY	NA	NA	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[29/200],(D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[11/200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	93	CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial +), CD13(partial +), CD15(-), CD19(-), CD22(partial +), CD33(partial and variably +), CD34(variably +), CD36(partial +), CD38(variably +), CD45(partial +), CD56(-), CD64(partial +), CD117 (partial +), HLA-DR(+), TdT(partial +), MPO(-)	5.8	7.5	negative	0	negative	RUNX1 (p.P333Rfs*261; 48.9%)|RUNX1 (p.D332G; 51.1%)|RUNX1 (p.R162G; 47.3%)	NA	NA	NA	1	5.125256674	1
BA2069R	2179	BA2069D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	MLLT3-KMT2A	55	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	4	Dead	246	1	8.082135524	Dead-Disease	1.4	75	23	8.5	NA	11.4	8.5	34	0.2	62	31	3.8	1.44	M5	38.1	12.2	46,XY,t(9;11)(p22;q23)[20]	497	87.6	MLL rearrangement and t(9;11) (86%)	32	CD11b, partial CD13, CD33, CD38, CD56, CD58, CD64, partial CD117, CD123, and HLA-DR+	7.9	10.21	positive	1.083333333	positive	NA	NA	NA	No gene mutations found in the 43 genes tested	1	8.082135524	4
BA2100R	2485	BA2100D	Waves1+2	yes	yes	yes	yes	Male	Male	Unknown	NA	White	2	NA	NA	73	FALSE	FALSE	TRUE	FALSE	FALSE	y	Prostate Cancer	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	74	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	7	Cytarabine, Fludarabine, Sorafenib|Crenolanib|Azacitidine|Sorafenib|Decitabine, Sorafenib |Clofarabine, Cytarabine|Sapacitabine (CYC682-06)	6	Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental|Re-induction	Refractory	Standard Chemotherapy	39	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	33	Dead	658	1	21.61806982	Dead-Unknown	1	32	67	2	NA	8	3	14	NA	15	30	4.1	NA	NA	32.8	11	46,XY,+1,dic(1;15)(q12;p11.2)[2]/46,XY[18]	NA	NA	18].nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2 [200],(RUNX1T1,RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	90	CD4(partial dim +), CD7(-), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variably +), CD34(+), CD36(-), CD38(variably +), CD45 (variably +), CD56(-), CD64(-), CD79a(-) | CD117(variably +), HLA-DR (variably +), MPO(predominantly -), TdT(-)	5.8	24.2	positive	1.222222222	negative	RUNX1 (p.R201Q; 47.2%)	NA	NA	FLT3-ITD (NOT FOUNDATION NO MAF AVAILABLE)	1	21.61806982	4
BA2681R	2288	BA2681D	Waves1+2	yes	yes	yes	no	Female	Female	NA	NA	White	3	NA	NA	68	FALSE	FALSE	TRUE	FALSE	FALSE	y	Not specified	y	n	n	n	n	n	y	y	MYELOPROLIFERATIVE NEOPLASMS	Secondary myelofibrosis	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	68	49	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	Cyclophosphamide, Fludarabine, TBI|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine	3	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Dead	339	1	11.137577	Dead-Disease	NA	29	40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX,der(9)t(9;12)(p13;q13),del(11)(q21q25),der(12)add(12)(p11.2)add(12)(q13),del(13)(q14q22)[9]/46,idem,add(12)(q24.3),+13,-del(13)[9]/46,idem,add(17)(p13)[2]	NA	NA	NA	NA	NA	NA	11.36	negative	0	negative	NA	ASXL1 (p.G645Vfs*58; 8.3%)|ASXL1 (p.C789Wfs*2; 30.5%)	NA	NA	1	11.137577	1
BA2248R	2105	BA2248D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	HispNative	2	NA	NA	21	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	22	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	13	HiDAC|Crenolanib|Etoposide|Topotecan|Decitabine|Clofarabine|Thioguanine|7+3 (Cytarabine, Idarubicin)|Cyclophosphamide|Thiotepa|Sorafenib|Mitoxantrone|Vinorelbine	4	Induction|Experimental|Re-induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	5	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	15	Dead	551	1	18.1026694	Dead-Disease	0	88	92	0	NA	8	0	0	NA	22	20	3.3	0.51	NA	25.8	9.1	NA	208	NA	NA	NA	NA	6.4	3.2	negative	0	negative	NA	NA	NA	NA	1	18.1026694	4
BA2832R	2108	NA	Waves1+2	yes	no	yes	yes	Male	Male	NA	NA	White	2	NA	NA	68	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	n	y	y	n	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	5	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	5	Dead	29	1	0.952772074	Dead-Disease	NA	NA	41	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	9.5	negative	0	negative	NA	NA	NA	NA	1	0.952772074	3
BA2308R	2248	BA2308D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	4	NA	GATA2-MECOM	71	FALSE	FALSE	FALSE	FALSE	FALSE	y	Prostate Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	72	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Induction|Experimental|Maintenance	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Dead	555	1	18.23408624	Dead-Disease	NA	82	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	45,XY,-7,t(3;3)[20]	NA	NA	NA	NA	CD34+ CD38, CD13,CD33, CD117, HLA-DR, DIM CD7, PARTIAL CD11C, CD2(SUBSET), CD15(MINOR SUBSET), DIM cCD79a(MINOR SUBSET), AND PARTIAL CD4	NA	NA	positive	5.25	negative	NA	NA	NA	FLT3-D835	1	18.23408624	1
BA2413R	2248	NA	Waves1+2	no	no	no	no	Male	Male	NA	NA	White	4	NA	GATA2-MECOM	71	FALSE	FALSE	FALSE	FALSE	FALSE	y	Prostate Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	72	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	n	y	y	n	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Induction|Experimental|Maintenance	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Dead	555	1	18.23408624	Dead-Disease	NA	82	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	45,XY,-7,t(3;3)[20]	NA	NA	NA	NA	CD34+ CD38, CD13,CD33, CD117, HLA-DR, DIM CD7, PARTIAL CD11C, CD2(SUBSET), CD15(MINOR SUBSET), DIM cCD79a(MINOR SUBSET), AND PARTIAL CD4	NA	NA	negative	0	negative	NA	NA	NA	FLT3-D835	1	18.23408624	1
BA2701R	2419	BA2701D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	Black	2	NA	NA	51	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	51	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	Alive	1487	0	48.85420945	Alive	NA	82	1	NA	NA	17	35	23	NA	16	14	3.7	0.8	NA	25	8.7	46,XY[20]	NA	83.8	NA	16	CD1a(-), CD2(-), surface CD3(-), cytoplasmic CD3(partial dim +), CD4(partial dim +), CD5(dim +), CD7(+), CD8(-), CD10(-), CD11b(partial +), CD13(+), CD14(-), CD15(-), CD16 (-), CD22(partial dim +), CD33(variably +), CD34(+), CD36(-), CD38(partial +), CD45(variably +), CD56(variably +), CD64(-), | CD117(variably +), HLA-DR(partial +), MPO(-), and TdT(+)	6.8	3.2	negative	0	negative	NA	NA	NA	NA	0	48.85420945	4
BA2634R	2047	BA2634D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	3	NA	NA	74	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	75	0	Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Etoposide, Mitoxantrone	3	Hypomethylating/Low Dose Cytarabine|Salvage|Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	-1	Dead	415	1	13.63449692	Dead-Disease	NA	60.1	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M2	NA	NA	46,XY,add(1)(p34),del(7)(q22),del(20)(q11.2)[20]	NA	NA	normal, no evidence of RUNX1T1/RUNX1 transloc or 11q23 or 16q22	NA	Increased CD34 positive myeloblasts, representing approximately 55% of the leukocytes	NA	NA	positive	1.941176471	negative	NA	NA	NA	NA	1	13.63449692	4
BA2677R	2186	BA2677D	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	61	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	62	43	Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	3	Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Salvage	126	Dead	370	1	12.15605749	Dead-Disease	NA	17	2	NA	NA	32.2	NA	34.2	NA	34	15	3.7	0.3	M5	32.4	10.4	46~49,XY,-21,+1~4mar[cp20]	NA	87.2	Monosomy 21 (45%)	21	Myeloid blasts:CD13, CD33, CD34, CD38, CD58, dimCD64, CD117, and HLA-DR+    Promonocytes/immature monocytes:CD11b, CD13, CD14, CD33, CD64, and HLA-DR+	7	7.2	negative	0	negative	NA	NA	NA	NA	1	12.15605749	4
BA2937R	2212	BA2937D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	61	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	61	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Hydroxyurea|Busulfan, Cyclophosphamide	5	Allogeneic - Sibling|Salvage|Induction|Re-induction|Symptom Control	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	Dead	213	1	6.997946612	Dead-Treatment	0	25	20	13	NA	6	12	55	0.9	45	34	3.1	0.8	NA	31.1	9.8	42~44,XY,t(1;10)(q12;q21),-5,-7,-11,add(13)(p11.1),der(18)t(11;18)(q14;q21.1),add(20)(q12),+1~3mar[cp4]/41~44,sl,add(4)(q23)[cp9]/41~44,sl,del(4)(q21q?27)[cp5]/41~42,	NA	88.9	Monosomy 5 (52%) | 5p deletion (39%) | Monosomy 7 (48%) | Abnormal 7q arm (48%)	243	CD13, CD33,CD34, CD38, dimCD56, CD58, CD117, and HLA-DR+	6.4	96.64	negative	0	negative	NA	NA	TP53 (p.R248Q; 96.4%)	NA	1	6.997946612	1
BA2600R	2254	BA2600D	Waves1+2	yes	yes	yes	no	Female	Female	NA	NA	White	4	NA	NA	64	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	64	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, BCNU, Melphalan|Decitabine, Midostaurin	2	Allogeneic - Sibling|Induction	Complete Response	Standard Chemotherapy	249	Bone Marrow Transplant	Fludarabine, BCNU, Melphalan	Allogeneic - Sibling	-1	Alive	1021	0	33.54414784	Alive	NA	79	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M4	NA	NA	46,XX,t(2;3)(p13;q25~26)[2]/46,idem,i(14)(q10)[18]	NA	NA	NA	NA	CD34, partial CD117, CD38, CD33, partial CD13,partial CD11C, CD4, partial CD14, partial CD64, partial CD2, and HLA-DR	NA	NA	positive	1	negative	RUNX1 (p.P430S; 60.0%)|RUNX1 (p.R166*; 41.2%)	NA	NA	FLT3-ITD	0	33.54414784	4
BA2019R	2365	BA2019D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	HispNative	3	NA	NA	39	FALSE	FALSE	FALSE	FALSE	FALSE	y	T lymphoblastic leukaemia/lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	39	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	7	Nelarabine|POMP (Prednisone, Methotrexate, 6-MP, Vincristine)|3+7 (Cytarabine, Daunorubicin)|HyperCVAD|Azacitidine|GCLAC (GCSF, Clofarabine & Cytarabine)|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	5	Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance|Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	GCLAC (GCSF, Clofarabine & Cytarabine)	Re-induction	-1	Dead	169	1	5.552361396	Dead-Disease	NA	59.3	28	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY,t(10;11)(p13;q14)[11]/45,sl,-Y[7]/46,sdl1,t(1;8)(q12;p21)[2]	NA	NA	Normal	NA	Increased atypical myeloblasts (partial CD34+, weak CD7+, partial CD61+), representing approximately 91% of the leukocytes, consistent with persistent acute myeloid leukemia.	NA	1.7	negative	0	negative	NA	NA	TP53 (p.R282W; 72.5%)	NA	1	5.552361396	4
BA2412R	2260	BA2412D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	85	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	86	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Supportive/Palliative Care	NA	NA	NA	Standard Chemotherapy	Decitabine	Supportive/Palliative Care	169	Dead	333	1	10.94045175	Dead-Disease	0	NA	NA	0	NA	17	44	39	0	15	9	3.5	0.9	M5	25.7	8.2	NA	175	88	NA	18	NA	6.9	13.22	negative	0	negative	NA	NA	TP53 (p.R248W; 72.2%)	NA	1	10.94045175	4
BA2334R	2270	BA2334D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	2	NA	DEK-NUP214	30	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(6;9)(p23;q34); DEK-NUP214	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(6;9)(p23;q34); DEK-NUP214	31	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine, Sorafenib |Quizartinib	3	Salvage|Induction|Experimental	Refractory	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	52	Dead	568	1	18.66119097	Dead-Disease	NA	65	47	NA	NA	NA	NA	NA	NA	49	31	4.2	0.85	NA	NA	NA	47~49,XX,t(6;9)(p23;q24),+8,+13,+15[cp8]/47~49,idem,+del(13)(q12q22)[cp12]	329	NA	NA	10	CD34(partial +), CD13(+), CD14(-), CD15(few +), CD30(-), CD33(+), CD38(variably +), CD45 (moderately +), CD64(variably +), CD4(partial +), CD117(+), CD123(variably +), HLA-DR(+), CD79a(-), CD22(-), intracellular CD3(-), TdT(-), MPO(partial +), other myeloid and lymphoid antigens(-).	6.3	20.2	positive	2.125	negative	NA	NA	NA	FLT3-D835|FLT3-ITD	1	18.66119097	4
BA2050R	2270	NA	Waves1+2	no	no	no	no	Female	Female	NA	NA	White	2	NA	DEK-NUP214	30	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(6;9)(p23;q34); DEK-NUP214	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(6;9)(p23;q34); DEK-NUP214	31	3	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	n	y	y	n	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine, Sorafenib |Quizartinib	3	Salvage|Induction|Experimental	Refractory	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	52	Dead	568	1	18.66119097	Dead-Disease	NA	65	52	0	NA	10	0	28	NA	NA	26	3.9	0.87	NA	22.4	7.9	47~49,XX,t(6;9)(p23;q24),+8,+13,+15[cp8]/47~49,idem,+del(13)(q12q22)[cp12]	NA	90.9	NA	20	CD34(partial +), CD13(+), CD14(-), CD15(few +), CD30(-), CD33(+), CD38(variably +), CD45 (moderately +), CD64(variably +), CD4(partial +), CD117(+), CD123(variably +), HLA-DR(+), CD79a(-), CD22(-), intracellular CD3(-), TdT(-), MPO(partial +), other myeloid and lymphoid antigens(-).	NA	43.3	positive	3.761904762	NA	NA	NA	NA	FLT3-D835|FLT3-ITD	1	18.66119097	3
BA3230R	2777	BA3230D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Induction	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Induction	-1	Dead	329	1	10.80903491	Dead-Disease	0.8	25	40	0	NA	4.7	1.6	38.9	1.3	13	49	2.4	0.68	M2	19.6	6.8	46,XX,del(12)(p12p13)[23]	NA	94.2	Normal	9	dim CD5, CD13, dim CD33, CD34, variable CD38, CD58, CD117, dim CD123 and HLA-DR positive	4.5	68.85	positive	0.694915254	negative	NA	ASXL1 (p.E635Rfs*15; 22.0%)	NA	CREBBP (W1745*; MAF ~50%)|FLT3-ITD (MAF ~50%)|SF3B1 (p.K666M; MAF ~50%)	1	10.80903491	4
BA2953R	2485	BA2953D	Waves1+2	no	no	no	no	Male	Male	Unknown	NA	White	2	NA	NA	73	FALSE	FALSE	TRUE	FALSE	FALSE	y	Prostate Cancer	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	74	37	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	7	Cytarabine, Fludarabine, Sorafenib|Crenolanib|Azacitidine|Sorafenib|Decitabine, Sorafenib |Clofarabine, Cytarabine|Sapacitabine (CYC682-06)	6	Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental|Re-induction	Refractory	Standard Chemotherapy	39	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	33	Dead	658	1	21.61806982	Dead-Unknown	6	66	40	2	NA	19	20	8	NA	22	36	4.3	NA	NA	34.7	11.6	46,XY	NA	NA	nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	67	CD2(-), CD4(-), CD7(-), CD8(-), CD10(-), CD11b(partial +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variable and bright +), CD34(variably +) (Within this population, there is a small subset of cells (1.7% of total events) that is CD10(partial +), CD13(partial +), CD19(+), CD20(partial +), CD22(partial +), CD33(+), CD34(variably +), CD38(+), CD45(+), CD79a(+), CD117(partial +), HLA-DR(+) and TdT(partial +).) | CD36(-), CD38(variably +), CD45(moderately +), CD56(-), CD64(partial +), CD117(variably +), HLA-DR(variably +).	6.2	13.9	positive	3	negative	RUNX1 (p.R201Q; 51.8%)	NA	NA	NA	1	21.61806982	2
BA2481R	2159	BA2481D	Waves1+2	no	no	no	no	Male	Male	NA	NA	White	2	NA	NA	NA	FALSE	FALSE	FALSE	TRUE	FALSE	n	NA	y	n	y	n	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Refractory anaemia with excess blasts	NonAML	MYELODYSPLASTIC SYNDROMES	Refractory anaemia with excess blasts	NA	4	Unknown	NA	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Induction	Unknown	Standard Chemotherapy	60	Standard Chemotherapy	Decitabine	Induction	60	Dead	116	1	3.811088296	Dead-Unknown	NA	3	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[20]	NA	NA	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	NA	The findings reveal a slightly expanded population of myeloblasts with an essentially unremarkable immunophenotype. There is no definitive immunophenotypic evidence of a hematolymphoid malignancy.	NA	NA	negative	NA	negative	NA	NA	NA	NA	1	3.811088296	4
BA2731R	2036	BA2731D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	2	bi	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Alive	1346	0	44.22176591	Alive	NA	86	85	0	NA	9	3	3	NA	16	27	2.9	0.75	NA	NA	NA	46,XY,del(11)(q14q23)[13]/46,XY[7].ishdel(11)(5'MLL-,3'MLL+)[2].	682	NA	nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(5'MLLx1,3'MLLx2)(5'MLL con 3'MLLx1)[118/200]	NA	CD7(+), CD11b(-), CD13(dim +), CD14(-), CD15(partial +), CD16(-), CD33(variably +/subset bright +), CD34(+), CD36(-), CD38(+), CD45(+), CD56(partial +), CD64(partial +), CD117(+), HLA-DR(+), MPO(+), TdT(-).	6.6	33	negative	0	negative	NA	NA	NA	NA	0	44.22176591	4
BA2294R	2499	BA2294D	Waves1+2	yes	yes	yes	yes	Female	Male	NA	NA	HispNative	4	NA	RUNX1-RUNX1T1	62	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Induction	-1	Alive	239	0	7.852156057	Alive	NA	52	57	NA	NA	NA	6	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY,t(8;21)(q22;q22)[14]	NA	NA	NA	NA	CD34, PARTIAL CD38, CD33, CD13, CD64, PARTIAL CD11C, PARTIAL CD19, HLA-DR, PARTIAL CD15, CD117, AND MPO	NA	12.9	negative	0	negative	NA	NA	NA	NRAS	0	7.852156057	2
BA2418R	2405	BA2418D	Waves1+2	yes	yes	yes	no	Female	Female	NA	NA	White	2	NA	NA	47	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	2	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Salvage|Experimental	NA	NA	NA	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	4	Dead	934	1	30.68583162	Dead-Unknown	0	84	72	0	NA	28	0	0	NA	10	17	2.8	0.56	NA	14.5	5.3	NA	291	NA	NA	10	NA	5.1	1.2	negative	0	positive	NA	NA	NA	NA	1	30.68583162	4
BA2816R	2016	BA2816D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	4	NA	NA	21	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	21	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	2	SWOG S1203 (7+3 +/- Vorinostat)|Fludarabine, Cyclophosphamide, TBI	2	Allogeneic - Sibling|Induction	Complete Response	Standard Chemotherapy	177	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, TBI	Allogeneic - Sibling	-1	Alive	605	0	19.87679671	Alive	NA	66	1	NA	NA	NA	17	NA	NA	NA	NA	NA	NA	M1	NA	NA	45,XY,-7[6]/47,XY,+13[cp5]/46,XY[12]	NA	NA	NA	NA	CD34, CD4, CD13, CD15, partial CD33, CD38, partial CD117, partial CD11c, HLA-DR, MPO and TdT	NA	2.1	negative	0	negative	RUNX1 (p.R201*; 33.3%)	NA	NA	NRAS	0	19.87679671	2
BA2656R	2553	BA2656D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	7	NA	NA	NA	unknown	unknown	unknown	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	20	2	Unknown	Unknown	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Unknown	0	0	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	negative	0	positive	NA	NA	NA	NA	0	0	2
BA2814R	2539	BA2814D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	3	NA	MLLT3-KMT2A	62	FALSE	FALSE	FALSE	FALSE	FALSE	y	Prostate Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	7+3 (Cytarabine, Idarubicin)|Fludarabine, TBI|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |ODSH (2 O, 3-O Desulfated Heparin)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, TBI	Allogeneic - Matched Unrelated Donor	-1	Dead	979	1	32.16427105	Dead-Disease	NA	93	58	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5a	NA	NA	47,XY,+8,t(9;11)(p21;q23)[9]/46,XY[11]	NA	NA	8q22 (RUNX1T1): gain present  11q23 (MLL): rearrangement present (83.5% 11q23, 84.5% 8q22)	NA	Large population of promonocytes/monoblasts that represent approximately 88% of the leukocytes, consider acute monoblastic leukemia.	NA	14.66	negative	0	negative	NA	NA	NA	NA	1	32.16427105	4
BA2631R	2369	BA2631D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	60	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	114	Alive	2769	0	90.97330595	Alive	0.8	30	55	4.5	NA	19.7	8.3	15.9	0.3	49	23	3.5	1.22	M2	30.6	10.6	46,XY[21]	536	95.6	Normal	141	CD7, CD13, CD33, partial CD34, CD38, CD58, CD117, CD123,HLA-DR, and MPO positive	7.2	11.93	negative	0	positive	NA	NA	NA	CEBPA (p. Q83fs*27 (c.245?246insTGTTCCA); MAF 50%)|FLT3 ( p.N841I; MAF 12%)|FLT3 (p.I836delI; MAF 25%)|NPM1 (p.W288fs*>9; MAF 40%)	0	90.97330595	4
BA2023R	2075	BA2023D	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	55	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	Refractory	Standard Chemotherapy	5	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	Dead	386	1	12.68172485	Dead-Treatment	0	54	40	0	NA	14	59.6	5.3	0	463	477	2.7	1.14	M4	19.3	6.6	47,XY,+8[16]/46,XY[4]	NA	93.7	Trisomy 8 (82%)	47	partial CD13, CD15,  CD33, CD56, CD38, CD58, CD64, dimCD123, HLA-DR and MPO positive	5.7	16.66	negative	0	negative	NA	ASXL1 (p.G646Wfs*12; 27.3%)	NA	NRAS (p.G12R, MAF 50%)	1	12.68172485	4
BA2375R	2330	BA2375D	Waves1+2	yes	yes	yes	no	Male	Male	Black	NON-HISPANIC	Black	1	NA	NA	72	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine	NA	NA	NA	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Dead	107	1	3.515400411	Dead-Disease	2.6	NA	41	0	NA	15.3	9.3	28.8	0.6	36	31	3.8	1.66	M0	23.3	7.2	46,XY,-7,+mar.ishder(7)del(7)(p11.2)del(7)(q11.2)(D7Z1+)[20]/45,XY,-7[2]/46,XY[3]	398	82	Two of twenty-five metaphase cells examined were monosomy 7, shown by  fluorescent in situ hybridization (FISH) in  a companion study  (GLC-13-06587) to be a true clone.  Twenty cells appeared to be missing a  chromosome 7 with an additional small marker.	42	CD13, dimCD19, partial CD33, partial CD34, CD38, CD58, dim cCD79a, CD117, and TdT positive.	6.6	12.44	negative	0	negative	RUNX1 (p.R166G; MAF 22%)	NA	NA	CBL (p.L370del; MAF 63%)|JAK2 (p.V617F; MAF 43%)|RUNX1 (p.R166G; MAF 22%)|U2AF1 (p.Q157R; MAF 40%)	1	3.515400411	2
BA2485R	2540	NA	Waves1+2	yes	no	yes	no	Male	Male	Multiracial	HISPANIC	HispNative	1	NA	NA	56	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	56	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	n	n	y	n	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	111	Alive	1389	0	45.63449692	Alive	0.8	95	NA	0	NA	25.6	0	0	0.7	27	16	3.4	0.97	M1	11.1	3.7	46,XY[20]	314	95.7	Normal	20	CD13, CD33, CD38, partial CD56 (7%), CD58, CD117, CD123, and partial MPO positive	7.1	13.26	positive	NA	positive	NA	NA	NA	FLT3-ITD (Internal tandem duplication; MAF: 40%)|IDH2 (p.R140Q; MAF: 50%)|NPM1 (p.W288fs*9; MAF: 40%)	0	45.63449692	3
BA2455R	2373	BA2455D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	4	NA	NA	72	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Supportive/Palliative Care	1	Hydroxyurea	1	Supportive/Palliative Care	NA	NA	NA	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	-1	Dead	33	1	1.084188912	Dead-Disease	NA	94	71	NA	NA	NA	0	NA	NA	NA	NA	NA	NA	M5	NA	NA	48,XYY,+8[21]	NA	NA	NA	NA	CD38, CD56, CD13(dim), CD64, CD11c, CD4, CD56, HLA-DR, and CD15	NA	24.2	negative	0	positive	NA	NA	NA	FLT3-D835|NPM1	1	1.084188912	4
BA2025R	2429	BA2025D	Waves1+2	no	no	no	no	Female	Female	Pacific Islander	NON-HISPANIC	Asian	1	NA	MLLT3-KMT2A	30	TRUE	FALSE	FALSE	FALSE	FALSE	y	Acute Promyelocytic Leukemia	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	31	147	Relapse|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	4	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	6	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	31	Dead	270	1	8.87063655	Dead-Disease	0	75	35	0	NA	9.9	9.9	37.2	0.8	37	39	3.1	0.56	M1	22.1	7.7	46,XX,t(9;11)(p22;q23)[20]/46,XX[1]	NA	89.8	MLL disruption and t(9;11) (70%)	39	dim/partial CD13, CD33, CD38, CD56, CD58, CD64, partialCD117, CD123 and HLA-DR positive	6	43.72	negative	0	negative	NA	NA	NA	FLT3-D835 (MAF 70%)	1	8.87063655	4
BA2636R	2576	BA2636D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	4	NA	NA	74	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	74	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	4	Hydroxyurea|Decitabine|Temozolomide, Vorinostat|Azacitidine, MLN4924	4	Salvage|Induction|Re-induction|Symptom Control	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Salvage	-1	Dead	357	1	11.72895277	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	NA	ASXL1 (p.G645Vfs*58; 43.8%)	NA	NA	1	11.72895277	1
BA2325R	2492	BA2325D	Both	no	no	no	no	Female	Female	White	NON-HISPANIC	White	1	NA	NA	74	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	74	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	6	Alive	29	0	0.952772074	Alive	0.9	60	9	0	NA	11.4	44.7	35.1	7.1	17	28	2.6	0.79	M4	28.1	9.4	46, XX,t(2;16)(p23;p13.3)(13)	645	98.3	NA	71	CD13, CD14, CD16, CD33, CD64 and HLA-DR	6.2	35.91	negative	0	positive	NA	NA	NA	NPM1 (p.W288fs*>9 (C-terminal frame-shift); MAF 44%)|PTPN11 (p.E76Q; MAF 40%)	0	0.952772074	4
BA2169R	2399	BA2169D	Waves1+2	yes	yes	yes	no	Male	Male	White	HISPANIC	HispNative	2	NA	NA	38	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	39	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Supportive/Palliative Care	4	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Salvage|Unknown|Induction|Maintenance	NA	Standard Chemotherapy	5	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Unknown	6	Alive	416	0	13.66735113	Alive	NA	N/A	16	NA	NA	20	10	54	NA	152	49	4.3	0.77	NA	30.5	10.6	NA	340	NA	NA	215	NA	7	4.01	negative	0	negative	NA	NA	NA	NA	0	13.66735113	1
BA2156R	2017	BA2156D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	bi	NA	55	FALSE	FALSE	FALSE	FALSE	FALSE	y	Other malignant neoplasm without specification of site	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Alive	2733	0	89.79055441	Alive	0	50	25	0	NA	45.3	19.6	9.3	6	27	20	3.7	1.01	M2	30.6	10.1	46,XY[20]	NA	98.4	Normal	15	CD7, CD13, CD33, CD34, CD38, CD64, CD123, HLA-DR, and MPO	6.3	3.85	negative	0	negative	NA	NA	NA	CEBPA (c.242?243insCTTGGTT (7bp out-of-frame insertion); MAF 50%)|CEBPA (c.912?913insTTG (3 bp in-frame insertion); MAF 50%)	0	89.79055441	2
BA2511R	2567	BA2511D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	4	NA	GATA2-MECOM	71	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	AG-221	1	Hypomethylating/Low Dose Cytarabine	NA	NA	NA	Standard Chemotherapy	AG-221	Hypomethylating/Low Dose Cytarabine	-1	Alive	1008	0	33.11704312	Alive	NA	22	8	NA	NA	NA	10	NA	NA	NA	NA	NA	NA	M4	NA	NA	46,XX,inv(3)?(q21q25)[21]	NA	NA	NA	NA	CD34, CD117, CD38, CD56 (minor subset), partial CD13, partial CD33, CD11c, and HLA-DR	NA	2.6	negative	0	negative	NA	NA	NA	IDH2	0	33.11704312	1
BA2939R	2055	NA	Waves1+2	no	no	no	no	Female	Female	NA	NA	White	4	NA	NA	35	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	37	160	Residual Disease|Post-Chemotherapy|Post-Transplant	Residual	Peripheral Blood	y	n	y	y	n	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cyclophosphamide, Etoposide, TBI	5	Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	53	Dead	761	1	25.00205339	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5	NA	NA	46,XX[5]	NA	NA	NA	NA	NA	NA	NA	negative	0	positive	NA	NA	NA	NA	1	25.00205339	4
BA2168R	2297	BA2168D	Waves1+2	yes	yes	yes	yes	Female	Female	Unknown	NA	HispNative	2	NA	NA	47	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	48	0	Post-Chemotherapy|Post-Transplant|Relapse	Relapse	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Consolidation|Salvage|Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	Dead	582	1	19.1211499	Dead-Unknown	0	62	66	0	NA	7	0	13	NA	24	40	3.4	NA	NA	35.5	12.1	46,XX	NA	NA	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	29	CD2(-), CD4(partial +), CD7(-), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(variably +), CD56(partial +), CD64(-), CD117(partial +), HLA-DR(partial dim +)	5.8	58.5	positive	3.166666667	negative	NA	NA	NA	FLT3-ITD	1	19.1211499	3
BA2505R	2023	NA	Waves1+2	yes	no	yes	no	Male	Male	NA	NA	White	4	NA	GATA2-MECOM	71	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	n	n	y	n	n	1	Standard Chemotherapy	3	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Lenalidomide|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction|Re-induction	Refractory	Standard Chemotherapy	23	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	4	Dead	262	1	8.607802875	Dead-Unknown	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M2	NA	NA	45,XY,inv(3)(q21q26),-7[20]	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	NA	1	8.607802875	4
BA2860R	2413	BA2860D	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	68	FALSE	FALSE	FALSE	TRUE	FALSE	n	NA	y	n	y	n	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Myelodysplastic syndrome, unclassifiable	NonAML	MYELODYSPLASTIC SYNDROMES	Myelodysplastic syndrome, unclassifiable	68	0	Unknown	NA	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	1	Azacitidine	1	Induction	Unknown	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine	Induction	6	Dead	299	1	9.823408624	Dead-Unknown	0	N/A	15	1.7	NA	38.7	3.4	30.3	0	27	23	3	1.18	NA	21	7	45~48,XY,del(5)(q22q35),+8,del(13)(q12q14),- 20,der(21)t(20;21)(p11.2;p11.1),+der(22)t(?;22)(?;q11.2)[cp15]/46,XY[4]	1138	88.6	NA	26	CD13, CD33, CD34, CD38, CD58, CD117, CD123 and HLA-DR positive	5.7	2.42	negative	NA	negative	NA	NA	NA	NA	1	9.823408624	1
BA2707R	2313	BA2707D	Both	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	68	TRUE	FALSE	FALSE	FALSE	FALSE	y	Lung Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	72	1207	Relapse|Post-Chemotherapy	Relapse	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|MiDAC|Decitabine	3	Consolidation|Induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	Decitabine	Supportive/Palliative Care	9	Dead	1238	1	40.67351129	Dead-Disease	0	NA	NA	0	NA	14.9	0.8	2.5	0	NA	NA	NA	NA	NOS	22.7	7.6	47,XY,del(9)(q22),+13[18]/48,idem,+mar[2]	556	93.8	Missing ABL and ASS signal (84%)	32	partial CD7, CD11b, CD13, CD33, CD34, partial CD64, partial CD117, CD123, HLA-DR, and TdT-positive.	NA	47.2	negative	0	negative	RUNX1 (p.A147Gfs*13; 42.3%)|RUNX1 (p.R162S; 46.5%)	ASXL1 (p.G646Wfs*12; 27.9%)	NA	RUNX1 (p.A147fs*13 (1 bp insertion frameshift); MAF 35%)|RUNX1 (p.R162S; MAF 50%)|SRSF2 (p.P95R; MAF 44%)	1	40.67351129	4
BA2871R	2273	BA2871D	Waves1+2	yes	yes	yes	no	Female	Female	NA	NA	White	3	NA	NA	80	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	80	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Unknown	1	Bevacizumab	1	Unknown	NA	NA	NA	Unknown	Bevacizumab	Unknown	-1	Dead	10	1	0.328542094	Dead-Disease	NA	84	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	44-47,XX,del(5)(q13q33),der(14;18)(q10;q10),-20,-21,+1-4mar[cp15]	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	NA	NA	TP53 (p.R306*; 28.8%)|TP53 (p.X187_splice; 21.9%)	NA	1	0.328542094	4
BA2655R	2458	BA2655D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	2	NA	NA	58	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	59	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	8	E7070, Idarubicin, Cytarabine|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|BL-8040|IGN523	4	Salvage|Induction|Experimental|Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	Dead	357	1	11.72895277	Dead-Disease	1	10	6	0	NA	32.7	12.6	53.7	NA	45	19	3.7	0.69	NA	26.8	9.4	46,XY[20]	88	NA	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x1[47/200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	75	CD2 (-), CD4(+), CD7(+), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD33(+), CD34(bright +), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(+).	5.8	1.6	negative	0	negative	NA	NA	NA	NA	1	11.72895277	1
BA2227R	2345	BA2227D	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	17	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	17	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	3	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Clofarabine, Cyclophosphamide, Etoposide|HAM (Cytarabine, Mitoxantrone)	2	Induction|Re-induction	Refractory	Standard Chemotherapy	74	Standard Chemotherapy	Clofarabine, Cyclophosphamide, Etoposide	Re-induction	5	Dead	713	1	23.42505133	Dead-Disease	0	90	NA	0	NA	48.5	0.6	1.2	1.6	18	11	3.5	0.7	M1	25.6	9.1	46,XY[20]	NA	87.4	Normal	25	CD13, partial CD33, CD34, CD38, moderate CD45, CD58, CD117, CD123, TdT, and partial MPO positive.	6.9	4.34	negative	0	negative	NA	NA	NA	MLL (PTD)|WT1 (MAF A382fs*6; 40%)|WT1 (MAF p.R462G; 40%)|WT1 (p.R462G ; MAF 40%)	1	23.42505133	2
BA2125R	2562	BA2125D	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	1	NA	NA	71	FALSE	FALSE	FALSE	FALSE	FALSE	y	Basal Cell Carcinoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|Azacitidine, Lenalidomide|Decitabine	3	Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine, Lenalidomide	Re-induction	28	Dead	295	1	9.691991786	Dead-Disease	0	46	49.1	0	NA	20.5	8	17	0.9	32	39	3.3	0.73	M2	20.7	6.4	42~45,XX,add(5)(q13),der(17)add(17)(p11.2)add(17)(q11.2),-18,-22[cp6]/43~44,sl,add(13)(q32),add(14)(q11.2),+mar[cp12]/43~44,sl,add(14)(q11.2),-21,	685	79	5q deletion (85%) | Loss of RARA on 17q21 (46%)	11	partial CD7, CD13, partial CD33, CD34, partial CD38, CD58, CD117, dim/partial CD123, partial TdT, HLA-DR positive.	6.6	12.87	negative	0	negative	NA	NA	TP53 (p.V173M; 77.4%)	SUZ12 (V186D)|TP53 (V173M; MAF 80%)	1	9.691991786	1
BA2523R	2225	BA2523D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	4	NA	NA	46	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	46	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	5	HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|SWOG S1203 (7+3 +/- Vorinostat)|MEC, Lenalidomide|Etoposide, Cytarabine	4	Consolidation|Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	-1	Alive	874	0	28.71457906	Alive	NA	90	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M4	NA	NA	46,XY[20]	NA	NA	NA	NA	MPO, HLA-DR, CD11c,CD13, CD33, DIM CD7, PARTIAL CD64, PARTIAL CD4, AND LACKING CD34	NA	NA	negative	0	positive	NA	NA	NA	DNMT3A|IDH1|NPM1|NRAS	0	28.71457906	2
BA2603R	2314	BA2603D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Alive	2438	0	80.09856263	Alive	1.7	29	14	0.8	NA	9.4	28.2	49.6	1.6	18	26	2.8	0.74	M4	21.2	7.3	46,XX[20]	514	101.4	Normal	57	CD13, CD33, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive (Myeloid blast phenotype) | CD11b, variable CD13, CD14, CD33, dimCD56, CD64, HLA-DR-positive (Monocytic phenotype)	6.1	63.75	negative	0	positive	NA	NA	NA	CREBBP (p.V319I; MAF 50%)|DNMT3A (p.R882H; MAF 50%)|DNMT3A (p.T138I; MAF 50%)|NPM1 (p.W288fs*12; MAF 50%)|NRAS (p.Q61H; MAF 40%)	0	80.09856263	4
BA2808R	2300	BA2808D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	4	NA	NA	56	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	56	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Re-induction	Complete Response	Standard Chemotherapy	27	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	Dead	198	1	6.50513347	Dead-Unknown	NA	72	88	NA	NA	NA	1	NA	NA	NA	NA	NA	NA	NA	NA	NA	40~43,XY,add(1)(p36),-2,-4,-5,-8,-12,-14,-15,-16,-17,?add(17)(p13),der(19)?t(8;19)(q11.2;p13),-20,-22,+7mar[cp18]	NA	NA	NA	NA	CD34, CD38 (dim), CD13, CD33 (dim),CD64 (partial), CD11c, CD4 (partial), CD15, CD117, HLA-DR, and MPO(partial).	NA	12.9	positive	0.388888889	negative	NA	NA	NA	NA	1	6.50513347	1
BA2282R	2574	BA2282D	Waves1+2	no	no	no	no	Male	Male	NA	NA	White	3	NA	PML-RARA	41	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	44	0	Post-Chemotherapy|Post-Transplant	Remission	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	7	Busulfan, Fludarabine|Etoposide, TBI|PETHEMA Trial LPA05 (ATRA (Tretinoin), Idarubicin, Mitoxantrone, Cytarabine)|Idarubicin, Mitoxantrone|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|ATRA, Arsenic Trioxide|ATRA, 6-MP, Methotrexate	5	Allogeneic - Sibling|Consolidation|Induction|Maintenance|Re-induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Etoposide, TBI	Allogeneic - Sibling	-1	Alive	2350	0	77.2073922	Alive	NA	1.2	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[20]	NA	NA	48% PML/RARA translocation	NA	CD117+, HLA-DR negative, partial CD34+ (Right inguinal biopsy)	NA	NA	negative	0	negative	NA	NA	NA	NA	0	77.2073922	4
BA2482R	2067	BA2482D	Both	no	no	no	no	Female	Female	White	NON-HISPANIC	White	1	NA	CBFB-MYH11	10	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	10	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	3	Induction|Intensification|Re-induction	Refractory	Standard Chemotherapy	10	Standard Chemotherapy	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)	Intensification	29	Alive	2453	0	80.59137577	Alive	0.8	50	NA	0	NA	10.5	21	7.3	0.5	NA	NA	2.1	0.41	M2	24.7	8.3	46,XX,inv(16)(p13q22)[17]/46,XX[3]	702	88.5	CBFB rearrangement and inverted 16 (85%)	31	CD13, dim CD33, CD34, CD38, CD58, CD117, CD123, dim/partial HLA-DR, and MPO positive	NA	55.35	negative	0	negative	NA	NA	NA	NA	0	80.59137577	2
BA2812R	2563	BA2812D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	3	NA	NA	46	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE	Mixed phenotype acute leukaemia, T/myeloid, NOS	MissingKaryo	ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE	Mixed phenotype acute leukaemia, T/myeloid, NOS	46	14	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Unknown	0	0	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	NA	0	0	4
BA2822R	2227	BA2822D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	37	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	38	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	2	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction|Maintenance	Refractory	Standard Chemotherapy	6	Supportive/Palliative Care	Azacitidine	Maintenance	-1	Dead	207	1	6.800821355	Dead-Disease	0	NA	95	0	NA	0.9	0	0	0.1	17	56	1.8	0.6	NA	23	7.9	48~54,XY,add(2)(p13),+5,add(5)(q13),del(5)(q13),+10,+11,+13,+13,del(13)(q32),+14,-15,-16,del(17)(p12),-20,+21,+21,+22,+mar[cp9]/49~52,sl,-del(17)(p12)[cp8]/51~54,sl	NA	86.8	Extra chromosome 5 (98%) | 5q deletion (98%) | Monosomy 16 (93%) | Extra copies of chromosome 21 (63%) | Monosomy 17 (99%) | Extra chromosome 11 (99%)	20	CD10, CD13, CD33, CD34, CD56 and HLA-DR positive	5.3	38.47	negative	0	negative	NA	NA	TP53 (p.R273H; 90.9%)	NRAS (p.G13D, MAF 46%)|TP53 (p.R273H, MAF 96%)	1	6.800821355	2
BA2594R	2554	BA2594D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	72	FALSE	FALSE	FALSE	FALSE	FALSE	y	Other malignant neoplasm without specification of site	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	Azacitidine|Decitabine	3	Consolidation|Induction|Maintenance	Unknown	Standard Chemotherapy	38	Standard Chemotherapy	Azacitidine	Maintenance	36	Dead	252	1	8.27926078	Dead-Disease	0	55	46	0	NA	27.8	27	20.6	0	32	31	2.2	1.37	M4	20.6	6.6	43~44,X,-Y,t(3;11)(p21.3;p11.2),del(5)(q11.1;q31.1),add(12)(p11.2),-21[cp17]/44~45,idem,-t(3;11),+9[cp4]	435	85.8	Previous FISH results were consistent with the deleted 5q and trisomy 9	33	CD13, CD33, CD34, partial CD56,variable CD117, dim CD123, and dim HLA-DR+	5.9	20.82	negative	0	negative	NA	NA	TP53 (p.H193R; 90.7%)	TP53 (p.H193R; MAF 92%)	1	8.27926078	4
BA2747R	2205	BA2747D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	Asian	4	NA	NA	85	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	85	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine, Midostaurin	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine, Midostaurin	Induction	-1	Dead	357	1	11.72895277	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M4	NA	NA	46,XY[14]	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	FLT3-ITD	1	11.72895277	2
BA2561R	2231	BA2561D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	3	NA	NA	75	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	75	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	5	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|MiDAC|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	21	Standard Chemotherapy	CLAG (Cladribine, Cytarabine, Filgrastim)	Consolidation	-1	Dead	335	1	11.00616016	Dead-Disease	NA	64	7	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M4	NA	NA	46,XY,add(8)(p21),t(8;19)(p11.2;q13.3)[18]/46,XY[2]	NA	NA	Normal	NA	Large population of atypical myelomonocytic cells (CD4+, bright CD64+, MPO positive, partial CD14), representing 85% of the total leukocytes	NA	4.67	negative	0	negative	NA	NA	NA	NA	1	11.00616016	4
BA2567R	2162	BA2567D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	3	NA	NA	46	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	MissingKaryo	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	46	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	3	DLI|Standard Chemotherapy|Bone Marrow Transplant	8	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Clofarabine|ODSH (2 O, 3-O Desulfated Heparin)	6	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction|Post-Transplant Relapse	Complete Response	Standard Chemotherapy	-1	DLI	Donor Lymphocyte Infusion	Post-Transplant Relapse	-1	Dead	1005	1	33.01848049	Dead-Disease	NA	25.9	0.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5	NA	NA	NA	NA	NA	Normal	NA	Increased atypical CD56 positive, weak CD117 positive myelomonocytic cells representing approximately 23% of the leukocytes	NA	3.6	negative	0	negative	NA	NA	NA	NA	1	33.01848049	4
BA2906R	2561	BA2906D	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1	NA	KMT2A_re	5	FALSE	FALSE	FALSE	FALSE	FALSE	y	B lymphoblastic leukaemia/lymphoma with t(v;11q23); MLL rearranged	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	5	0	Initial Acute Leukemia Diagnosis|Post-Transplant|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	ADE (Cytarabine, Daunorubicin & Etoposide)|Cyclophosphamide, TBI|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Allogeneic - Sibling|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	9	Bone Marrow Transplant	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	-1	Dead	2241	1	73.62628337	Dead-Other	0	NA	80	0	NA	33	0	0	0	12	32	3	0.44	M5	17.1	5.7	46,XY[25]	1072	98.8	MLL rearrangement (76%)	34	CD4, CD11b, CD15, CD33, bright CD34, CD38, CD58, CD64,CD71, CD117, CD123, HLA-DR and dim/partial MPO positive	7.4	95.2	negative	0	negative	NA	NA	NA	NA	1	73.62628337	4
BA2956R	2123	BA2956D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	2	NA	CBFB-MYH11	56	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	57	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	Standard Chemotherapy	3	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	3	Dead	421	1	13.83162218	Dead-Disease	0	N/A	54	0	NA	38	8	0	NA	15	23	3	1.3	NA	NA	NA	46,XY,del(5)(q15q35),inv(16)(p13.1q22)[20]	409	NA	nuc ish(D5S721x2,D5S23x2,EGR1x1)[182/200],(D7Z1,D7S522)x2[199], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[192],(PML,RARA)x2[198],(5'CBFB,3'CBFB)x2(5'CBFB sep 3'CBFBx1)[176/200]	NA	CD2(-), CD4(partial dim +), CD7(partial dim +), CD11b(-), CD13(+), CD14(-), CD15(+), CD16(-), CD19(-), CD20(-), CD22(few dim +), CD25(-), CD33(+), CD34(+), CD36 (-), CD38(variably +), CD45(moderately +), CD56(-), CD64(few dim +), CD79a(-), CD117(+), CD123(+) (PB) | HLA-DR(variably +), MPO(+), TdT(+). (PB)	6.6	8.2	negative	0	negative	NA	NA	NA	NRAS (G12D; MAF 16%)|NRAS (G13D; MAF 13%)|NRAS (Q61H; MAF 5%)	1	13.83162218	2
BA2474R	2029	BA2474D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	46	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	46	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	5	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC	3	Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	4	Dead	1373	1	45.10882957	Dead-Disease	0	80	NA	1.6	NA	9.9	14.9	10.7	0	52	28	2.5	0.77	M4	25.2	8.4	46,XX[20]	550	88.1	Normal	107	dim CD11b, CD13, CD33, partial CD34, dim CD45, dim CD64, CD117, CD123, and dim HLA-DR+	6.3	57.23	negative	0	positive	NA	NA	NA	DNMT3A (p.R882C; MAF 46%)|NPM1 (p.W288fs*12; MAF 43%)|PTPN11 (p.E76Q; MAF 40%)	1	45.10882957	4
BA2737R	2241	NA	Waves1+2	yes	no	yes	yes	Female	Female	NA	NA	White	2	NA	RUNX1-RUNX1T1	57	FALSE	FALSE	FALSE	FALSE	FALSE	y	Ovarian cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	57	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	n	y	y	n	y	2	Standard Chemotherapy|Supportive/Palliative Care	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|Decitabine, Hydroxyurea	4	Consolidation|Induction|Re-induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	5	Supportive/Palliative Care	Decitabine, Hydroxyurea	Supportive/Palliative Care	-1	Dead	138	1	4.533880903	Dead-Unknown	0	76	79	0	NA	9	5	4	NA	45	41	3.2	NA	NA	28.6	9.6	46~47,XX,t(1;11)(p34;p15),der(8)del(8)(p11.2p23)t(1;8)(q21;q24.3),add(9)(q34),del(9)(q13q22),add(16)(p13.3),+1~2mar[cp11] /47~48,idem,+13[cp2]/47~48,idem,-13,der(21)t(8;21)(q13;p12),+2~3mar[cp6]/46,XX[1]	NA	NA	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(RUNX1T1x3,RUNX1x2)[69/200]/(RUNX1T1x2,RUNX1x3)[7/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	64	CD2(-), CD4(+), CD5(equivocal), CD7(-), CD11b(+), CD13(-), CD14(partial +), CD15(+), CD16(-), CD33 (bright +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56(+), CD64(+), CD117(partial +), HLA-DR(+)	6.3	19.5	negative	0	negative	RUNX1 (Y414*; MAF 16%)	NA	NA	CREBBP (MYST3-CREBBP fusion; MAF unlisted)|RUNX1 (Y414*; MAF 16%)	1	4.533880903	4
BA2110R	2305	BA2110D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Fludarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC	4	Consolidation|Salvage|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Fludarabine	Consolidation	4	Dead	439	1	14.42299795	Dead-Disease	0.1	70	NA	0.1	1.7	8.3	85.2	4.6	0.2	16	13	2.7	0.87	M4	30.4	9.6	46,XX[20]	506	101.7	Normal	112	CD11b, partial CD13, partial CD14, dim CD15, partial      CD16, CD33, CD38, CD58, CD64, partial CD123 and HLA-DR positive	7.4	58.86	positive	NA	positive	NA	NA	NA	DNMT3A ( p.R882H; MAF 50%)|FLT3-ITD (MAF 10%)|FLT3-N676K (MAF 12%)|NPM1 (p.W288fs*12; MAF 50%)|PTPN11 (p.F71L; MAF 14%)	1	14.42299795	4
BA2992R	2348	BA2992D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	HispNative	4	NA	CBFB-MYH11	52	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	52	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	Complete Response	Standard Chemotherapy	8	Standard Chemotherapy	SWOG S1203 (7+3 +/- Vorinostat)	Induction	8	Alive	36	0	1.18275154	Alive	NA	91	79	NA	NA	NA	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX,inv(16)(p13.1q22)[cp20]	NA	NA	NA	NA	CD34, PARTIAL CD117, CD15, CD38, PARTIAL CD13, CD33, CD64, PARTIAL CD14(SUBSET), PARTIAL CD11c, DIM CD4, HLA-DR AND BRIGHT MPO	NA	28.1	negative	0	negative	NA	NA	NA	NA	0	1.18275154	4
BA2220R	2394	BA2220D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	23	FALSE	FALSE	FALSE	FALSE	FALSE	y	Mediastinum mass	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	23	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Trametinib|HAEP (Cytarabine, Etoposide, Cisplatin)	3	Consolidation|Induction|Experimental	Complete Response	Standard Chemotherapy	8	Targeted Therapy - Kinase Inhibitor(s)	Trametinib	Experimental	197	Dead	318	1	10.4476386	Dead-Disease	3.2	3	30	2.1	NA	25.8	1.1	36.6	43.4	32	131	3	0.91	M6b	17.9	5.7	48,XY,add(6)(p22),der(7)t(7;19)(p11.1;p12),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp20]	16499	95.2	Low-level tetraploidy or near-tetraploidy (5%)	24	NA	5.6	40.76	negative	0	negative	NA	NA	TP53 (p.G245S; 83.1%)	NRAS (p.G12C; MAF 86%)|TP53 (p.G245S; MAF 87%)	1	10.4476386	1
BA2772R	2397	BA2772D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	HispNative	2	NA	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	5	Alive	71	0	2.332648871	Alive	1	81	68	NA	NA	5	2	2	NA	85	52	3.1	0.85	NA	28.8	10.1	46,XY[20]	1205	NA	nuc ish(D4Z1,D10Z1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200]	20	CD2(-),CD4(partial dim +), CD7(-), CD11b(few +), CD13(+), CD14(-), CD15(partialCD22(-), CD25(appears partial dim +), CD33(bright +), CD34(few +), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(partial +), CD79a(-), CD117(+), CD123(partial +), HLA-DR(partial +), MPO(+), TdT(-).	6.2	152.75	negative	0	positive	NA	NA	NA	NA	0	2.332648871	4
BA2935R	2130	BA2935D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	4	NA	NA	78	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	78	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	3	Azacitidine|Sorafenib|Decitabine, Midostaurin	3	Induction|Experimental|Re-induction	Refractory	Standard Chemotherapy	317	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	8	Dead	705	1	23.16221766	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5	NA	NA	46,XY[25]	NA	NA	NA	NA	NA	NA	NA	positive	0.886792453	negative	NA	NA	NA	FLT3-ITD	1	23.16221766	4
BA2260R	2447	BA2260D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	3	NA	CBFB-MYH11	58	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	58	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin)	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	210	Alive	1250	0	41.06776181	Alive	NA	50.8	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M4	NA	NA	48,XY,+8,inv(16)(p13.1q22),+22[18]/49,sl,+21[2]	NA	NA	8q22 (RUNX1T1): gain present  16q22 (CBFB): rearrangement present  21q22 (RUNX1): gain or rearrangement present (96%, 71.5%, 11% respectively)	NA	Relative increase of CD34 positive myeloblasts representing approximately 20% of the leukocytes and increased promonocytes/monoblasts consistent with acute myeloid leukemia with   myelomonocytic differentiation	NA	NA	negative	0	negative	NA	NA	NA	NA	0	41.06776181	2
BA2676R	2008	BA2676D	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	48	FALSE	FALSE	FALSE	TRUE	FALSE	n	NA	y	n	y	n	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Refractory anaemia with excess blasts	NonAML	MYELODYSPLASTIC SYNDROMES	Refractory anaemia with excess blasts	48	0	Unknown	NA	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	Decitabine|Busulfan, Cyclophosphamide	2	Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	116	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Alive	2114	0	69.45379877	Alive	0	17	5.3	0	NA	67.3	22.1	5.3	0	36	20	3.5	0.82	NA	32.5	10.2	47,XY,+8[18]/46,XY[2]	155	83.5	Trisomy 8 (84%)	105	CD13, CD33, CD34, CD38, CD58, CD117, CD123, MPO+	7.9	0.94	negative	NA	negative	NA	NA	NA	DNMT3A (p.R882C; MAF 45%)|IDH1 (p.R132C; MAF 44%)|TET2 (p.P455R; MAF 45%)	0	69.45379877	1
BA2948R	2279	BA2948D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	3	NA	NA	67	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	67	0	Post-Chemotherapy|Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	3	Azacitidine|Decitabine|Clofarabine	2	Hypomethylating/Low Dose Cytarabine|Induction	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Dead	30	1	0.985626283	Dead-Disease	NA	33	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	42,X,add(Y)(p11.1),add(3)(q12),add(4)(q25),del(5)(q12q33),-7,add(8)(p11.2),-11,add(13)(p11.2),del(16)(q22),-17,add(19)(q12.3),-20,add(21)(p11.2),-22,+mar[20]	NA	NA	43% del 5q31, 56% del 7q31, 58% del20q	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	NA	1	0.985626283	1
BA2524R	2134	BA2524D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	4	NA	CBFB-MYH11	51	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Stanford Protocol 9022 (BU/CY)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	Stanford Protocol 9022 (BU/CY)	Allogeneic - Matched Unrelated Donor	-1	Alive	839	0	27.56468172	Alive	NA	74	61	NA	NA	NA	1	NA	NA	NA	NA	NA	NA	M4eo	NA	NA	46,XX,inv(16)(p13q22)[20]	NA	NA	NA	NA	CD34+ EXPRESSING CD38, CD13, CD33, PARTIAL DIM CD2, PARTIAL CD64; DIM PARTIAL CD11C, PARTIAL DIM CD4, COEXPRESSION OF CD117 AND CD15, HLA-DR, MPO, AND PARTIAL DIM TDT	NA	34.4	negative	0	negative	NA	NA	NA	NA	0	27.56468172	2
BA2811R	2448	BA2811D	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	1	NA	PML-RARA	47	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	ATRA, Arsenic Trioxide|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	26	Standard Chemotherapy	ATRA, Arsenic Trioxide	Consolidation	31	Alive	2197	0	72.18069815	Alive	0	85	75	0	NA	14.8	13.1	13.9	0.9	19	37	3.3	0.6	M3	19.5	6.5	46,XX,t(15;17)(q24;q21)[4]/45,idem,-22[15]/46,XX[1]	819	70.8	NA	9	CD2, CD13, CD33, CD34, CD56, CD58, CD64, CD117, CD123, dim/partial HLA-DR, dim/partial TdT and MPO positive	7.1	25.11	positive	NA	negative	NA	NA	NA	FLT3-ITD (MAF 40%)	0	72.18069815	3
BA2540R	2176	BA2540D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	4	NA	MLLT3-KMT2A	69	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Hydroxyurea	1	Induction	Unknown	Standard Chemotherapy	365	Standard Chemotherapy	Hydroxyurea	Induction	NA	Unknown	0	0	0	NA	NA	94	83	NA	NA	NA	0	NA	NA	NA	NA	NA	NA	M5a	NA	NA	46,XX[1]	NA	NA	NA	NA	CD38, CD56, slightly dim CD4, CD33, dim CD13, CD64, CD11c, CD15 and partial CD117	NA	137.6	negative	0	negative	NA	NA	NA	NA	0	0	4
BA2928R	2490	BA2928D	Both	no	no	no	no	Female	Female	White	NON-HISPANIC	HispNative	1	NA	MLLT3-KMT2A	48	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	48	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan|Idarubicin and Cytarabine	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Dead	1705	1	56.0164271	Dead-Treatment	0	NA	NA	0	NA	9.5	0	6	0	51	152	3.1	0.85	M5	30.4	9.7	47,XX,+8,t(9;11)(p22;q23)[20]	4484	80.4	MLL rearrangement (80%) | Trisomy 8 (78%)	87	CD4, partial CD11b, CD15, CD33, CD56, CD58, CD64, CD117, CD123, HLA-DR, and butyrate esterase positive	6	49.29	negative	0	negative	NA	NA	NA	FLT3-D835 (MAF 10%)|JAK1 (p.I878V; MAF 50%)	1	56.0164271	4
BA2302R	2336	BA2302D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	4	NA	NA	78	FALSE	FALSE	FALSE	FALSE	FALSE	y	Uterine Sarcoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	78	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine, MLN4924	1	Induction	Refractory	Standard Chemotherapy	111	Standard Chemotherapy	Azacitidine, MLN4924	Induction	111	Dead	161	1	5.289527721	Dead-Disease	NA	78	77	NA	NA	NA	1	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX[20]	NA	NA	NA	NA	CD34 and MPO, with partial CD38, CD33, CD13, CD11c, CD117 and HLADR	NA	5.6	negative	0	negative	NA	NA	NA	IDH1	1	5.289527721	2
BA2595R	2148	BA2595D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	4	NA	NA	65	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	66	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	n	y	y	n	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other	8	HiDAC|AG-221|Gilteritinib (ASP2215)|3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|MEC, Lenalidomide|Clofarabine, Cytarabine	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Other	AG-221	Experimental	-1	Dead	395	1	12.97741273	Dead-Disease	NA	96	85	NA	NA	NA	5	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY,t(4;15)(q31;q22),add(12)(p11~12)[cp7]/46~51,XY,del(7)(q11.2q36),add(12)(p11~12),add(20)(q11.2)[cp5]/46,XY,?inv(8)(p21q22)[cp7]/46,XY[cp2]	NA	NA	NA	NA	CD38, CD33; WITH PARTIAL CD34, CD56, CD13, CD11C, CD2 AND CD15/CD117	NA	0.1	negative	0	negative	NA	NA	NA	IDH2	1	12.97741273	4
BA2792R	2166	BA2792D	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	51	FALSE	FALSE	FALSE	TRUE	FALSE	n	NA	y	n	y	n	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Refractory anaemia with excess blasts	NonAML	MYELODYSPLASTIC SYNDROMES	Refractory anaemia with excess blasts	51	0	Unknown	NA	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan|Azacitidine, Lenalidomide	2	Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	117	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	Dead	286	1	9.396303901	Dead-Treatment	0	4	6	0	NA	38.9	1.1	56.7	NA	58	51	3.5	0.87	NA	22.4	7.5	47,XY,+8[2]/46,XY[18]	438	93.7	Trisomy 8	20	CD34/CD117 positive myeloid blasts comprise about 4% of total CD45+ cells with possible partial TdT expression	5.9	2.23	negative	NA	negative	NA	NA	NA	WT1 (p.A382fs*4; MAF 44%)	1	9.396303901	4
BA2651R	2160	BA2651D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	4	NA	MLLT3-KMT2A	22	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	22	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	4	ATRA (Tretinoin)|Cyclophosphamide, TBI|3+7 (Cytarabine, Daunorubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)	4	Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	7	Bone Marrow Transplant	Cyclophosphamide, TBI	Allogeneic - Matched Unrelated Donor	-1	Alive	826	0	27.137577	Alive	NA	65	90	NA	NA	NA	0.1	NA	NA	NA	NA	NA	NA	M1	NA	NA	46,XX,t(9;11)(p22;q23)[22]	NA	NA	NA	NA	CD34, CD38 (dim partial), CD13, CD33 (dim partial), CD11c, CD4 (dim partial), HLA-DR, CD117 and MPO	NA	40.2	negative	0	negative	NA	NA	NA	FLT3-D835	0	27.137577	4
BA2619R	2184	BA2619D	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	1	NA	NA	62	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Salvage|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HAM (Cytarabine, Mitoxantrone)	Salvage	7	Dead	167	1	5.486652977	Dead-Other	6.1	22	17.4	5.2	16.5	31.3	1.7	21.8	0.2	13	11	3.2	0.78	M2	29.5	9.5	59~62,XX,+X,+1,+2,del(5)(q13q34),+6,+8,+8,+9,+11,+11,i(11)(q10),+12,+14,+16,+19,+22,+mar[cp19]/46,XX[1]	444	101.4	Trisomy 9 (88%) | Missing ERG1 signal (75%) | 2 small red/2 \normal\" red pattern with the PML probe (79%) | Trisomy 11 and i(11q) (92%) | Tetrasomy 8 (87%) | Trisomy 16 (81%)"	34	CD13, CD34, CD58 and CD117	7	10.75	negative	0	negative	NA	NA	TP53 (p.R280T; 41.1%)|TP53 (p.X33_splice; 37.9%)	GATA1 (p.N160S; MAF:40%)|NRAS (p.G12D; MAF 11%)|TP53 (Intron 4, 3' Splice site (C.97-1G>A); MAF 26%)|TP53 (p.R280T;  MAF 36%	1	5.486652977	1
BA3013R	2457	BA3013D	Waves1+2	yes	no	yes	no	Male	Male	NA	NA	HispNative	4	NA	KMT2A_re	47	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	3	Standard Chemotherapy|Supportive/Palliative Care|Intrathecal	5	HiDAC|Cytarabine|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|MEC, Lenalidomide	5	Consolidation|Induction|CNS|Re-induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	7	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	9	Dead	228	1	7.490759754	Dead-Disease	NA	70	79	NA	NA	NA	2	NA	NA	NA	NA	NA	NA	M5	NA	NA	46,XY,t(11;19)(q23;p13.1)[20]	NA	NA	NA	NA	CD34+ BLAST POPULATION, 40%, EXPRESSING CD117, CD15 (DIM PARTIAL), CD13 (DIM PARTIAL), CD33 (DIM PARTIAL), CD38, CD4 (DIM PARTIAL), CD11C (DIM PARTIAL), CD64 (DIM PARTIAL), MPO (BRIGHT), AND ABERRANT CD7 (MINOR SUBSET DIM), WITH POSSIBLE CD19	NA	261.2	positive	0.075268817	negative	NA	NA	NA	NA	1	7.490759754	4
BA2405R	2354	BA2405D	Waves1+2	yes	yes	yes	no	Female	Female	NA	NA	White	3	NA	NA	44	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	44	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Ponatinib	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction	Unknown	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Ponatinib	Experimental	-1	Dead	342	1	11.23613963	Dead-Disease	NA	86.1	65	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX[20]	NA	NA	Normal	NA	Large population of atypical CD34 positive myeloblasts (weak CD4+, weak CD33+), representing approximately 78% of the leukocytes suggestive of acute myeloid leukemia	NA	11.38	positive	0.449275362	negative	RUNX1 (p.Q262*; 72.4%)	NA	NA	FLT3-ITD	1	11.23613963	1
BA2735R	2079	BA2735D	Waves1+2	no	no	no	no	Male	Male	NA	NA	White	2	NA	NA	62	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	64	254	Post-Chemotherapy|Post-Transplant|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	24	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	141	Dead	568	1	18.66119097	Dead-Unknown	NA	NA	NA	NA	NA	NA	NA	NA	NA	23	26	2.9	NA	NA	27.9	9.6	45,XY,der(12;16)(q10;p10)[2]/46,XY[18]	NA	NA	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[31/200]	30	NA	5	27.4	positive	5.666666667	positive	NA	NA	NA	CCND3 (P203S; MAF unlisted)|CHEK2 (T367fs*15; MAF unlisted)|DNMT3A (R882H; MAF unlisted)|FLT3-ITD|NPM1 (W288fs*10+; MAF unlisted)	1	18.66119097	4
BA2856R	2376	BA2856D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	3	NA	NA	55	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin)	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	129	Alive	1022	0	33.57700205	Alive	NA	37	20	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[20]	NA	NA	Normal	283	Increased atypical CD117 positive myeloid blasts (weak CD7  positive, HLA-DR negative), representing 18% of the total  leukocytes, consistent with a myeloid neoplasm	NA	16.11	negative	0	positive	NA	NA	NA	NPM1	0	33.57700205	4
BA2377R	2385	BA2377D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	2	NA	MLLT3-KMT2A	35	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	35	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Cyclophosphamide, Thymoglobulin	Allogeneic - Matched Unrelated Donor	-1	Alive	1156	0	37.97946612	Alive	NA	86	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY,der(4)t(4;9;11)(p14;p22;q23),der(9)del(9)(p13p22)t(4;9;11),der(11)t(4;9;11)[19]/46,XY[1].isht(4;9;11)(5'MLL-,3'MLL+;5'MLL-,3'MLL-;5'MLL+,3'MLL-)[1]	NA	NA	nuc ish(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1)[189/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]	NA	CD2(-), CD4(+), CD7(-), CD11b(+), CD13(partial +), CD14(-), CD15(+), CD16(-), CD33(+), CD34(-), CD36(partial +), CD45(+), CD56(variably +), CD64(+), CD117(partial +), CD79a(-), HLA-DR(+), MPO(-), Tdt(-)	NA	NA	positive	2.448275862	positive	NA	ASXL1 (p.D943Qfs*6; 38.5%)	NA	ASXL1 (D943fs*6; MAF 25%)|FLT3-D835 (BMA)|KMT2A (MLL-AF9 fusion)	0	37.97946612	4
BA2499R	2003	BA2499D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	2	NA	NA	71	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	71	0	Post-Chemotherapy|Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	NA	NA	NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	107	Dead	53	1	1.741273101	Dead-Disease	0	N/A	50	1	NA	17	1	13	NA	19	42	3.2	1.83	NA	23.7	7.7	NA	766	92.2	NA	11	NA	7.1	45.6	negative	0	negative	RUNX1 (p.R320*; 46.2%)	NA	NA	NA	1	1.741273101	1
BA2463R	2241	NA	Waves1+2	no	no	no	no	Female	Female	NA	NA	White	2	NA	RUNX1-RUNX1T1	57	TRUE	FALSE	FALSE	FALSE	FALSE	y	Ovarian cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	58	111	Relapse|Post-Chemotherapy	Relapse	Peripheral Blood	y	n	y	y	n	y	2	Standard Chemotherapy|Supportive/Palliative Care	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|Decitabine, Hydroxyurea	4	Consolidation|Induction|Re-induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	5	Supportive/Palliative Care	Decitabine, Hydroxyurea	Supportive/Palliative Care	-1	Dead	138	1	4.533880903	Dead-Unknown	0	N/A	58	0	NA	14	3	19	NA	24	116	3.7	NA	NA	21.4	7.7	46~47,XX,t(1;11)(p34;p15),der(8)del(8)(p11.2p23)t(1;8)(q21;q24.3),add(9)(q34),del(9)(q13q22),add(16)(p13.3),+1~2mar[cp11] /47~48,idem,+13[cp2]/47~48,idem,-13,der(21)t(8;21)(q13;p12),+2~3mar[cp6]/46,XX[1]	NA	NA	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(RUNX1T1x3,RUNX1x2)[69/200]/(RUNX1T1x2,RUNX1x3)[7/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	10	CD2(-), CD4(+), CD7(-), CD11b(partial +), CD13(partial +), CD14(partial +),CD15(variably +), CD16(-), CD33(variably +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56 (variable +), CD64(partial +), CD117(-), HLA-DR(+).	6	11.2	negative	0	negative	NA	NA	NA	NA	1	4.533880903	4
BA3023R	2149	BA3023D	Waves1+2	yes	yes	yes	no	Female	Female	NA	NA	HispNative	4	NA	NA	27	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	27	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	2	HiDAC|SWOG S1203 (7+3 +/- Vorinostat)	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	8	Standard Chemotherapy	HiDAC	Consolidation	137	Alive	791	0	25.98767967	Alive	NA	69	68	NA	NA	NA	1	NA	NA	NA	NA	NA	NA	M2	NA	NA	48,XX,+3,+10[2]/46,XX[18]	NA	NA	NA	NA	CD34, CD38, CD13, CD33, CD11C, CD19, PARTIAL CD4, HLA-DR, PARTIAL CD15, CD117, PARTIAL CD61, AND PARTIAL CD7	NA	5.1	negative	0	positive	NA	NA	NA	NPM1	0	25.98767967	4
BA2095R	2054	NA	Waves1+2	yes	no	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	PML-RARA	69	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	n	y	y	n	y	1	Standard Chemotherapy	1	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	Induction	-1	Alive	33	0	1.084188912	Alive	0	83	77	0	0	16.1	5.3	4.5	1.2	31	51	3.2	1.05	M3	22.7	8.1	45,XX,dic(12;18)(p11.2;p11.2),t(15;17)(q22;q21)[19]/46,XX[1]	1816	92.3	PML/RARA fusion (91%)	33	dim CD2, CD13, CD33, CD34 (variable), CD56, CD58, CD64, CD117, CD123 and cytoplasmic MPO positive; HLA-DR negative	5.7	16.03	negative	0	negative	NA	NA	NA	NA	0	1.084188912	3
BA2901R	2529	BA2901D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	2	NA	NA	68	FALSE	FALSE	FALSE	FALSE	FALSE	y	Melanoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation|Induction|Re-induction|Maintenance	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Maintenance	-1	Alive	1203	0	39.52361396	Alive	0	79	54	NA	NA	10	42	30	NA	8	26	4	NA	NA	20.8	6.8	46,XY	NA	NA	IGH-MYEOV and IGH-CCND1 rearrangement; MAF unlisted	61	CD2(-), CD4(equivocal), CD7(partial +), CD11b (equivocal), CD13(+), CD14(-), CD15(-), CD16(equivocal), CD33(-), CD34(bright +), CD36(-), CD38(dim +), CD45(+), CD56(equivocal), CD64(-), CD117(+), CD123(equivocal), HLA-DR(dim +), MPO(partial +), TdT(-) (Population 1 of 4 (0.02% of total events), consists of small myeloblasts) | CD2(-), CD4(equivocal), CD7(-), CD11b (-), CD13(partial +), CD14(-), CD15(partial +), CD16(-), CD25(-), CD33(variably +), CD34(-), CD36(-), CD38(moderately bright +), CD45(dim +), CD56(-), CD64(-), CD117(+), CD123(+), HLA-DR(partial +), MPO(partial +), TdT(-) (Population 2 of 4 (3.8% of total events), consists of immature myeloid cells) | CD13(partial +), CD14(partial +), CD36(variably +), CD45(variably +), CD56(partial +), HLA-DR(partial +), MPO(partial +) (Population 3 of 4 (61% of total events), consists of monocytes) | CD19(-), CD20(-), CD38(bright +), CD45(-), CD56(+), surface Ig(-), intracellular kappa(+), intracellular lambda(-) (Population 4 of 4 (0.34% of total events), consists of plasma cells)	7.1	41.4	negative	0	positive	NA	NA	NA	DNMT3A (R882C; MAF 50%)|NPM1 (W288fs*10+; MAF 34%)|NRAS (G13D; MAF 44%)	0	39.52361396	4
BA2275R	2199	BA2275D	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	57	FALSE	FALSE	FALSE	FALSE	FALSE	y	Brain Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	57	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	Decitabine	1	Induction	Unknown	Standard Chemotherapy	10	Standard Chemotherapy	Decitabine	Induction	10	Dead	35	1	1.149897331	Dead-Unknown	0	45	NA	0.9	27.8	18.2	12.2	40.9	0	32	19	2	0.83	M2	26.9	9.1	44~48,XY,-5,del(7)(q22),+11,idic(11)(p11.2)x2,-12,der(13)t(1;13)(p13;p12),add(17)(q25),der(18)t(12;18)(q13;q11.2),-22,+2mar[cp14]/44~47,sl,-9,+16[cp3]/46~47,sl,der(1)t(1;3)(q21;q21),der(3)t(1;3)(q21;q21)ins(3)(3;?)(p21;?),-idic(11)(p11.2)[cp4]/46,XY[1]	NA	97.1	EGR1/5p; 88% , consistent with monosomy 5  | D7S486; 96% , consistent with deletion 7q  | BCR; 84% of cells had three signals for BCR (22q11.2)| MLL; 28% of cells had three intact signals for MLL, while another 76% of cells had four intact signals.	77	CD13, CD33, CD34, CD71, CD117, dim CD123 and HLA-DR+	6.7	5.92	negative	0	negative	NA	NA	TP53 (p.R248Q; 95.8%)	TP53 (p.R248Q; MAF 80%)	1	1.149897331	4
BA2387R	2454	BA2387D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	71	FALSE	FALSE	FALSE	FALSE	FALSE	y	Thyroid Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Mismatched Unrelated Donor	-1	Dead	462	1	15.17864476	Dead-Treatment	0	95	88	0	0	6.7	5.1	0	0.1	20	20	2.6	0.62	M5	21.4	7	46,XX,idic(7)(q11.2)[20]	373	93.9	NA	19	CD11b, CD13, CD33, partial CD34,      CD38, CD58, CD64, CD117, CD123, partial HLA-DR and cMPO positive	5.8	78.71	negative	0	negative	NA	NA	NA	BCOR (p.T870fs*46 (2 bp deletion); MAF 50%)|IDH1 (p.R132C; MAF 50%)|MLL (PTD)|PTPN11 (p.S502L; MAF 50% )	1	15.17864476	3
BA2962R	2558	BA2962D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	75	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	IntermediateOrAdverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	75	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|Cytarabine|Fludarabine, TBI|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, TBI	Allogeneic - Mismatched Unrelated Donor	-1	Dead	327	1	10.74332649	Dead-Disease	0	90	NA	0	0	6	2.6	0	0.1	18	49	2.6	0.94	M5	26.8	9.1	46,XY[20]	1173	105.5	Normal	45	dim partial CD11b, dim variable CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, CD123, HLA-DR, partial TdT, dim MPO positive	6.8	98.9	positive	NA	negative	NA	NA	NA	DNMT3A (intron 7 splice site (at invariant AG splice donor); MAF 50% )|DNMT3A (p.P777L; MAF 50%)|FLT3-ITD (MAF 40%)|IDH2 (p.R140Q; MAF 45%)|MLL (PTD; no MAF available)|WT1 (Intron 1 splice site (at invariant AG splice donor); MAF 90% )	1	10.74332649	4
BA2195R	2013	BA2195D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	Black	4	N/A	NA	68	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	CPX-351 (Liposomal Cytarabine + Daunorubicin)	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	-1	Dead	70	1	2.299794661	Dead-Disease	NA	33	37	NA	NA	NA	8	NA	NA	NA	NA	NA	NA	NA	NA	NA	42~45,XX,-18[cp14]/43~45,idem,+2~3mar[cp3]/47,XX,+8[cp2]/45,X,-X[1]	NA	NA	NA	NA	CD34+ BLAST POPULATION, 33%, EXPRESSING PARTIAL CD38, PARTIAL CD4, PARTIAL CD11C, HLA-DR, CD117, PARTIAL CD13, PARTIAL CD33, PARTIAL CD15, AND MPO	NA	29.1	negative	0	negative	RUNX1 (p.S322Nfs*277; 9.7%)	NA	TP53 (p.I195T; 22.2%)|TP53 (p.P151R; 54.8%)	CEBPA (Triple positive)|IDH2	1	2.299794661	1
BA2688R	2289	BA2688D	Waves1+2	yes	yes	yes	no	Female	Female	NA	NA	White	2	NA	NA	53	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute erythroid leukaemia	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute erythroid leukaemia	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin|Fludarabine, Cyclophosphamide, TBI	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, TBI	Allogeneic - Matched Unrelated Donor	-1	Dead	137	1	4.501026694	Dead-Treatment	0	9	4	0	NA	61	10	22	NA	14	40	3.3	0.65	M6	22.1	7.4	46,XX,del(9)(q22q34)[20].	NA	93.4	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	38	CD34 (partial +), CD2(partial dim +), CD13(dim +), CD33(variably to bright +), CD25(-), CD38(+), CD45(moderately +), CD15 (partial +), CD117(+), CD123(dim +), HLA-DR(partial +), MPO(+), TdT(-), other myeloid and lymphoid antigens (-)	5.8	2.1	negative	0	negative	NA	NA	NA	DNMT3A (R882C; MAF 43%)|IDH2 (R140Q; MAF 3%)|WT1 (splice site 1099-6_1104delCTGCAGGATGTG; MAF 28%)	1	4.501026694	1
BA2787R	2447	BA2787D	Waves1+2	no	no	no	no	Male	Male	NA	NA	White	3	NA	NA	58	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	58	100	Post-Chemotherapy	Remission	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin)	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	210	Alive	1250	0	41.06776181	Alive	NA	0.4	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M4	NA	NA	46,XY[20]	NA	NA	Normal	NA	NA	NA	29.18	negative	0	negative	NA	NA	NA	NA	0	41.06776181	4
BA2420R	2106	BA2420D	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	69	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	3	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	63	Dead	470	1	15.44147844	Dead-Disease	0	80	NA	0	0	78.5	15.1	6.4	2.9	21	15	3.1	1.01	M0	23.5	7.5	47,XY,+8[2]/46,XY[18]	NA	101.7	Consistent with karyotype	47	dim CD13, dimCD33, CD34, dim CD38, CD58, dimCD64, CD117, CD123, dim HLA-DR, TdT positive	6.7	2.05	negative	0	negative	RUNX1 (p.H242Afs*14; 24.5%)	NA	NA	MLL (PTD)|RUNX1 (p.H242fs*14; MAF 42% )|RUNX1 (p.N136K; MAF 30%)|U2AF1 (p.S34F; MAF 40%)	1	15.44147844	2
BA2756R	2169	BA2756D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	4	NA	NA	69	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	69	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	4	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine, Midostaurin|FLAG-IDA, Gemtuzumab|MEC, Lenalidomide	3	Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	79	Standard Chemotherapy	MEC, Lenalidomide	Salvage	5	Dead	304	1	9.987679671	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[22]	NA	NA	NA	NA	NA	NA	NA	positive	NA	negative	NA	NA	NA	FLT3-ITD|IDH1	1	9.987679671	3
BA2122R	2026	BA2122D	Waves1+2	no	no	no	no	Female	Female	NA	NA	White	4	NA	NA	75	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	77	716	Post-Chemotherapy	Remission	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	NA	NA	NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	1131	Dead	1134	1	37.25667351	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M2	NA	NA	46,XX[8]	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	RUNX1 (p.R162K; 95.1%)	ASXL1 (p.Q512*; 56.3%)|ASXL1 (p.G645Vfs*58; 9.1%)	NA	NA	1	37.25667351	4
BA2053R	2370	BA2053D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	2	NA	CBFB-MYH11	31	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	31	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	5	Alive	595	0	19.54825462	Alive	NA	80	56	2	NA	17	21	3	NA	63	39	3.9	0.91	NA	28.8	10.2	46,XY,inv(16)(p13.1q22)[7]/46,idem,add(17)(p11.2)[13]	434	NA	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198],(PML,RARA)x2[198],(CBFBx2)(5’CBFB sep 3’CBFBx1)[164/200]	34	CD2(partial +), CD4(partial +), CD5(partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CDCD33(variably +), CD34(variably +), CD36(few +), CD38(variably +), CD45(moderate to dim +), CD56(-), CD64(partial +),CD117(+), CD123(variably +), HLA-DR(partial +), MPO(+), TdT(few +).	8.2	41.35	negative	0	negative	NA	NA	NA	NA	0	19.54825462	2
BA2080R	2135	BA2080D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	2	mono	NA	77	FALSE	FALSE	FALSE	FALSE	FALSE	y	Lung Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	78	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	5	7+3 (Cytarabine, Idarubicin)|Cytarabine|Bortezomib|Decitabine|Fludarabine, Cytarabine	5	Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Alive	344	0	11.30184805	Alive	NA	73	84	NA	NA	10	NA	6	NA	9	13	4.2	0.82	NA	NA	NA	46,XY[20]	165	NA	NA	NA	CD2(-), CD4(- to partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(few +), CD16(-), CD19(few +), CD33(variably +), CD34(variably +), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(+), HLA-DR (+), MPO(partial +), TdT(partial +).	6.5	13.8	negative	0	negative	NA	NA	NA	ATM (S1993fs*23; MAF 44%)|CEBPA (L81fs*72; MAF 92%)|MUTYH (G382D; MAF 49%)|STAG2 (R1205*; MAF 92%)|TET2 (C1273S; MAF 46%)|TET2 (M823fs*1; MAF 47%)	0	11.30184805	2
BA2081R	2358	BA2081D	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	1	NA	NA	64	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	64	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	6	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|R-CEOP (Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine)|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |R-CHOP (Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine)	4	Consolidation|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	R-CEOP (Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine)	Induction	3	Alive	2485	0	81.64271047	Alive	0	90	30	0	0	37.5	27.7	0	2.6	37	31	1.8	0.52	M4	23.5	7.7	46,XX,del(17)(q25)[3]/46,sl,del(3)(q12q21)[cp17]	452	94.4	NA	56	dim CD4, partial variable CD7, CD13, CD33, partial CD34, CD38, partial CD58, CD117, CD123, HLA-DR, TDT and partial MPO positive.	6.2	6.44	negative	0	negative	RUNX1 (p.R162K; 82.0%)	NA	NA	KRAS (p.G12V; MAF 30%)|NRAS (p.G12D; MAF 7%)|RUNX1 (p.R162K; MAF 85% )	0	81.64271047	4
BA2354R	2050	BA2354D	Waves1+2	yes	yes	yes	yes	Male	Male	Asian	NON-HISPANIC	Asian	1	NA	RUNX1-RUNX1T1	37	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	37	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Busulfan, Cyclophosphamide	4	Salvage|Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	0	Alive	1348	0	44.28747433	Alive	0.8	NA	NA	0	7.5	17.5	0	37.5	0.4	22	13	3	0.89	M2	15.8	5.5	45,X,-Y,t(8;21)(q22;q22)[20]	411	100.6	RUNX1T1/RUNX1:   94% of cells had the dual fusion signal pattern consistent with RUNX1T1/RUNX1 fusion and t(8;21), as seen on metaphase analysis.	42	dim CD7, CD13, dim CD33, CD34, CD38, CD56, dim partial      CD64, CD117, dim CD123, HLA-DR, MPO, dim TdT positive	7	8.15	negative	0	negative	NA	NA	NA	EZH2 (p.F445fs*3; MAF 30% )|KIT (p.N822K (exon 17); MAF 5% )|KIT (p.Y418_D419insFL (exon 8); MAF 29%)|TET2 (p.G1160E; MAF 49% )	0	44.28747433	2
BA3273R	2729	BA3273D	Waves3+4	yes	yes	yes	yes	Male	Male	NA	NA	NA	2	NA	NA	NA	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	NA	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	Cyclophoshamide, TBI, ATG|CALGB 10403	2	Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Cyclophoshamide, TBI, ATG	Allogeneic - Matched Unrelated Donor	-1	Alive	560	0	18.39835729	Alive	NA	96	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5	NA	NA	47,XY,der(7)t(1;7)(q21;q36),+14[4]/46,XY[16]	NA	NA	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2, D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2 [198],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	NA	CD2(-), CD4(+), CD7(-), CD11b(few dim +), CD13(-), CD14(-), CD15(partial +), CD16(-), CD19(partial +), CD20(-), CD22(partial +), CD25(partial +), CD33(partial +), CD34(+), CD36(-), CD38(+), CD45(partial +) | CD64(-), CD79a(partial +), CD117 (-), HLA-DR(partial +), CD123(variably +), MPO(+), TdT(+)	NA	NA	negative	0	negative	NA	NA	NA	IKZF1 (Foundation; S63fs*2)	0	18.39835729	4
BA2893R	2455	BA2893D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	3	NA	NA	59	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	59	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	Azacitidine, Sorafenib|Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine, Sorafenib	Hypomethylating/Low Dose Cytarabine	-1	Dead	254	1	8.344969199	Dead-Disease	NA	51.5	72	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX[20]	NA	NA	Normal	NA	Large population of CD117 positive myeloblasts (predominantly CD34 negative, HLA-DR negative), representing approximately 71% of the leukocytes consistent with acute myeloid leukemia.	NA	89.17	positive	1	positive	NA	NA	NA	NPM1	1	8.344969199	3
BA2044R	2267	BA2044D	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	57	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	57	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, TBI	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	371	Bone Marrow Transplant	Fludarabine, Melphalan, TBI	Allogeneic - Sibling	-1	Dead	245	1	8.049281314	Dead-Treatment	0.3	50	NA	0	0.6	32.6	14.7	51.8	0	82	52	3.4	0.78	M2	29.6	10.1	46,XY,hsr(6)(p21p23)[17]/46,XY[5]	160	93.7	Normal	91	CD13, CD33, CD34, CD38, CD58, CD117, CD123, and HLA-DR+	7.5	3.53	negative	0	negative	RUNX1 (p.Y377*; 11.5%)|RUNX1 (p.I114Afs*25; 33.0%)	NA	NA	RUNX1 (p.I114fs*25; MAF ~50% )|U2AF1 (p.S34F; MAF 43%)	1	8.049281314	4
BA2489R	2480	BA2489D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	Black	2	NA	NA	63	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	3	AG-221|Azacitidine|Fludarabine, Melphalan, TBI, ATG	3	Hypomethylating/Low Dose Cytarabine|Experimental|Allogeneic - Child	NA	NA	NA	Bone Marrow Transplant	Fludarabine, Melphalan, TBI, ATG	Allogeneic - Child	-1	Alive	1156	0	37.97946612	Alive	0	20	0	0	NA	76	0	24	NA	18	16	4.1	1.24	NA	24.9	8.3	46,XY[20]	148	100.4	NA	72	NA	7.4	1.8	negative	0	negative	NA	ASXL1 (p.G646Wfs*12; 31.2%)	NA	ASXL1 (G646fs*12; MAF 30%)|CIITA (Q320fs*41; MAF 51%)|CUX1 (P442fs*16; MAF 38%)|IDH2 (R140Q; MAF 46%)|SRSF2 (P95H; MAF 40%)|STAG2 (R614*; MAF 90%)	0	37.97946612	1
BA2309R	2335	BA2309D	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	7	NA	NA	64	FALSE	FALSE	FALSE	TRUE	FALSE	n	NA	y	n	n	n	n	n	y	n	MYELOPROLIFERATIVE NEOPLASMS	Essential thrombocythaemia	NonAML	MYELOPROLIFERATIVE NEOPLASMS	Essential thrombocythaemia	77	0	Post-Chemotherapy|Residual Disease	NA	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	Ruxolitinib|Imatinib|Hydroxyurea	2	Induction|Re-induction	NA	Standard Chemotherapy	4626	Standard Chemotherapy	Ruxolitinib	Re-induction	-1	Alive	5397	0	177.3141684	Alive	NA	15	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	47,XY,+der(1;9)(q10;p10)[17]/94,idemx2[2]/46,XY[1]	NA	NA	Fluorescent in situ hybridization (FISH) was performed with a 9p/CEP 9 probe set. Both probes hybridized to the derivative chromosome. 90/100 (90%) interphase cells scored had a 3 red/ 3 green signal pattern, reflecting the extra derivative.	NA	dimCD7, CD13, dim CD33, CD34, CD71, and CD117 positive	NA	NA	negative	NA	negative	NA	NA	NA	NA	0	177.3141684	1
BA2720R	2394	BA2720D	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	23	FALSE	FALSE	FALSE	FALSE	FALSE	y	Mediastinum mass	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	24	163	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Trametinib|HAEP (Cytarabine, Etoposide, Cisplatin)	3	Consolidation|Induction|Experimental	Complete Response	Standard Chemotherapy	8	Targeted Therapy - Kinase Inhibitor(s)	Trametinib	Experimental	197	Dead	318	1	10.4476386	Dead-Disease	0	5	10	0	2.9	36.2	1.5	47.8	NA	30	146	3.4	0.82	M6b	25.5	7.9	48,XY,add(6)(p22),der(7)t(7;19)(p11.2;p12),del(9)(p13p22),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp2]/46~48,sl,add(17)(p1?3),add(22)(q13)[cp9]/46~48,sl,add(21)(p11.2)[cp6]/47~48,sl,add(1)(p36.1)[cp2]/48,sl,t(2;17)(p21;p11.2)[1]	NA	98.5	Low-level tetraploidy or near-tetraploidy	48	A CD34 positive blasts population comprises approximately 4% of cellular gated events. Approximately 3% of cells are lymphocytes composed of 28% B cells, 45% T cells and 27% NK cells. | T cells are present in a CD4:CD8 ratio of about 1.1:1 and do not demonstrate aberrant antigen expression. A monoclonal B cell population is not identified.	6.1	11.28	negative	0	negative	NA	NA	TP53 (p.G245S; 89.1%)	NRAS (p.G12C; MAF 97%)|TP53 (p.G245S; MAF 96%)	1	10.4476386	1
BA2908R	2516	BA2908D	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Decitabine	4	Consolidation|Induction|Maintenance|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Supportive/Palliative Care	58	Alive	666	0	21.88090349	Alive	0	90	60	0	0	31.2	0.9	0	0	19	25	3.3	0.78	M1	21.4	7.4	46,XY,del(13)(q12q2?1)[14]	509	103.4	all 100 interphase cells scored (100%) were missing one set of 13S319 and RB1 probe signals, consistent with deleted 13q and the metaphase karyotype	17	CD13, partial/dim CD33, CD38, CD58, CD117 and MPO	6.6	5.39	negative	0	negative	NA	NA	NA	DNMT3A (p.R882H; MAF 44% )|IDH2 (p.R172K; MAF 43%)	0	21.88090349	2
BA2054R	2058	BA2054D	Waves1+2	yes	yes	yes	no	Female	Female	NA	NA	White	3	NA	NA	49	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	49	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	-1	Alive	1168	0	38.37371663	Alive	NA	54	3	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5	NA	NA	46,XX,del(17)(p11.2)[15]/46,XX[5]	NA	NA	consistent with karyotype (68% del 17p13)	NA	Most of the atypical cells (data not shown) are myeloid blasts that express CD117, partial CD7 (about 30% positive), CD13, CD33, HLA-DR, weak CD4, and partial CD15 (about 50% positive), but do not express CD34, CD14(MO2), or CD64. (The monocytic cells (percentages shown) are atypical in that they express weaker than normal CD13, with brighter than normal and more uniform than normal CD15, with phenotypically normal expression of bright CD33, bright CD64, CD4, and HLA-DR, and include approximately 80% that are phenotypically consistent with promonocytes/monoblasts, based on the lack of CD14(MO2).)	NA	NA	negative	0	positive	NA	NA	NA	NA	0	38.37371663	4
BA2872R	2415	BA2872D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	65	FALSE	FALSE	FALSE	FALSE	FALSE	y	Pancreatic adenocarcinoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	65	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	3+7 (Cytarabine, Daunorubicin)|Decitabine|5+2 (Ara-C, Daunorubicin)	3	Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Salvage	9	Dead	158	1	5.190965092	Dead-Disease	0	18	12	0.9	32	7.4	35.2	18.5	4.8	44	165	2.9	1.65	M2	20.1	6.7	46,XY,i(17)(q10)[20]	3923	81	TP53/CEP17: 85% of cells were missing a signal for TP53, consistent with deletion due to the i(17) seen on metaphase analysis.  PML/RARA: 69% of cells had three signals for RARA (17q21), consistent with three copies of 17q due to the i(17) seen on metaphase analysis.	40	CD13, CD33, CD34, CD117, and HLA-DR positive	5.7	161.89	negative	0	negative	NA	NA	NA	ASXL1 (p.R693fs*10; MAF 49% )|CREBBP (p.S893L; MAF 52% )|NRAS (p.G12D; MAF 46% )	1	5.190965092	4
BA2526R	2308	NA	Waves1+2	yes	no	yes	no	Female	Female	NA	NA	White	4	NA	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	55	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	n	n	y	n	n	2	Standard Chemotherapy|Supportive/Palliative Care	5	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Decitabine|MEC, Lenalidomide	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Supportive/Palliative Care	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Dead	1938	1	63.67145791	Dead-Disease	NA	72	81	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	50,XX,del(1)(q32),+8,+9,t(15;16)(q15~21;q12~22),+19,+21[cp20]	NA	NA	NA	NA	ABNORMAL CD34+ BLAST POPULATION, 72%, EXPRESSING DIM PARTIAL CD4, DIM PARTIAL CD7, DIM PARTIAL CD8, CD33, CD38, PARTIAL CD64, CD117, PARTIAL HLA-DR, AND DIM PARTIAL TdT	NA	3.8	negative	0	negative	NA	NA	NA	NA	1	63.67145791	3
BA2041R	2121	BA2041D	Waves1+2	yes	yes	yes	no	Female	Female	White	NA	White	2	NA	NA	32	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	32	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	-1	Alive	1101	0	36.1724846	Alive	0	24	2	2	NA	54	0	44	NA	10	22	4.4	0.49	NA	25.9	9	47,XX,+8[13]/46,XX[7]	125	97.1	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[197],(D8Z2x3,D20S108x2)[101/200], (RUNX1T1x3,RUNX1x2)[91/200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[188], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	67	CD2(-), CD4(dim +), CD7(partial +), CD11b(-), CD13(variably +), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(-), CD36(-), CD38(+), CD41(-), CD45(+), CD56(-), CD64(-), CD71(+), CD117(+), CD123(+), GLy-A(-), HLA-DR(partial + and variable), TdT(-), MPO(+).	7.1	1.4	negative	0	negative	NA	NA	NA	PTPN11 (G60A; MAF 18%)	0	36.1724846	3
BA2464R	2575	BA2464D	Waves1+2	yes	yes	yes	no	Female	Female	White	HISPANIC	HispNative	1	NA	PML-RARA	40	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	40	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	33	Standard Chemotherapy	ATRA, Arsenic Trioxide	Consolidation	193	Alive	2505	0	82.29979466	Alive	0	90	20	0	0.8	75.9	0	2.6	2.6	24	15	3.2	0.68	M3	20.3	7.1	46,XX,t(15;17)(q22;q21)[17]/46,XX[3]	259	85.3	58% PML-RARA  (c/w karyotype)	53	CD13, CD33, CD58, CD64, CD117, CD123 and MPO positive	7.3	1.9	negative	0	negative	NA	NA	NA	IKZF1 (p.E80X; MAF 37%)|WT1 (p.E340X; MAF 32%)	0	82.29979466	3
BA2902R	2144	BA2902D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	Asian	4	NA	NA	83	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	83	1	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	Azacitidine|Decitabine, Midostaurin	2	Hypomethylating/Low Dose Cytarabine|Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine, Midostaurin	Induction	-1	Dead	47	1	1.544147844	Dead-Disease	NA	78	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[13]	NA	NA	NA	NA	ABNORMAL CD34-NEGATIVE BLAST POPULATION, 65%, EXPRESSING MYELOPEROXIDASE, CD117, CD13, CD33, AND CD56, AND SHOWING PARTIAL EXPRESSION OF CD38, CD64(DIM), CD11c(DIM), CD4(DIM) AND HLA-DR	NA	NA	positive	1.083333333	positive	NA	NA	NA	FLT3-ITD|NPM1	1	1.544147844	3
BA2541R	2484	BA2541D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	KMT2A_re	39	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	39	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Intrathecal	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Methotrexate	3	Induction|CNS|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	4	Dead	216	1	7.09650924	Dead-Disease	0	>90	NA	0	0	28.3	17.7	3.5	0	19	14	3	0.97	M5	31.1	10.7	46,XY,t(6;11)(q27;q23)[20]	NA	98.4	MLL: 80% of cells had a split signal pattern consistent with the disruption of MLL due to the t(6;11).	31	dim CD4, partial CD11b, CD13, CD33, CD34, partial      CD38, partial CD64, CD117, CD123, HLA-DR and dim MPO positive.	6.2	21.12	negative	0	negative	NA	NA	NA	MLL (PTD)	1	7.09650924	4
BA2143R	2127	BA2143D	Waves1+2	no	no	no	no	Female	Female	NA	NA	White	2	NA	PML-RARA	51	FALSE	FALSE	FALSE	TRUE	FALSE	y	Breast Cancer	y	n	y	n	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Myelodysplastic syndrome, unclassifiable	NonAML	MYELODYSPLASTIC SYNDROMES	Myelodysplastic syndrome, unclassifiable	51	0	Unknown	NA	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine	NA	NA	NA	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	4	Alive	507	0	16.65708419	Alive	0	9	11	0.8	NA	28.2	13.7	43.6	NA	19	28	2.6	0.7	NA	27.2	9.1	44,XX,der(5)t(5;9)(p15;q22)del(5)(q11.2q15),-7,-9,-18,del(20)(q11.2q13.1),+mar[cp8]/43~44,XX,-der(5),del(7)(q11.2q32),add(11)(p15),del(12)(p11.2p13),der(15)t(15;17)(p12;q11.2),-16,-18,+mar[cp9]/43,XX,del(5)(q13q33),del(7),add(11),del(12),der(15),-16,-18,+mar[cp3].ishder(15)(PML+,RARA+)[1].	517	92.4	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[108/200]	74	CD2 (-), CD4(- to dim +), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(-), CD16(-), CD25(dim +), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(moderate to slightly dim +), CD56(-), CD64(-), CD117(+), CD123(dim +), HLA-DR(variably+), MPO(-), TdT(-)	6.2	NA	negative	NA	negative	NA	NA	NA	NA	0	16.65708419	1
BA2094R	2231	NA	Waves1+2	no	no	no	no	Male	Male	NA	NA	White	3	NA	NA	75	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	75	265	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	n	n	y	n	n	1	Standard Chemotherapy	5	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|MiDAC|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	21	Standard Chemotherapy	CLAG (Cladribine, Cytarabine, Filgrastim)	Consolidation	-1	Dead	335	1	11.00616016	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M4	NA	NA	46,XY[20]	NA	NA	Normal	NA	NA	NA	9.7	negative	0	negative	NA	NA	NA	NA	1	11.00616016	4
BA2769R	2482	BA2769D	Waves1+2	yes	yes	yes	no	Female	Female	NA	NA	White	4	NA	NA	72	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	72	0	Residual Disease	Residual	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine, Midostaurin	3	Induction|Maintenance|Re-induction	Complete Response	Standard Chemotherapy	186	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Re-induction	62	Alive	417	0	13.70020534	Alive	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX[20]	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	RUNX1 (p.R320*; 24.2%)|RUNX1 (p.R207W; 20.0%)	NA	NA	NA	0	13.70020534	4
BA2843R	2178	BA2843D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	4	NA	NA	84	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	84	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine, Midostaurin	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine, Midostaurin	Induction	-1	Dead	67	1	2.201232033	Dead-Disease	NA	85	88	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M0	NA	NA	46,XY[20]	NA	NA	NA	NA	CD34, CD38, CD117, CD13, CD4, HLA-DR, AND TDT	NA	30	positive	0.851851852	negative	NA	NA	NA	FLT3-ITD	1	2.201232033	2
BA2592R	2070	BA2592D	Waves1+2	no	no	no	no	Female	Female	NA	NA	White	2	NA	NA	31	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	38	1496	Post-Chemotherapy|Post-Transplant|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	4	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	9	Fludarabine, Melphalan|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Rituximab|Busulfan, Cyclophosphamide	7	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Experimental|Re-induction	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Dasatinib	Experimental	24	Dead	2661	1	87.42505133	Dead-Unknown	NA	7	1	NA	NA	NA	NA	NA	NA	15	21	4.2	NA	NA	31.9	11	46,XX[20]	NA	NA	nuc ish(DXZ1x2)[200]	45	NA	6.2	2.2	negative	0	negative	NA	NA	NA	BCOR (S259fs*10; MAF 15%)|CCND2 (P281R; MAF 19%)|FLT3-D835 (D835E; MAF 13%)|GATA2 (N297S; MAF 18%)|IKZF1 (Q44*; MAF 14%)|MLL2 (Y2907*; MAF 7%)|PTPN11 (E76V; MAF 17%)|PTPN11 (V45L; MAF 13%)|SETBP1 (H1100R; MAF 51%)|SF3B1 (K700E; MAF 18%)	1	87.42505133	1
BA2497R	2517	BA2497D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	KMT2A_re	71	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	MiDAC	Consolidation	5	Dead	162	1	5.32238193	Dead-Disease	0	80	80	0	2	21	4	1	0.8	29	282	3.2	1.61	M5	31.8	10	47,XY,t(1;11)(p32;q23),+8[cp20]	7759	102.3	CEP 8:  56% had three signals, consistent with the trisomy 8 in the metaphase karyotype|RUNX1T1: 70% had three signals, consistent with the trisomy 8 in the metaphase karyotype|MLL: 72% reflected MLL rearrangement and its involvement in the 1;11 translocation.	59	CD11b, CD13, partial CD14, CD15, CD33,CD38, CD45, CD56, CD58, CD64, HLA-DR and MPO-positive	6.1	71.19	negative	0	negative	NA	NA	NA	CREBBP (p.Q1765*; MAF 4% )|KRAS (p.G13D; MAF 27%)	1	5.32238193	4
BA2718R	2119	BA2718D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	bi	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Sibling	-1	Alive	2423	0	79.60574949	Alive	0	90	90.5	0	0	8.2	2.2	0.9	0.8	22	43	3.1	1.21	M1	17.3	5.2	46,XY[20]	1873	96.1	Normal	34	CD7, CD13, CD33, CD34, CD117, HLA-DR, cMPO (+)	6.9	427.46	negative	0	negative	NA	NA	NA	CEBPA (p.A30fs*130; MAF 40%)|CEBPA (p.N307_V308ins; MAF 50%)	0	79.60574949	2
BA2575R	2043	BA2575D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	CBFB-MYH11	36	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	36	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	Dead	15	1	0.492813142	Dead-Treatment	0	74	82	1.7	1.7	6.7	82.3	3.4	0	45	36	2.7	0.68	M4	20.4	7.1	46,XX,inv(16)(p13.1q22)[20]	NA	87.6	CBFB; 76/100 cells (76%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement.	12	Immunophenotyping done on the peripheral blood on 12/1/2014      identified a myeloid blast population with the following immunophenotype:      CD13, partial CD15, CD33, CD34, CD38, CD58, variable CD64, CD117, HLA-DR      and cMPO. And, it identified a promonocyte/monoblast population expressing:	5.8	117.53	negative	0	negative	NA	NA	NA	KRAS (p.G12D; MAF 9% )|NRAS (p.G12D; MAF 10%)	1	0.492813142	4
BA2096R	2121	NA	Waves1+2	no	no	no	no	Female	Female	White	NA	White	2	NA	NA	32	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	32	46	Post-Chemotherapy	Remission	Bone Marrow Aspirate	y	n	y	y	n	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	-1	Alive	1101	0	36.1724846	Alive	0	2	0	0	NA	NA	44	56	NA	NA	NA	NA	NA	NA	23.2	7.7	47,XX,+8[3]/46,XX[17]	130	89.9	nuc ish(D8Z2x3,D20S108x2)[27/200]	113	CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(+ to bright +), CD34(-), CD38(+), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR(dim +).	NA	0.9	negative	0	negative	NA	NA	NA	NA	0	36.1724846	1
BA2593R	2461	NA	Waves1+2	yes	no	yes	yes	Male	Male	NA	NA	White	3	NA	NA	53	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	y	n	y	y	n	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	Alive	21	0	0.689938398	Alive	NA	66	56	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M4	NA	NA	46,XY[20]	NA	NA	Normal	123	large population of atypical CD117 positive myeloblasts (partial CD34+, weak CD4+, weak partial CD7+, partial CD64+), representing approximately 57% of the leukocytes and increased   promonocytes/monoblasts representing approximately 13% of the total leukocytes	NA	180	positive	1.083333333	negative	NA	NA	NA	FLT3-ITD	0	0.689938398	4
BA2791R	2573	BA2791D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	HispNative	2	NA	PML-RARA	26	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	26	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	ATRA, Arsenic Trioxide	Consolidation	5	Alive	211	0	6.932238193	Alive	NA	81	37	3	NA	33	1	15	NA	47	44	4.4	0.8	M3	18.6	6.3	46,XY,t(15;17)(q24;q21.1)[10]/46,XY[10]	484	NA	nuc ish(PML,RARA)x3(PML con RARAx2)[173/200]	105	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD25(-), CD33(bright +), CD34(-/small subset +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(equivocal/appears partial dim +), CD117(+), CD123(-), HLA-DR(-), MPO(appears partial +), TdT(few +).	6.7	4.95	negative	0	negative	NA	NA	NA	NA	0	6.932238193	3
BA2620R	2150	BA2620D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	0	Alive	2426	0	79.70431211	Alive	0.8	NA	30	0	12.5	24.2	28.3	18.4	0	23	29	3	0.78	NA	22.4	7.4	NA	561	107.2	NA	60	CD7, minor subset CD11b, CD13, minor subset CD14,      dim CD33, CD34, CD38, CD58, minor subset CD64, CD117, CD123, HLA-DR, subset      myeloperoxidase positive	6.6	31.66	positive	NA	negative	NA	ASXL1 (p.R549Pfs*2; 42.0%)	NA	FLT3-ITD (MAF 45%)	0	79.70431211	4
BA2629R	2486	BA2629D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	44	Dead	104	1	3.416837782	Dead-Treatment	0	80	NA	0	0	45.5	0.8	0	0.3	14	18	2.4	0.73	M0	21.3	6.9	46,XY,t(1;4)(q21;p14)[20]	178	103.4	Normal	57	partial CD7, partial CD13, CD34, partial CD38,      partial CD117, dim CD123, HLA-DR and TDT positive	7	13.68	negative	0	negative	RUNX1 (p.R250Lfs*13; 50.0%)	NA	NA	BCOR (p.S571*; MAF 90% )|MLL (PTD)|ZRSR2 (p.C181F; MAF 88%)	1	3.416837782	2
BA2870R	2364	BA2870D	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	1	NA	NA	77	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	77	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	Azacitidine|Decitabine	1	Hypomethylating/Low Dose Cytarabine	NA	NA	NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	6	Dead	16	1	0.525667351	Dead-Disease	0	95	9	0	0.9	53	0	28.7	0.8	10	16	4	1.02	M5	25.8	8.6	47,XX,+1,add(1)(p22)[15]/47,XX,+1,i(1)(q10)[5]	601	97	1p36/1q25: 81% of cells had three signals for 1q25 and two for 1p36, consistent with the larger clone above (ie. the clone with add(1)(p22). Another 13% of cells had four signals for 1q25 and two signals for 1p36, consistent with the smaller clone above (ie. the clone with the i(1)(q10)).	8	CD4, CD11b, CD15, CD33, CD38, CD58, CD64, CD123 and partial HLA-DR positive	8.2	3.65	negative	0	positive	NA	NA	NA	FLT3-V491L (p.V491L; MAF 9%)|NPM1 (p.W288fs*12; MAF ~50% )|PTPN11 (p.S502L; MAF 44%)	1	0.525667351	4
BA2423R	2151	BA2423D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	4	NA	NA	57	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	58	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Binimetinib (MEK162)	3	Consolidation|Induction|Experimental	Refractory	Standard Chemotherapy	-1	Targeted Therapy - Other	Binimetinib (MEK162)	Experimental	-1	Dead	111	1	3.646817248	Dead-Disease	NA	70	8	NA	NA	NA	10	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[14]	NA	NA	NA	NA	NA	NA	7.1	negative	0	negative	NA	NA	NA	NA	1	3.646817248	4
BA2682R	2103	BA2682D	Waves1+2	yes	yes	yes	no	Female	Female	NA	NA	White	4	NA	NA	75	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	75	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	1	Decitabine, Midostaurin	1	Induction	Refractory	Standard Chemotherapy	206	Standard Chemotherapy	Decitabine, Midostaurin	Induction	206	Dead	320	1	10.51334702	Dead-Unknown	NA	90	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M4	NA	NA	46,XX,t(5;16)(q31;p13)[3]/46,XX[14]	NA	NA	NA	NA	Partial CD34, cd38, cd117, cd15, cd33, partial cd13, partial cd64, cd11c, dim partial cd4, hla-dr and mpo	NA	NA	negative	0	negative	NA	NA	NA	FLT3-ITD	1	10.51334702	4
BA2276R	2294	BA2276D	Waves1+2	yes	yes	yes	no	Male	Male	Unknown	NON-HISPANIC	White	2	NA	NA	80	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	80	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	Decitabine, ABT-199|Hydroxyurea	2	Unknown|Supportive/Palliative Care	NA	NA	NA	Standard Chemotherapy	Decitabine, ABT-199	Unknown	-1	Dead	364	1	11.95893224	Dead-Disease	0	21	47	0	NA	5	10	41	NA	25	52	4.1	1.26	NA	35	11.1	46,XY[20]	639	90.4	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	110	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(bright +), CD14(-), CD15(few +), CD16 (-), CD33(variably +), CD34(+), CD36(-), CD38(partial + with an unusual pattern of expression vs. CD34), CD45(moderate to slightly dim +), CD56(-), CD64(-), CD117(+), HLA-DR(dim +). (21% population of medium-sized to large cells)	7.5	64.6	negative	0	negative	NA	NA	NA	NA	1	11.95893224	1
BA2348R	2032	BA2348D	Waves1+2	no	no	no	no	Female	Female	NA	NA	White	5	NA	NA	43	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	44	0	Post-Chemotherapy	Remission	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Re-induction	Refractory	Standard Chemotherapy	12	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	Alive	1105	0	36.30390144	Alive	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX,add(3)(q21)[12]/52,sl,+6,+8,+10,+13,+20,+21[8]	NA	NA	Positive for an EVI1 rearrangement: < 0.9% |ABNORMAL - Low level gain of chromosome 8 and 20q12 sequences, trisomy:  < 0.3%)	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	NA	0	36.30390144	4
BA2709R	2346	BA2709D	Waves1+2	yes	yes	yes	yes	Female	Female	Unknown	NA	White	2	NA	CBFB-MYH11	30	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	30	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	40	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	-1	Alive	1024	0	33.64271047	Alive	0	36	22	0	NA	12	44	5	NA	61	44	4.2	0.59	NA	31.8	11	46,XX,inv(16)(p13q22)[20]	441	NA	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2 [199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(RUNX1T1,RUNX1)x2[200],(PML,RARA)x2[200], (5'CBFBx2,3'CBFBx1)(5’CBFB sep 3'CBFBx1)[195/200],(ABL1,BCR)x2[200]	33	CD34, CD13, partialCD15, CD38, CD45, CD117, CD123, HLA-DR, dimMPO (15% population of variably-sized blasts)	7	55	negative	0	negative	NA	NA	NA	NA	0	33.64271047	2
BA2789R	2141	BA2789D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	66	FALSE	FALSE	FALSE	FALSE	FALSE	y	Breast Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	2	Dead	1715	1	56.3449692	Dead-Other	0	95	90.2	0	2.5	4.9	0.8	1.6	0.6	19	23	3	0.5	M1	18.9	6.1	NA	501	100.5	Normal	10	CD13, CD33, dim CD71, CD117, CD123, and MPO	6.4	66.67	negative	0	positive	NA	NA	NA	IDH2 (p.R140Q; MAF 46%)|NPM1 (p.W288fs*9; MAF 42%)	1	56.3449692	3
BA2694R	2552	BA2694D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	5	NA	NA	76	FALSE	FALSE	TRUE	FALSE	FALSE	y	Basal Cell Carcinoma	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	76	0	Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	2	AG-221|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Experimental	NA	NA	NA	Targeted Therapy - Other	AG-221	Experimental	-1	Dead	680	1	22.34086242	Dead-Disease	NA	70	55	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[20]	NA	NA	Normal	46	positive for CD13, CD34, CD38, CD117, and HLA-DR; negative for MPO, and B-cell and T-cell markers	NA	4.5	negative	0	negative	RUNX1 (p.E422Afs*173; 58.1%)	ASXL1 (p.E657*; 50.0%)	NA	NA	1	22.34086242	4
BA2538R	2283	BA2538D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	2	NA	NA	81	FALSE	FALSE	FALSE	FALSE	FALSE	y	Colon Cancer	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	81	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	2	Supportive/Palliative Care|Targeted Therapy - Other	2	AG-221|Hydroxyurea	2	Experimental|Supportive/Palliative Care	NA	NA	NA	Targeted Therapy - Other	AG-221	Experimental	14	Dead	72	1	2.36550308	Dead-Disease	0	NA	12	0	NA	69	5	12	NA	30	41	3.3	0.76	NA	30.3	10.5	46,XY[20]	227	85.6	nuc ish(RUNX1T1,RUNX1)x2[199],(ABL1,BCR)x2[200],(CCND1,IGH)x2[199]	117	NA	8.8	33.1	negative	0	negative	RUNX1 (p.Q213Rfs*24; 85.5%)	ASXL1 (p.G646Wfs*12; 25.0%)	NA	ASXL1 (Foundation, G646fs*12; MAF 33%)|FLT3 (Foundation, E596_Y597INSYEYDLPYDPRS; MAF 27%)|IDH2 (Foundation, R140Q; MAF 45%)|RUNX1 (Foundation, Q213fs24; MAF 82%)|SRSF2 (FOUNDATION, P95R; MAF 48%)	1	2.36550308	2
BA2583R	2175	BA2583D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	5	NA	NA	80	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	n	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	80	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Targeted Therapy - Other	1	AG-221	1	Experimental	NA	NA	NA	Targeted Therapy - Other	AG-221	Experimental	-1	Dead	34	1	1.117043121	Dead-Disease	NA	90	48	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY,del(20)(q11.2q13.1)[12]/45,sl,-7[3]/45,XY,-7[5]/46,XY[2]	NA	NA	Tetrasomy 5p/q; Monosomy 7; Loss 20q12 (15.5%); Tetrasomy 8cen and 20q12 (7	65	positive for CD13, dim CD33, CD34, CD38, dim CD45, CD117, HLA-DR and TdT	NA	6.6	negative	0	negative	RUNX1 (p.R162G; 80.6%)	NA	NA	IDH1 (C.G395A; p.R132H; MAF unknown)	1	1.117043121	1
BA2415R	2200	BA2415D	Waves1+2	no	no	no	no	Male	Male	NA	NA	White	3	NA	NA	48	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	49	152	Post-Chemotherapy	Remission	Bone Marrow Aspirate	y	y	n	y	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	6	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|FLAG-IDA, Gemtuzumab|Cytarabine, Methotrexate	5	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|CNS|Re-induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)	Allogeneic - Mismatched Unrelated Donor	-1	Dead	443	1	14.55441478	Dead-Disease	NA	1.6	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M4	NA	NA	46,XY[20]	NA	NA	Normal	NA	Relative increase of phenotypically normal, slightly left shifted myeloid cells without flow cytometric evidence of monoclonality, acute leukemia, plasma cell dyscrasia, or   lymphoproliferative disorder.	NA	NA	negative	0	negative	NA	NA	NA	NA	1	14.55441478	4
BA2722R	2244	BA2722D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	82	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	82	0	Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	NA	NA	NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	122	Dead	35	1	1.149897331	Dead-Disease	7.6	NA	NA	4.2	8.5	28	6.8	12.7	0.1	24	22	3.1	0.96	NA	31.5	11	43~46,XX,add(2)(q11.2),-4,del(5)(q23),add(7)(q32),+8,add(11)(q23),-16,del(17)(p12),-18,+22[cp19]/46,XX[1]	1304	86.8	NA	21	NA	7.3	17.63	negative	0	negative	NA	NA	TP53 (p.P151S; 96.9%)	NA	1	1.149897331	1
BA2806R	2285	BA2806D	Waves1+2	yes	yes	yes	yes	Male	Male	Unknown	NA	White	2	NA	NA	42	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	42	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	-1	Alive	1016	0	33.3798768	Alive	NA	81	85	NA	NA	4	7	4	NA	89	50	3	0.94	NA	27.8	9.5	NA	945	95.5	NA	39	partialCD4, partial/dimCD7, partialCDllb, CD13, partialCD15, partialCD22, partialCD25, brightCD33, partialCD34, CD38, CD45, CD117, partialCD123, HLA-DR, partialMPO, partialTdT	5.7	48.03	positive	0.960784314	positive	NA	ASXL1 (p.G645Vfs*58; 8.0%)	NA	FLT3-ITD|NPM1	0	33.3798768	4
BA2221R	2529	BA2221D	Waves1+2	no	no	no	no	Male	Male	NA	NA	White	2	NA	NA	68	FALSE	FALSE	FALSE	FALSE	FALSE	y	Melanoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	68	184	Post-Chemotherapy	Remission	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation|Induction|Re-induction|Maintenance	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Maintenance	-1	Alive	1203	0	39.52361396	Alive	NA	1	0	0	NA	42.6	0	57.4	NA	23	24	4.6	NA	NA	35.4	12	46,XY	NA	NA	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	61	CD38(bright +), CD45(-), CD56(+), intracellular kappa(+), intracellular lambda(-)	7.5	2.6	negative	0	negative	NA	NA	NA	NA	0	39.52361396	4
BA3025R	2262	BA3025D	Waves1+2	yes	yes	yes	yes	Female	Female	White	HISPANIC	HispNative	1	bi	NA	28	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	30	2	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	6	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Fludarabine, Cyclophosphamide, TBI	6	Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Dead	843	1	27.69609856	Dead-Disease	0	NA	NA	0	0	4.1	0	2.1	32.3	54	37	3.7	0.3	NOS	27.3	9.2	46,XX,t(2;9)(q31;p21)[17]/46,X,t(X;9)(q22;p21)[3]	NA	91.3	NA	8	CD7, CD13, CD33, CD34, CD38, CD58, dim CD71, CD117, HLA-DR, MPO and partial TDT positive.	6.3	20.18	negative	0	negative	NA	NA	NA	NA	1	27.69609856	2
BA2514R	2409	BA2514D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	Black	2	NA	NA	67	FALSE	FALSE	FALSE	FALSE	FALSE	y	Acute Myeloid Leukemia	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	67	0	Post-Chemotherapy|Post-Transplant|Post-DLI|Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	4	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other|Bone Marrow Transplant	4	AG-120|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea	3	Salvage|Experimental|Supportive/Palliative Care	NA	NA	NA	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	-1	Dead	449	1	14.75154004	Dead-Disease	0	24	6	0	NA	77	10	7	NA	29	37	4.1	0.89	NA	30.1	9.9	46,XX[20]	511	NA	nuc ish(DXZ1x2)[182]//(DXZ1,DYZ3)x1[18]. nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2) [200]	288	CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD33(variably +), CD34(+), CD36 (-), CD38(+), CD45(+), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(+)	8	3.3	negative	0	negative	NA	NA	TP53 (p.R283C; 47.5%)	NA	1	14.75154004	1
BA2520R	2400	BA2520D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	5	NA	NA	80	FALSE	FALSE	FALSE	FALSE	FALSE	y	Mature B-Cell Neoplasm	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	80	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	3	Cytarabine|Decitabine|PF-04449913 (Hedgehog Inhibitor), LDAC	3	Consolidation|Salvage|Experimental	NA	NA	NA	Targeted Therapy - Kinase Inhibitor(s)	Decitabine	Salvage	-1	Dead	309	1	10.15195072	Dead-Disease	NA	80	86	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M0	NA	NA	46,XY,del(20)(q11.2q13.1)[15]/46,XY[5]	NA	NA	Positive for deletion of 20q12 in 11.5% of 200 cells	4	positive for dim CD7, dim CD10, CD34, CD38, dim CD45, cCD79a, CD99, HLA-DR, TdT, dim PAX5	NA	NA	negative	0	negative	RUNX1 (p.R204*; 45.5%)|RUNX1 (p.S141*; 45.1%)	ASXL1 (p.D720Rfs*18; 14.1%)	NA	ASXL1 (p.718_724del; MAF 50.3%)|RUNX1 (p.R177X; MAF 47%)|RUNX1 (p.S114X; MAF 44.8%)|SRSF2 (p.P95H; MAF 45.1%)	1	10.15195072	2
BA2441R	2250	BA2441D	Waves1+2	yes	yes	yes	yes	Male	Male	White	HISPANIC	HispNative	1	NA	NA	50	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	50	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Salvage|Induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	4	Dead	99	1	3.252566735	Dead-Disease	0	76	93	0	0	6.1	1.7	1.8	0	7	10	2.2	0.44	M0	18.8	6.3	43~47,XY,del(1)(q42),r(2)(p2?3q37),t(3;5)(q27;q31),del(4)(q31),+del(5)(q31),add(5)(q11.2),-7,del(11)(q23),add(12)(p13),-22,+mar[cp11]/43~46,idem,add(14)(q24)[cp8]	NA	85.8	deleted 5q and three short arm signals; monosomy 7 and the metaphase karyotype; no evidence for MLL deletion or rearrangement	14	CD7, CD11b, CD13, dim CD33, CD34, CD38, CD58,   CD117 and HLA-DR+	5.9	50.74	negative	0	negative	NA	NA	TP53 (p.R273H; 53.6%)|TP53 (p.G105D; 52.9%)	NRAS ( p.Q61K; MAF 37%)|TP53 (p.G105D, MAF 60%)|TP53 (p.R273H; MAF 44%)	1	3.252566735	1
BA2153R	2301	BA2153D	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	70	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	70	15	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Supportive/Palliative Care	4	7+3 (Cytarabine, Idarubicin)|Azacitidine, Itacitinib|Azacitidine|Decitabine	2	Salvage|Induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine, Itacitinib	Salvage	449	Dead	1389	1	45.63449692	Dead-Disease	0	90	91	0	0	78.1	0.9	1.7	0	46	27	2	0.74	M0	24.4	8.1	47,XY,+4[9]/46,XY[11]	NA	103.8	NA	23	CD7, CD13, CD33, CD34, CD38, CD56, CD117, CD123, HLA-DR and MPO+ (see Note) (Expression of the following antigens is dim and/or partial:  CD7, CD33, CD34, CD38, CD56, CD123, HLA-DR and MPO.) | Small clonal B cell population (<1% of total cells); CD19, CD20, and kappa+	4.7	4.85	negative	0	negative	NA	ASXL1 (p.Q588*; MAF 43% )	NA	ASXL1 (p.Q588*; MAF 43% )	1	45.63449692	2
BA2479R	2362	NA	Waves1+2	yes	no	yes	no	Female	Female	NA	NA	White	5	NA	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	n	n	y	n	n	1	Standard Chemotherapy	1	Venetoclax (ABT-199), Azacitidine	1	Induction	Complete Response	Standard Chemotherapy	115	Standard Chemotherapy	Venetoclax (ABT-199), Azacitidine	Induction	115	Alive	1044	0	34.29979466	Alive	NA	65	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX[20]	NA	NA	NA	96	positive for CD33, CD13, CD117, and myeloperoxidase; negative for CD34 and HLA-DR	NA	1.6	negative	0	positive	NA	NA	NA	ASXL1 (p.A1312V; MAF 33.6%)|IDH1 (p.A1312V; MAF 32.1%)|NPM1 (p.L258fs; MAF 31.1%)	0	34.29979466	1
BA2281R	2303	NA	Waves1+2	yes	no	yes	no	Male	Male	White	NON-HISPANIC	White	1	NA	PML-RARA	25	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	25	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	n	n	y	n	n	1	Standard Chemotherapy	1	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	28	Standard Chemotherapy	APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	Induction	28	Alive	35	0	1.149897331	Alive	0	90	NA	0	0	22.3	0	0.9	0.7	25	50	3.2	0.9	M3	21.3	7.7	46,XY,t(4;15;17)(q21;q22;q21),add(12)(p12)[1]/46,idem,t(5;22)(q11.2;q11.2)[18]/46,XY[1]	921	92.2	FISH c/w PML/RARA fusion	16	CD13, dim CD15, CD34, bright CD33, variable CD56, CD64, CD117, CD123, variable HLA-DR, and bright MPO	6.8	18.25	positive	NA	negative	NA	NA	NA	FLT3-ITD (MAF 44%)	0	1.149897331	3
BA2657R	2104	BA2657D	Waves1+2	no	no	no	no	Male	Male	White	HISPANIC	HispNative	1	NA	NA	45	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	46	196	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Supportive/Palliative Care	5	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone)	Salvage	4	Dead	259	1	8.509240246	Dead-Disease	0	NA	NA	0	1.7	7.8	51.3	18.3	0	29	19	3	0.52	M2	20.6	7	47,XY,der(7)t(1;7)(q10;p10)+8[20]	NA	87.3	NA	5	NA	5.8	11.13	negative	0	negative	RUNX1 (p.S308Qfs*292; 42.4%)	NA	NA	NA	1	8.509240246	4
BA2932R	2069	BA2932D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	29	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	IntermediateOrAdverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	29	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	24	Standard Chemotherapy	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Alive	2383	0	78.29158111	Alive	0	95	78	0.9	0	11.7	0	13.5	1.8	20	25	3	0.54	M1	23	7.9	46,XX[20]	1119	95.8	Normal	12	dim CD2, dim CD7, CD13, dim CD19, dim CD20,      CD33, partial CD34, variable CD38, dim CD64, CD117, CD123, and HLA-DR      positive.	6.1	68.79	positive	NA	negative	NA	NA	NA	FLT3-ITD (MAF 50%)|MLL (PTD)	0	78.29158111	4
BA2123R	2000	BA2123D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	2	NA	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine	NA	NA	NA	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	214	Dead	269	1	8.837782341	Dead-Treatment	NA	10	1	0	NA	80	2	17	NA	24	27	4.3	1.48	NA	20.4	7.2	46,XY[20]	275	93.3	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199](RUNX1T1, RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	23	CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33 (bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR (+), GLy-A(-), MPO(partial +), TdT(-).	6.9	1.6	negative	0	positive	NA	NA	NA	DNMT3A (W297*; MAF 44%)|FLT3-D835 (D835Y; MAF 6%)|GATA2 (P161A; MAF 51%)|NPM1 (W288fs*10+; MAF 26%)	1	8.837782341	4
BA2844R	2275	BA2844D	Waves1+2	yes	yes	yes	yes	Male	Male	Unknown	NA	HispNative	2	N/A	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Alive	195	0	6.406570842	Alive	0	64	47.4	1.7	NA	23.3	27.6	0	NA	29	26	3.7	1.01	NA	32.9	10.3	46,XY[20]	578	99.7	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	20	CD2(-), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD19(few appear very dim +), CD25(-), CD33(variably +), CD34(variably +), CD36(subset +), CD38(+), CD45 (variably +), CD56(+), CD64(partial +), CD117(+), CD123(-), HLA-DR(+), MPO(+), TdT(-). (73% population of medium to large sized cells)	7.2	20.8	negative	0	negative	NA	NA	NA	ASXL1 (G967DEL; MAF 45%)|CEBPA (A111FS*56; MAF 48%)|GATA2 (A318V; MAf 37%)|GATA2 (L321F; MAF 7%)|NRAS (G13V; MAF 37%)	0	6.406570842	2
BA2660R	2170	BA2660D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	43	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	43	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	3	7+3 (Cytarabine, Idarubicin)|Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Induction|Re-induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	6	Supportive/Palliative Care	Cytarabine	Supportive/Palliative Care	125	Dead	245	1	8.049281314	Dead-Disease	0	NA	NA	0	0	31.9	12.4	2.6	0.1	26	16	3	0.77	M4	22.1	7.5	46,XX[20]	297	95.7	Normal	59	Myeloid blast (52%) immunophenotype: CD13, variable CD33, CD34, variable CD38, variable CD117, HLA-DR, and TdT positive | Monocytic blast/promonocyte (28%) immunophenotype: dim CD2, CD11b, CD13, variable CD14, bright CD33, dim CD34, CD38, CD58, CD64, and HLA-DR positive	6.5	22.95	positive	NA	negative	RUNX1 (p.R250Lfs*13; 46.7%)	NA	NA	FLT3-ITD (MAF 47%)|RUNX1 (p.K110Q; MAF 38%)|SUZ12 (p.E261fs*2; MAF 52%)	1	8.049281314	2
BA2836R	2242	BA2836D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	2	NA	NA	59	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	59	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	107	Dead	430	1	14.12731006	Dead-Unknown	0	35	27.4	0	NA	36.8	6.6	29.2	NA	13	25	2.9	1.4	NA	23.6	7.6	46,XY[20]	383	NA	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	35	CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(- to partial dim +), CD16(-), CD25(-), CD33(+ to slightly bright +), CD34(partial +), CD36(equivocal), CD38(slightly dim and variable), CD45(dim +), CD56(-), CD64(-), CD117(+), CD123(+), HLA-DR(+), MPO(+), TdT(-).	6	3.6	negative	0	positive	NA	NA	NA	CEBPA (H224fs*97; MAF 7%)|CEBPA (Y181*; MAF 15%)|IDH2 (R140Q; MAF 35%)|NPM1 (W288fs*10+; MAF 26%)|POT1 (splice site 1164-1G>A; MAF 48%)|SRSF2 (P95R; MAF 37%)	1	14.12731006	4
BA3027R	2324	BA3027D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	5	NA	NA	53	FALSE	FALSE	FALSE	FALSE	FALSE	y	Ovarian cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	53	33	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)	2	Induction|Re-induction	Complete Response	Standard Chemotherapy	29	Standard Chemotherapy	GCLAC (GCSF, Clofarabine & Cytarabine)	Re-induction	17	Dead	72	1	2.36550308	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	53~55,XX,+1,+2,der(5)t(5;13)(q13;q12),+6,add(7)(q32),+8,+11,-13,+14,i(17)(q10),+19,+19,+21,+mar[cp7]/46,XX[7]	NA	NA	Gain of 8 (4/301 cells); Gain of 8q22/21q22 (7.7/301 cells); Gain 11q23 (5/200 cells)	NA	NA	NA	NA	negative	0	negative	NA	NA	TP53 (p.S215R; 15.2%)	NA	1	2.36550308	4
BA2714R	2366	BA2714D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	60	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)	3	Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	167	Standard Chemotherapy	Azacitidine	Salvage	6	Dead	870	1	28.58316222	Dead-Disease	0	90	61	1	4	47	10	1	0.1	30	26	2.4	1.17	M4	14	4.6	46,XY[20]	612	104.5	Normal	80	dim CD4, dim CD7, dim CD11b, CD13, CD33, variable CD34, CD38, CD58, variable CD64, CD117, CD123, dim HLA-DR, MPO, and dim TdT	5.8	70.84	negative	0	positive	NA	NA	NA	FLT3-V491L (p.V491L; MAF 51%)|NPM1 (p.W288fs*12; MAF 50%)|SF3B1 (p.K666Q; MAF 47%)|WT1 (p.Y395fs*51; MAF 49%)	1	28.58316222	4
BA2139R	2342	BA2139D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	3	NA	NA	48	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	48	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|TBI, VP-16	4	Consolidation|Induction|CNS|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	TBI, VP-16	Allogeneic - Matched Unrelated Donor	-1	Alive	939	0	30.85010267	Alive	NA	86	77	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5b	NA	NA	46,XX	NA	NA	NA	NA	Large population of atypical monocytic cells (weaker than  normal CD33, partial loss of CD13) including  promonocytes/monoblasts representing approximately 50% of  the leukocytes suggestive of acute monoblastic or monocytic  leukemia. | Large population of atypical monocytic cells (weaker than normal CD33, partial loss of CD13) including promonocytes/monoblasts representing approximately 50% of the leukocytes	NA	81	positive	0.785714286	positive	NA	NA	NA	DNMT3A (p.Arg882Cys; MAF 47.1%)|FLT3-ITD|NPM1 (p.Trp288fs (NM_002520.6); MAF 27.9%)	0	30.85010267	4
BA2251R	2334	BA2251D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	bi	NA	85	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	85	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	NA	NA	NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	105	Dead	167	1	5.486652977	Dead-Disease	0	NA	NA	2.5	0	14.6	2.4	0	0.5	14	15	3.5	0.98	NA	33.2	10.7	46,XY[20]	289	89.5	Normal	8	NA	7.4	25.63	negative	0	negative	NA	NA	NA	CEBPA (p.F77*83; MAF 50%)|CEBPA (p.K313_V314insK; MAF 50%)|TET2 (p.I1025L; MAF 50%)	1	5.486652977	2
BA2952R	2114	BA2952D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	MLLT3-KMT2A	16	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	16	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine, Mitoxantrone|Etoposide, Cytarabine	2	Induction|Intensification	Complete Response	Standard Chemotherapy	10	Standard Chemotherapy	Cytarabine, Mitoxantrone	Intensification	-1	Alive	2272	0	74.64476386	Alive	0	93	NA	0	0	33	67	0	0	NA	NA	NA	0.72	M5	18.2	6.1	46,XX,t(9;11)(p22;q23)[3]/50,sl,+6,+8,+der(9)t(9;11),+19[14]/51,sdl1,+5[3]	934	100	MLL:   14% of cells had a pattern consistent with the t(9;11) seen on metaphase analysis.  An addition 65% of cells had a signal pattern, consistent with the clone with the +der(9). | BCR/ABL+ASS:   62% of cells had three signals for both ABL and ASS (9q34), consistent with the clone with +9. | RUNX1T1 (8q22):   69% of cells had three signals for RUNX1T1, consistent with the clone with +8. | EGR1:   7% of cells had three signals for EGR1 (5q31), consistent with the clone with +5.	39	CD11b, dim CD13, dim CD15, CD33, CD38, dim CD45, CD56,      CD58, bright CD64, dim CD117, CD123, HLA-DR, and variable MPO positive	NA	24.72	negative	0	negative	NA	NA	NA	KRAS (p.G13D; MAF 6%)|NRAS (p.Q61H; MAF 19%)	0	74.64476386	4
BA2440R	2263	BA2440D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	5	NA	NA	76	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	76	1	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Alive	31	0	1.018480493	Alive	NA	20	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	41~42,XY,del(3)(p13p21),add(4)(q21),add(5)(q11.2),-7,-10,add(12)(p11.2),-15,add(15)(q21),add(17)(p11.2),-19,-20,-22,+2mar[cp6]/42~43,sl,+21[cp5]/42,sl,i(21)(q10)[cp2]/43~44,sl,+add(7)(p11)[cp2]/43~46,sl,+add(7)(p11),+21[cp4]/81~87<4n>,slx2[cp2]	NA	NA	Loss of chromosome 5q31 sequences (73.5%)|Loss of chromosome 7 sequences (monosomy 7) (61.5%)|Gain of 21q22 (AML1) sequences (11.5%)|Polysomy for 8, 20q (7.5%), 11q, 15q, 16q and 17q sequences	91	NA	NA	5.6	negative	0	negative	NA	NA	NA	ASXL1 (p.E1102D; MAF 31.1%)|DNMT3A (p.F543C; MAF 35.7%)	0	1.018480493	1
BA2036R	2445	BA2036D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	3	NA	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	Dead	21	1	0.689938398	Dead-Treatment	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Large population of atypical myeloblasts (CD56 positive,  weak CD117 positive, CD34 negative, HLA-DR negative),  representing approximately 87% of the leukocytes,  consistent with acute myeloid leukemia	NA	NA	negative	0	positive	NA	NA	NA	KMT2A (p.Ile3572Ser (NM_001197104.1); MAF 44.1%)|NPM1 (p.Trp288fs (NM_002520.6); MAF 27.4%)|TET2 (p.His724fs; MAF 43.5%)	1	0.689938398	3
BA2828R	2306	BA2828D	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1	NA	CBFB-MYH11	64	FALSE	FALSE	FALSE	FALSE	FALSE	y	Mature B-Cell Neoplasm	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	64	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	2	Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	5	Alive	2175	0	71.45790554	Alive	0	NA	NA	0	0.9	48.7	30.1	5.3	0	10	7	2.6	1.33	M4	23.2	7.7	46,XY,inv(16)(p13q22)[17]/46,XY[3]	NA	87.2	c/w karyotype	53	NA	5.9	8.69	negative	0	negative	NA	NA	NA	KRAS (p.G12D; MAF 27%)|NOTCH1 (p.G2299S; MAF 47%)	0	71.45790554	2
BA2292R	2056	BA2292D	Waves1+2	no	no	no	no	Male	Male	NA	NA	White	5	NA	NA	69	FALSE	FALSE	TRUE	FALSE	FALSE	y	Squamous cell carcinoma	y	y	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	70	55	Post-Chemotherapy	Remission	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	3	7+3 (Cytarabine, Idarubicin)|Azacitidine, Lenalidomide|Rituximab	2	Induction|Experimental	Unknown	Standard Chemotherapy	-1	Targeted Therapy - Other	Rituximab	Experimental	-1	Alive	454	0	14.91581109	Alive	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M6a	NA	NA	46,XY[18]	NA	NA	Normal	NA	NA	NA	NA	positive	1.222222222	negative	NA	NA	NA	NA	0	14.91581109	1
BA2410R	2495	BA2410D	Waves1+2	yes	yes	yes	no	Female	Female	NA	NA	White	2	NA	NA	57	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	57	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin) plus Crenolanib	1	Induction	Complete Response i	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin) plus Crenolanib	Induction	-1	Dead	81	1	2.661190965	Dead-Treatment	NA	55	47	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX[20]	NA	NA	Normal	NA	It reveals 0.23% CD34 (+) myeloid blasts with the following immunophenotype: CD2(-), CD7(-), CD13(+), CD15(-/few +), CD33 (bright +), CD36(few +), CD38(partial +), CD45(+), CD64(-), CD117(+), HLA-DR(-), MPO (partial +). (A limited/targeted immunophenotypic analysis could be performed on this paucicellular specimen.) | CD2(-), CD4(partial dim +), CD7(-), CD11b(-), CD13(variably +), CD15(-/few +), CD33(bright +), CD34(-), CD36(- /few +), CD38(+), CD45(+), CD56(-), CD64(few +), CD117(+), and HLA-DR(-) (There is also a 16% population of medium-sized cells with the following immunophenotype)	NA	26.5	positive	NA	positive	NA	NA	NA	ASXL1 (E981G; MAF 49%)|DNMT3A (F290fs*24; MAF 40%)|FLT3-ITD (MAF 18%)|JAK2 (N322I; MAF 51%)|NPM1 (W288fs*10+; MAF 38%)	1	2.661190965	3
BA2051R	2464	BA2051D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	5	NA	CBFB-MYH11	60	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	HiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Fludarabine, Cyclophosphamide, Thiotepa, TBI	3	Consolidation|Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Dead	581	1	19.08829569	Dead-Disease	NA	33	23	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY,inv(16)(p13.1q22)[18]/47,sl,+22[2]	NA	NA	FISH positive for CBFB rearrangement in 49% of cells	42	Flow cytometry shows the large majority of analyzed cells fall within the monocyte gate, which are predominantly mature as evidenced by coexpression of CD14 and CD64. A smaller subset of cells within the monocyte gate consists of immature monocytes with decreased expression of CD14 and/or CD64. (A discrete population of myeloblasts is also present.)	NA	29	negative	0	negative	NA	NA	NA	NRAS (p.Q61K; MAF 24.1%)	1	19.08829569	2
BA2532R	2323	BA2532D	Waves1+2	yes	yes	yes	yes	Female	Female	Unknown	NA	White	2	NA	PML-RARA	42	FALSE	FALSE	FALSE	FALSE	FALSE	y	Cervical Cancer|Pituitary Tumor	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	42	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Targeted Therapy - Other|Intrathecal	3	ATRA, Arsenic Trioxide|ATRA, 6-MP, Methotrexate|Methotrexate	3	Induction|Experimental|Maintenance	Complete Response	Standard Chemotherapy	22	Standard Chemotherapy	ATRA, 6-MP, Methotrexate	Maintenance	-1	Alive	952	0	31.27720739	Alive	0	92	83	0	NA	11	4	0	NA	35	35	3.9	0.66	M3	22.2	7.6	46,XX,t(15;17)(q24;q21.1)[1]	475	88.4	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x3(PML con RARAx2)[154/200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	35	CD2(-), CD4(partial +), CD11b(few dim +), CD13(+), CD14(-), CD15(-), CD16 (-), CD25(-), CD33(bright +), CD34(-), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(+), CD117(variably +), CD123(+), HLA-DR(-), myeloperoxidase(+), and TdT(-).	5.8	NA	negative	0	negative	NA	NA	NA	NA	0	31.27720739	3
BA2986R	2110	BA2986D	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	1	NA	NA	48	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	56	0	Residual Disease|Post-Chemotherapy|Post-DLI|Post-Transplant	Residual	Bone Marrow Aspirate	y	y	n	y	y	n	3	DLI|Standard Chemotherapy|Bone Marrow Transplant	7	7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Mitoxantrone|Busulfan, Cyclophosphamide	5	Allogeneic - Sibling|Consolidation|Unknown|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	5	Dead	3069	1	100.8295688	Dead-Disease	0	62	5	0	0	83.2	1.8	0	0	28	21	2.5	0.8	NA	24.1	8.3	46,XX,t(1;11)(q44;q13),del(6)(p23)[9]/46,idem,t(17;20)(q25;q11.2)[11]	290	94.5	All probe results were within normal laboratory limits.      *Note: while it was not disrupted, MLL (11q23) was observed on the end of      the derivative chromosome 1 on available metaphase cells, reflecting the      t(1;11).	53	dim CD2, CD13, CD33, CD34, CD38, CD117, dim CD123, dim      HLA-DR, and TdT positive	6.5	1.46	negative	0	negative	NA	NA	NA	BCOR (p.A1262S; MAF 45% )|DNMT3A (p.R882H; MAF 15% )|GATA1 (c.-12C>T; MAF 35%)	1	100.8295688	4
BA2494R	2246	BA2494D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	5	NA	NA	60	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	n	n	y	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute megakaryoblastic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute megakaryoblastic leukaemia	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	1	Azacitidine	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Induction	-1	Dead	204	1	6.702258727	Dead-Disease	NA	13	rare	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M7	NA	NA	46,XY,del(13)(q12q14)[3]/46,XY[17]	NA	NA	Normal	136	CD3  - Scattered cells positive, 5-10% of marrow cells CD20  - Scattered cells positive, 5-10% of marrow cells CD34  - Rare cells positive, <1% of marrow cells CD30  - Negative CD43  - Positive in >60% of marrow cells, including the clusters of immature cells (CD117  - Scattered and small loose clusters of cells positive, 10-15% of marrow cells CD138  - Occasional cells positive, 2% of marrow cells Glycophorin A - Occasional cells positive, 3-5% of marrow cells MPO  - Scattered and clusters of cells positive, 20% of marrow cells)	NA	3.1	negative	0	negative	RUNX1 (p.A338Rfs*262; 22.2%)	NA	NA	JAK2 (p.V617F; MAF 3.8%)|TET2 (p.R1261L; MAF 27.7%)	1	6.702258727	1
BA2515R	2533	BA2515D	Waves1+2	yes	yes	yes	yes	Male	Male	Unknown	NA	White	2	mono	NA	74	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	75	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	48	Dead	324	1	10.64476386	Dead-Unknown	0	32	5	0	NA	69	8	18	NA	23	22	4.3	1.21	NA	32.9	11.1	46,XY[18]	199	NA	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[198],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	178	CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial dim +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD22 (-), CD25(-), CD33(variably +), CD34(bright +), CD36(-), CD38(bright +), CD45(moderate/dim +), CD56(-), CD64(-), CD79a (-), CD117(+), CD123(-), HLA-DR(+), MPO(+), TdT(partial +) (34% population of variably-sized cells)	7.1	2.3	negative	0	negative	NA	NA	NA	NA	1	10.64476386	2
BA2748R	2566	BA2748D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	bi	NA	10	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	10	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|ADE (Cytarabine, Daunorubicin & Etoposide)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	33	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Alive	2143	0	70.40657084	Alive	0	80	75	1.7	6.1	17.4	7.8	11.3	0.7	24	22	3.7	0.51	M2	30.3	9.1	46,XX[20]	688	83.7	Normal	74	variable CD7, variable CD13, CD33, partial CD34, bright CD38, partial CD56, CD58, variable CD71, CD117, CD123, HLA-DR, and MPO positive	7.3	39.69	negative	0	negative	NA	NA	NA	CEBPA (p.G96fs*12; MAF ~50% )|CEBPA (p.G96fs*12; MAF ~50%)|CEBPA (p.R306_N307insPPT; MAF ~50%)|MLL (PTD (low level mutation))|NRAS (p.G12A, MAF 6%)|NRAS (p.G12A; MAF 6% )|NRAS (p.G12D; MAF 5% )|NRAS (p.G12D; MAF 5%)|NRAS (p.G13D; MAF 8%)|NRAS (p.G13R; MAF 5%)|NRAS (p.Q61H; MAF 10%)	0	70.40657084	2
BA2970R	2327	BA2970D	Waves1+2	yes	yes	yes	yes	Male	Male	Black	NON-HISPANIC	Black	2	NA	NA	63	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	n	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	63	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Supportive/Palliative Care	2	Ruxolitinib|Hydroxyurea	1	Supportive/Palliative Care	NA	NA	NA	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	103	Dead	8	1	0.262833676	Dead-Disease	1	9	15.4	2.9	NA	20.2	16.3	42.3	NA	NA	NA	NA	0.6	NA	22.7	7	46,XY[20]	1086	NA	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	126	CD34(+), CD7(partial +), CD13(+), CD33(+), CD38(partial +), CD45(moderately +), CD56 (+), CD117(+), HLA-DR(variably +), other myeloid and lymphoid antigens(-).	NA	73.4	positive	9	positive	NA	ASXL1 (p.W898*; 42.1%)	NA	ASXL1 (Foundation; W898*; MAF 47%)|KRAS (Foundation; A59T mutation; MAF 47%)|KRAS (Foundation; G13C; MAF 3%)|SUZ12 (Foundation; W617*; MAF 49%)	1	0.262833676	1
BA2622R	2453	BA2622D	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	76	FALSE	FALSE	FALSE	FALSE	FALSE	y	Basal Cell Carcinoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	76	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	3	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	35	Standard Chemotherapy	Incyte trial (azacitidine and JAK 1 inhibitor)	Induction	77	Dead	520	1	17.08418891	Dead-Unknown	0	50	5	2	0.2	52.2	37.1	8.5	0	18	16	3.7	1.45	M0	22.3	7.6	47,XY,+8[3]/46,XY[17]	NA	118.6	5% trisomy 8	104	#1 Immunophenotype: CD13, CD34, CD38, dim CD45, CD58, CD117, HLA-DR and TdT positive | #2 Immunophenotype: dim CD4, partial CD13, dim CD34, CD38, CD58, CD123, HLA-DR, and partial TdT positive	7.7	4.48	negative	0	negative	RUNX1 (p.A338Rfs*256; 73.3%)	ASXL1 (p.G646Wfs*12; 20.0%)	NA	CBL (p.Y371H; MAF 43%)|EZH2 (p.K30fs*8; MAF 48%)|RUNX1 (p.A338fs*; MAF 41%)|SF3B1 (p.H662Q; MAF 28%)	1	17.08418891	4
BA2839R	2107	BA2839D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NA	White	2	NA	NA	44	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	n	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	44	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	6	1	0.197125257	Dead-Disease	0	62	19	1	NA	18	35	25	NA	24	90	1.8	0.73	NA	22.4	7.2	47,XY,+21[19]/46,XY[1]	NA	NA	nuc ish(RUNX1T1x2,RUNX1x3)[140/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	18	CD2(-­), CD7(dim + to -­), CD11b(-­), CD13(+), CD14(-­), CD15 (partial +), CD33(bright +), CD34(partial +), CD36(-­), CD38(variably +), CD45(+), CD56(-­), CD64(partial +), CD117(+), HLA-­DR(variably +)	7.1	8	positive	0.960784314	negative	RUNX1 (p.E223*; 64.8%)	NA	NA	NA	1	0.197125257	4
BA2052R	2412	BA2052D	Waves1+2	yes	yes	yes	yes	Male	Male	Unknown	NA	White	2	NA	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Supportive/Palliative Care	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	NA	NA	NA	Supportive/Palliative Care	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Dead	288	1	9.46201232	Dead-Unknown	0.9	34	NA	2.8	NA	NA	NA	NA	NA	28	27	4.2	1.18	NA	29.3	9.8	46,XY,inv(4)(p14p16.1)[3]/46,XY[16]	194	NA	nuc ish(D5S2064,D5S630,EGR1)x4[32/200],(D7Z1,D7S522)x4[17/200],(D8Z2, D20S108)x4[27/200],(RUNX1T1,RUNX1)x4[32/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[21/200],(PML,RARA)x4 [34/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[35/200]	73	CD2 (-), CD7(few +), CD11b(-), CD13(partial dim +), CD14(-), CD15(partial dim +), CD16(-), CD22(partial dim +), CD33(-), CD34(bright +), CD36(-), CD38(moderately bright +), CD45(partial +), CD56(-), CD64(-), CD117(partial +), HLADR(+) (32% population of medium to large cells)	7.1	NA	negative	0	negative	NA	NA	NA	BCOR (Foundation; Q1337*; MAF 56%)|CTCF (Foundation; R49H; MAF 19%)|RUNX1 (Foundation; loss, splice site 477_508+22>GGG; MAF 50%)|SRSF2 (Foundation; R94_S101del;MAF 39%)|TET2 (Foundation; splice site 3409+2T>G; MAF 51%)	1	9.46201232	1
BA3011R	2236	BA3011D	Waves1+2	yes	yes	yes	yes	Male	Male	Multiracial	HISPANIC	HispNative	1	NA	PML-RARA	32	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	32	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	1	ATRA, Arsenic Trioxide	2	Consolidation|Experimental	NA	NA	NA	Standard Chemotherapy	ATRA, Arsenic Trioxide	Consolidation	232	Alive	2104	0	69.12525667	Alive	0	80	NA	0	19.6	56.3	0.9	3.6	0.1	31	20	3	0.84	M3	19.1	6.3	46,XY,t(15;17)(q22;q21)[20]	NA	96.5	70% PML/RARA	49	CD13, CD33, CD64, CD117, CD123 and  MPO-positive	6.9	7.19	positive	NA	negative	NA	NA	NA	FLT3-ITD (MAF 7%)|MPL (p.E484G, MAF 3%)|WT1 (p.F451C; MAF 51% )	0	69.12525667	3
BA2868R	2442	BA2868D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	3	bi	NA	69	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Induction	-1	Dead	250	1	8.213552361	Dead-Disease	NA	60	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	weak  CD7, CD13, partial CD15, weak CD33, CD34, weak CD64, CD117,  myeloperoxidase, and HLA-DR, but do not express CD14(MO2),  CD42b, or CD61.	NA	33	negative	0	negative	NA	NA	NA	CEBPA (c.117delC; MAF 27.2%)|CEBPA (c.938_939insATC; MAF 18.1%)|TET2 (c.3454G>T; MAF 40.9%)|WT1 (c.1137_1138insA; MAF 43.7%)|WT1 (c.872+1G>A; MAF 40%)	1	8.213552361	2
BA2510R	2073	BA2510D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	5	NA	KMT2A_re	65	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	3	7+3 (Cytarabine, Idarubicin)|Venetoclax (ABT-199), Azacitidine|Fludarabine, Cyclophosphamide, TBI	3	Experimental|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	NA	NA	NA	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Dead	210	1	6.899383984	Dead-Disease	NA	95	62	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	48,XY,+8,der(11)t(11;?)(q23;?),+21[19]/46,XY[1]	NA	NA	Gain of 8q22 and 21q22 (88%)	33	positive for CD11b, CD13, CD33, CD38, dim CD45, dim CD56, CD64, and HLA-DR	NA	19.8	negative	0	negative	NA	ASXL1 (p.W960*; 48.8%)	NA	ASXL1 (p.W960X; MAF 29.4%)|PTPN11 (p.E76V; MAF 29.5%)	1	6.899383984	4
BA2065R	2029	BA2065D	Waves1+2	no	no	no	no	Female	Female	White	NON-HISPANIC	White	1	NA	NA	46	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	424	Relapse	Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	5	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC	3	Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	4	Dead	1373	1	45.10882957	Dead-Disease	0	70	59	3.5	0.9	17.7	0	13.3	0	184	77	2.8	0.72	M4	37	12.6	46,XX[20]	NA	94.4	Normal	138	CD13, CD33, partial CD34, partial CD38, dim partial  CD64, CD117 and CD123 positive	5.7	16.95	negative	0	positive	NA	NA	NA	DNMT3A (p.R882C; MAF 39%)|NPM1 (p.W288fs*>9 ; MAF 39%)|PTPN11 (p.E76Q; MAF 41%)	1	45.10882957	4
BA2691R	2521	BA2691D	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	83	FALSE	FALSE	FALSE	FALSE	FALSE	y	Prostate Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	MissingKaryo	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	83	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	50	1	1.642710472	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	NA	1	1.642710472	4
BA2374R	2487	BA2374D	Waves1+2	yes	yes	yes	no	Female	Female	Black	NON-HISPANIC	Black	1	NA	PML-RARA	36	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	36	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	2	ATRA, Arsenic Trioxide|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	2	Induction|Experimental	Complete Response	Standard Chemotherapy	27	Targeted Therapy - Other	ATRA, Arsenic Trioxide	Experimental	-1	Alive	2180	0	71.62217659	Alive	0	90	90	0	28.8	1.8	1.8	0.9	0.4	37	27	3.9	0.76	M3	26.3	8.2	46,XX,der(15)t(15;17)(q22;q21),der(17)t(15;17)del(17)(q21)[15]/46,XX[1]	605	89.2	95% of cells had a variant abnormal signal pattern with PML/RARA fusion.  PML (15q22) (SO) / RARA (17q21) (SG) t(15;17)	25	Immunophenotype: CD13, CD33, partial CD34, CD64, CD117, CD123 and MPO positive	7.5	103.66	positive	NA	negative	NA	NA	NA	FLT3-ITD (MAF 50%)	0	71.62217659	3
BA2804R	2101	BA2804D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	5	mono	NA	87	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	87	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	2	AG-120|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Experimental	NA	NA	NA	Targeted Therapy - Other	AG-120	Experimental	-1	Dead	249	1	8.180698152	Dead-Disease	NA	60	39	NA	NA	NA	2	NA	NA	NA	NA	NA	NA	M5	NA	NA	47,XY,+21[3]/46,XY[9]	NA	NA	9.5% gain 21q22	43	A distinct blastic population, expressing CD7, CD13, CD15, CD33, CD34, CD38, dim CD45, CD64, MPO, and HLA-DR | A large monocytic population, positive for CD11b, CD13, CD14, CD15, CD33, CD38, CD45, CD64, HLA-DR and MPO	NA	139.9	negative	0	negative	NA	NA	NA	ASXL1 (p.G642fs; MAF 31.6%)|CEBPA (p.A66fs; MAF 37.3%)|CEBPA (p.Q162fs; MAF 50.3%)|IDH1 (p.R132C; MAF 48.7%)|TP53 (p.N107D; MAF 97.6%)	1	8.180698152	2
BA2670R	2456	BA2670D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NA	White	2	NA	NA	72	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	73	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Other	4	Lenalidomide|Azacitidine|Decitabine|Clofarabine, Cytarabine	2	Hypomethylating/Low Dose Cytarabine|Maintenance	NA	NA	NA	Other	Clofarabine, Cytarabine	Hypomethylating/Low Dose Cytarabine	-1	Dead	465	1	15.27720739	Dead-Disease	0	NA	25	0	NA	2	54	18	NA	41	34	3.6	0.58	NA	27.5	8.8	46,XX,+1,der(1;21)(q10;q10)[6]/46,XX[14]	NA	NA	nuc ish(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200]	NA	NA	6.2	58.2	negative	0	negative	NA	NA	NA	RUNX1 (PB)|SF3B1 (PB)	1	15.27720739	4
BA2675R	2133	BA2675D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	mono	NA	10	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	IntermediateOrAdverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	10	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	4	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Other	4	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|Unknown|MiDAC	3	Unknown|Induction|Re-induction	Refractory	Standard Chemotherapy	10	Bone Marrow Transplant	Unknown	Unknown	-1	Alive	2095	0	68.82956879	Alive	0	75	86	0	0	7.5	1.8	4.7	0.1	13	23	3.6	0.47	M2	21.6	6.9	46,XY[20]	970	96	NA	42	variable CD7, dim CD11b, CD13, CD33, partial CD34, dim CD64, CD117, CD123, HLA-DR, and dim MPO positive	7.8	133.63	positive	NA	negative	NA	NA	NA	CEBPA (p.R142fs*19; MAF 52%)|FLT3-ITD (MAF 48%)	0	68.82956879	4
BA2589R	2064	BA2589D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	HispNative	5	NA	NA	42	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	42	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	3	7+3 (Cytarabine, Idarubicin)|AG-221|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	3	Salvage|Induction|Experimental	Refractory	Standard Chemotherapy	-1	Targeted Therapy - Other	AG-221	Experimental	-1	Dead	448	1	14.71868583	Dead-Disease	NA	50	51	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX[20]	NA	NA	Normal	256	positive for CD13, CD34, CD38, dim CD45, CD117, HLA-DR, and MPO	NA	10.7	negative	0	negative	NA	NA	NA	ASXL1 (p.G652S; MAF 41.3%)|ASXL1 (p.S1231F; MAF 50.4%)|DNMT3A (p.S307fs; MAF 45.6%)|IDH1 (c.C315T; p.G105G; MAF 46.6%)|IDH2 (p.R140Q; MAF 43.8%)|SRSF2 (p.P95H; MAF 42.2%)	1	14.71868583	4
BA2031R	2387	BA2031D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	KMT2A_re	2	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	2	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	4	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	136	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Alive	1937	0	63.6386037	Alive	0	80	70	0	1.8	46	0	0	0.2	22	53	NA	0.24	M5	22	6.9	46,XX,t(6;11)(q27;q23)[19]/46,XX[1]	NA	92.8	NA	40	CD4, CD11b, variable CD13, CD15, CD33, variable CD56, CD58, CD64, lysozyme, and dim HLA-DR positive	NA	57.08	negative	0	negative	NA	NA	NA	NA	0	63.6386037	4
BA2198R	2338	BA2198D	Waves1+2	yes	no	yes	no	Male	Male	NA	NA	White	3	NA	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	Dead	42	1	1.379876797	Dead-Disease	NA	84	91	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M2	NA	NA	46,XY[20]	NA	NA	Normal	NA	partial  weak CD4 (20% positive), CD13, partial weak CD11b (60%  positive), partial weak CD15 (20% positive), CD34, CD117,  myeloperoxidase, and partial HLA-DR (60% positive)	NA	25	negative	0	negative	RUNX1 (p.R166Q; 46.0%)|RUNX1 (p.R162K; 44.5%)	ASXL1 (p.E635Rfs*15; 10.5%)	NA	ASXL1 (p.Glu635Argfs*15; MAF 9%)|CSF3R (p.Tyr779*; MAF 5.4%)|IDH2 (p.Arg140Gln; 37.7%)|PHF6 (p.Arg319*; MAF 88.6%)|RUNX1 (p.Arg162Lys; MAF 43%)|RUNX1 (p.Arg166Gln; MAF 35.3%)|SMC1A (p.Arg790Gln; 9.2%)|U2AF1 (p.Gln157Pro; MAF 51.3%)	1	1.379876797	2
BA2066R	2066	BA2066D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	KMT2A_re	62	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Other	4	3+7 (Cytarabine, Daunorubicin)|MiDAC|Hydroxyurea|Fludarabine, Melphalan, TBI, ATG	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Child	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	Fludarabine, Melphalan, TBI, ATG	Allogeneic - Child	-1	Dead	317	1	10.41478439	Dead-Other	0	95	70	0	0	9.5	23.3	0	0.1	54	57	3.3	0.78	M5	27.4	9.1	46,XX,t(1;11)(p36.1;q23),add(9)(p22)[13]/46,sl,del(2)(p21p23),del(20)(q11.2-13.1)[4]/46,sl,add(12)(p11.2)[2]	861	93.2	MLL: 85%  The t(1;11) with these breakpoints in not common, but has been associated with monoblastic leukemia	26	CD4, partial CD11b, CD15, CD33, CD38, moderate CD45, partial CD56, CD64, CD123, partial CD117, and HLA-DR	6.8	87.72	negative	0	negative	NA	ASXL1 (p.R693*; 19.8%)	NA	ASXL1 (p.R693*; MAF 19%)|BCOR (p.S209L (possibly a benign germline polymorphism); MAF 48%)|FLT3 (p.A680V; MAF 17%)|FLT3 (p.I836delI (in-frame deletion of one amino acid in TK domain); MAF 11%)|NRAS (p.G12S; MAF 19%)	1	10.41478439	4
BA2344R	2077	BA2344D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	3	NA	NA	71	FALSE	FALSE	FALSE	FALSE	FALSE	y	Follicular lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	71	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	5	7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Hydroxyurea|Mitoxantrone	4	Hypomethylating/Low Dose Cytarabine|Induction|Re-induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	-1	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	-1	Dead	280	1	9.199178645	Dead-Disease	NA	82	66	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX,del(7)(q22q36)[20]	NA	NA	ABNORMAL FISH RESULT 7cen (D7Z1), 7q31 (D7S486): deletion present	NA	CD7, CD13, weak CD33, CD34, CD117, and HLA-DR	NA	133.7	negative	0	negative	NA	NA	NA	FLT3-ITD (MAF 4%)|WT1 (c.1138delinsAA; MAF 31.2%)	1	9.199178645	2
BA2459R	2350	BA2459D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	2	NA	NA	55	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	Standard Chemotherapy	8	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	8	Alive	45	0	1.478439425	Alive	0	91	61	0	NA	46.1	1.7	9.4	NA	391	343	2.8	0.74	M1	22.8	7.1	92<4n>,XXYY[13]/46,XY[7]	NA	NA	The AML FISH panel analysis showed evidence of extra copies of the RUNX1T1 (8q24) and RUNX1 (21q22) genes in 95.5%, extra copies of the PML (15q24) and RARA (17q21.1) genes in 95.5%, and extra copies of the CBFB (16q22) gene in 96% of the cells examined.)	34	CD2(-), CD4(partial dim +), CD7(-), CD11b (variably +), CD13(variably +), CD14(predominantly -), CD15(predominantly -/few scattered +), CD16(-), CD20(small subset +), CD33(partial +), CD34(variably +), CD36(small subset +), CD38(variably +), CD45(variably +), CD56(-), CD61 (-), CD64(-), (cont.above) (CD79a(small subset +), CD117(small subset +), HLA-DR(predominantly + and variable), TdT(+), MPO(-))	5.8	9.4	positive	0.234567901	negative	NA	NA	NA	IDH1 (p.R132C; MAF unlisted)	0	1.478439425	1
BA2229R	2240	BA2229D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	5	NA	NA	61	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	Cyclophosphamide, Fludarabine, TBI|7+3 (Cytarabine, Idarubicin) plus Sorafenib	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Cyclophosphamide, Fludarabine, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Alive	884	0	29.04312115	Alive	NA	40	28	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX,del(5)(q31q33),der(21)(qter->q22::p11.2->qter),del(21)(q22)[19]	NA	NA	65% Loss 5q31; 14.5% Gain of 8 centromere, trisomy; Trisomy for 21q22  (40.5%), and trisomy for 8q22 and 21q22 (7.0%)	26	positive CD13, CD34, dim CD45, CD117 and HLA-DR	NA	4.8	negative	0	negative	NA	NA	NA	BCOR (p.1189_1192del; MAF 33.1%)|NRAS (p.G12D; MAF 10%)|SRSF2 (p.P95H; MAF 34.4%)	0	29.04312115	1
BA2559R	2329	BA2559D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	5	NA	NA	42	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	42	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Fludarabine, Cyclophosphamide, TBI	3	Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Alive	878	0	28.84599589	Alive	NA	35	2	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5	NA	NA	46,XX[20]	NA	NA	Normal	35	The immature cells were positive for CD13, CD33, and many showed aberrant expression of CD7. The myeloblast portion was positive for CD34, CD117, and HLA-DR.  The immature monocyte portion was negative for CD34 and CD117, and expressed variable CD64 (including some cells with bright CD64), CD11b, an	NA	49.7	positive	NA	negative	NA	NA	NA	FLT3-ITD (MAF 34.8%)|RUNX1 (p.L29S; MAF 52.7%)	0	28.84599589	4
BA2093R	2343	BA2093D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	51	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)|Bu/Cy/TBI	5	Consolidation|Salvage|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine	Salvage	62	Dead	628	1	20.63244353	Dead-Disease	0	90	NA	0	0	85.8	1.9	8.5	0	25	25	3	0.93	M0	25.1	8.2	60~61<3n>,XYY,-1,-2,-3,-4,-5,del(5)(q13q33),-6,-7,+8,-9,+11,-12,+13,-15,-16,-17,-18,+21,+22[cp15]/70~73,idem,+Y,+1,+2,+5,+del(5)(q13q33),+6,+9,+11,+12,+20,+20[cp4]/46,XY[1]	634	81.8	EGR-1/ D5S23, D5S721: 60/100 cells (60%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the first clone, above; 38 cells (38%) had a 2 red/ 4 green signal pattern, consistent with two copies of the deleted 5q in the second clone.	77	partial CD7, CD13, dim partial CD22, CD33, CD3,  partial CD56, dim CD71, CD117, dim CD123, and dim HLA-DR	6.5	0.5	negative	0	negative	NA	NA	TP53 (p.X187_splice; 40.1%)|TP53 (p.X125_splice; 28.4%)	NRAS (p.G13D; MAF ~40%)|TP53 (Splice site (3' splice site mutation, intron 5); MAF 42%)|TP53 (Splice site (5' splice site mutation in intron 4); MAF 44%)	1	20.63244353	1
BA2000R	2304	BA2000D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	Asian	3	mono	NA	24	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	24	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	6	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	5	Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	-1	Dead	633	1	20.79671458	Dead-Disease	NA	85	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX[20]	NA	NA	Normal	NA	weak CD4, partial  CD7, partial CD11b, CD13, CD33, partial CD34, weak CD64,  CD117, MPO, and HLA-DR	NA	NA	positive	0.666666667	negative	NA	NA	NA	CEBPA (p.Gln41fs; MAF 4%)|FLT3-ITD (p.Glu611_Phe612ins27; MAF 8%)|JAK3 (p.Gln865Glu; MAF 48.9%)	1	20.79671458	4
BA2425R	2532	BA2425D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	68	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	Dead	314	1	10.31622177	Dead-Disease	2.6	NA	49	5.1	6.8	36.8	0.9	14.5	0.2	18	16	2.8	0.67	NA	21.9	7.5	43-45,XX,del(5)(q16q33),der(7)t(7;12)(q11.1;q12)ins(7;?)(q11.1;?),-12,der(21;22)(q10;q10),+mar[cp20]/46,XX[1]	821	88.7	NA	8	CD13, CD33, CD34, CD71, CD117, dimCD123, HLA-DR, and dim CD 64 positive (Peripheral Blood)	7.2	11.01	negative	0	negative	NA	NA	TP53 (p.L130Pfs*19; 33.3%)	TP53 (p.I254N; MAF 40%)	1	10.31622177	1
BA2905R	2019	BA2905D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	5	N/A	NA	77	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	77	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	3	AG-221|Azacitidine|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Experimental|Maintenance	NA	NA	NA	Targeted Therapy - Other	AG-221	Experimental	-1	Dead	38	1	1.248459959	Dead-Disease	NA	70	72	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	47,XY,+11[8]/46,XY[12]	NA	NA	35% gain of 11q23	174	CD34, CD117, HLA-DR, CD13, and CD33. A subset of the myeloblasts showed aberrant co-expression of CD34 and myeloperoxidase.  A subset of the myeloblasts showed aberrant expression of CD56.	NA	33.1	negative	0	negative	NA	NA	NA	ASXL1 (p.G642fs; MAF 32.1%)|CEBPA (p.K90fs; MAF 39.1%)|EZH2 (p.F246fx; MAF 91.4%)|IDH2 (p.R140Q; MAF 49.2%)|RUNX1 (p.L29S; MAF 52.9%)|STAG2 (p.D884fs; MAF 89.8%)|TET2 (p.P1723S; MAF 48.4%)|TET2 (p.Y867H; MAF 50.3% )	1	1.248459959	2
BA2304R	2010	BA2304D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	3	NA	MLLT3-KMT2A	52	FALSE	FALSE	FALSE	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	52	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, ATG, Methotrexate	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Melphalan, ATG, Methotrexate	Allogeneic - Matched Unrelated Donor	-1	Alive	804	0	26.41478439	Alive	NA	51	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5	NA	NA	46,XX,t(9;11)(p22;q23)[5]	NA	NA	11q23 (MLL): rearrangement present (89.5%)	NA	The monocytic cells (percentages shown) are  atypical in that they express partial CD56 (about 50%  positive), but otherwise demonstrate phenotypically normal  expression of CD13, bright CD33, bright CD64, CD15, HLA-DR,  and partial myeloperoxidase (Flow cytometric analysis of the bone marrow aspirate  specimen indicates that 4% of the CD45 positive leukocytes  are lymphocytes, 89% are monocytic cells, and 7% are  myeloid cells.) | CD10, CD11b, CD13,  CD16, CD33, and CD64 (Myeloid (phenotypically normal))	NA	NA	negative	0	negative	NA	NA	NA	KRAS (p.Gly13Asp; MAF 38.9%)	0	26.41478439	4
BA2976R	2494	BA2976D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	85	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	85	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Maintenance	NA	NA	NA	Standard Chemotherapy	Azacitidine	Maintenance	232	Dead	80	1	2.628336756	Dead-Disease	0	36	NA	0	8.7	20.2	27.2	20.2	1.6	24	23	3.4	0.88	M4	31.5	9.6	46,XY,del(12)(p11.2p13)[20]	200	95.7	ETV6: 84% of cells were missing a signal for ETV6 (12p13), consistent with the deletion seen on metaphase analysis.	46	CD34, CD117, dim CD123, CD33, dim HLA-DR, CD13, and CD58. (Blasts) | CD64, CD11b, CD33, CD15, dim HLA-DR, CD13, dim CD71, and CD58. (Monoblasts/promonocytes.)	7	40.53	negative	0	negative	NA	NA	NA	NRAS (p.Q61R; MAF 30%)|U2AF1 (p.S34F ; MAF 50%)	1	2.628336756	4
BA2386R	2292	BA2386D	Waves1+2	yes	yes	yes	yes	Female	Female	Unknown	NA	White	2	NA	NA	52	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	52	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	Dead	633	1	20.79671458	Dead-Disease	0	83	48.6	0	NA	9.4	0.9	40.2	NA	21	47	3.3	0.55	M1	25.3	8.3	46,XX[20]	NA	NA	nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	48	CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(+ and dim +), CD14(-), CD15(+), CD16(-), CD25(-), CD33(slightly bright +), CD34(-), CD36(-), CD38(variably +), CD45(+), CD56(small subset +), CD64(-), CD117(dim and variably +), CD123(variably +), HLA-DR(+), TdT(-), MPO(+).	6.6	22.1	negative	0	positive	NA	NA	NA	FLT3 (Foundation; A680V; MAF 6%)|FLT3 (Foundation; Y842C; MAF 2%)|KDM6A (Foundation; P738fs*2;MAF 31%)|NPM1 (Foundation; W288fs*10+; MAF 25%)|TET2 (Foundation; Q742*; MAF 45%)|TET2 (Foundation; R1712fs*6;MAF 44%)	1	20.79671458	4
BA2035R	2424	BA2035D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	5	Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC|Midostaurin|Hydroxyurea	5	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Maintenance	Complete Response	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Midostaurin	Maintenance	284	Alive	2182	0	71.68788501	Alive	0	92	98	0	0.8	2.6	0	0	0.1	35	23	3.2	0.86	M1	19.9	6.8	NA	330	106.4	Normal	49	dim CD33, CD34, CD38, dim CD45, CD117, and MPO	8	84.96	positive	NA	negative	NA	NA	NA	DNMT3A (p.R882H; MAF ~50%)|FLT3-ITD (MAF 40%)|IDH1 (p.R132S; MAF ~50%)|SRSF2 (p.P95L; MAF ~40% )	0	71.68788501	2
BA2760R	2524	BA2760D	Waves1+2	yes	yes	yes	no	Female	Female	NA	NA	White	5	NA	NA	54	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	54	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin) plus Sorafenib	1	Induction	Complete Response	Standard Chemotherapy	19	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin) plus Sorafenib	Induction	19	Dead	36	1	1.18275154	Dead-Treatment	NA	75	NA	NA	NA	NA	39	NA	NA	NA	NA	NA	NA	NA	NA	NA	50,XX,+8,+10,+12,+21[20]	NA	NA	- Gain of chromosome 8 in 55% of cells - Gain of 8q22 (ETO) sequence in 77.8% of cells; 21q22 (AML1) gain in 12% and loss in 77.8% cells	9	CD11b, CD13, CD14 (subset), CD33, CD34 (subset), CD38, CD45, CD64 (subset), HLA-DR and MPO	NA	37.2	negative	0	negative	RUNX1 (p.D198N; 35.5%)	NA	NA	EZH2 (p.D146H; MAF 51.6%)|RUNX1 (p.D171N; MAF 19.8%)	1	1.18275154	4
BA2201R	2291	BA2201D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	68	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	HiDAC|3+7 (Cytarabine, Daunorubicin)|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	23	Bone Marrow Transplant	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	-1	Dead	861	1	28.28747433	Dead-Other	0.9	86	NA	0	0	2.6	20.8	0.9	0.2	20	28	2.9	1.49	M5	33	10.8	46,XY[20]	1211	95.9	Normal	83	Variable CD13, variable CD14, CD33, variable CD64, CD117, CD123, and partial HLA-DR positive	7.2	134.36	positive	NA	positive	NA	NA	NA	FLT3-ITD (MAF 91%)|IKZF1 (p.Q156H; MAF 45%)|NPM1 (p.W288fs*; MAF 49%)|SF3B1 (p.K666Q; MAF 50%)	1	28.28747433	4
BA2355R	2072	NA	Waves1+2	yes	no	yes	no	Female	Female	NA	NA	White	5	NA	KMT2A_re	83	FALSE	FALSE	FALSE	FALSE	FALSE	y	Squamous cell carcinoma|Lung Cancer	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	83	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	n	n	y	n	n	1	Targeted Therapy - Other	1	AG-221	1	Experimental	NA	NA	NA	Targeted Therapy - Other	AG-221	Experimental	-1	Alive	112	0	3.679671458	Alive	NA	45	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.1),del(19)(p13.3)[20]	NA	NA	FISH assays were positive for findings consistent with trisomy 8 in 79% to 90% of assayed cells, and positive for loss of 16q22 sequences in 91.5% of assayed cells.	133	positive for CD34, CD117, HLA-DR, and CD13, with aberrant loss of CD33, and with a subset of the blasts showing aberrant co-expression of CD34 and myeloperoxidase	NA	2.2	negative	0	negative	NA	NA	NA	IDH1 (p.G105G; MAF 50%)|IDH2 (p.R140Q; MAF 37.8%)	0	3.679671458	1
BA2113R	2088	BA2113D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Induction	Unknown	Standard Chemotherapy	9	Standard Chemotherapy	Decitabine	Induction	9	Dead	25	1	0.821355236	Dead-Disease	1.8	41	NA	0.9	0	79.6	0.9	14.2	0	21	19	2.7	0.98	M2	27.7	9.4	45~46,XX,add(1)(q42),del(5)(q31q35),del(6)(q13),del(9)(q13q34),del(17)(p13),i(21)(q10)[cp12]/46~47,idem,+mar[cp6]/46,XX[2]	404	88.5	EGR1 (5q31): 73% of cells were missing a signal for EGR1 (5q31), consistent with the deletion seen on metaphase analysis.  TP53 (17p13.1): 71% of cells were missing a signal for TP53 (17p13.1), consistent with the deletion seen on metaphase analysis.  RUNX1 (21q22): 77% of cells had three signals fo	6	CD13, dimCD33, CD34, CD38, CD58, partial CD64, CD117, CD123, and HLA-DR positive.	7.6	1.61	negative	0	negative	NA	NA	TP53 (p.R248Q; 53.3%)	TP53 (p.R248Q; MAF 56%)|U2AF1 (p.Q157P; MAF 41%)	1	0.821355236	2
BA2155R	2402	BA2155D	Waves1+2	yes	yes	yes	yes	Female	Female	Unknown	NA	White	2	bi	NA	72	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	73	0	Relapse|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	-1	Supportive/Palliative Care	Azacitidine	Hypomethylating/Low Dose Cytarabine	112	Dead	565	1	18.56262834	Dead-Disease	0	81	94	0	NA	51	3	2	NA	11	16	4.5	0.99	M0	28.2	9.6	46,XX,der(3)t(3;17)(q29;q21)[19]/46,XX,t(3;21)(q26.2;q22)[2]	NA	NA	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1, D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	10	CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(variably +), CD14(-), CD15(partial +), CD16(-), CD19 (-/few dim +), CD25(-), CD33(partial +), CD34(partial +), CD36(-), CD38(bright and variably +), CD45(+), CD56(variably +), CD64(-), CD117(variably +), CD123(-/few +), MPO(+), TdT(-/few dim +) (87% pop of med to large size cells) | HLA-DR(partial +)	6.9	35	negative	0	negative	NA	NA	TP53 (p.X187_splice; 30.4%)	CEBPA (Foundation; M1fs*60; MAF 34%)|CEBPA (Foundation; N307_V308insVETQQK; MAF 36%)|TP53 (Foundation; splice site 560-2insA; MAF 44%)	1	18.56262834	2
BA2955R	2039	BA2955D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	66	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	4	3+7 (Cytarabine, Daunorubicin), Bortezomib|MiDAC|Fludarabine, Cytarabine|Ibrutinib	4	Allogeneic - Sibling|Consolidation|Induction|Maintenance	Refractory	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Ibrutinib	Maintenance	382	Alive	2175	0	71.45790554	Alive	0	60	52	0	0.9	29.8	54.4	1.8	0.5	23	19	2.5	0.84	M5	24.2	7.7	47,XX,+6[6]/46,XX[19]	453	104.8	IGH/MAF: 74/100 cells (74%) had variant abnormal 0-1 red/ 1-4 green/ 2-7 yellow signal patterns reflecting IGH/MAF fusion. The majority of cells (56%) were 0 red/ 1 green/ 3 yellow. IGH: 68/100 (68%) cells scored had signal patterns consistent with IGH rearrangement and the 14;16 translocation,above | CDKN2C/CKS1B: 61/100 cells (61%) had 3-6 CKS1B (1q21) signals and 2 CDKN2C signals, reflecting gain of 1q. | The IGH/CCND1 and IGH/FGFR3 probe sets had extra IGH signals reflecting IGH involvement in the 14;16	92	dimCD4, CD11b, CD13, dimCD14, CD33, CD56, CD58, CD64, dimCD123 and HLA-DR positive; Minor subset of blasts with immunophenotype: CD13, CD33, CD34, CD58, CD117, dimCD123, HLA-DR and MPO positive.	7.4	14.94	positive	NA	negative	RUNX1 (p.P240Qfs*22; 40.0%)	NA	NA	BCOR (p.G1659E MAF ~10%,)|FLT3-ITD (MAF 38%)|NRAS (p.Q61R MAF ~5%)|RUNX1 (p.P240fs*22; MAF 37%)|RUNX1 (splice site [at invariant AG (G>A) splice acceptor site at end of Intron 6];  MAF 36% ))	0	71.45790554	4
BA2502R	2328	BA2502D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	50	0	Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Other	6	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Hydroxyurea	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Other	Hydroxyurea	Hypomethylating/Low Dose Cytarabine	365	Dead	302	1	9.921971253	Dead-Disease	0	NA	NA	0	2.6	8.8	17.6	2.6	0	NA	NA	NA	NA	M0	19.8	6.4	48,XX,+11,+13[19]	NA	93.4	NA	31	NA	NA	206.64	negative	0	negative	NA	NA	NA	NA	1	9.921971253	4
BA2322R	2060	BA2322D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	CBFB-MYH11	35	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	35	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	10	Standard Chemotherapy	HiDAC	Consolidation	112	Alive	1937	0	63.6386037	Alive	1.7	42	NA	0.9	0	40	18.3	7.8	0.2	54	23	3.5	0.6	M2	20.3	6.8	46,XX,inv(16)(p13.3q22)[21]	319	102.5	CBFB:  83/100 cells (83%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting CBFB rearrangement and consistent with the inverted  chromosome 16 in the metaphase karyotype.	63	Partial CD2, CD33, CD34, CD38, CD117, CD123, partial HLA-DR, dim MPO and partial TdT positive.	6.7	12.78	negative	0	negative	NA	NA	NA	NRAS (p.Q61P; MAF 15% )	0	63.6386037	2
BA2376R	2513	BA2376D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	Alive	1891	0	62.12731006	Alive	0.4	68	NA	0.1	3	17	62.6	16.9	0.1	29	17	3.7	1.51	M5	27.7	8.9	46,XY[20]	296	104.9	Normal	74	dim CD4, CD11b, partial CD14, CD15, dim CD33, CD38, CD56, CD58, CD64 and HLA-DR positive	8	16.84	negative	0	positive	NA	NA	NA	DNMT3A (p.S714C; MAF 35%)|NPM1 (p.W288fs*12; MAF 40%)|NRAS (p.G13V; MAF 6%)|PTPN11 (p.A72V; MAF 10%)|TET2 (p.Q876*; MAF 6%)	0	62.12731006	4
BA2020R	2065	BA2020D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	HispNative	3	NA	NA	51	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Consolidation|Induction	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	-1	Alive	762	0	25.0349076	Alive	NA	78.5	71	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M4	NA	NA	46,XY[20]	NA	NA	Normal	NA	CD13, partial CD15, CD33, CD117,  myeloperoxidase, and partial HLA-DR (\atypical cells with dim CD45\" - 45% of leukocytes) | CD13,  bright CD33, and bright CD64 (Monocytic (19% of leukocytes)) | CD13, CD33, and CD64, with  a left shift (increased percentage that lack CD10, CD11b,  and CD16) (Myeloid (19% of leukocytes))"	NA	12	positive	NA	positive	NA	NA	NA	FLT3-ITD (c.1775_1816dup; MAF 3%)|IDH2 (R140Q; MAF 42.3%)|NPM1 (c.860_863dup; MAF 14.5%)|PTPN11 (c.1507G>A; MAF 4%)|PTPN11 (c.1508G>A; MAF 15.4%)	0	25.0349076	4
BA2226R	2014	BA2226D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	53	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	Complete Response	Standard Chemotherapy	153	Standard Chemotherapy	SWOG S1203 (7+3 +/- Vorinostat)	Induction	153	Alive	1833	0	60.22176591	Alive	0	93	80	0	1.7	19.3	20.2	13.2	0.6	47	37	3.1	0.79	M5	26.8	8.8	46,XX[20]	977	92.1	Normal	36	Blast immunophenotype: partial CD11b, CD13, CD33, CD38, CD58, partial CD64, partial CD117 and a subset with MPO - Blast/promonocyte immunophenotype: CD11b, CD13, partial CD14, CD15, CD33, CD38, CD58 and CD64	6	42.34	negative	0	positive	NA	NA	NA	FLT3-D835 (p.D835Y; MAF: 40%)|NPM1 (p.W288fs*12; MAF 40%)	0	60.22176591	4
BA2200R	2371	BA2200D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	3	NA	NA	59	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	59	0	Relapse|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	Azacitidine, Sorafenib|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)	3	Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine, Sorafenib	Re-induction	-1	Dead	256	1	8.410677618	Dead-Disease	NA	93.2	47.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY,t(3;4)(p21;q25)[3]/46,XY[17]	NA	NA	NA	NA	CD4, CD7, CD11b, CD13,  CD33, partial CD34, CD117, HLA-DR, partial weak TdT and  partial CD64	NA	42.91	positive	NA	positive	NA	NA	NA	DNMT3A (c.2251T>C; MAF 36.9% (33.1% on 3/13/15))|FLT3-ITD (c.1759_1800dup; MAF 24% (39% on 3/13/15))|NPM1 (c.860_863dup; MAF 9.9% (24% on 3/13/15))	1	8.410677618	3
BA2121R	2356	BA2121D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	RUNX1-RUNX1T1	36	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	36	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	HiDAC|3+7 (Cytarabine, Daunorubicin)|Hydroxyurea	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	103	Alive	552	0	18.13552361	Alive	0	25	38	0	3.4	29.1	2.6	23.9	0	32	39	2.3	0.7	M2	21	7.5	45,X,-Y,t(8;2;21)(q22;p21;q22)[20]	NA	104.5	RUNX1T1/RUNX1: (92%)	29	CD13, CD33, partial CD34, CD64, CD19 dim, CD71, CD117 partial, HLA-DR, dim CD123, CD58 and MPO	6.7	24.98	negative	0	negative	NA	NA	NA	CBL (p.E369_Y371delinsH; MAF 31%)	0	18.13552361	2
BA2944R	2577	BA2944D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	3	NA	RUNX1-RUNX1T1	23	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	23	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	7+3 (Cytarabine, Idarubicin)|Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG)	2	Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG)	Allogeneic - Matched Unrelated Donor	-1	Alive	747	0	24.54209446	Alive	NA	88	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M1	NA	NA	46,XY,add(6)(q23),del(7)(q33),t(8;21)(q22;q22)[2]/46,sl,add(17)(p11.1)[5]/46,sdl1,add(16)(p11.2)[2]/46,sdl2,add(3)(q21)[8]/46,sdl3,add(20)(q11.2)[3]	NA	NA	62% t(8;21) (RUNX1T1;RUNX1) translocation present	NA	CD13, CD33, CD34, CD38, CD117, HLA-DR, cMPO, CD19 and partial CD56	NA	NA	negative	0	negative	NA	NA	NA	BRCA2 (c.6275_6276delTT; MAF unlisted)|BRCA2 (c.6859A>T; MAF unlisted)|FLT3-ITD (MAF unlisted)	0	24.54209446	3
BA2033R	2432	BA2033D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	5	NA	NA	71	FALSE	FALSE	TRUE	FALSE	FALSE	y	Non-Hodgkins Lymphoma	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	71	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	Lenalidomide|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care	NA	NA	NA	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Dead	11	1	0.361396304	Dead-Disease	NA	60	14	NA	NA	NA	7	NA	NA	NA	NA	NA	NA	NA	NA	NA	45,XY,add(3)(p10),add(5)(q11.2),psu dic(9;?;6)(6qter- > 6p22::?::9p22- > 9qter)[1]/44,sl,-add(3)(p10), +der(3;13)(q10;q10)[2]/48,sdl1,+8,+14,+21,+22[8]/42-44,sl,-add(3)(p10),add(4)(p15),-7,-8, add(12)(p11.2),+mar,+1-2r[cp7]/80-82 < 4n > ,slx2,-2,add(4)(q22)x2,-6,+8,+8,add(8)(p23)x2, (dic(8;11)(p12;p11.2)x2,-psu dic(9;?;6)(6qter- > 6p22::?::9p22- > 9qter),-10,der(10;17)(q10;q10), der(12;13)(p10;q10),der(14;17)(q10;q10),-16,-17,-18,add(20)(p11.2)[cp4])	NA	NA	FISH assays were positive for loss of 5q31 sequences in 85.5% of cells, positive for findings consistent with trisomy 8 in 49% of cells, and positive for findings consistent with monosomy 7 in around 8% of cells.	17	Flow cytometry was negative for increased myeloblasts. The flow showed a mild increase in   immature monocytic cells, but not to the degree seen in the marrow smears. This is likely   attributable to hemodilution of the sample received for flow cytometry. (Aberrant CD56, unusually dim CD38 - but only 3-4% assayed cells are myeloblasts)	NA	21.6	negative	0	negative	NA	NA	TP53 (p.P151H; 97.9%)	TET2 (p.G355D; MAF 33.8%)|TP53 (p.P19H; MAF 8.9%)	1	0.361396304	4
BA2867R	2116	BA2867D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NON-HISPANIC	White	2	mono	NA	78	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	78	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine	NA	NA	NA	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Dead	347	1	11.40041068	Dead-Disease	0.2	25	4	1	NA	25	10	60	NA	22	21	4.5	0.82	NA	47.3	15.3	46,XY[20]	NA	NA	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	15	CD2(-), CD7 (-), CD10(-), CD11b(-), CD13(dim +), CD14(-), CD15(+), CD16(-), CD19(-), CD22(partial +), CD33(-), CD34(bright +), CD36 (-), CD38(variably +), CD45(partial dim +), CD56(-), CD64(-), CD117(partial +), HLA-DR(partial +), MPO(-) and TdT(+) (Population #1 - 5.3%) | CD2(-), CD7(-), CD10 (-), CD11b(-), CD13(bright and variably +), CD14(-), CD15(-), CD16(-), CD22(-), CD33(partial +), CD34 (variably +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR(partial +), MPO(partial +), and TdT (-). (Population #2 - 25%)	7.5	5.79	negative	0	negative	RUNX1 (p.P383Afs*217; 46.0%)	NA	NA	NA	1	11.40041068	1
BA2089R	2080	BA2089D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	68	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	68	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Leukapheresis	y	y	y	y	y	y	1	Standard Chemotherapy	2	3+7 (Cytarabine, Daunorubicin)|Azacitidine	2	Induction|Maintenance	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	7	Dead	122	1	4.008213552	Dead-Unknown	0	NA	83	0	0.8	8.1	9.8	1.6	0.7	29	137	3.3	2.67	M5	35.5	11.4	46,XY[20]	3615	92.4	normal	104	NA	6.4	140.18	negative	0	negative	NA	ASXL1 (p.G645Wfs*12; 60.0%)	NA	ASXL1 (p.G645fs*12; MAF 52%)|IDH1 (p.R132L; MAF 47%)|KRAS (p.G12A; MAF 36%)|MLL (Partial tandem duplication )|SRSF2 (p.P95H; MAF 49%)	1	4.008213552	4
BA2224R	2202	BA2224D	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	62	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	Decitabine|Hydroxyurea	2	Induction|Re-induction	Complete Response i	Standard Chemotherapy	-1	Standard Chemotherapy	Hydroxyurea	Re-induction	263	Dead	424	1	13.9301848	Dead-Disease	0	21	2.5	1.7	0	68.3	1.7	25	0	22	9	3.2	0.81	M2	20.6	6.8	46,XY,del(5)(q22q35),del(12)(q24.1q24.1),add(17)(p11.2)[19]/46,XY[1]	NA	100.5	EGR1 (73.5%) ;  TP53: (85.5%)	174	CD7, CD34, CD117, HLA-DR, CD13, CD33, dim CD123, variable CD15 and subset MPO	5.8	3.74	negative	0	negative	NA	NA	TP53 (p.G266V; 65.7%)	JAK2 (p.V617F; MAF 1.5%)|SF3B1 (p.G742D; MAF 35%)|TP53 (p.G266V; MAF 55%)	1	13.9301848	2
BA2046R	2265	BA2046D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	2	NA	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction|Re-induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	-1	Alive	496	0	16.29568789	Alive	0	45	48	2	NA	69	4	2	NA	12	15	3.8	NA	NA	22.7	7.6	46,XY[19]	NA	NA	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	27	CD2(-), CD4(-), CD7(subset +), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(-), CD34(+), CD36(-), CD38(variably +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(+).	6.8	1.39	negative	0	negative	RUNX1 (N260fs*223+; MAF 26%)	NA	NA	IDH1 (R132C; MAF 42%)|NF1 (N935H; MAF 49%)|RUNX1 (N260fs*223+; MAF 26%)|SRSF2 (P95L; MAF 38%)	0	16.29568789	1
BA2972R	2111	BA2972D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	bi	NA	40	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	40	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	HiDAC|3+7 (Cytarabine, Daunorubicin)|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	-1	Alive	2163	0	71.06365503	Alive	0	80	27.8	0	0	62.6	4.4	5.2	0	26	22	3.9	0.78	M1	37.6	13.2	46,XY[20]	NA	91.7	normal	66	dim CD7, CD13, CD33, CD34, CD38, partial CD56 (25%), CD58, dim CD64, CD117, dim CD123, HLA-DR, and MPO+.	7.4	2.68	negative	0	negative	NA	NA	NA	CEBPA (p.K313_V314insK; MAF 39%)|CEBPA (p.S28fs*81; MAF 28%)|ZRSR2 (p.R378W; VAF 100%)	0	71.06365503	2
BA2978R	2411	BA2978D	Waves1+2	yes	yes	yes	yes	Female	Female	Declined	HISPANIC	HispNative	1	NA	RUNX1-RUNX1T1	14	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	14	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	DLI|Standard Chemotherapy|Bone Marrow Transplant	8	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Donor Lymphocyte Infusion|HiDAC|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide|Clofarabine, Cytarabine	4	Allogeneic - Sibling|Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	189	Bone Marrow Transplant	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)	Allogeneic - Sibling	-1	Alive	2083	0	68.43531828	Alive	NA	18	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M2	NA	NA	46,XX,t(8;21)(q21.3;q22)[17]/49,sl,+4,+15,+der(21)t(8;21)[2]/53,sdl,-4,+13,+18,+19,+20,+21[4]	NA	NA	All twenty-three metaphase cells examined were abnormal, with t(8;21), leading to RUNX1/RUNX1T1 fusion.   Two subclones, comprising 6 cells total, had an additional copy of the der(21).	NA	CD13, CD33, CD34, CD38, CD56, CD58, dim/partial CD64, CD117, CD123, HLA-DR and MPO	NA	NA	negative	0	negative	NA	NA	NA	FBXW7 (p.G79S; MAF 50%)|KIT (p.D816Y; MAF 45%)|NRAS (p.G12D; MAF 45%)	0	68.43531828	4
BA2829R	2238	BA2829D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	53	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	54	7	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction|Experimental|Re-induction|Maintenance	Refractory	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	49	Dead	168	1	5.519507187	Dead-Disease	0	9	NA	1.7	0.9	6.1	8.8	43	0.4	38	29	3.4	0.71	NA	27	9.1	46,XY,add(3)(p24)[cp4]/46,XY[14]	321	95.1	normal	170	CD117 (Initial diagnosis on 7/27/2015 BMBX: CD7, dim CD11b, CD13, CD33, partial CD34, CD58, CD117, CD123, dim MPO, and HLA-DR positive)	6.7	16.65	positive	NA	positive	NA	NA	NA	CBL (p.I423N; MAF <0.5%)|DNMT3A (p.R882C; MAF 0.9%)|FLT3-ITD (MAF 2.9)|NPM1 (p.W288fs*12; MAF 0.7%)|TET2 (p.Q548*; MAF 0.7%)	1	5.519507187	4
BA2851R	2437	BA2851D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	53	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	2	Induction|Re-induction	Refractory	Standard Chemotherapy	4	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Re-induction	7	Dead	128	1	4.205338809	Dead-Disease	0	45	50	0	19.4	6.4	1.6	11.3	0	73	83	3.3	0.88	M2	29.4	9.6	46,XX[20]	2008	109.3	Normal	33	partial CD7, CD13, CD33, CD34, variable CD38, CD117, CD123, partial HLA-DR and dim MPO	6.8	137.54	negative	0	negative	NA	NA	NA	DNMT3A (p.R882H; MAF 45%)|FLT3-D835 (p.D835Y; MAF 3%)|MLL (Partial Tandem Duplication)|NRAS (p.G13D; MAF 35%)|NRAS (p.Q61R; MAF 3%)	1	4.205338809	4
BA2587R	2215	BA2587D	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1	NA	CBFB-MYH11	64	FALSE	FALSE	FALSE	FALSE	FALSE	y	Esophageal Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	64	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	6	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC|Hydroxyurea|Cytarabine, Methotrexate	5	Consolidation|Induction|Allogeneic - Child|CNS|Re-induction	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)	Allogeneic - Child	-1	Dead	629	1	20.66529774	Dead-Disease	0.9	90	60	4.3	0.9	9.6	44.3	13.9	0.1	31	45	2.6	0.79	M5	22.7	7.7	46,XY,inv(16)(p13q22)[20]	1151	93.8	CBFB (77%)	10	dim CD2, variable CD5, CD13, CD33, CD34, CD38, variable CD64, CD117, dim CD123, HLA-DR, and MPO (Blast immunophenotype) | dim CD4, CD11b, CD14, dim CD15, CD33, dim CD34, CD38, CD64, dim HLA-DR, and bright MPO (Monocytic/blast equivalent immunophenotype)	5.5	24.64	negative	0	negative	NA	NA	NA	KIT (p.D816V; MAF 45% )	1	20.66529774	2
BA2461R	2025	BA2461D	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	66	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	66	0	Post-Chemotherapy	Remission	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Dead	231	1	7.589322382	Dead-Disease	0.8	0	0	0	2	18.6	9.3	69.3	0	NA	NA	NA	NA	NA	32.1	10.2	46,XY[20]	NA	94.7	Normal	345	The analysis was performed by flow cytometry on the bone marrow aspiratespecimen. The analysis shows CD34+ blasts account for 1% of CD45+ events. Maturing myeloid precursors and monocytic cells demonstrate a normal pattern of myelomonocytic antigen expression. | Lymphocytes account for 5% of CD45+ events and include 90% T cells and 7% NK cells. T cells demonstrate a CD4:CD8 ratio of 2.4:1 without aberrant antigen expression. B cells are essentially absent; no definitive monoclonal B cell population is identified	NA	8.94	negative	0	negative	NA	NA	NA	NA	1	7.589322382	4
BA2695R	2409	BA2695D	Waves1+2	no	no	no	no	Female	Male	NA	NA	Black	2	NA	NA	67	FALSE	FALSE	FALSE	FALSE	FALSE	y	Acute Myeloid Leukemia	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	68	254	Post-Chemotherapy|Post-DLI|Post-Transplant|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	4	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other|Bone Marrow Transplant	4	AG-120|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea	3	Salvage|Experimental|Supportive/Palliative Care	NA	NA	NA	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	-1	Dead	449	1	14.75154004	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	18	25	4.1	NA	NA	20.4	6.8	47,XX,+11[5]/48,idem,+19[15]	NA	NA	nuc ish(DXZ1x2)[181]//(DXZ1,DYZ3)x1[19] nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[176/200],(PML,RARA)x2[196], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	24	NA	7.4	27.5	positive	1.325581395	negative	NA	NA	TP53 (p.R283C; 45.1%)	FLT3-ITD|IDH1 (R132G)|IDH1 (p.R132G; MAF 51%)|KMT2A (MLL-PTD (exons 2-10))|TP53 (p.R283C; MAF 49%)	1	14.75154004	4
BA2623R	2049	BA2623D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	3	NA	CBFB-MYH11	72	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	72	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Azacitidine|Momelotinib	2	Hypomethylating/Low Dose Cytarabine|Experimental	NA	NA	NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Dead	188	1	6.176591376	Dead-Disease	NA	NA	58	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY,inv(16)(p13.1q22)[20]	NA	NA	NA	NA	NA	NA	8.21	negative	0	negative	NA	NA	NA	NA	1	6.176591376	2
BA2024R	2122	BA2024D	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	48	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	48	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	ADE (Cytarabine, Daunorubicin & Etoposide)	1	Induction	Unknown	Standard Chemotherapy	7	Standard Chemotherapy	ADE (Cytarabine, Daunorubicin & Etoposide)	Induction	7	Dead	33	1	1.084188912	Dead-Disease	0.2	13	NA	0	0.5	10.2	4.4	84.7	0	84	28	3.9	0.95	NA	42.1	14	46,XY[20]	231	89.2	Normal	330	CD33, CD117 positive, negative for CD34 and HLA-DR	8.2	6.3	positive	NA	positive	NA	NA	NA	FLT3-ITD (MAF 33%)|IDH2 (p.R140Q; MAF 40%)|NPM1 (p.W288fs*12; MAF 40%)	1	1.084188912	4
BA2426R	2511	BA2426D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	5	NA	CBFB-MYH11	62	FALSE	FALSE	FALSE	FALSE	FALSE	y	Non-Hodgkins Lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	Alive	26	0	0.854209446	Alive	NA	50	20	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY,inv(16)(p13.1q22)[20]	NA	NA	positive for rearrangement of CBFB in 60.5% of cells.	32	positive for CD13, CD33, HLA-DR, CD34, and CD117, with partial aberrant expression of CD7. (Peripheral blood) | positive for CD34, CD117, HLA-DR, CD13, and CD33 (Marrow)	NA	52.8	negative	0	negative	NA	NA	NA	EZH2 (p.D146H; MAF 50%)	0	0.854209446	2
BA2271R	2386	BA2271D	Waves1+2	yes	yes	yes	yes	Male	Male	White	HISPANIC	HispNative	1	NA	NA	8	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid leukaemia associated with Down syndrome	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid leukaemia associated with Down syndrome	8	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Intrathecal	2	ADE (Cytarabine, Daunorubicin & Etoposide)|Cytarabine	2	Induction|CNS	Complete Response	Standard Chemotherapy	151	Intrathecal	Cytarabine	CNS	151	Alive	1957	0	64.29568789	Alive	10.8	70	NA	0	1.8	8.1	13.5	8.1	0	13	25	3.2	0.72	M1	26.8	9.3	47,XY,+21c[20]	NA	90.5	RUNX1 (21q22): 89% of cells had three signals for RUNX1 (21q22) consistent with the three copies of chromosome 21 seen on metaphase analysis.	40	dim CD11b, variable CD13, dim variable CD14, CD15, CD38, CD58, dim CD64, and MPO	8.2	67.53	negative	0	positive	NA	NA	NA	NPM1 (p.W288fs*12; MAF 50%)	0	64.29568789	4
BA3004R	2420	BA3004D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	76	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	76	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	5+2 (Cytarabine, Idarubicin)|Decitabine	2	Induction|Re-induction	Refractory	Standard Chemotherapy	8	Standard Chemotherapy	5+2 (Cytarabine, Idarubicin)	Re-induction	4	Dead	26	1	0.854209446	Dead-Disease	0	95	54	0	0.9	16.8	3.5	24.8	1.1	23	22	3.5	1.33	M1	31.5	10.3	46,XX[22]	244	92.6	Normal	29	dimCD13, CD33, CD45, CD56, dimCD117 and MPO positive	7	27.17	positive	NA	positive	NA	NA	NA	ASXL1 (p.G966delG; MAF 50%)|DNMT3A (p.R736H; MAF 45%)|FLT3-ITD (MAF 20%)|NPM1 (p.W288fs*12; MAF 35%)	1	0.854209446	3
BA2579R	2238	BA2579D	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	53	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	54	30	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction|Experimental|Re-induction|Maintenance	Refractory	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	49	Dead	168	1	5.519507187	Dead-Disease	0	8	1	4.7	0.9	40.6	10.4	43.4	0	40	34	3.8	0.73	NA	20.2	7.1	46,XY[12]	235	93.5	normal	17	dim variable CD7, dim CD11b, CD13, CD33, CD34, CD58, CD117, and CD123	6.8	1.06	positive	NA	positive	NA	NA	NA	DNMT3A (p.R882C; MAF 6%)|FLT3-ITD (MAF 15-20%)|NPM1 (p.W288fs*12; MAF 6%)|TET2 (p.Q548*, MAF 6%)	1	5.519507187	4
BA3010R	2478	BA3010D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	6	NA	NA	71	FALSE	FALSE	TRUE	FALSE	FALSE	y	Non-Hodgkins Lymphoma	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	71	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	Vidaza|Rituximab|Decitabine	2	Consolidation|Maintenance	NA	NA	NA	Standard Chemotherapy	Decitabine	Maintenance	86	Dead	51	1	1.675564682	Dead-Disease	NA	20	10	1	NA	22	48	16	NA	6	33	3.7	1.57	NA	26	8.1	46,XY[20]	NA	91.9	NA	13	Positive for CD34, CD117, HLADR, CD33, CD13 but negative for CD14, CD64, CD11b, CD19, and CD3 (Peripheral Immunophenotyping) | The blasts are positive for CD34 and CD117 (Bone marrow Immunophenotyping)	7	44.8	negative	0	negative	RUNX1 (p.R320*; 40.9%)	ASXL1 (p.G646Wfs*12; 39.4%)	NA	BCOR (p.A603pfs*66; MAF55%)|KRAS (p.G12V; MAF 49%)|RUNX1 (pR320*; MAF 47%)|SRSF2 (p.P95H; MAF 49%)|STAG2 (p.Y636*; MAF 96%)	1	1.675564682	4
BA2662R	2393	BA2662D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Other	4	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea	4	Consolidation|Unknown|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Alive	1962	0	64.45995893	Alive	0	74	60	1.9	15.1	21.7	50	11.3	0	23	32	2.6	0.78	M5	21.6	7.2	46,XX[20]	905	100.5	Normal	150	NA	6.7	84.69	positive	NA	positive	NA	NA	NA	CEBPA (p.K298Q; MAF 25%)|DNMT3A (p.R882C; MAF 44%)|FLT3-ITD (MAF 25%)|IDH2 (p.R140Q; MAF 18%)|NPM1 (p.W288fs*12; MAF 46%)	0	64.45995893	4
BA2674R	2301	BA2674D	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	70	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	71	281	Post-Chemotherapy|Relapse	Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	4	7+3 (Cytarabine, Idarubicin)|Azacitidine, Itacitinib|Azacitidine|Decitabine	2	Salvage|Induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine, Itacitinib	Salvage	449	Dead	1389	1	45.63449692	Dead-Disease	0	90	NA	0	0	27.8	2.9	8.6	0.4	81	43	3.3	NA	M0	31.9	10.2	47,XY,+4[2]/46,XY[18]	235	94.7	Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously.	91	partial CD7 (~35%), CD13, partial dim CD33, CD34, CD38, variable CD56, and CD117	6.6	73.42	negative	0	negative	NA	ASXL1 (p.Q588*; MAF 49%)	NA	ASXL1 (p.Q588*; MAF 49%)	1	45.63449692	4
BA2280R	2044	BA2280D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	72	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	72	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	3	7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib	2	Induction|Experimental	Refractory	Standard Chemotherapy	10	Targeted Therapy - Kinase Inhibitor(s)	Ponatinib	Experimental	15	Dead	118	1	3.876796715	Dead-Disease	0.9	90	78	0	0	2.7	3.6	17.3	1.4	28	23	2.8	0.56	M1	31.7	9.9	46,XX[20]	261	98.1	Normal	211	CD13, CD33, CD38, partial CD56, partialCD64, CD117, dimCD123, and MPO	6.5	24.01	positive	NA	positive	NA	NA	NA	CEBPA (p.E163*; MAF 39%)|FLT3-ITD (MAF 40%)|NPM1 (p.W288fs*12; MAF 40%)	1	3.876796715	4
BA2512R	2257	BA2512D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	3	NA	NA	72	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Targeted Therapy - Other	1	SGN-CD33A	1	Experimental	NA	NA	NA	Targeted Therapy - Other	SGN-CD33A	Experimental	-1	Dead	179	1	5.880903491	Dead-Disease	NA	41	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5	NA	NA	NA	NA	NA	Normal	NA	partial CD56, bright CD33,  CD13, bright CD64, HLA-DR (Monocytic cells)	NA	NA	negative	0	positive	NA	NA	NA	DNMT3A (c.2645G>A; MAF 45.4%)|FLT3-D835 (c.2503G>T (D835Y); MAF 15.5%)|NPM1 (c.860_863dup; MAF 11%)|PTPN11 (c.178G>C; MAF 8.4%)|PTPN11 (c.211T>C; MAF 10%)|TET2 (c.3955-2A>G; MAF 45.4%)	1	5.880903491	4
BA2658R	2218	BA2658D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	24	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	24	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	7	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Decitabine|Fludarabine, Cyclophosphamide, TBI |Busulfan, Cyclophosphamide	7	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction|Maintenance|Double Umbilical Cord Blood Transplant (DUCBT)	Refractory	Standard Chemotherapy	7	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Alive	2133	0	70.07802875	Alive	0	NA	NA	1.8	0.9	23.9	23	7.9	0	37	28	3.7	0.95	M4	32.3	11.3	46,XY[20]	243	92.8	Normal	102	dimCD13, CD33, CD34, CD56, CD117, and  CD123	7.1	21.84	negative	0	negative	NA	NA	NA	NRAS (p.G12C; MAF 40%)	0	70.07802875	4
BA2394R	2381	BA2394D	Waves1+2	yes	yes	yes	yes	Male	Female;Male	NA	NA	White	3	NA	NA	73	FALSE	FALSE	FALSE	FALSE	FALSE	y	Lung Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	73	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	NA	NA	NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	7	Dead	36	1	1.18275154	Dead-Disease	NA	NA	79	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	45,X,-Y[20]	NA	NA	Normal	NA	NA	NA	19.64	negative	0	negative	RUNX1 (c.319C>G; MAF 73.9%)	ASXL1 (c.1940dup; MAF 37.9%)	NA	ASXL1 (c.1940dup; MAF 37.9%)|BCORL1 (c.3496dup: MAF 7.5%)|RUNX1 (c.319C>G; MAF 73.9%)|TET2 (c.3803+1G>A; MAF 39.3%)	1	1.18275154	2
BA2950R	2018	BA2950D	Waves1+2	yes	yes	yes	yes	Female	Female	Black	NA	Black	6	NA	NA	44	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	47	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	1	Targeted Therapy - Other	1	Radiation	1	Unknown	NA	NA	NA	Targeted Therapy - Other	Radiation	Unknown	14	Alive	1231	0	40.44353183	Alive	NA	90	45	0	NA	28	5	1	NA	30	41	3.3	0.82	NA	29.3	9.6	46,XX[20]	NA	89.9	This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small precentage of tumor cells with chromosome abnormalities may not be detected due to the cells examined.	5	The blasts are positive for HLA-DR, CD34, CD117 (PARTIAL), CD13, CD(PARTIAL/DIM), CD33, TDT (DIM, SUBSET) and are negative for CD11b, CD14, CD64, MPO and all B and T cell markers. (Bone Marrow Immunophenotyping)	7.3	6.5	positive	1	negative	RUNX1 (p.L98Pfs*40; 46.8%)	NA	NA	NA	0	40.44353183	4
BA2981R	2156	BA2981D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	6	NA	NA	76	FALSE	FALSE	FALSE	FALSE	FALSE	y	Breast Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	77	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	1	Unknown	1	Azacitidine	1	Unknown	NA	NA	NA	Unknown	Azacitidine	Unknown	424	Dead	151	1	4.960985626	Dead-Unknown	NA	86	50	1	NA	14	5	20	NA	32	20	2.9	0.62	NA	24.3	7.8	48-51,XX,del(4)(q25),del(5)(q11.2),-17,-18,+22,+3-5mar[20]	NA	84.1	NA	27	POSITIVE FOR DIM CD45, HLADR, CD34, CD117, CD13, CD33, CD43, CD81, CD58. (Bone Marrow Immunophenotyping)	5.4	14.3	negative	0	negative	NA	NA	TP53 (p.R175H; 91.7%)	NA	1	4.960985626	1
BA2934R	2226	NA	Waves1+2	no	no	no	no	Female	Female	White	NON-HISPANIC	White	1	NA	NA	74	FALSE	FALSE	FALSE	FALSE	FALSE	y	Acute Myeloid Leukemia	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	74	0	Post-Chemotherapy	Remission	Peripheral Blood	y	n	n	y	n	n	1	Standard Chemotherapy	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|MiDAC	2	Consolidation|Induction	Refractory	Standard Chemotherapy	8	Standard Chemotherapy	MiDAC	Consolidation	3	Alive	2346	0	77.07597536	Alive	0.9	NA	NA	1.9	0.2	27.7	3.5	65.8	0	30	36	4.3	0.8	NA	38.7	13	46,XX[20]	NA	102.9	normal	206	NA	7.3	4.26	NA	NA	NA	NA	NA	NA	NA	0	77.07597536	4
BA2539R	2351	BA2539D	Waves1+2	no	no	no	no	Female	Female	NA	NA	White	3	NA	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	50	0	Post-Chemotherapy	Remission	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)|MiDAC	4	Consolidation|Induction|Re-induction|Maintenance	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Maintenance	8	Dead	425	1	13.96303901	Dead-Treatment	NA	0.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX[20]	NA	NA	\showed multiple RUNX1 signals as well as a 3rd RUNX1 signal at 7p consistent with t(7;21)(p22;q22).\""	NA	NA	NA	10.08	negative	0	negative	NA	NA	NA	NA	1	13.96303901	4
BA2249R	2238	BA2249D	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	53	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	54	63	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction|Experimental|Re-induction|Maintenance	Refractory	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	49	Dead	168	1	5.519507187	Dead-Disease	1.8	48	NA	3.6	6.2	23.2	18.7	17	1.3	29	41	3.6	1	NA	20.9	6.9	46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3]	NA	96.3	normal	21	dimCD7, CD13, dimCD11b, CD33, variable CD34, CD58,  CD117, CD123, and HLA-DR positive	6.8	20.77	positive	9	positive	NA	NA	NA	DNMT3A (p.R882C; MAF 45%)|FLT3-D835 (p.D835H; MAF 15%)|FLT3-ITD (MAF 78%)|NPM1 (p.W288fs*12; MAF 40%)|TET2 (p.Q548*; MAF 45%)	1	5.519507187	4
BA2034R	2080	BA2034D	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	68	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	68	72	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	3+7 (Cytarabine, Daunorubicin)|Azacitidine	2	Induction|Maintenance	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	7	Dead	122	1	4.008213552	Dead-Unknown	0.8	NA	NA	0.9	0	9.3	0	0	0.5	12	14	2.5	0.9	M5	20.6	6.4	46,XY[19]	NA	90.4	normal	60	NA	6.3	6.21	negative	0	negative	NA	NA	NA	NA	1	4.008213552	2
BA2109R	2251	BA2109D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	52	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	MissingKaryo	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	52	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	8	Standard Chemotherapy	HiDAC	Consolidation	81	Dead	585	1	19.21971253	Dead-Disease	0	NA	NA	30	13	9	21	19	0.1	54	50	2.2	0.84	M4	18.8	6.5	NA	NA	98.9	NA	21	NA	6.5	65.58	negative	0	negative	NA	NA	NA	NOTCH1 (p.K2181R ; MAF 50%)|SRSF2 (p.P95H ; MAF 50%)	1	19.21971253	4
BA2242R	2507	BA2242D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	6	Fludarabine, Melphalan|Ruxolitinib|7+3 (Cytarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC|Ibrutinib	5	Consolidation|Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Ruxolitinib	Maintenance	-1	Alive	2027	0	66.59548255	Alive	0	>95	NA	0	0	89.9	9.3	0.8	0	43	31	2.4	0.5	M1	19.5	6.5	NA	313	92.4	normal	32	partial CD13, CD33, CD38, moderate CD45, CD56, CD58,  CD64, dim CD117, CD123 and MPO+	5.8	67.36	negative	0	positive	NA	NA	NA	CREBBP (p.R2353Q; MAF 51%)|NPM1 (p.W288fs*12; MAF 46%)|TET2 (p.Q270*; MAF 90%)	0	66.59548255	4
BA2277R	2044	BA2277D	Waves1+2	no	no	no	no	Female	Female	White	NON-HISPANIC	White	1	NA	NA	72	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	72	40	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	3	7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib	2	Induction|Experimental	Refractory	Standard Chemotherapy	10	Targeted Therapy - Kinase Inhibitor(s)	Ponatinib	Experimental	15	Dead	118	1	3.876796715	Dead-Disease	0	NA	70	0	1.8	34.8	3.6	0.9	23.2	13	40	3.2	0.55	M1	22.7	7.5	46,XX[5]	339	89.7	Normal	32	NA	6.4	6.04	positive	0.639344262	positive	NA	NA	NA	CEBPA (p.E163*; MAF 40%)|FLT3-ITD (MAF 45%)|NPM1 (p.W288fs*12; MAF 32%)	1	3.876796715	3
BA2727R	2510	BA2727D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	GATA2-MECOM	36	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	38	494	Residual Disease|Post-Chemotherapy|Post-DLI|Post-Transplant	Residual	Peripheral Blood	y	y	y	y	y	y	3	DLI|Standard Chemotherapy|Bone Marrow Transplant	7	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Decitabine|Busulfan, Cyclophosphamide	6	Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	4	Standard Chemotherapy	Decitabine	Salvage	4	Dead	533	1	17.51129363	Dead-Disease	0	NA	NA	0.9	0	13.9	0	0.9	0.4	59	28	2.8	NA	NA	32.6	10.3	46,XX,inv(3)(q21q26)[5]	NA	99.4	FISH) was performed with a MECOM/RPN1 probe set. 125/200 (62.5%) interphase cells scored had a 1 red/ 1 green/ 2 yellow double fusion signal pattern reflecting MECOM/RPN1 fusion and the paracentric inversion of the long arm of a chromosome 3 observed in the metaphase karyotype.  FISH was also perfor	38	NA	6.7	7.08	negative	0	negative	NA	NA	NA	NA	1	17.51129363	1
BA2132R	2140	BA2132D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	6	NA	NA	70	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	70	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Induction	Unknown	Standard Chemotherapy	37	Standard Chemotherapy	Azacitidine	Induction	37	Alive	37	0	1.215605749	Alive	NA	90	17	NA	NA	20	18	2	NA	24	26	3.8	0.76	NA	25	8.2	46,XX,del(5)(q22q35)[20]	NA	87.7	Positive for 5q deletion in 91% of cells.	35	POSITIVE FOR CD34, HLA-DR, CD117 AND CD33, AND NEGATIVE FOR MPO, TdT, CD13, CD19, CD20 AND CD10. (Bone Marrow Immunophenotyping)	6.2	7.7	positive	0.333333333	negative	NA	NA	NA	FLT3-ITD|MLL |U2AF1 (p.S34F; MAF 35%)	0	1.215605749	4
BA2618R	2498	BA2618D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	83	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	83	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	2	AG-221|Azacitidine, SGN-CD33A	2	Induction|Experimental	Refractory	Standard Chemotherapy	-1	Targeted Therapy - Other	AG-221	Experimental	-1	Dead	434	1	14.2587269	Dead-Disease	0.3	12	3	0	9.4	26.9	24.5	38.9	0	42	47	3.2	1.3	NA	21.1	6.8	46,XY[20]	NA	87.9	Normal	213	NA	6	3.72	negative	0	negative	NA	ASXL1 (p.Y425*; 46.8%)	NA	CREBBP (p.M2408V; MAF 48%)|IDH2 (p.R140Q; MAF 47%)|NRAS (p.G12D; MAF 49%)	1	14.2587269	1
BA2521R	2433	BA2521D	Both	no	no	no	no	Female	Female	White	NON-HISPANIC	White	1	NA	NA	44	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	44	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	6	Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea|Busulfan, Cyclophosphamide|7+3 (Cytarabine, Idarubicin) plus Dasatinib	5	Allogeneic - Sibling|Induction|Experimental|Re-induction|Post-Transplant Relapse	Complete Response i	Standard Chemotherapy	28	Standard Chemotherapy	Azacitidine	Post-Transplant Relapse	81	Dead	319	1	10.48049281	Dead-Disease	0	75	80	0	7.7	10.3	22.2	6.8	0	21	25	2.4	1.25	M5	22.9	7.4	46,XX[20]	705	96.2	Normal	42	CD13, CD33, subset CD34, variable CD117, CD123, HLA-DR, and variable MPO positive - Monocytic/blast equivalent immunophenotype: CD11b, CD13, subset CD14, variable CD16, CD33, CD64, dim CD123, and HLA-DR positive	6.2	69.84	positive	2.333333333	positive	NA	NA	NA	DNMT3A (p.R882H; MAF 48%)|FLT3-ITD (MAF 70%)|NPM1 (p.W288fs*12; MAF 46%)	1	10.48049281	4
BA2846R	2004	BA2846D	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	75	FALSE	FALSE	FALSE	FALSE	FALSE	y	Rectal Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	75	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Supportive/Palliative Care	2	Hydroxyurea|Decitabine	1	Supportive/Palliative Care	NA	NA	NA	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	4	Dead	17	1	0.558521561	Dead-Disease	0	90	90	0	0	5.1	0.8	0.9	1	23	51	2.9	0.97	M1	25.3	8.5	46,XY[20]	728	91.3	Normal	28	CD33, dim CD38, variable CD56, CD58, dim CD64, CD117, CD123, and MPO positive.	6.6	62.87	negative	0	positive	NA	NA	NA	IDH2 (p.R140Q; MAF 47%)|NPM1 (p.W288fs*12 (4 nt insertion with frameshift); MAF 17%)|SRSF2 (p.P95L; MAF 37%)	1	0.558521561	2
BA2885R	2139	BA2885D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	81	FALSE	FALSE	FALSE	FALSE	FALSE	y	Skin cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	81	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Induction	Unknown	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine	Induction	6	Dead	14	1	0.459958932	Dead-Disease	0	90	70	0	0.8	6.1	72.2	12.2	0.4	62	50	2.9	4.22	M5	22.8	7.3	46,XX[20]	262	90.8	Normal	29	CD11b, variable CD13, variable CD14, CD33, CD56, CD64, dim CD123 and dim HLA-DR positive	5.8	97.26	negative	0	positive	NA	ASXL1 (p.G645Vfs*58; 16.7%)	NA	ASXL1 (p.W796fs*22; MAF 48%)|NPM1 (p.W288fs*12; MAF 40%)|TET2 (p.S825fs*1; MAF 49%)	1	0.459958932	4
BA2639R	2368	BA2639D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	CBFB-MYH11	36	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	36	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	6	Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Hydroxyurea|Busulfan, Cyclophosphamide	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	1	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Alive	2075	0	68.1724846	Alive	0	40	60	1.7	0	33.4	5.1	18.8	0.1	38	28	3.2	0.53	M2	22.9	7.6	46,XX,t(16;16)(p13.2;q22)[20]	508	99.6	CBFB: 191/200 cells (95.5%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement, consistent with the 16;16 translocation observed in the metaphase karyotype.	24	Immunophenotype: CD13, partial CD15, dim CD33, CD34, CD38, dim CD45, CD58, variable CD64, variable CD117, CD123, and dim HLA-DR positive.	7.3	20.44	negative	0	negative	NA	NA	NA	KIT (p.T417_D419delinsY; MAF 33%)	0	68.1724846	2
BA2775R	2138	BA2775D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NA	White	3	NA	NA	26	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	27	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	16	Standard Chemotherapy	HiDAC	Consolidation	-1	Alive	647	0	21.25667351	Alive	NA	35	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[15]	NA	NA	Normal	NA	weak  CD13, CD33, partial CD117, and myeloperoxidase	NA	NA	negative	0	positive	NA	NA	NA	IDH2 (p.Arg140Gln; MAF 45.9%)|NPM1 (p.Trp288fs; MAF 19.5%)	0	21.25667351	4
BA2402R	2410	BA2402D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	82	FALSE	FALSE	FALSE	FALSE	FALSE	y	Breast Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	82	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	268	1	8.804928131	Dead-Disease	0	50	NA	0	1.8	42.8	0	5.4	3.7	13	18	2.8	1.03	NA	27.7	9.2	46,XX	279	91.1	trisomy 8 in 5 of 20 metaphase cells	44	NA	7	1.36	negative	0	negative	NA	NA	NA	DNMT3A (p.R882H; MAF 39%)|GATA1 (p.R191C; MAF 51%)|IDH2 (p.R172K; MAF 36%)	1	8.804928131	4
BA2097R	2201	BA2097D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NA	White	4	NA	NA	77	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	77	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	Azacitidine, Sorafenib|Decitabine, Midostaurin	2	Induction|Re-induction	Refractory	Standard Chemotherapy	165	Standard Chemotherapy	Azacitidine, Sorafenib	Re-induction	-1	Alive	288	0	9.46201232	Alive	NA	41	18	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[20]	NA	NA	CD15, AND PARTIAL CD56 -7/DEL(7q) TRISOMY #8MLL GENE REARRANGEMENTDEL(20q)	NA	ABNORMAL CD34+ BLAST POPULATION EXPRESSING ABERRANT CD7,CD4, AND CD2, AND CD38, CD10, CD22, CD11C, HLA-DR, CD117,CD13, CD33,CD15, AND PARTIAL CD56	NA	2.2	positive	0.612903226	negative	NA	NA	NA	FLT3-ITD	0	9.46201232	4
BA2786R	2177	BA2786D	Both	no	no	no	no	Female	Female	NA	NA	AdmixedBlack	6	NA	MLLT3-KMT2A	30	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	31	25	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response i	Standard Chemotherapy	27	Standard Chemotherapy	HiDAC	Consolidation	93	Alive	486	0	15.96714579	Alive	NA	79	64	NA	NA	2	15	1	NA	44	53	4	0.52	NA	NA	9.6	46,XX,t(4;15)(q31;q22),t(9;11)(p22;q23)[20]	NA	89.4	This test has detected t(4;15) and t(9;11) in 19 of 20 cells analyzed. Translocation t(9;11) was reported previously in this case as the primary abnormality. Translocation t(4;15) represents a secondary chromosome change, that was already reported on previous sample. (Cytogenetics)	69	POSITIVE FOR CD33, CD11B, CD64, CD4 AND MPO (SUBSET/DIM) AND ARE NEGATIVE FOR CD117, CD13, CD34, HLA-DR AND TDT (Bone Marrow Immunophenotyping)	NA	20.3	negative	0	negative	NA	NA	NA	NA	0	15.96714579	4
BA2399R	2196	BA2399D	Waves1+2	yes	yes	yes	yes	Male	Male	Asian	NA	AdmixedWhite	2	NA	NA	55	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI |7+3 (Cytarabine, Idarubicin) plus Crenolanib	4	Consolidation|Induction|Allogeneic - Child|Maintenance	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	Cyclophosphamide	Maintenance	1	Alive	668	0	21.94661191	Alive	0	91	99.2	0	NA	0.8	0	0	NA	33	27	3	0.85	NA	18.8	6.2	46,XY[29]	808	NA	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	28	CD2(-), CD4(partial dim +), CD7(-), CD11b(-), CD13(dim +), CD14(-), CD15(-/few dim +), CD16(-), CD33(+), CD34 (partial +), CD36(equivocal/small subset appears +), CD38(partial +), CD45(+), CD56(-), CD64(-/few dim +), CD117(+), HLA-DR(+ and variable), TDT(-), MPO(+)	6.1	181.08	positive	1	negative	NA	NA	NA	FLT3-ITD (S584_S585INSSDNEYFYVDFRE; MAF 29.0%)|IDH1 (R132H; MAF 47.0%)|MLL (Foundation; MLL-PTD Exons 2-8; not GeneTrails)|TET2 (SPLICE SITE 3500+1G>A; MAF 48.0%)	0	21.94661191	2
BA2850R	2210	BA2850D	Waves1+2	yes	yes	yes	yes	Male	Male	Multiracial	NA	White	6	NA	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	50	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	-1	Alive	576	0	18.92402464	Alive	NA	75	73	NA	NA	6	6	8	NA	44	20	3.5	1	NA	24.8	8	46,XY[20]	NA	91.5	NA	26	These are postive for CD34, CD117, HLADR, CD13 and CD33. These are negative for CD3, CD20, CD4, CD11b. (Bone Marrow Immunophenotyping)	5.8	17.1	positive	1.5	negative	RUNX1 (p.E454Gfs*149; 21.4%)	NA	NA	NA	0	18.92402464	3
BA2174R	2341	BA2174D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	Asian	1	NA	NA	46	FALSE	FALSE	FALSE	FALSE	FALSE	y	Anaplastic Astrocytoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	46	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	7	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Hydroxyurea|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG	4	Consolidation|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	Refractory	Standard Chemotherapy	1	Bone Marrow Transplant	Fludarabine, Melphalan, ATG	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Dead	637	1	20.92813142	Dead-Disease	0.9	25	16	1.7	4.3	6.1	32.2	48.7	0.2	14	15	3.1	0.64	NA	32	9.5	46,XX,del(3)(p25),add(6)(p22),t(10;12)(p15;q13)[5]/46,XX[18]	440	80.6	Normal	92	Immunophenotype: CD13, CD34, CD38, CD58, CD117, CD123, HLA-DR and TdT-positive; small subset of blasts also express CD19, CD22, and CD79a	6.8	42.57	negative	0	negative	NA	NA	NA	DNMT3A (p.I824V; VAF 50%)|GATA1 (p.S412R; MAF 60%)|NRAS (p.G13R; MAF 50%)|RUNX1 (p.T196I ; MAF 50%)|U2AF1 (p.I24T; MAF 5%)	1	20.92813142	4
BA2004R	2136	BA2004D	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	1	NA	NA	77	FALSE	FALSE	FALSE	FALSE	FALSE	y	Breast Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	77	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	NA	NA	NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	253	Dead	341	1	11.20328542	Dead-Unknown	0.8	NA	NA	2.5	0	15.8	0	70.9	0	62	28	3.3	1.01	M2	24.2	7.9	NA	241	87.7	EGR-1/ D5S23, D5S721: 58/200 cells (29%) had a 1 red/ 2 green signal pattern, consistent with a deleted 5q. D7S522/CEP 7: 38/200 cells (19%) had a 1 red/ 2 green signal pattern, consistent with a deleted 7q. CBFB: 40/200 cells (20%) had a single signal indicating deleted 16q22. TP53/CEP 17: 12/200 c	16	NA	8	8.29	negative	0	negative	NA	NA	TP53 (p.V272_R273insL; MAF 75%)	DNMT3A (p.E285D; MAF 40% )|KDM6A (p.Y215fs*2; MAF 40%)|TP53 (p.V272_R273insL; MAF 75%)	1	11.20328542	1
BA3001R	2344	BA3001D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	51	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	HiDAC|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	2	Standard Chemotherapy	HiDAC	Consolidation	-1	Alive	1910	0	62.75154004	Alive	0	95	95	0	0	7.8	0	3.1	0.1	22	12	2.9	0.93	M1	20.6	6.6	46,XX[20]	189	112.6	Normal	57	Immunophenotype: CD7, CD13, CD33, CD38, CD117, CD123 and MPO positive	6.5	25.02	negative	0	positive	NA	NA	NA	CBL (p.R420Q; MAF ~20%)|FLT3 (p.N841K; MAF ~30%)|IDH2 (p.R140Q; MAF ~30%)|NPM1 (p.W288fs*12; MAF ~25%)	0	62.75154004	3
BA2311R	2222	BA2311D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	HISPANIC	HispNative	2	NA	NA	53	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI	4	Consolidation|Induction|Allogeneic - Child|Maintenance	Complete Response	Standard Chemotherapy	-1	Supportive/Palliative Care	Cyclophosphamide	Maintenance	1	Alive	653	0	21.45379877	Alive	0	20	8	0	NA	37	20	30	NA	18	23	3.3	0.86	M4	20	6.2	46,XX[20]	426	105.3	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	38	CD34(+), CD13(dim +), CD15(partial +), CD33(dim to partial +), CD34(+), CD38(variably +), CD45(dim +), CD56(-), CD64 (small subset +), CD117(+), HLA-DR(partial +), other myeloid and lymphoid antigens(-).	7	6.63	negative	0	negative	NA	NA	NA	IDH2 (R140Q; MAF 51.0%)|KMT2A (Foundation; MLL-PTD exons 2-10)|PAX5 (V26G; MAF 1.0%)|SRSF2 (R94_S101DEL; MAF 40.0%)	0	21.45379877	4
BA2483R	2172	BA2483D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	KMT2A_re	63	FALSE	FALSE	FALSE	FALSE	FALSE	y	Cervical Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	64	44	Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other	6	7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	-1	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	29	Dead	348	1	11.43326489	Dead-Disease	1.5	85	38.5	0	0	55	3.5	1.5	0	25	22	3.8	1.3	NA	21.1	7.1	48,XX,+8,+21[16]/46,XX[4]	NA	91.3	RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21, as seen on metaphase analysis.  MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) rearrangement. Disruption of MLL was not apparent on banded chromosomes and the partner remains unkn	18	CD4, partial CD11b, partial CD13, CD33, CD34, CD38,  partial CD56, CD64, partial CD117, CD123, and dim HLA-DR positive | CD4, partial CD11b, partial CD13, CD33, CD34, CD38, partial CD56, CD64, partial CD117, CD123, and dim HLA-DR positive	7.7	19.76	negative	0	negative	NA	NA	NA	NA	1	11.43326489	4
BA3040R	2183	BA3040D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NA	White	4	NA	NA	69	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	7	Dead	238	1	7.819301848	Dead-Disease	NA	39	11	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	45,XY,add(1)(p13),del(5)(q13q33),add(6)(q13),-7,del(7)(q11.2),der(9)t(1;9)(p13;q22),add(12)(p13),-15,-16,-17,+3mar[19]/43~45,idem,der(3)t(3;17)(p21;q11.2),-17[cp3]	NA	NA	COMPLEX DEL(5q)/DEL(7q)/-7 CLONE OBSERVED, CONSISTENT WITH AML	NA	Positive (ABNORMAL CD34+ BLAST POPULATION, 29%, EXPRESSINGMYELOPEROXIDASE (VARIABLE), CD34, CD38, CD117, CD33, CD4, HLA-DR,CD13 (PARTIAL), CD56 (dim minor subset), AND CD61 (dim subset))	NA	1.6	negative	0	negative	NA	NA	TP53 (p.Y220C; 48.0%)|TP53 (p.F113V; 39.4%)	NA	1	7.819301848	1
BA2837R	2322	BA2837D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NA	White	2	NA	NA	78	FALSE	FALSE	FALSE	FALSE	FALSE	y	Esophageal Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	80	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	5	AG-120|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	4	Consolidation|Induction|Experimental|Maintenance	Complete Response	Standard Chemotherapy	7	Targeted Therapy - Other	AG-120	Experimental	-1	Dead	605	1	19.87679671	Dead-Disease	0	NA	70	0	NA	7	3	9	NA	11	57	2.6	1.28	NA	25.6	8.1	45,XY,-7[2]/45,XY,t(6;8)(q21;q21.2),-7,del(10)(q24q26),t(12;15)(p13;q15)[19]	1897	NA	nuc ish(D5S2064,D5S630,EGR1)x2 [200],(D7Z1x2,D7S522x1)[1/200]/(D7Z1,D7S522)x1[185/200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	23	CD2(subset +), CD4(dim +), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial +), CD38(variably +), CD45(+), CD56(partial +), CD64(-), CD117(+), HLA-DR(partial +). (63% population)	4.3	240.43	negative	0	negative	NA	NA	NA	NA	1	19.87679671	1
BA2724R	2041	BA2724D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NA	White	2	NA	NA	67	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Supportive/Palliative Care	NA	NA	NA	Standard Chemotherapy	Decitabine	Supportive/Palliative Care	-1	Alive	34	0	1.117043121	Alive	0.8	85	7.7	0	NA	5.1	42.7	40.2	NA	27	41	1.9	0.66	NA	28.7	9.5	46,XX[20]	670	102.5	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	42	CD2(-), CD4(partial dim +), CD7(few dim +), CD11b(-), CD13 (variably +), CD14(-), CD15(partial +), CD16(-), CD19(partial dim +), CD33(variably +), CD34(-), CD36(-), CD38(+), CD45 (moderate +), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(+), MPO(+). (Population #1; 6.5% medium-sized cells) | CD2(dim +), CD4(dim +), CD11b(variably +), CD13(variably +), CD14(partial +), CD15(variably +), CD16(partial +), CD33(slightly bright +), CD34(-), CD36(+), CD38 (variably +), CD45(+), CD64(+), CD117(-), HLA-DR(partial +), MPO(+). (Population #2; 42% medium-sized to large monocytic cells)	5.7	56.03	negative	0	positive	NA	NA	NA	NPM1 (W288FS*10+; MAF 37.0%)|NRAS (Q61K; MAF 43.0%)	0	1.117043121	4
BA2911R	2090	BA2911D	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	1	NA	NA	24	FALSE	FALSE	FALSE	FALSE	FALSE	y	Hodgkin Lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	24	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Leukapheresis	y	y	n	y	y	n	3	Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	6	AG-120|ATRA (Tretinoin)|HiDAC|3+7 (Cytarabine, Daunorubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|5+2 (Ara-C, Daunorubicin)	5	Consolidation|Salvage|Induction|Experimental|Re-induction	Complete Response	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	AG-120	Salvage	77	Dead	861	1	28.28747433	Dead-Disease	0	N/A	97	0	0	1.9	0	1.9	0.2	14	18	2.7	0.51	NA	19.6	6.2	NA	364	108.3	normal	15	CD13, CD33, CD38, CD58, CD117 and CD123 positive.	6.4	181.66	positive	NA	positive	NA	NA	NA	FLT3 (p.V592G; MAF 6%)|FLT3-ITD ((57 bp in-frame insertion); MAF 3% )|IDH1 (p.W288fs*12; MAF 50%)|NPM1 (p.W288fs*12; MAF 50% )	1	28.28747433	3
BA2256R	2074	BA2256D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	AdmixedBlack	6	NA	NA	25	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	26	49	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	4	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Cladribine, Cytarabine, Idarubicin	3	Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine, Sorafenib	Re-induction	67	Dead	324	1	10.64476386	Dead-Unknown	NA	98	95	NA	NA	2	3	NA	NA	46	30	4.1	0.54	NA	27.2	8.9	46,XX,t(7;12)(q22;p13)[12]/46,XX,t(7;17)(p10;q10),-9,+mar[7]/46,XX[1]	NA	90.4	This test has detected a translocation between 7 and 12 in 12 cells; a translocation between 7 and 17 with loss of a chromosome 9 and a marker in 7 cells.	81	These are positive for CD34, CD117, HLADR, CD33 but negative for CD13 and CD11b. TdT and CD79a are partially expressed. (Bone Marrow Immunophenotyping)	6.9	67.7	positive	1	negative	NA	NA	NA	NA	1	10.64476386	3
BA2821R	2145	BA2821D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	37	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	37	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	4	HiDAC|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Hydroxyurea	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction	Refractory	Standard Chemotherapy	8	Standard Chemotherapy	Azacitidine	Consolidation	-1	Dead	542	1	17.80698152	Dead-Disease	1.7	95	74	2.5	0.8	13.6	14.4	10.2	0.4	23	14	3.1	0.46	M0/M1	27.9	9.2	46,XX[20]	NA	89.4	Normal	49	variable CD11b, CD13, dim CD19, dim CD33, CD34, variable CD64, CD117, CD123, and HLA-DR	7	26.57	negative	0	negative	NA	NA	NA	ASXL1 (p.A1312V; MAF 50%)|KRAS (p.K117N; MAF 48%)|WT1 (p.L378P; MAF 48%)|WT1 (p.R380fs*69 (1 bp deletion with frameshift); MAF 48%)	1	17.80698152	4
BA2233R	2316	BA2233D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NA	White	4	NA	NA	72	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Hydroxyurea	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	-1	Alive	95	0	3.121149897	Alive	NA	97	96	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M1	NA	NA	46,XY[5]	NA	NA	D5S721, EGR1  del(5q)/monosomy 5, D7Z1, D7S522  del(7q)/monosomy 7, D8Z2 trisomy #8, D20S108, 20qter del(20q)	NA	CD117, MPO,CD38(PARTIAL), CD33(DIM) AND NOT EXPRESSING CD34 AND HLA-DR	NA	125.9	negative	0	positive	NA	NA	NA	FLT3 (p.D839G; MAF~45%)|IDH2 (p.R140L; MAF ~50%)|MLL2 (p.V2338I; MAF ~50%)|NPM1 (p.W288fs*12;MAF ~35%)|SRSF2 (p.P95H, MAF~55%)	0	3.121149897	3
BA2744R	2232	BA2744D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	76	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	n	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	76	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	y	y	y	y	y	y	1	Supportive/Palliative Care	1	Hydroxyurea	1	Supportive/Palliative Care	NA	NA	NA	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	7	Dead	8	1	0.262833676	Dead-Unknown	0	NA	96	0	0.7	4.7	0	1.3	0.6	23	43	2.3	0.46	M1	31	10.4	46,XY[20]	839	93.9	Normal	17	CD13, CD33, CD38, variable CD56, CD58, CD117 and MPO positive	5.1	230.05	positive	0.176470588	positive	NA	NA	NA	FLT3-ITD (MAF 45%)|NPM1 (p.W288fs*12; MAF 50%)|TET2 (p.W564*; MAF 50%)	1	0.262833676	3
BA2880R	2568	BA2880D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	5	NA	NA	85	FALSE	FALSE	FALSE	FALSE	FALSE	y	Not specified	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid sarcoma	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid sarcoma	85	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Alive	34	0	1.117043121	Alive	1.5	2	NA	24	NA	11.5	8	55	NA	4	8	3.7	1.2	NA	48.8	16.1	46,XY[20]	NA	NA	Normal	141	NA	6.3	11.4	negative	0	negative	NA	NA	NA	EZH2 (c.436G>C; p.D146H)|TET2 (c.5182G>T; p.E1728X)	0	1.117043121	4
BA2621R	2347	BA2621D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NA	White	6	NA	NA	74	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	74	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	14	1	0.459958932	Dead-Disease	NA	19	7	4	NA	12	2	51	NA	29	38	3.7	0.86	NA	24.2	7.8	45,XY,-7,del(12)(p11.2p13)[20]	NA	90.6	Monosomy 7 is detected in 87% of cells.	35	NA	6.6	47.5	negative	0	negative	NA	NA	NA	NA	1	0.459958932	4
BA3002R	2172	BA3002D	Waves1+2	no	no	no	no	Female	Female	White	NON-HISPANIC	White	1	NA	KMT2A_re	63	FALSE	FALSE	FALSE	FALSE	FALSE	y	Cervical Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	64	58	Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other	6	7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	-1	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	29	Dead	348	1	11.43326489	Dead-Disease	0	85	NA	0	0	12.6	0	0	0.2	16	36	3.1	1.57	NA	20.9	7	48,XX,+8,+21[16]/46,XX[4]	887	89.7	RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21 MLL: 68% of cells had a split signal pattern consistent with MLL (11q23)	21	CD4, partial CD11b, partial CD13, CD33, CD34, CD38, partial CD56, CD64, partial CD117, CD123, and dim HLA-DR positive	7.3	49.93	negative	0	negative	NA	NA	NA	NA	1	11.43326489	4
BA2501R	2031	BA2501D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	3	NA	PML-RARA	36	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	36	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	Methotrexate, Mercaptopurine, Tretinoin|ATRA, Idarubicin|ATRA, Cytarabine, Idarubicin	3	Consolidation|Induction|Maintenance	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Methotrexate, Mercaptopurine, Tretinoin	Maintenance	-1	Alive	604	0	19.84394251	Alive	NA	91.8	95	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M3	NA	NA	46,XY,t(15;17)(q24;q21)[18]/46,XY[2]	NA	NA	Normal	NA	weak partial CD2, CD13, CD33, CD64, CD117, and  myeloperoxidase	NA	55.42	positive	0.25	negative	NA	NA	NA	CEBPA (c.935A>G; MAF 45%, except VUS)|FLT3-ITD (c.1780_1800dup; MAF 17%)	0	19.84394251	3
BA2993R	2210	BA2993D	Waves1+2	no	no	no	no	Male	Male	Multiracial	NA	White	6	NA	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	50	30	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	-1	Alive	576	0	18.92402464	Alive	NA	NA	68	NA	NA	12	NA	3	NA	20	11	3.8	0.81	NA	24.1	7.9	46,XY[20]	NA	89.6	NA	39	NA	6.4	2.1	positive	1.5	negative	RUNX1 (p.E454Gfs*149; MAF 51%)	NA	NA	DNMT3A (p.r882H; MAF 45%)|FLT3-ITD|MLL |RUNX1 (p.E454Gfs*149; MAF 51%)	0	18.92402464	3
BA2301R	2197	BA2301D	Waves1+2	yes	yes	yes	no	Female	Female	White	NA	White	5	NA	NA	42	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	42	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	-1	Alive	673	0	22.11088296	Alive	0	90	NA	0	NA	17	NA	20	NA	17	13	3.6	0.98	NA	21.7	7.3	46,XX[19]	NA	NA	Normal	71	Positive (\A large blastic population is noted, positive for CD45 and CD64. A small subset of blasts also express CD13 and CD14. The blasts are negative for CD10, CD16, CD19, CD34 and CD117.\")"	6.6	18.3	negative	0	positive	NA	NA	NA	NPM1 (c.859_860insTCTG; p.W288fs)|WT1 (c.933_934ins10; p.R312fs; c.938_939insCGGTC; p.A314fs)	0	22.11088296	4
BA2852R	2436	BA2852D	Waves1+2	yes	yes	yes	no	Male	Male	White	NA	White	6	NA	NA	74	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	75	0	Post-Chemotherapy|Relapse	Relapse	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	1	Azacitidine, MLN4924	1	Induction	Complete Response	Standard Chemotherapy	498	Standard Chemotherapy	Azacitidine, MLN4924	Induction	498	Alive	539	0	17.70841889	Alive	NA	6	NA	3.8	NA	48.1	9.5	38.1	NA	41	25	4.4	0.73	NA	36.5	12.7	48,XY,+8,del(20)(q11.2),+21[14]/46,XY[6]	NA	94.8	This test has detected a 20q deletion, trisomy 8, and trisomy 21 in 14 cells. All these abnormalities are commonly seen in AML and MDS.	43	These are positive for CD34, CD117, HLA-DR, and CD33. (Bone Marrow Immunophenotyping)	6.4	2.1	negative	0	negative	RUNX1 (p.G165Dfs*2; 11.1%)	NA	NA	NA	0	17.70841889	4
BA2133R	2383	BA2133D	Waves1+2	no	no	no	no	Female	Female	White	NA	White	6	NA	NA	73	FALSE	FALSE	TRUE	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	73	0	Post-Chemotherapy	Remission	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	4	Ruxolitinib|AG-221|Cytarabine|Azacitidine	4	Induction|Experimental|Maintenance|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	90	Standard Chemotherapy	Cytarabine	Supportive/Palliative Care	8	Dead	560	1	18.39835729	Dead-Unknown	NA	NA	NA	0.5	NA	39.2	7.5	52.5	NA	10	21	4.5	0.87	NA	34.1	10.9	NA	NA	92.4	NA	6	NA	7.6	3.8	negative	0	positive	NA	NA	NA	IDH2 (p.R140Q; MAF 32%)|JAK2 (p.V617F; MAF 30%)|NPM1 (p.W288Cfs*12; MAF 35%)|SRSF2 (p.R94dup; MAF 31%)|WT1 (p.R440Tfs*14; MAF 29%)	1	18.39835729	4
BA2866R	2465	BA2866D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	HispNative	4	NA	NA	58	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	58	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	4	Sorafenib|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Experimental	Complete Response	Standard Chemotherapy	1	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	Alive	192	0	6.308008214	Alive	NA	57	24	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M2	NA	NA	47,XY,t(8;22)(p11.2;q11.2),+19[20]	NA	NA	t(8;22) clone observed, consistent with a neoplastic process	NA	Positive (CD34-Dim)	NA	100.2	negative	0	negative	RUNX1 (p.S322Ffs*278; 45.9%)	NA	NA	ATM (p.P604S; VAF ~50%)|PHF6 (p.G306R; VAF ~75%)|RUNX1 (p.S322fs*278 (Single base pair insertion, frame shift  mutation); MAF ~40%)	0	6.308008214	2
BA2212R	2035	BA2212D	Waves1+2	yes	yes	yes	yes	Male	Male	Asian	NA	Asian	2	NA	NA	75	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	75	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	Vidaza|Decitabine|Fludarabine, Cytarabine	2	Salvage|Supportive/Palliative Care	NA	NA	NA	Standard Chemotherapy	Fludarabine, Cytarabine	Salvage	-1	Dead	159	1	5.223819302	Dead-Disease	0	27	2	0	NA	60.2	8.4	29.4	NA	12	15	4.8	0.98	NA	30.7	9.3	46,XY,t(1;12)(p32;p13)[3]/46,XY[17]	215	NA	nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[194],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]	121	CD2(-), CD4(-),CD7(-), CD10(partial +), CD11b(-), CD13(dim +), CD14(-), CD38(variably +/small subset -), CD45(dim to moderately +), CD56(-), CD64(-), CD117(variably +), HLA-DR(variably +). | Population #2 (0.48% of total events) comprises small cells with the following immunophenotype: CD5(- to partial dim +),CD10(-), CD19(slighty bright +), CD20(bright +), CD38(-), CD45(+), kappa(-), lambda(dim +).	7.5	3.09	negative	0	negative	NA	ASXL1 (p.G646Wfs*12; 39.3%)	NA	ASXL1 (G646fs*12; MAF 37.0%)|BCOR (S1608*; MAF 3.0%)|KRAS (G12R; MAF 5.0%)|STAG2 (Q932fs*6; MAF 91.0%)|SUZ12 (E601fs*10; MAF 38.0%)|TET2 (C127fs*92; MAF 6.0%)|TET2 (S1870*; MAF 45.0%)	1	5.223819302	1
BA2685R	2266	BA2685D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	6	NA	NA	67	FALSE	FALSE	TRUE	FALSE	FALSE	y	Not specified	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	67	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	4	Vidaza|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Decitabine	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	8	Standard Chemotherapy	Decitabine	Salvage	83	Dead	230	1	7.556468172	Dead-Unknown	NA	60	NA	NA	NA	NA	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	46, XY, del (3) (q12q21) [2]/47, idem, +8[11]/47, idem, der (15) t (1;15) (q21;p11.2) [7]	NA	NA	Trisomy 8 is detected in 28% of cells.	NA	Positive for CD34, CD117, HLADR, CD33, CD13 and Negative for CD11b and CD64 (Bone Marrow Immunophenotyping)	NA	NA	negative	0	negative	NA	ASXL1 (p.G646Wfs*12; 28.0%)	NA	BCOR (p.KB39Qfs*5; MAF 45%)|KIT (p.T916A; MAF 50%)|NRAS (p.G12A; MAF 24%)|SRSF2 (p.P95R; MAF 40%)	1	7.556468172	1
BA2273R	2544	BA2273D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	6	NA	NA	67	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	Cytarabine|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	Cytarabine	Consolidation	35	Dead	165	1	5.420944559	Dead-Unknown	NA	80	10	2	NA	68	4	8	NA	8	10	3.9	0.85	NA	21.2	7.2	46,XY[20]	NA	110.4	The translocations commonly seen in AML are not detected. Loss of RARA and CBFB genes are detected in 14-39% of cells.	84	These are positive for CD34, CD117, HLADR, CD33, CD13, CD14 and CD11b. (Bone Marrow Immunophenotyping)	5.9	0.9	negative	0	negative	NA	NA	TP53 (p.Y220C; 42.0%)	BCOR (MAF 49%)|IDH1 (p.R132C MAF 12%)|JAK2 (p.V617F; MAF 43%)|MLL |NF1 (MAF 18%)|TP53 (p.Y220C; MAF 35%)	1	5.420944559	1
BA2477R	2219	BA2477D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	67	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	5	AG-120|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC	5	Consolidation|Salvage|Induction|Experimental|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	Dead	864	1	28.38603696	Dead-Other	0	93	94	0	0	1	2.8	1.9	0.1	20	30	2.4	1.23	M4	31.2	10.1	46,XY[20]	NA	96.3	Normal	30	partial CD7, CD13, dim CD15, CD33, CD38, CD58, CD117, dim CD123, HLA-DR and partial MPO+. (BM) | dim CD4, CD11b, variable CD13, partial CD14, dim CD15, variable CD16, CD33, CD38, CD58, CD64, CD123 and HLA-DR. (Promonocyte/blast equivalents)	NA	125.16	negative	0	positive	NA	NA	NA	DNMT3A (p.R882H; MAF 46% )|FLT3 (p.V592D; MAF 43% )|IDH1 (p.R132H; MAF 46%  )|NPM1 (p.W288fs*12 MAF 47% )|SETBP1 (p.K459E; MAF 50% )	1	28.38603696	4
BA2659R	2057	BA2659D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	mono	NA	86	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	86	0	Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	3	AG-221|Azacitidine|Hydroxyurea	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Experimental	NA	NA	NA	Standard Chemotherapy	Hydroxyurea	Consolidation	55	Dead	596	1	19.58110883	Dead-Disease	0	23	NA	0	0.8	8.6	19	59.5	0	16	15	3.4	1.52	NA	27.8	9	47,XY,+8[20]	398	97.5	(FISH) was performed with a chromosome 8 probe, listed below. 95/100 (95%) interphase cells scored had three signals, consistent with trisomy 8 and the metaphase karyotype.	299	dimCD7, CD13, dimCD14, dimCD20, CD33, CD34, CD117, CD123, dim HLA-DR and MPO positive	7.6	10	negative	0	negative	NA	NA	NA	BCOR (p.S1139*; MAF 80%)|CEBPA (p.R343fs*79; MAF 40%)|DNMT3A (p.E285*; MAF 45%)|DNMT3A (p.G707fs*72; MAF 45%)|IDH2 (p.R140Q; MAF 40%)|SRSF2 (p.P95H; MAF 40%)	1	19.58110883	4
BA2124R	2310	BA2124D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	3	NA	NA	67	FALSE	FALSE	FALSE	FALSE	FALSE	y	Skin cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|IDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	IDAC	Consolidation	-1	Alive	579	0	19.02258727	Alive	NA	71.5	56	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[20]	NA	NA	Normal	NA	CD33, CD38, CD56, CD117, and myeloperoxidase	NA	16.24	negative	0	positive	NA	NA	NA	NPM1 (p.Trp288fs; MAF 16.4%)|TET2 (p.Leu1081fs; MAF 42.3%)|TET2 (p.Leu1780fs; MAF 46.3%)|ZRSR2 (p.Arg126*; MAF 97.7%)	0	19.02258727	3
BA2363R	2337	BA2363D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	79	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	79	35	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other	4	Azacitidine|Decitabine|Hydroxyurea|V212	2	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care	NA	NA	NA	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	-1	Dead	152	1	4.993839836	Dead-Disease	1.7	NA	35	0	0	0.9	64.4	8.7	0.2	9	22	3.1	2.11	NA	25.5	7.8	46,XY[22]	722	95.5	Normal	438	CD13, dim CD33, bright CD34, CD38, CD117, dim HLA-DR positive	5.8	116.52	negative	0	negative	RUNX1 (p.R320*; 44.9%)	NA	NA	NA	1	4.993839836	4
BA2369R	2276	BA2369D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	6	NA	NA	75	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	75	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Vidaza	1	Supportive/Palliative Care	NA	NA	NA	Standard Chemotherapy	Vidaza	Supportive/Palliative Care	-1	Alive	302	0	9.921971253	Alive	NA	60	50	NA	NA	NA	2	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[20]	NA	NA	NA	NA	These are positive for HLA-DR, CD34,CD117, CD33, CD11B, CD64 but Negative for CD13, CD14, CD16, MPO, TDT and all B and T cell markers (Bone Marrow Immunophenotyping)	NA	25	negative	0	negative	NA	NA	NA	NA	0	9.921971253	4
BA2534R	2077	BA2534D	Waves1+2	no	no	no	no	Female	Female	NA	NA	White	3	NA	NA	71	FALSE	FALSE	FALSE	FALSE	FALSE	y	Follicular lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	72	249	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Supportive/Palliative Care	5	7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Hydroxyurea|Mitoxantrone	4	Hypomethylating/Low Dose Cytarabine|Induction|Re-induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	-1	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	-1	Dead	280	1	9.199178645	Dead-Disease	NA	95	99	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX,del(7)(q22q36)[18]/46,sl,t(1;10)(p13;q24)[2]	NA	NA	- 3 copies of the MECOM locus at 3q26.2, suggestive of a  rearrangement or gain of this locus, in 156/200 (78.0  percent) cells scored.  - deletion 7q31 involving the D7S486 locus in 162/200 (81.0  percent) cells scored.	NA	NA	NA	20.39	positive	0.315789474	negative	NA	NA	NA	NA	1	9.199178645	3
BA2400R	2426	BA2400D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	44	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	44	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	8	Standard Chemotherapy	HiDAC	Consolidation	99	Alive	1856	0	60.97741273	Alive	0	65	11.2	3.5	0	76.7	0	8.6	0	19	11	2.8	0.53	M2	23.7	7.8	NA	197	100.4	Normal	222	CD13, CD33, CD117, CD123, dim HLA-DR and MPO | CD11b, CD13, CD33, CD117, CD64, CD123, and dim HLA-DR. (Blasts with monocytic differentiation (about 10% of blasts).)	6.1	2.41	negative	0	positive	NA	NA	NA	FLT3-ITD (MAF 2%)|IDH1 (p.R132H; MAF 44%)|NPM1 (p.W288fs*12; MAF 44%)|PTPN11 (p.R265Q; MAF 3%)	0	60.97741273	4
BA2762R	2061	BA2762D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NA	White	2	NA	NA	22	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	22	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Fludarabine, Melphalan|Crenolanib|7+3 (Cytarabine, Idarubicin) plus Crenolanib	3	Allogeneic - Sibling|Induction|Experimental	Complete Response	Standard Chemotherapy	39	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Sibling	-1	Alive	603	0	19.8110883	Alive	0	63	42	0	NA	32.7	4.4	26.6	NA	27	39	3.1	0.68	NA	19.3	6	46,XX[20]	NA	NA	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con3'CBFBx2)[200]	176	CD2(-), CD4(partial dim +), CD7(variably +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(+), HLA-DR(partial +).	6.3	22.01	positive	0.666666667	positive	NA	NA	NA	FLT3-ITD (K602_W603INSCEYDLK; MAF 33.0%)|NPM1 (K292FS*6+; MFA 35.0%)|TCL1A (E54FS*28; MAF 44.0%)|WT1 (A382FS*4; MAF 40.0%)	0	19.8110883	4
BA2312R	2537	BA2312D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	3	mono	NA	62	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	7	Dead	169	1	5.552361396	Dead-Disease	NA	20.4	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX[20]	NA	NA	Normal	NA	partial weak  CD7, CD13, CD33, CD34, CD117, myeloperoxidase, and partial  HLA-DR	NA	NA	negative	0	negative	NA	NA	NA	CEBPA (c.68dup; MAF 21%)|DNMT3A (c.2645G>A; MAF 43.9%)|NRAS (c.35G>A; MAF 30.2%)|WT1 (c.1140dup; MAF 4%)|WT1 (c.1142C>A; MAF 36.4%)	1	5.552361396	4
BA2813R	2206	BA2813D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NA	White	5	NA	NA	64	FALSE	FALSE	FALSE	FALSE	FALSE	y	Prostate Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	64	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	41	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Alive	636	0	20.89527721	Alive	0	83	74	0	NA	13	0	13	NA	15	45	4	1.27	NA	25.2	8.7	46,XY[20]	NA	NA	Normal	39	Positive (\The large majority of cells (around 90%) are an abnormal population of myeloblasts. The myeloblasts are positive for CD33, CD13, HLA-DR, and CD117, and show uniform aberrant expression of CD7. A subset of the blasts are positive for myeloperoxidase, and a smaller subset shows dim aberrant expression of CD19. The blasts are almost entirely negative for CD34.\")"	6	53.3	positive	0.428571429	positive	NA	NA	NA	DNMT3A (c.2645G>A; p.R882H)|FLT3-ITD (FLT3-ITD 63bp insertion)|NPM1 (c.859_860insTCTG; p.W288fs)	0	20.89527721	4
BA2211R	2471	BA2211D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib	2	Consolidation|Induction	Complete Response i	Standard Chemotherapy	17	Standard Chemotherapy	Azacitidine	Consolidation	34	Dead	142	1	4.665297741	Dead-Disease	0	95	92.9	0	0.7	3.6	1.4	1.4	0.1	101	55	3.2	0.83	M1	37	12.4	46,XX[20]	697	95.1	normal	42	CD13, CD33, CD38, CD56, CD58, partial CD64, CD117, CD123, and MPO positive	6.3	166.91	positive	1	positive	NA	NA	NA	FLT3-ITD (MAF 50%)|NPM1 (p.W288fs*12; MAF 45%)	1	4.665297741	3
BA2171R	2321	BA2171D	Waves1+2	yes	yes	yes	yes	Female	Female	Unknown	UNKNOWN	White	1	NA	NA	73	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	Standard Chemotherapy	3	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	3	Dead	4	1	0.131416838	Dead-Disease	0	90	98.4	0	0	0.8	0	0.8	0.1	18	36	2.9	1.44	M1	25.9	8.2	46,XX[20]	NA	90.6	Normal	19	CD13, CD33, CD38, CD58, dim CD64, CD117, CD123, and MPO	7.7	122.89	positive	0.428571429	positive	NA	NA	NA	DNMT3A (p.R326P; MAF 50%)|FLT3-ITD (MAF 46%)|IDH2 (p.R140Q; MAF 40%)|NPM1 (p.W288fs*12; MAF 40%)	1	0.131416838	3
BA2746R	2522	BA2746D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	HISPANIC	HispNative	5	NA	NA	56	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	56	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	4	Consolidation|Salvage|Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	27	Standard Chemotherapy	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	-1	Dead	323	1	10.61190965	Dead-Disease	0	1.5	2	0	NA	23	57	13	NA	67	33	3	1.87	NA	29	9.5	46,XX[19]	NA	NA	Normal	28	Positive (\Approximately 55% of assayed cells are an abnormal population of immature monocytic cells (consistent with monoblasts and promonocytes). Approximately 30% of assayed cells are mature monocytes. Both the immature and mature monocytic cells show uniform aberrant expression of CD56. A small population of myeloblasts (CD117+/CD34neg) is present, accounting for less than 5% of assayed cells.)"	7.5	58.7	positive	0.111111111	positive	NA	NA	NA	ASXL1 (c.1954G>A; p.G652S)|DNMT3A (c.2644C>T; p.R882C)|FLT3 (c.2503G>T; p.D835Y)|FLT3-ITD (FLT3-ITD 21 bp insertion)|NPM1 (c.859_860insTCTG; p.W288fs)	1	10.61190965	4
BA2798R	2395	BA2798D	Waves1+2	yes	yes	yes	no	Male	Male	White	NA	White	6	N/A	NA	71	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	71	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	5	AG-120|KB004|Lenalidomide|Venetoclax (ABT-199), Azacitidine|Decitabine	4	Salvage|Induction|Experimental|Maintenance	Refractory	Standard Chemotherapy	32	Standard Chemotherapy	Venetoclax (ABT-199), Azacitidine	Salvage	77	Dead	548	1	18.00410678	Dead-Unknown	NA	75	26	2	NA	15	8	43	NA	118	53	3.8	1.26	NA	22.9	7.7	46,XY,del(7)(q32),add(13)(p11.2)[15]	NA	81.8	This test has detected 7q deletion and an abnormal chromosome 13 in all 15 metaphase cells analyzed. 7q deletion is the most cp,,om abnormality in MDS and other types of myeloid malignancies.	24	These are positive for CD34, CD117, HLADR, CD33 and CD13 (Bone Mrrow Immunophenotyping)	8.7	5	negative	0	negative	RUNX1 (p.G408Vfs*193; 34.8%)	ASXL1 (p.Q428*; 43.9%)	NA	ASXL1 (p.Q428*; MAF 44%)|CEBPA (p.A4S; MAF 47%)|IDH1 (p.R132C; MAF 45%)|JAK2 (p.V617F; MAF 57%)|MLL |RUNX1 (p.G406Vfs*193; MAF 39%)|TET2 (p.R1366S; MAF 40%)	1	18.00410678	2
BA2809R	2301	BA2809D	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	70	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	72	423	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	4	7+3 (Cytarabine, Idarubicin)|Azacitidine, Itacitinib|Azacitidine|Decitabine	2	Salvage|Induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine, Itacitinib	Salvage	449	Dead	1389	1	45.63449692	Dead-Disease	0	NA	NA	0	0	15.5	6.9	5.2	0	79	38	3.1	0.8	M0	27.9	9.1	47,XY,+4[2]/46,XY[18]	NA	87.7	Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously.	44	NA	6.3	50.58	negative	0	negative	NA	NA	NA	NA	1	45.63449692	4
BA2288R	2515	BA2288D	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	HispNative	7	NA	NA	72	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	unknown	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	unknown	73	0	Residual Disease	Residual	Bone Marrow Aspirate	y	y	n	y	y	n	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Unknown	0	0	0	NA	NA	20	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	NA	0	0	2
BA2801R	2146	BA2801D	Waves1+2	no	no	no	no	Male	Male	NA	NON-HISPANIC	White	6	NA	NA	72	FALSE	FALSE	FALSE	TRUE	FALSE	y	Lung Cancer	y	n	y	n	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Myelodysplastic syndrome, unclassifiable	NonAML	MYELODYSPLASTIC SYNDROMES	Myelodysplastic syndrome, unclassifiable	73	0	Residual Disease	NA	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Vidaza	1	Supportive/Palliative Care	NA	NA	NA	Standard Chemotherapy	Vidaza	Supportive/Palliative Care	268	Dead	292	1	9.593429158	Dead-Unknown	NA	NA	4	1	NA	13	5	23	NA	13	57	2.5	1.83	NA	25	8.2	NA	NA	105.9	NA	32	NA	5.8	66.7	negative	NA	negative	RUNX1 (p.S322Nfs*277; 44.4%)	ASXL1 (p.R693*; 38.7%)	NA	ASXL1 (p.R693* MAF 48%)|EZH2 (p.1131T, MAF 71%)|EZH2 (p.C565R MAF 27%)|JAK2 (p.V617F, MAF 26%)|KRAS (p.Q61P, MAF 13%)|RUNX1 (p.S322Nfs*277, MAF 42%)|TET2 (p.Q1813*, MAF 51%)|TET2 (p.Q866Rfs*14, MAF 39%)|ZRSR2 (p.R295*, MAF 97%)	1	9.593429158	4
BA3030R	2046	BA3030D	Waves1+2	no	no	no	no	Female	Female	Unknown	UNKNOWN	White	1	NA	NA	70	FALSE	FALSE	FALSE	TRUE	FALSE	n	NA	n	n	n	n	y	n	n	n	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	Atypical chronic myeloid leukaemia, BCR-ABL1 negative	NonAML	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	Atypical chronic myeloid leukaemia, BCR-ABL1 negative	70	0	Unknown	NA	Bone Marrow Aspirate	y	y	y	y	y	y	1	Targeted Therapy - Kinase Inhibitor(s)	1	Hydroxyurea	1	Induction	Unknown	Targeted Therapy - Kinase Inhibitor(s)	-1	Targeted Therapy - Kinase Inhibitor(s)	Hydroxyurea	Induction	-1	Dead	33	1	1.084188912	Dead-Disease	1.6	13	6.8	0.8	0	5.7	2.5	72.1	5.7	24	36	2.9	0.95	NA	29.1	8.9	46,XX[20]	953	105.1	Normal	208	CD13, CD33, CD34, partial CD117, CD123, HLA-DR	6.7	109.77	positive	0.428571429	negative	NA	NA	NA	FLT3-ITD (MAF 45%)|IKZF1 (p.N159S ; MAF 45%)|SF3B1 (p.K666N ; MAF 45%)	1	1.084188912	1
BA2588R	2441	BA2588D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	59	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	59	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC	3	Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	4	Dead	597	1	19.61396304	Dead-Disease	0	30	10.5	0	0	19.7	0.9	71.4	0	77	27	3.4	1.01	M2	26.4	8.9	46,XY[20]	479	96.4	Normal	101	CD13, CD33, CD117, CD123, and HLA-DR	6.4	4.4	negative	0	positive	NA	NA	NA	DNMT3A (p.R882C; MAF 40%)|NPM1 (p.W288fs*12 ; MAF 40%)|PTPN11 (p.K70R; MAF 40%)|SOCS1 (p.Q210H ; MAF 55%)	1	19.61396304	4
BA2296R	2497	BA2296D	Waves1+2	yes	yes	yes	yes	Female	Female	White	HISPANIC	HispNative	1	bi	NA	46	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	46	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	120	Alive	1950	0	64.06570842	Alive	NA	40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M2	NA	NA	46,XX[19]	NA	NA	Normal	NA	CD13, CD33, CD34, partial CD64, CD71, CD117, CD123, and HLA-DR	NA	NA	negative	0	negative	NA	NA	NA	CEBPA (p.R297P ; MAF 50%)|CEBPA (p.T98fs*10 ; MAF 40%)|TET2 (p.Q758*; MAF 45%)	0	64.06570842	2
BA2300R	2037	BA2300D	Waves1+2	yes	yes	yes	yes	Male	Female;Male	NA	NA	White	3	NA	NA	79	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	79	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	1	1	0.032854209	Dead-Disease	NA	86	87	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	43-45,X,-Y,del(5)(q22q35),del(7)(q22),+8,-9,add(9)(p13),+11,-13,-14,add(16)(q24),-17,-18,del(20)(q11.2q13.2),+2-3mar[cp21]	NA	NA	5q31 (EGR1): deletion present  8q22 (RUNX1T1): gain present  11q23 (KMT2A; also known as MLL): gain present	27	NA	NA	70.01	negative	0	negative	NA	NA	TP53 (p.X225_splice; 93.2%)	KIT (p.Asp816Val; MAF 44.4%)|TP53 (p.?; MAF 91%)	1	0.032854209	4
BA2903R	2161	BA2903D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	HISPANIC	HispNative	6	NA	NA	59	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	59	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	6	HiDAC|Lenalidomide|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Etoposide, Mitoxantrone|Cytarabine, OXi4503	5	Salvage|Induction|Experimental|Frontline|Re-induction	Refractory	Standard Chemotherapy	8	Targeted Therapy - Other	Cytarabine, OXi4503	Experimental	4	Dead	207	1	6.800821355	Dead-Unknown	NA	NA	1	9	NA	1	6	58	NA	135	44	3.2	0.79	NA	21.6	7.3	NA	NA	85	NA	22	NA	5.9	9.1	negative	0	negative	NA	ASXL1 (p.G646Wfs*12; 50.0%)	NA	NRAS (p.Q61H, MAF 21%)|RAD21 (p.G273V ,MAF 64%)	1	6.800821355	4
BA2473R	2383	BA2473D	Both	no	no	no	no	Female	Female	White	NA	White	6	NA	NA	73	FALSE	FALSE	TRUE	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	73	56	Post-Chemotherapy	Remission	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	4	Ruxolitinib|AG-221|Cytarabine|Azacitidine	4	Induction|Experimental|Maintenance|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	90	Standard Chemotherapy	Cytarabine	Supportive/Palliative Care	8	Dead	560	1	18.39835729	Dead-Unknown	NA	5	NA	NA	NA	NA	1	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX[20]	NA	NA	This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small percentage of tumor cells with chromosome abnormalities may not be detected due to the limited number of cells examined. (Cytogenetics)	24	CD34 positive blasts are rare, <1% (Bone Marrow Immunophenotyping)	NA	1.8	negative	0	positive	NA	NA	NA	NA	1	18.39835729	4
BA2545R	2488	BA2545D	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	37	FALSE	FALSE	FALSE	FALSE	FALSE	y	Not specified	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid sarcoma	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid sarcoma	37	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Unknown	Standard Chemotherapy	24	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	-1	Alive	1894	0	62.22587269	Alive	1.1	1	NA	2.8	0.2	30.3	5.2	60.4	0	34	20	4.2	0.93	NA	39.2	14.4	46,XY[20]	154	94.9	Normal	162	NA	7.5	5.35	negative	0	negative	NA	NA	NA	TET2 (p.L307R; MAF 51%)	0	62.22587269	4
BA2840R	2468	BA2840D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	78	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	78	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	3	Ruxolitinib|Hydroxyurea|Decitabine, Ruxolitinib	3	Induction|Experimental|Maintenance	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	Decitabine, Ruxolitinib	Induction	7	Dead	24	1	0.788501027	Dead-Unknown	0	60	NA	0	1.6	43.7	9.4	29.7	5.5	27	39	2	0.41	M7	26.2	8.2	46,XX,t(7;13)(q22;q12),del(20)(q11.2)[1]/46,sl,dup(1)(p25),del(2)(q21q23),add(8)(q13q22)[3]/46,sdl,add(5)(p15)[8]/46,sdl,add(12)(p13)[3]/46,sdl,add(12)(p13),add(13)(p12)[4]/46,XX[1]	1024	89.4	RUNX1T1 (8q21.3): 35% of cells had three signals for RUNX1T1 on 8q. No evidence for t(8;21). | FISH was also performed with a probe for chromosome 20, so that the stemline clone and all subclones could be followed by interphase FISH. 88/100 cells were missing a signal for D20S108 (20q12), consistent with the deletion of 20q seen in all abnormal cells above.	17	CD33, CD34 (subset), CD41, CD58, CD61 and Factor-8 positive	5.5	6.28	negative	0	negative	NA	NA	NA	GATA1 (p.M1V; MAF 32%)|MPL (p.S505N; MAF 70%)|TET2 (p.V636fs*3; MAF 46%)	1	0.788501027	1
BA2528R	2531	BA2528D	Waves1+2	yes	yes	yes	no	Male	Male	Declined	NON-HISPANIC	White	1	NA	NA	75	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	75	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|Azacitidine	3	Induction|Frontline|Maintenance	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	Azacitidine	Maintenance	-1	Alive	1936	0	63.60574949	Alive	0	23	rare	1	NA	51	11.2	36.8	NA	23	16	3.4	0.55	M2	27.1	9.1	46,XY[19]	178	88	Normal	28	CD13, CD33, CD34, CD38, CD117, CD123, dim HLA-DR, TdT, and MPO positive	6.4	1	negative	0	negative	NA	NA	NA	DNMT3A (p.R882H; MAF 41%)|SF3B1 (p.K700E; MAF 43%)	0	63.60574949	4
BA2646R	2535	BA2646D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	PML-RARA	62	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	ATRA, Arsenic Trioxide	Induction	-1	Alive	1719	0	56.47638604	Alive	0	90	NA	0.9	3.5	35.7	1.7	5.2	0.7	28	24	2.8	1.12	M3	19.8	7	46,XY,t(3;16)(p13;q22),t(13;14)(q32;q24),t(15;17)(q22;q21)[20]	519	85.7	PML/RARA: 98/100 cells (98%) had a 1 red/ 1 green/ 2 yellow signal pattern, reflecting PML/RARA fusion and consistent with the 15;17 translocation observed in the metaphase karyotype.	38	CD13, CD33, CD38, CD58, CD64, dim CD71, CD123, CD117, MPO positive -FISH for t(15;17)	5.4	9.87	negative	0	negative	NA	NA	NA	NA	0	56.47638604	3
BA3407R	2691	BA3407D	Waves3+4	no	no	no	no	Female	Female	NA	HISPANIC	NA	6	NA	KMT2A_re	29	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	29	38	Post-Chemotherapy	Remission	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	Bu/Cy/ATG|HiDAC|3+7 (Cytarabine, Daunorubicin)|Etoposide, Mitoxantrone|Clofarabine, Cytarabine	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	Clofarabine, Cytarabine	Re-induction	6	Dead	246	1	8.082135524	Dead-Disease	NA	1	NA	NA	NA	NA	2	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX,t(6;11)(q27;q23)[18]/46,XX[2]	NA	NA	This test has detected  a 6;11 translocation in 18 of 20 metaphase cells analyzed. The translocation has led to rearrangement of the MLL gene as shown by FISH. This result is consistent with the diagnosis of AML. (Cytogenetics) | Except for 9;11 translocation, all translocations involving the MLL gene in AMLare associated with an unfavorable prognosis. (Cytogenetics (Continued))	NA	Myeloblasts 1% positive for CD34, CD117, HLADR, CD13, CD33, for TDT and all B and T-cell markers. (Bone marrow Immunophenotyping)	NA	NA	negative	0	negative	NA	NA	NA	NA	1	8.082135524	1
BA2240R	2181	BA2240D	Waves1+2	yes	yes	yes	yes	Female	Female	White	HISPANIC	HispNative	1	NA	NA	61	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Sorafenib|Hydroxyurea	4	Consolidation|Induction|Experimental|Re-induction	Complete Response	Standard Chemotherapy	7	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	61	Dead	263	1	8.640657084	Dead-Disease	0	NA	NA	0	0	30.8	10.3	0	0.3	195	75	3.6	0.68	NA	25.4	8.2	NA	1033	95.5	NA	49	NA	6.7	73.28	positive	9	positive	NA	NA	NA	NA	1	8.640657084	4
BA2926R	2185	BA2926D	Waves1+2	yes	yes	yes	no	Male	Male	NA	NA	White	3	NA	NA	58	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	58	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Supportive/Palliative Care	3	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|Azacitidine	3	Salvage|Induction|Symptom Control	Refractory	Standard Chemotherapy	10	Supportive/Palliative Care	Azacitidine	Symptom Control	-1	Dead	278	1	9.133470226	Dead-Disease	NA	44.6	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	[46,XY]	NA	NA	Normal	NA	Increased CD117 positive, partial CD34 positive myeloblasts representing approximately 61% of the leukocytes most consistent with acute myeloid leukemia	NA	4.17	negative	0	negative	NA	NA	NA	ASXL2 (p.Val1277Ala; MAF 89.5%)|DNMT3A (p.Trp297* (NM_175629.2); MAF 82.1%)|IDH1 (p.Arg132Cys (NM_005896.3); MAF 39.1%)	1	9.133470226	4
BA2272R	2052	BA2272D	Waves1+2	yes	yes	yes	yes	Male	Male	White	HISPANIC	HispNative	1	NA	NA	12	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	12	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	4	Cytarabine|Sorafenib|Cytarabine, Daunorubicin, and Etoposide|Busulfan, Cyclophosphamide	3	Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	Refractory	Standard Chemotherapy	0	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	-1	Alive	1905	0	62.58726899	Alive	0	70	85	0	1.8	14.7	51.4	8.3	50	28	150	3.7	0.64	M4	14.3	4.6	47,XY,+8[19]/46,XY[1]	NA	132.4	RUNX1T1 signal consistent with the trisomy 8 clone	49	dimCD11b, dimCD13, CD14, dimCD33, CD64, variable CD123, HLA-DR CD13,dimCD33, dim variable CD34, CD117, CD123, HLA-DR	7.1	214.49	positive	0.538461538	negative	NA	NA	NA	FLT3-ITD (~16 amino acid insertion; MAF 11%)|FLT3-ITD (~8 amino acid insertion; MAF 20%)	0	62.58726899	4
BA2306R	2085	NA	Waves1+2	yes	no	yes	yes	Male	Male	Black	NA	AdmixedBlack	6	NA	RUNX1-RUNX1T1	50	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	50	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	n	y	y	n	y	1	Standard Chemotherapy	2	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	Refractory	Standard Chemotherapy	20	Standard Chemotherapy	HiDAC	Consolidation	182	Alive	424	0	13.9301848	Alive	NA	70	91	0	NA	7	2	0	NA	23	25	2.4	0.66	NA	26.6	8.7	46,XY,t(8;21)(q22;q22)[20]	NA	94.7	NA	28	NA	6.3	71.1	negative	0	negative	NA	NA	NA	ASXL1 (p.P581R, MAF 46%)|PDGFRB (p.D111N, MAF 52%)|SMC1A (p.R586Q, MAF 96%)	0	13.9301848	2
BA2765R	2550	BA2765D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	3	NA	NA	39	FALSE	FALSE	TRUE	FALSE	FALSE	y	Leiomyosarcoma	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	40	0	Post-Chemotherapy|Post-Transplant|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	5	Allogeneic - Sibling|Salvage|Induction|Re-induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	30	Standard Chemotherapy	Azacitidine	Salvage	4	Dead	232	1	7.622176591	Dead-Treatment	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX,der(7)t(3;7)(q26;q21)[9]/46,XX[11]	NA	NA	NA	NA	Increased atypical CD34 positive, CD7 positive myeloblasts	NA	NA	negative	0	negative	NA	NA	NA	NA	1	7.622176591	4
BA2904R	2450	BA2904D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	3	NA	CBFB-MYH11	60	FALSE	FALSE	FALSE	FALSE	FALSE	y	Adenocarcinoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	61	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|IDAC	2	Consolidation|Induction	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	IDAC	Consolidation	-1	Dead	336	1	11.03901437	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX,inv(16)(p13q22)[20]	NA	NA	NA	NA	Increased atypical CD34+myeloblasts representing 80%of leukocytes suggestive of recurrent AML.	NA	NA	negative	0	negative	NA	NA	NA	NA	1	11.03901437	2
BA2883R	2395	BA2883D	Waves1+2	no	no	no	no	Male	Male	White	NA	White	6	N/A	NA	71	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	71	57	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	5	AG-120|KB004|Lenalidomide|Venetoclax (ABT-199), Azacitidine|Decitabine	4	Salvage|Induction|Experimental|Maintenance	Refractory	Standard Chemotherapy	32	Standard Chemotherapy	Venetoclax (ABT-199), Azacitidine	Salvage	77	Dead	548	1	18.00410678	Dead-Unknown	NA	33	NA	NA	NA	NA	8	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY,del(7)(q32),add(13)(p11.2)[20]	NA	NA	This test has detected 7q deletion and an abnormal chromosome 13 in all 15 metaphase cells analyzed. 7q deletion is the most cp,,om abnormality in MDS and other types of myeloid malignancies.	22	They are positive for CD34, HLADR, CD117, CD13 and MPO and negative for TDT. (Bone Marrow Immunophenotyping)	NA	NA	negative	0	negative	RUNX1 (p.G408Vfs*193; 20.4%)	ASXL1 (p.Q428*; 43.4%)	NA	NA	1	18.00410678	4
BA2726R	2309	BA2726D	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	1	NA	NA	29	FALSE	FALSE	FALSE	FALSE	FALSE	y	Basal Cell Carcinoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	29	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	5	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib	3	Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	5	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	2	Dead	129	1	4.238193018	Dead-Disease	0	98	NA	2	1	60	13	24	1.7	393	350	2.5	0.69	M5	27.2	9.4	47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]	NA	105.4	Normal	18	CD11b, CD13, CD14, CD33, CD56 and bright CD64+	5.4	2.42	negative	0	positive	NA	NA	NA	NA	1	4.238193018	4
BA2234R	2247	BA2234D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	KMT2A_re	72	FALSE	FALSE	FALSE	FALSE	FALSE	y	Non-Hodgkins Lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	72	1	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	4	3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea	3	Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Salvage	5	Dead	148	1	4.862422998	Dead-Disease	0	90	90	1.9	0	4.6	89.8	3.7	0.2	NA	NA	2.8	0.93	M5	37.1	11.9	46,XX,t(1;11)(p32;q23)[20]	NA	96.6	MLL: 94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal	33	dim CD4, CD11b, partial CD13, partial CD14, CD15, CD33, partial CD56, CD58, bright CD64, partial CD123 and HLA-DR-positive	NA	104.44	negative	0	negative	NA	NA	NA	DNMT3A (p.E283*; MAF 30%)	1	4.862422998	4
BA2022R	2318	BA2022D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	3	NA	PML-RARA	33	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	33	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	ATRA, Arsenic Trioxide	Consolidation	-1	Alive	559	0	18.36550308	Alive	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M3	NA	NA	NA	NA	NA	This analysis showed evidence of a PML-RARA rearrangement in 177/200 (88.5 percent) interphase cells scored.	26	Large population of CD117pos, CD34neg, HLA-DR neg myeloblasts, representing 78% of leukocytes consistent w/AML.	NA	12.75	positive	0.923076923	negative	NA	NA	NA	FLT3-ITD (p.Leu601_Lys602ins9; MAF 15%)	0	18.36550308	3
BA2228R	2572	BA2228D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NA	White	2	NA	NA	60	FALSE	FALSE	FALSE	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	60	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	5	HiDAC|AG-221|3+7 (Cytarabine, Daunorubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation|Salvage|Induction|Experimental	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Other	AG-221	Experimental	-1	Dead	259	1	8.509240246	Dead-Disease	2	2	0	1	NA	12	12	71	NA	27	NA	4.4	0.99	NA	33.5	11.4	46,XX[20]	NA	95.4	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	219	The study reveals a minute subset of myeloblasts with mild immunophenotypic variation; the significance of this finding is unclear and it is not diagnostic for recurrent or persistent myeloid neoplasia. (No evidence of disease by flow)	7.1	5.54	negative	0	positive	NA	NA	NA	FLT3 (R311Q; MAF 48%)	1	8.509240246	1
BA2037R	2182	BA2037D	Waves1+2	yes	yes	yes	yes	Male	Male	White	HISPANIC	HispNative	1	NA	GATA2-MECOM	34	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	34	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	5	7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|anti-CD33|Azacitidine	3	Induction|Experimental|Re-induction	Refractory	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	anti-CD33	Experimental	-1	Dead	291	1	9.560574949	Dead-Disease	0	60	40	0	2.1	44.3	8.2	16.5	5.5	117	61	3.9	1	M1	35.6	11.7	46,XY,t(3;3)(q21;q26),der(7)del(7)(p11.1)del(7)(q11.1)[13]/45,idem,-der(7)[6]/46,XY[1]	424	96	D7S522/CEP 7: 65/100 cells (65%) had a signal pattern consistent with the deleted chromosome 7 long arm from the small marker observed in the metaphase karyotype; 9 cells (9%) had a signal pattern consistent with the monosomy 7 sideline observed in the metaphase karyotype.	916	CD2, CD11b, CD13, CD33, CD34, CD38, CD56, CD58, CD117,  CD123, and HLA-DR positive	7.7	6.13	negative	0	negative	NA	NA	NA	NRAS (p.Q61H; MAF 45%)	1	9.560574949	1
BA2184R	2320	BA2184D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	bi	NA	47	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	Cyclophosphamide, Fludarabine, TBI	Allogeneic - Sibling	-1	Dead	582	1	19.1211499	Dead-Disease	0	75	NA	0	0	20.3	3.4	3.4	6.9	49	21	3.5	1.08	M1	42.6	15	46,XY[20]	353	86.8	Normal	34	CD7, CD13, CD33, CD34, CD38, CD58, CD117, dim CD123 HLA-DR and MPO+ ,	7.4	8.98	negative	0	negative	NA	NA	NA	CEBPA (p.D320_N321ins22; MAF 50%)|CEBPA (p.R35fs*125; MAF 50%)|CREBBP (p.P505L; VAF 45%)	1	19.1211499	2
BA3009R	2213	BA3009D	Waves1+2	yes	yes	yes	yes	Female	Female	Asian	NON-HISPANIC	Asian	1	NA	NA	26	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	26	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	4	Consolidation|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Cyclophosphamide, Fludarabine, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Alive	1610	0	52.89527721	Alive	0	75	NA	0	0	45.5	9.8	4.5	0.2	32	58	3.1	0.69	M0	22.3	7.4	46,XX,r(2)(p23q31),der(4)t(4;16)(q21;q12-13)del(16)(q22q22),der(16)t(4;16)(q21;q12-13),add(18)(p11.2),del(20)(q13.2)[16]/46,XX[4]	NA	97.8	CBFB: 88% of cells were missing a signal for CBFB, consistent withdeletion associated with the unbalanced t(4;16) seen on chromosome analysis. No evidence for disruption. This probe will be useful in following this abnormal clone.	154	CD13, partial CD15, CD34, CD38, partial CD56, CD58, partial CD117 and CD123+	5.8	9.27	negative	0	negative	NA	NA	NA	PTPN11 (p.D61G; MAF 15%)|TET2 (p.S1039L; MAF 50%)	0	52.89527721	1
BA2842R	2085	BA2842D	Waves1+2	no	no	no	no	Male	Male	Black	NA	Black	6	NA	RUNX1-RUNX1T1	50	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	50	21	Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	Refractory	Standard Chemotherapy	20	Standard Chemotherapy	HiDAC	Consolidation	182	Alive	424	0	13.9301848	Alive	NA	8	0	0	NA	12	29	54	NA	19	9	2.3	0.51	NA	22.8	7.5	46,XY,t(8;21)(q22;q22)[20]	NA	88.7	RUNX1/RUNX1T1 fusion positive in 6.5% of cells	224	NA	5.1	6.8	negative	0	negative	NA	NA	NA	ASXL1 (p.P581R, MAF 46%)|PDGFRB (p.D111N, MAF 52%)|SMC1A (p.R586Q, MAF 96%)	0	13.9301848	4
BA2442R	2549	BA2442D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	3	NA	NA	66	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	UNKNOWN	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	Dead	13	1	0.427104723	Dead-Treatment	NA	NA	16	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	47,XX,+8[18]	NA	NA	Normal	NA	Large population of CD117 pos myeloblasts, representing 80% of leukocytes, consistent w/ AML.	NA	129.5	positive	0.428571429	negative	NA	NA	NA	FLT3-ITD (p.Tyr591_Val592ins16; MAF 10%)|WT1 (p.Val379fs; MAF 13%)|ZRSR2 (p.Arg415Trp; MAF 48.9%)	1	0.427104723	4
BA2882R	2463	BA2882D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	HispNative	1	NA	MLLT3-KMT2A	29	FALSE	FALSE	FALSE	FALSE	FALSE	y	Non-Hodgkins Lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	29	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	2	Induction|Re-induction	Complete Response	Standard Chemotherapy	19	Standard Chemotherapy	HiDAC	Re-induction	4	Dead	65	1	2.135523614	Dead-Unknown	0.9	82	20	0	2.6	26.3	33.4	7.9	3.6	40	19	3.1	0.84	M5	27.3	9.1	46,XY,t(9;11)(p22;q23)[20]	324	89.5	94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, consistent with MLL rearrangement and the 9;11 translocation observed in the metaphase karyotype.	52	CD11b, varibleCD13, CD14, brightCD33, CD64, and HLA-DR positive	6.7	3.88	negative	0	negative	NA	NA	NA	NA	1	2.135523614	4
BA2758R	2453	BA2758D	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	76	TRUE	FALSE	FALSE	FALSE	FALSE	y	Basal Cell Carcinoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	77	417	Post-Chemotherapy|Relapse	Relapse	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	35	Standard Chemotherapy	Incyte trial (azacitidine and JAK 1 inhibitor)	Induction	77	Dead	520	1	17.08418891	Dead-Unknown	0	50	10	0.9	NA	60.3	38.5	0.3	NA	19	19	3.2	1	M0	24.2	8.6	47,XY,+8[cp14]/47,sl,der(21)t(1;21)(q11;p11.1)[2]/46~47,sl,der(22)t(1;22)(q11;p11.2)[cp2]/46,XY[1]	261	102.5	50/100 (50%) interphase cells scored had a signal pattern reflecting trisomy 8.	7	dim CD4, CD13, bright CD34, dim CD45, CD117, HLA-DR, and dim TdT positive	7.2	3.4	negative	0	negative	RUNX1 (p.A338Rfs*256; 71.0%)	ASXL1 (p.G646Wfs*12; 21.1%)	NA	NA	1	17.08418891	4
BA2705R	2100	BA2705D	Waves1+2	yes	yes	yes	no	Male	Male	White	NA	White	5	NA	NA	39	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	40	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	2	Unknown|GCLAC (GCSF, Clofarabine & Cytarabine)	2	Induction|Re-induction	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	GCLAC (GCSF, Clofarabine & Cytarabine)	Re-induction	-1	Alive	82	0	2.694045175	Alive	0	41	14	0	NA	5	5	76	NA	12	17	3.6	0.83	NA	29.4	10.2	46,XY[15]	NA	NA	Negative	24	Positive (CD7, CD11b, CD13, CD33, dim CD34, CD38, dim CD45, CD117, HLA-DR)	5.9	3.6	positive	0.923076923	positive	NA	NA	NA	FLT3-ITD (ITD (39bp ins); VAF 39%)|NPM1 (c.859_860insTCTG; p.W288fs)	0	2.694045175	4
BA2663R	2519	BA2663D	Waves1+2	no	no	no	no	Male	Male	NA	NA	White	7	NA	NA	67	FALSE	FALSE	FALSE	TRUE	FALSE	n	NA	y	n	n	n	y	y	n	n	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	Chronic myelomonocytic leukaemia	NonAML	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	Chronic myelomonocytic leukaemia	66	0	Residual Disease	NA	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	Cytarabine|Decitabine	2	Induction|Supportive/Palliative Care	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	Cytarabine	Induction	-1	Alive	304	0	9.987679671	Alive	NA	17	7	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Trisomy 8	NA	NA	NA	NA	negative	0	negative	RUNX1 (p.R166*; 44.9%)	NA	NA	ASXL1|EZH2|PTPN11|RUNX1|STAG2	0	9.987679671	4
BA2570R	2367	BA2570D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	HISPANIC	HispNative	2	NA	NA	46	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	46	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	Dead	9	1	0.295687885	Dead-Disease	NA	92	75	NA	NA	5	19	1	NA	NA	NA	2.8	1.13	NA	18.4	6.2	46,XY[20]	NA	113.6	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	31	CD2(+), surface CD3(-),  cytoplasmic CD3(dim +), CD4(-), CD7(partial +), CD11b(partial +),  CD13(variably +), CD14(few +), CD15(-), CD16(-),  CD33(-), CD34(partial +), CD36(-), CD38(bright +), CD45(dim  +), CD56(small subset +), CD64(-), CD117(+), HLA-DR(partial +), MPO(partial +), TdT(partial dim+)	NA	151.6	negative	0	negative	NA	NA	NA	NA	1	0.295687885	4
BA2764R	2209	BA2764D	Waves1+2	no	no	no	no	Male	Male	White	NA	White	7	NA	NA	77	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	79	0	Post-Chemotherapy	Remission	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Induction	-1	Alive	500	0	16.42710472	Alive	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Translocation between the long arm of chromosome 3 and short arm of chromosome 12.	NA	NA	NA	NA	positive	NA	positive	NA	NA	NA	FLT3-ITD|NPM1	0	16.42710472	1
BA2209R	2363	BA2209D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NA	White	5	NA	NA	59	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	64	0	Relapse	Relapse	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, TBI	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Dead	1824	1	59.92607803	Dead-Disease	0	59.5	12	0	NA	55	3	29	NA	37	22	4.1	NA	NA	25.2	8.3	47,XY,+13[2]/94,slx2[2]/46,XY[19]	NA	NA	5p15.2/5q31(EGR1), 7 centromere/7q31, 8 centromere/20q12, 12 centromere/13q14 D13S319/13q34 (13qter)	46	Negative (CD10, CD19, CD20, CD22, Cyt CD79a, Cyt CD3, CD7, CD16, CD56, CD11b, CD14, CD15, CD33, CD64, MPO) | Positive (CD38, CD13, CD34, Dim CD45, Dim CD117, HLA-DR, TdT)	6.4	NA	negative	0	negative	NA	NA	NA	NA	1	59.92607803	2
BA2989R	2332	BA2989D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NA	HispNative	2	NA	NA	70	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	71	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	Azacitidine|Decitabine	1	Hypomethylating/Low Dose Cytarabine	NA	NA	NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	98	Alive	305	0	10.02053388	Alive	0	44	31	2	NA	46	0	14	NA	41	18	3.7	0.91	NA	21.6	7.1	47,XY,+21[19]/46,XY[1]	91	NA	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],	35	CD2(-), CD4(dim +), CD7(-), CD10(-), CD11b(-), CD13(bright +), CD14(-), CD15(partial +), CD16(-), CD22(-), CD19(partial +), CD33(partial +), CD34(+), CD36(-), CD38(bright and variably +), CD45(+), CD56(-), CD64(-), CD79a(-), CD117(+), HLA-DR(predominantly + and variable), TdT(partial +), and MPO(-) | In addition, there is a 0.92% population of CD117(bright +)/CD34(-)/CD45(dim +)/CD33(- to dim +) small cells with low orthogonal light scatter. The exact identity of these cells is uncertain	7.7	5.05	positive	0.086956522	negative	RUNX1 (p.I366Vfs*231; 65.5%)	NA	NA	BCOR (Foundation; R1480*; MAFs: 88%)|BCORL1 (Foundation; P304fs*117; MAFs: 72%)|FLT3-ITD|NF1 (Foundation; I679fs*21; MAFs: 5%)|NF1 (Foundation; V2649fs*31 (subclonal); MAFs: 12%)|PHF6 (Foundation; R225*; MAFs: 87%)|PTPN11 (Foundation; A72T; MAFs: 8%)|RUNX1 (Foundation; I366fs*114+; MAFs: 57%)|TET2 (Foundation; Q742*; MAFs: 41%)	0	10.02053388	1
BA2855R	2085	BA2855D	Waves1+2	no	no	no	no	Male	Male	Black	NA	Black	6	NA	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	50	73	Post-Chemotherapy	Remission	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	Refractory	Standard Chemotherapy	20	Standard Chemotherapy	HiDAC	Consolidation	182	Alive	424	0	13.9301848	Alive	NA	0	NA	NA	NA	NA	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[20]	NA	NA	RUNX1/RUNX1T1 fusion negative	126	No morphological evidence of acute leukemia (Bone Marrow Immunophenotyping)	NA	7.7	negative	0	negative	NA	NA	NA	NA	0	13.9301848	4
BA2261R	2528	BA2261D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NA	White	2	NA	NA	62	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	62	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	4	Vidaza|7+3 (Cytarabine, Idarubicin)|Lenalidomide|Hydroxyurea	3	Hypomethylating/Low Dose Cytarabine|Induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	7	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	-1	Dead	198	1	6.50513347	Dead-Disease	0.8	34	3.3	1.6	NA	14.9	5	68.6	NA	13	11	2.6	0.5	NA	32.4	10.7	46~47,XX,del(5)(q15q35),i(8)(q10),add(11)(q23),add(17)(p11.2),add(21)(q22),+2~3mar[cp3]/47~49,idem,add(7)(q11.2),-add(11),+11,+14,-20[cp4]/45~49,idem,del(7)(q22q36),-add(11),+11,+14,-20[cp2]/45~48,idem,der(7)del(7)(q22q31)dic(7;20)(q36;q11.2),-add(11),+11,+14[	304	NA	nuc ish(D5S2064x2,D5S630x2,EGR1x1)[184/200],(D7Z1x2,D7S522x1)[115/200],(D8Z2x2,D20S108x1)[142/200],(RUNX1T1x3,RUNX1x2)[180/200],(5'MLL amp,3'MLL amp)(5'MLL con 3'MLL amp)[66/200],(PML,RARA)x2[197],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	36	CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(+),CD56(+), CD64(-), CD117(partial +), HLA-DR(partial +). | In addition, there is a 0.01% population of small cells with the following immunophenotype: CD5(+), CD10(-), CD19(+), CD20(dim+), CD38(-), CD45(+), lambda(dim +), and kappa(-).	5.3	8.35	negative	0	negative	NA	NA	TP53 (p.R213Dfs*34; 85.5%)	TP53 (R213fs; MAF 34%)	1	6.50513347	1
BA2721R	2556	BA2721D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	69	FALSE	FALSE	FALSE	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other	8	7+3 (Cytarabine, Idarubicin)|Sorafenib|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC|IMGN779 (Immunogen Trial)|Fludarabine, Cyclophosphamide, Thiotepa, TBI|ALRN-6924|Azacitidine, Midostaurin, Ponatinib	4	Salvage|Induction|Experimental|Re-induction	Refractory	Standard Chemotherapy	6	Targeted Therapy - Other	IMGN779 (Immunogen Trial)	Salvage	-1	Dead	565	1	18.56262834	Dead-Disease	1.8	NA	40	0.9	8.8	10.5	9.6	26.3	2.8	27	22	3.4	0.64	M2	23.5	7.1	46,XX[20]	399	103.5	normal	12	CD13, CD34, CD58, CD117, partial MPO and HLA-DR +	6.5	61.22	positive	1	negative	RUNX1 (p.A187T; MAF 42%)	NA	NA	CREBBP (p.S893L; MAF 41%)|FLT3-ITD (MAF 47%)|RUNX1 (p.A187T; MAF 42%)|SF3B1 (p.K700E; MAF 51%)|TET2 (p.K751fs*61; MAF 44%)	1	18.56262834	4
BA2930R	2453	BA2930D	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	76	FALSE	FALSE	FALSE	FALSE	FALSE	y	Basal Cell Carcinoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	77	472	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	35	Standard Chemotherapy	Incyte trial (azacitidine and JAK 1 inhibitor)	Induction	77	Dead	520	1	17.08418891	Dead-Unknown	0	54	occasional	6.9	NA	51.6	39.6	1.9	NA	20	23	3.2	1	M0	25.4	8.6	47,XY,+8[cp15]/47,sl,der(22)t(1;22)(q11;p11.2)[2]/46,XY,dup(1)(q21q42)[cp2]	NA	92	60/100 (60%) interphase cells scored had a signal pattern reflecting trisomy 8.	22	Positive (The myeloid blasts are CD13, CD34, CD38, CD117, and HLA-DR;Atypical monocytic cells comprise approximately 41% of analyzed events and are CD11b, CD13, CD14, CD64, and dim HLA-DR positive. T cells show a CD4:CD8 ratio of 6.9:1 without aberrant antigen expression. B cells are polytypic by surface light chain expression)	7.2	4.5	negative	0	negative	RUNX1 (p.A338Rfs*256; 76.9%)	NA	NA	NA	1	17.08418891	4
BA2728R	2094	BA2728D	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	1	NA	GATA2-MECOM	58	FALSE	FALSE	TRUE	FALSE	FALSE	y	Basal Cell Carcinoma|Squamous cell carcinoma	y	n	y	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	58	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	Azacitidine|SWOG S0919 (Ida/Ara+Pravastatin) |Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Maintenance	Complete Response	Standard Chemotherapy	70	Standard Chemotherapy	Azacitidine	Maintenance	102	Alive	1911	0	62.78439425	Alive	0	21	0	0	2.3	41.7	25.9	30.1	0.1	NA	NA	NA	NA	M2	35.1	11	46,XX,t(3;3)(q21;q26)[20]	NA	107	98/100 (98%) interphase cells scored had a 1 red/ 1 green/ 2 yellow signal pattern, interphase cells scored had a 1 red/ 1 green/ 2 yellow signal pattern, consistent with RPN1/MECOM fusion. Two metaphases showed a fusion signal on one derivative 3 and red, yellow and green signals on the other deriv	360	variable CD11b, CD13, dim CD33, CD34, CD58, CD117, CD123	NA	13.83	negative	0	negative	NA	NA	NA	NRAS (p.G12D; MAF 47%)|SF3B1 (p.K666N; MAF 47%)	0	62.78439425	4
BA2715R	2192	BA2715D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NA	White	2	NA	NA	81	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	n	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	81	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	1	Supportive/Palliative Care	2	Vidaza|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care	NA	NA	NA	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	3	Dead	97	1	3.186858316	Dead-Disease	NA	33	8	4	NA	28	24	44	NA	22	20	4.1	1.07	NA	27.5	9.5	45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5]	333	NA	nuc ish(D5S2064x3,D5S630x3,EGR1x1)[97/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1x3,RUNX1x2)[110/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5’CBFB con 3’CBFB dimx1,5’CBFB con 3’CBFBx1)[200]	28	CD4(+), CD5(partial +), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(predominantly -), CD16(-), CD33(+), CD34(+), CD36(-),CD38(variably +), CD45(variably +), CD56(predominantly -), CD64(partial +), CD117(+), HLA-DR(predominantly + and variable),MPO(-), TdT(-).	6.6	2.2	negative	0	negative	NA	NA	TP53 (p.R273H; 39.7%)|TP53 (p.L206Wfs*41; 32.4%)	EP300 (Foundation; EP300-ZNF205 fusion)|TP53 (Foundation; L206fs*41; MAFs: 31%)|TP53 (Foundation; R273H; MAFs: 38%)	1	3.186858316	1
BA2469R	2530	BA2469D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	HISPANIC	White	6	NA	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	51	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	Busulfan, Fludarabine|5+2 (Cytarabine, Idarubicin)|HiDAC|7+3 (Cytarabine, Idarubicin, Bortezomib	3	Unknown|Induction|Re-induction	Unknown	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Unknown	-1	Alive	716	0	23.52361396	Alive	NA	12	NA	NA	NA	NA	17	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX[20]	NA	NA	NA	16	FLT3 (ITD) Not detected. Not detected for the FLT3 TKD Mutation. Pathogenic alterations are detected in the BCOR, IDH2 and WT1 genes. Positive for CD34, HLADR, CD117, CD13, CD33 and CD43 and negative for CD11B, CD14, CD64, TDT and MPO. (Bone Marrow Immunophenotyping)	NA	1.5	negative	0	negative	NA	NA	NA	BCOR (p.E1348Ifs, MAF 32%)|IDH2 (p.R172K, MAF 41%)|WT1 (p.T171Cfs*116, MAF 39%)	0	23.52361396	1
BA2269R	2033	BA2269D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	HISPANIC	HispNative	6	NA	NA	34	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	34	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Intrathecal	3	7+3 (Cytarabine, Idarubicin)|Cytarabine|Etoposide, Mitoxantrone	3	Unknown|Induction|Re-induction	Refractory	Standard Chemotherapy	35	Intrathecal	Cytarabine	Unknown	6	Dead	157	1	5.158110883	Dead-Unknown	NA	15	NA	NA	NA	NA	12	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX[20]	NA	NA	NA	426	NA	NA	26.4	negative	0	negative	NA	NA	TP53 (p.R282Q; 46.6%)	CSF3R (p.A470V, MAF 51%)|DNMT3A (p.R882C, MAF 51%)|NRAS (p.G13R, MAF 48%)|TP53 (p.R282Q, MAF 51%)	1	5.158110883	4
BA2098R	2414	BA2098D	Waves1+2	yes	yes	yes	yes	Female	Female	White	UNKNOWN	White	1	NA	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Alive	1830	0	60.12320329	Alive	0	83	NA	1.8	1.8	13.3	63.7	7.9	0.1	69	35	3	0.87	M5	34.7	11.6	46,XX[20]	337	95.6	Normal	146	Positive (dim CD4, CD11b, variable CD13, partial CD14, CD33, variable CD56, bright CD64, dim CD123 and HLA-DR-positive, comprising ~75% of WBCs. There is also about 5% of blasts are positive for CD117, CD13, CD33, HLA-DR, CD123, amd CD11b. Lymphocytes account for 13% of WBCs and include 74% T cells, 19% B cells and 7% NK cells. T cells show a CD4:CD8 ratio of 5:1 without aberrant antigen expression.) | Positive (B cells are polytypic by surface light chain expression with a kappa to lambda ratio of 1.2:1.)	6.1	44.83	negative	0	positive	NA	NA	NA	IDH1 (p.R132H; MAF 37%)|NPM1 (p.W288fs*12; MAF 40%)|NRAS (p.G13D; MAF 38%)	0	60.12320329	4
BA2778R	2083	BA2778D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	60	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	6	Fludarabine, Melphalan|Ruxolitinib|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC|Hydroxyurea	5	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction|Maintenance	Refractory	Standard Chemotherapy	18	Targeted Therapy - Kinase Inhibitor(s)	Ruxolitinib	Maintenance	496	Alive	1801	0	59.17043121	Alive	0	75	44	0	0.9	28.7	46.1	24.3	0	18	13	2.9	1.19	M5	26.4	8.8	46,XX[20]	222	96.4	Normal	175	Positive (CD11b, variable CD13, CD14, CD33, dim CD56, bright CD64, and HLA-DR+)	6.9	34.6	negative	0	positive	NA	NA	NA	FBXW7 (p.T15_G16insP; MAF 48%)|NPM1 (p.W288fs*12; MAF 40%)|NRAS (p.G12S; MAF 40%)|TET2 (p.H437fs*7; MAF 42%)	0	59.17043121	4
BA2951R	2228	BA2951D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	3	NA	GATA2-MECOM	65	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	n	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	65	3	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Alive	27	0	0.887063655	Alive	NA	59.4	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	47,XX,+X,inv(3)(q21q26.2),-7,+22[2]/48,sl,+21[18]	NA	NA	evidence of monosomy 7 in 191/200 (95.5 percent) cells scored	NA	NA	NA	NA	negative	0	negative	RUNX1 (p.D198G; 66.7%)	NA	NA	CALR (p.Leu367fs; MAF 24%)|CBL (p.? ; MAF 16.5%)|DNMT3A (p.Ala571Pro; MAF 51.5%)|EZH2 (p.Pro636Ala; MAF 94.7%)|FLT3 (p.Val579Ala; MAF 2.3 %)|PTPN11 (p.Gly60Ser; MAF 49.1%)|RUNX1 (p.Asp198Gly; MAF 63.7%)	0	0.887063655	1
BA2163R	2129	BA2163D	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	67	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	67	0	Residual Disease	Residual	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	4	Fludarabine, Melphalan|Azacitidine|Hydroxyurea|Idarubicin and Cytarabine	3	Allogeneic - Sibling|Induction|Re-induction	Refractory	Standard Chemotherapy	1932	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Sibling	-1	Dead	452	1	14.85010267	Dead-Disease	2.6	42.5	54	0.9	0	44.2	2.7	0.9	0	21	15	2	2.62	NA	23.1	7.9	45,XY,+5,dic(5;8)(q11.2;p12)x2,del(7)(q22q32),-18,del(20)(p11.2)[cp20]	NA	91.7	5p/5q: 88/100 (88%) cells had one signal for EGR1 (5q31) and three signals for 5p, consistent with the metaphase karyotype; 5 cells (5%) had one EGR1 signal and four 5p signals, consistent with a previous sideline with three copies of the dicentric 5;8 chromosome.   | BCR: 15/200 (7.5%) cells had three signals for BCR (22q11.2) consistent with a previous sideling that had trisomy 22 (the same sideline with three copies of the dicentric 5;8 chromosome). There was no evidence for BCR/ABL fusion.	22	Positive (CD7, CD13, dimCD33, CD34, variable CD38, CD56, dim CD58, variable CD117, dimCD123 and dim HLA-DR positive)	5.3	1.27	negative	0	negative	NA	NA	TP53 (p.K132R; 39.4%)|TP53 (p.X126_splice; 51.3%)	DNMT3A (p.G570E; MAF 44%)|JAK2 (p.V617F; MAF 3%)|TP53 (Intron 4 3' splice site mutation; MAF 42%)|TP53 (p.K132R; MAF 45%)	1	14.85010267	1
BA2379R	2440	BA2379D	Waves1+2	no	no	no	no	Male	Male	White	NA	White	6	NA	NA	62	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	y	n	n	n	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	Chronic myelomonocytic leukaemia	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	62	81	Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	Azacitidine|Fludarabine, Melphalan, ATG	2	Unknown|Allogeneic - Matched Unrelated Donor	NA	NA	NA	Bone Marrow Transplant	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	-1	Alive	281	0	9.232032854	Alive	NA	9	NA	NA	NA	NA	7	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[12]	NA	NA	The abnormalities normally seen in MDS are not detected.	NA	A very dim/negative CD45 population was also detected by the flow analysis. This population is negative for all the myeloid and lymphoid markers including CD34. This is mentioned here for documentation purposes but we believe that they do not represent blasts. (Bone Marrow Immunophenotyping)	NA	NA	negative	0	negative	NA	NA	NA	NA	0	9.232032854	4
BA2817R	2557	BA2817D	Waves1+2	yes	yes	yes	yes	Male	Male	Black	NA	Black	2	NA	NA	73	FALSE	FALSE	FALSE	FALSE	FALSE	y	Prostate Cancer	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	77	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Supportive/Palliative Care|Targeted Therapy - Other	6	Vidaza|AG-221|Bortezomib|Cytarabine|Lenalidomide|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Experimental|Supportive/Palliative Care	NA	NA	NA	Targeted Therapy - Other	AG-221	Experimental	267	Dead	1490	1	48.95277207	Dead-Disease	NA	95	48	1	NA	42	6	2	NA	14	14	3.5	1.1	NA	27.3	9.4	88<4n>,XXYY,+del(1)(p22p36),i(2)(p10),-5,-7,-7,-21,-21[12]	453	NA	nuc ish(RUNX1T1x4,RUNX1x2)[200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[200],(PML,RARA)x4[200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[174/200]	23	92% population of variably-sized cells with the following immunophenotype: CD2(-), CD4(-), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(+), CD16(-), CD33(-), CD34(+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(variably +), HLA-DR(partial +).	6.5	3	negative	0	negative	RUNX1 (loss)	NA	NA	IDH2 (R140Q)|PTPN11 (E76Q)|RUNX1 (loss)	1	48.95277207	4
BA3153R	2664	BA3153D	Waves3+4	yes	yes	yes	yes	Male	Male	Black	NA	NA	5	mono	NA	49	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE	Mixed phenotype acute leukaemia, T/myeloid, NOS	Intermediate	ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE	Mixed phenotype acute leukaemia, T/myeloid, NOS	49	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Alive	455	0	14.9486653	Alive	0	15	50	1	NA	10	2	40	NA	37	34	3.4	NA	NA	NA	12.2	46,XY[20]	NA	NA	Normal	210	Positive (CD38, CD7, CD2) | Negative (CD10, CD19, CD22, CD16, CD56, CD13, CD14, CD15, CD33, CD34, CD117, MPO, HLA-DR) | Dim Positive (cCD3, CD11b, CD64)	NA	7.9	negative	0	negative	NA	NA	NA	CEBPA ([c.937A>C; c.940G>A; c.941T>A;c.943C>G] p.K313_V314_L315delinsQKV)	0	14.9486653	2
BA2820R	2542	BA2820D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	73	FALSE	FALSE	TRUE	FALSE	FALSE	y	Prostate Cancer	y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)|Hydroxyurea	1	Induction	unknown	Standard Chemotherapy	167	Standard Chemotherapy	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)	Induction	21	Dead	28	1	0.919917864	Dead-Disease	0	88	38	0	1.7	20.9	60.9	1.7	0.1	27	40	3	1.2	M4	33	11.2	46,XY[20]	NA	105.8	normal	55	Positive (Myeloid blast immunophenotype: CD13, CD33, dim CD64, CD117, CD123 (+) Monocytic/monoblastic immunophenotype: bright CD11b, CD13, bright CD14, CD33, bright CD64, HLA-DR (+))	7.5	58.97	positive	1	positive	NA	NA	NA	DNMT3A (p.R882H; MAF 42%)|EP300 (p.N674D; MAF 50%)|EP300 (p.V2140I; MAF 50%)|FLT3-ITD (MAF ~48%)|MLL2 (p.M3398V; MAF 51%)|NPM1 (p.W288fs*12; MAF 43%)	1	0.919917864	4
BA2723R	2390	BA2723D	Waves1+2	yes	yes	yes	no	Male	Male	White	HISPANIC	White	6	NA	NA	25	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	26	0	Relapse|Post-Chemotherapy|Post-Transplant	Relapse	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	5	Bu/Cy/ATG|HiDAC|3+7 (Cytarabine, Daunorubicin)|Decitabine|Clofarabine, Cytarabine	5	Consolidation|Salvage|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	Decitabine	Salvage	9	Dead	463	1	15.21149897	Dead-Disease	NA	NA	14	8	NA	17	2	54	NA	39	49	3.2	0.79	NA	19.3	6.5	NA	NA	101	NA	33	NA	4.9	1.6	negative	0	negative	NA	NA	NA	NA	1	15.21149897	1
BA2704R	2255	BA2704D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	3	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Hydroxyurea	1	Induction	Unknown	Standard Chemotherapy	8	Standard Chemotherapy	Hydroxyurea	Induction	8	Dead	8	1	0.262833676	Dead-Disease	0	93	85	0.8	0	16.5	0.8	1.6	0.2	19	21	2.7	0.78	M1	21.1	7.1	46,XX[20]	360	84.4	Normal	43	partial CD13, CD33, dim/partial CD56, CD58, dim CD117, CD123 and MPO	5.7	30.54	positive	0.851851852	positive	NA	NA	NA	FLT3-ITD (MAF ~50%)|IDH2 (p.R140Q; MAF ~50%)|NPM1 (p.W288fs*12; MAF ~50%)	1	0.262833676	3
BA2088R	2153	BA2088D	Waves1+2	no	no	no	no	Female	Female	Black	NON-HISPANIC	Black	6	NA	NA	45	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	46	0	Post-Chemotherapy	Remission	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	4	HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)|3+7 (Cytarabine, Daunorubicin)|Cyclophosphamide, Etoposide, Cytarabine	4	Consolidation|Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	25	Standard Chemotherapy	CLAG (Cladribine, Cytarabine, Filgrastim)	Salvage	23	Alive	465	0	15.27720739	Alive	NA	3	NA	NA	NA	NA	4	NA	NA	NA	NA	NA	NA	NA	NA	NA	45,XX,-7[4]/46,sl,+mar[2]/46,XX[14]	NA	NA	NA	69	MLL-PTD is not detected. FLT3-ITD not detected. FLT3-TKD mutation not detected. Pathogenic alterations are detected in the DNMT3A and IDH1 genes. Genomic alteration of uncertain significance is detected in the DNMT3A gene. (Bone Marrow Immunophenotyping)	NA	1.3	negative	0	negative	NA	NA	NA	NA	0	15.27720739	1
BA2116R	2192	BA2116D	Waves1+2	no	no	no	no	Male	Male	White	NA	White	2	NA	NA	81	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	n	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	81	41	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	1	Supportive/Palliative Care	2	Vidaza|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care	NA	NA	NA	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	3	Dead	97	1	3.186858316	Dead-Disease	0	N/A	70	0	NA	3	1	36	NA	25	33	4.1	1.26	NA	24.1	8.1	45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5]	853	98	nuc ish(D5S2064x3,D5S630x3,EGR1x1)[97/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1x3,RUNX1x2)[110/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5’CBFB con 3’CBFB dimx1,5’CBFB con 3’CBFBx1)[200]	74	NA	NA	39.12	negative	0	negative	NA	NA	TP53 (p.R273H; 56.3%)|TP53 (p.L206Wfs*41; 40.7%)	NA	1	3.186858316	4
BA2584R	2422	BA2584D	Waves1+2	yes	yes	yes	yes	Male	Male	NA	NA	White	3	NA	KMT2A_re	42	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	42	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	4	Allogeneic - Sibling|Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	-1	Alive	427	0	14.02874743	Alive	NA	80	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	45,XY,t(3;17)([21;q11.2),add(4)(q21),add(5)(p15),ins(10;11)(p12;q23q13),der(12;18)(q10;q10)[19]/46,XY[1]	NA	NA	11q23 rearrangement involving the  KMT2A (MLL) locus in 184/200 (92.0 percent) cells scored | One cell line showed the following clonal abnormalities in 19/20 (95%) cells: an apparent insertion of material form the long arm of chromosome 11 into the short arm of chromosome 10;  a translocation between chromosomes 3 and 17; added material on the long arm of chromosome 4 and on the short arm of chromosome 5; an unbalanced whole arm rearrangement between the long arms of chromosomes 12	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	NA	0	14.02874743	4
BA3079R	2830	BA3079D	Waves3+4	yes	yes	yes	yes	Male	Male	NA	NA	NA	3	NA	NA	68	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	Alive	23	0	0.755646817	Alive	NA	67	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	45,XY,+1,der(1;14)(p10;q10),add(3)(p25),-5,del(12)(p11.2p13)[6]/44,XY,sl,del(7)(q11.2),der(8)del(8)(p21)t(8;17)(q24;q21),-17,+19,-22[cp10]/63<3n>,sdl1,-3,-4,-6,+8,del(8)(p21)x2,+9,+13,-15,-18,-21[cp4]	NA	NA	5p15.2 (D5S23): gain present  5q31 (EGR1): deletion present  7cen (D7Z1), 7q31 (D7S486): deletion and monosomy present  | t(8;21)(q22;q22) (RUNX1T1;RUNX1): gain present  11q23 (KMT2A; also known as MLL): gain present  16q22 (CBFB): gain present  17q21 (RARA): gain present	NA	NA	NA	NA	negative	0	negative	NA	NA	TP53 (p.N239*; 57.9%)	TP53 (p.Asn239*; MAF 58.4%)|TP53 (p.Ser166_Gln167del; MAF 12%)	0	0.755646817	1
BA2417R	2333	BA2417D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NA	White	2	NA	NA	70	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	70	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	Vidaza|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Vidaza	Hypomethylating/Low Dose Cytarabine	4	Alive	486	0	15.96714579	Alive	0	85	77.8	0	NA	7.4	0	11.1	NA	12	32	2.8	0.62	NA	21.8	7	NA	1195	NA	NA	103	CD11b(partial +), CD13(equivocal), CD15(bright +), CD16(-), CD33(bright +), CD34(-), CD36(-), CD38(bright +), CD45(bright +), CD56(+),CD64(bright+), CD117(-), and HLA-DR(+).	5.2	25.85	negative	0	negative	NA	NA	NA	NA	0	15.96714579	4
BA2361R	2444	BA2361D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NA	White	5	NA	NA	55	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	7+3 (Cytarabine, Idarubicin) plus Enasidenib|Busulfan, Cyclophosphamide	2	Allogeneic - Sibling|Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	Alive	428	0	14.06160164	Alive	1	30	0	0	NA	31	4	6.8	NA	10	11	4.3	NA	NA	32.4	9.9	46,XX,del(5)(q22q35)[2]/46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.2)[14]/46,XX[3]	NA	NA	Probe: 8 centromere/20q12 | Normal (5p15.2/ 5q31 (EGR1); 7 centromere/ 7q31)	83	Negative (CD19) | Negative (CD22) | Positive (CD38) | Negative (CD7) | Negative (CD56) | Negative (CD11b) | Positive (CD13) | Negative (CD14) | Negative (CD15) | Negative (CD33) | Positive (CD34) | Negative (CD45) | Negative (CD64) | Negative (CD117) | Negative (MPO) | Positive (HLA-DR)	7.2	10.6	negative	0	negative	NA	NA	NA	ASXL1 (c.190 0_1922 delAGAGAGGCGGCCACCACTGCCAT; p.R634Rfs; MAF 33%)|IDH2 (c.419G>A; P.R140Q; MAF 46%)	0	14.06160164	4
BA2450R	2284	BA2450D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	46	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	46	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	5	7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	32	Standard Chemotherapy	Sunitinib	Consolidation	2	Dead	269	1	8.837782341	Dead-Disease	0	NA	NA	0	0	20.4	0	66.7	1	58	44	3.3	1.04	NA	23.8	8.1	NA	401	88.5	metaphases positive for 45XX monosomy chromosome 17,20/22 metaphases positive for 46XX diploid	14	NA	7.3	6.18	positive	0.25	positive	NA	NA	NA	NA	1	8.837782341	3
BA2492R	2390	BA2492D	Waves1+2	no	no	no	no	Male	Male	White	HISPANIC	AdmixedHispNative	6	NA	NA	25	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	26	28	Residual Disease|Post-Chemotherapy|Post-Transplant	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	Bu/Cy/ATG|HiDAC|3+7 (Cytarabine, Daunorubicin)|Decitabine|Clofarabine, Cytarabine	5	Consolidation|Salvage|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	Decitabine	Salvage	9	Dead	463	1	15.21149897	Dead-Disease	NA	70	8	NA	NA	NA	4	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY,-3,del(5)(q31q35),der(7)t(7;?)(p11.2;?),+der(11)(q23),-12,+mar[20]	NA	NA	NA	10	MONOBLASTS, 61%. These are dim45positive and also express CD13, CD33, CD11b, CD14, CD64  but lack CD16, CD34, CD117, HLADR  (Bone Marrow Immunophenotyping)	NA	30.2	negative	0	negative	NA	NA	NA	NA	1	15.21149897	4
BA2552R	2203	BA2552D	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	6	NA	NA	67	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	69	0	Relapse|Post-Chemotherapy|Post-Transplant	Relapse	Peripheral Blood	y	y	n	y	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	6	AG-120|7+3 (Cytarabine, Idarubicin)|Cytarabine|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG	6	Consolidation|Salvage|Induction|Experimental|Post-Transplant Relapse|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Cytarabine	Post-Transplant Relapse	3	Dead	944	1	31.01437372	Dead-Unknown	NA	NA	94	0	NA	3	0	1	NA	18	52	3.2	1.03	NA	24.6	8.6	NA	NA	93.5	NA	28	NA	5.7	108.9	positive	0.666666667	positive	NA	NA	NA	IDH1 (p.R132S, MAF 46%)|NPM1 (p.W288Cfs*12, MAF 57%)	1	31.01437372	3
BA2472R	2546	BA2472D	Waves1+2	yes	yes	yes	yes	Male	Male	Asian	NA	Asian	2	NA	NA	78	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	78	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	5	7+3 (Cytarabine, Idarubicin)|Decitabine|7+3 (Cytarabine, Idarubicin) plus Azacitidine|IDAC|Etoposide, Cytarabine	4	Induction|Re-induction|Maintenance|Supportive/Palliative Care	Refractory	Supportive/Palliative Care	-1	Standard Chemotherapy	Etoposide, Cytarabine	Supportive/Palliative Care	-1	Dead	372	1	12.22176591	Dead-Disease	0	20	3.8	7.8	NA	40	5.2	40	NA	9	49	3.1	1.41	NA	25.7	8.5	46,XY[20]	675	NA	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	30	CD2(-), CD3(-), CD4(dim +), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(small subset+), CD16(-), CD19(-), CD20(-), CD33(+), CD34(+),CD36(-), CD38(dim+), CD45(dim +), CD56(-), CD64(variably+), CD117(+), HLA-DR(dim +), MPO(partial +), and TdT(-).	6.9	4.9	negative	0	negative	RUNX1 (p.L89Pfs*49; 15.8%)	NA	NA	NA	1	12.22176591	4
BA2994R	2284	BA2994D	Waves1+2	no	no	no	no	Female	Female	White	NON-HISPANIC	White	1	NA	NA	46	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	14	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	5	7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	32	Standard Chemotherapy	Sunitinib	Consolidation	2	Dead	269	1	8.837782341	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	metaphases positive for 45XX monosomy chromosome 17,20/22 metaphases positive for 46XX diploid	NA	NA	NA	NA	negative	0	positive	NA	NA	NA	NA	1	8.837782341	3
BA2047R	2467	BA2047D	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	1	NA	PML-RARA	69	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	69	1	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	2	ATRA, Idarubicin|ATRA, Arsenic Trioxide	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	ATRA, Arsenic Trioxide	Consolidation	-1	Alive	1542	0	50.66119097	Alive	1.7	90	NA	1.7	0.8	13.5	5	6.7	0.9	45	41	3.4	1.09	M3	24.1	8.6	46,XX,t(15;17)(q24;q21)[20]	NA	92.7	PML/RARA fusion	39	dim CD2, CD13, dim CD15, CD33, CD38, CD58, CD64, CD117, CD123, variable HLA-DR and bright MPO positive	6.5	34.36	positive	0.851851852	negative	NA	NA	NA	FLT3-ITD (MAF 42%)|NOTCH1 (p.P2438L ; MAF 47%)	0	50.66119097	3
BA2101R	2483	BA2101D	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1	NA	CBFB-MYH11	68	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	Alive	35	0	1.149897331	Alive	0	24	10	0.9	0	81.8	4.6	10.9	0	27	26	4.1	1	M2	33.6	11.9	46,XY,del(7)(q22),inv(16)(p13.1q22)[18]/46,XY[2]	330	106.7	CBFB, D7S486/ CEP 7	106	CD5, CD19, dim CD20, dim CD22, CD23 and light chain negative	6.9	2.16	negative	0	negative	NA	NA	NA	FLT3-ITD (MAF 3%)|FLT3(p.D839G; MAF 3%)|DNMT3A(p.R882H; MAF 16%)	0	1.149897331	2
BA2082R	2126	BA2082D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	2	NA	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Unknown	0	0	0	NA	0	48	6	0	NA	31	14	47	NA	27	27	4.2	0.86	NA	36.9	12.6	47,XY,t(8;19)(q24.1;q13.1),+10[17]/46,XY[3]	294	NA	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200], (D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	175	NA	7	2.43	negative	0	negative	NA	NA	NA	NA	0	0	2
BA2879R	2292	BA2879D	Waves1+2	no	no	no	no	Female	Female	Unknown	NA	White	2	NA	NA	52	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	53	462	Relapse	Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	Dead	633	1	20.79671458	Dead-Disease	NA	76	1	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M1	NA	NA	46,XX[20]	NA	NA	nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	NA	1	20.79671458	4
BA2577R	2566	BA2577D	Waves1+2	no	no	no	no	Female	Female	White	NON-HISPANIC	White	1	bi	NA	10	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	12	568	Post-Chemotherapy|Relapse	Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|ADE (Cytarabine, Daunorubicin & Etoposide)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	33	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Alive	2143	0	70.40657084	Alive	0	46	NA	0	0	81.3	8.3	10.4	18.1	31	27	3.8	0.53	M2	30.5	10.2	47,XX,+10[19]/46,XX[1]	NA	96.8	Normal	11	variable CD7,  dim CD13, CD33, CD34 bright CD38,CD56, CD58, CD117, HLA-DR positive	7	1.93	negative	0	negative	NA	NA	NA	NA	0	70.40657084	2
BA2456R	2481	BA2456D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NA	White	2	NA	NA	65	FALSE	FALSE	FALSE	FALSE	FALSE	y	Skin cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Cytarabine	1	Supportive/Palliative Care	NA	NA	NA	Standard Chemotherapy	Cytarabine	Supportive/Palliative Care	-1	Dead	2	1	0.065708419	Dead-Unknown	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	nuc ish (PML,RARA)x2[199]	NA	NA	NA	NA	negative	0	positive	NA	NA	NA	NA	1	0.065708419	4
BA2175R	2382	BA2175D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NA	White	2	NA	NA	72	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Supportive/Palliative Care	NA	NA	NA	Standard Chemotherapy	Decitabine	Supportive/Palliative Care	-1	Alive	373	0	12.25462012	Alive	NA	30	5	NA	NA	NA	NA	NA	NA	37	93	NA	NA	NA	NA	NA	45,XX,der(5)inv(5)(p13q15)del(5)(q15q33),-16,-17,der(17)t(17;17)(p13;q11.2),der(18;22)(q10;q10),+22,+r[cp20] .ish r(MLL+)[2]	NA	NA	nuc ish(D4Z1,D10Z1)x2[200],(D5S2064x2,D5S630x2,EGR1x1)[196/200],(D7Z1,D7S522)x2[200], (D8Z2,D20S108)x2[197],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3) [142/200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[200]	16	NA	NA	44.63	negative	0	negative	NA	NA	NA	NA	0	12.25462012	1
BA2824R	2284	BA2824D	Waves1+2	no	no	no	no	Female	Female	White	NON-HISPANIC	White	1	NA	NA	46	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	23	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	5	7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	32	Standard Chemotherapy	Sunitinib	Consolidation	2	Dead	269	1	8.837782341	Dead-Disease	0	90	90	0	0	5	0	0	0	27	43	1.6	0.93	NA	22.5	7.9	NA	NA	82.1	Positive	43	variable CD7, CD13, dim CD33, partial CD34, CD38,dim CD58, partial and variable CD117 and CD123 positive	5.1	18.38	positive	0.515151515	positive	NA	NA	NA	NA	1	8.837782341	3
BA2507R	2377	BA2507D	Waves1+2	yes	yes	yes	yes	Male	Male	Black	NA	Black	5	NA	CBFB-MYH11	33	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	33	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	-1	Alive	402	0	13.2073922	Alive	0	72	95	0	NA	3	0	1	NA	29	24	3.4	NA	NA	19.8	6.5	46,XY,inv(16)(p13.1q22)[20]	NA	NA	Positive for CBFB rearrangment for 91% of cells	31	Positive (CD38, CD13, CD33, CD34, CD45, CD117, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD11b, CD14, CD15, CD64, TdT)	6.6	93.2	negative	0	negative	NA	NA	NA	TET2 (c.652G>A; p.V218M; MAF 50%)	0	13.2073922	2
BA2563R	2493	BA2563D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NA	White	3	NA	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine|IDAC plus Midostaurin|7+3 (Cytarabine, Daunorubicin) plus Sorafenib	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	-1	Alive	398	0	13.07597536	Alive	NA	86	89	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[20]	NA	NA	Normal	57	NA	NA	115.15	positive	0.063829787	positive	NA	NA	NA	DNMT3A (p.Arg326Cys; MAF 44.5%)|FLT3-ITD (p.Phe594_Asp600dup; MAF 45%)|NPM1 (p.Trp288fs; MAF 20.7%)|TET2 (p.Ala911fs; MAF 40.6%)|TET2 (p.His1036fs; MAF 39.4%)	0	13.07597536	3
BA2244R	2219	BA2244D	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	67	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	68	261	Post-Chemotherapy	Remission	Leukapheresis	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	5	AG-120|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC	5	Consolidation|Salvage|Induction|Experimental|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	Dead	864	1	28.38603696	Dead-Other	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M4	NA	NA	46,XY,t(4;8)(q21;p23)[2]/46,XY[18]	NA	NA	Normal	NA	NA	NA	NA	negative	0	positive	NA	ASXL1 (p.G645Vfs*58; 10.0%)	NA	NA	1	28.38603696	4
BA2470R	2202	BA2470D	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	62	TRUE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	412	Relapse	Relapse	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	Decitabine|Hydroxyurea	2	Induction|Re-induction	Complete Response i	Standard Chemotherapy	-1	Standard Chemotherapy	Hydroxyurea	Re-induction	263	Dead	424	1	13.9301848	Dead-Disease	0.9	NA	NA	0	0	7.8	1.7	4.3	0.1	18	21	2.8	1.43	M2	25	8.2	46,XY,del(5)(q22q35),del(12)(q24.1q24.1),add(17)(p11.2)[19]/46,XY[1]	564	102.5	EGR1 (73.5%) ;  TP53: (85.5%)	139	NA	6.6	46.79	negative	0	negative	NA	NA	TP53 (p.G266V; 91.4%)	NA	1	13.9301848	1
BA2984R	2520	BA2984D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	81	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	81	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Vidaza, BI836858 (anti-CD33)	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Vidaza, BI836858 (anti-CD33)	Induction	-1	Dead	581	1	19.08829569	Dead-Disease	0	80	80	0	7	7.8	0	6.9	0.5	31	42	3.2	1.3	M1	25.1	8.8	46,XY[19]	665	85.1	Normal	16	dim CD13, CD33, CD38, CD58, dim CD64, CD71, dim CD117 and CD123-positive	7.2	33.81	negative	0	positive	NA	NA	NA	CSF3R ( p.T640N; MAF: 14%)|EZH2 (p.G709D; MAF: 17%)|EZH2 (p.R684C; MAF: 4%)|IDH2 (p.R140Q; MAF: 46%)|KDM6A (Splice site-Intron 5 3' end mutation; MAF:3%)|NPM1 (p.W288fs*12; MAF: 39%)	1	19.08829569	2
BA2414R	2307	BA2414D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NA	White	5	NA	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	y	Hodgkin Lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	50	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Dead	201	1	6.603696099	Dead-Unknown	0	75	82	2	NA	4	0	8	NA	39	45	3.7	NA	NA	20.1	6.5	46,XY,add(1)(p11),del(5)(q15q33),del(7)(q22q36),der(11)t(1;11)(p31;p12-14)[20]	NA	NA	Loss of 5q31 sequences for 99% of total cells | Loss of 7q31 sequences for 96% of total cells	12	Positive: CD38, CD56, CD13, CD34, CD45, CD117, HLA-DR | Partially positive: CD7, CD11b, CD33, CD64 | Negative: CD19, CD22, Cyt CD79a, Cyt CD3, CD14, CD15, MPO, TdT	6.3	119.6	positive	0.818181818	negative	NA	NA	NA	BCOR (C.3067T>C; p.F1023L)|FLT3-ITD|NOTCH1 (c.7625G>A; p.S2542N)	1	6.603696099	2
BA2697R	2168	BA2697D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	White	3	NA	NA	65	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	65	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Vidaza|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)	3	Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Alive	338	0	11.10472279	Alive	NA	20.6	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	45,XX,-7[20]	NA	NA	7cen (D7Z1), 7q31 (D7S486): monosomy present	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	DNMT3A (p.Gln231fs; MAF 33.2%)|IDH2 (p.Arg140Gln; MAF 44.2%)|NRAS (p.Gln61Glu; MAF 47.8%)	0	11.10472279	4
BA2079R	2224	BA2079D	Waves1+2	no	no	no	no	Female	Female	White	NON-HISPANIC	White	1	NA	NA	52	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	52	34	Post-Chemotherapy	Remission	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	5	MiDAC|Idarubicin and Cytarabine|FLAG-IDA plus Midostaurin|Azacitidine, Midostaurin, Ponatinib|7+3 (Cytarabine, Idarubicin) plus Dasatinib	4	Consolidation|Salvage|Induction|Maintenance	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Idarubicin and Cytarabine	Salvage	3	Dead	559	1	18.36550308	Dead-Disease	1.4	1.5	NA	0.2	NA	9.2	24.3	64.9	NA	119	151	3.2	0.76	M5	28.4	9.2	46,XX[20]	380	93.4	Normal	395	NA	6.6	6.5	negative	0	negative	NA	NA	NA	DNMT3A (p.R882C; MAF 14%)	1	18.36550308	4
BA2999R	2117	BA2999D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	NA	NA	53	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	54	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	7	AG-120|7+3 (Cytarabine, Idarubicin)|Azacitidine|MGD006 (CD123 x CD3) |MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	5	Salvage|Induction|Experimental|Re-induction|Maintenance	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Incyte trial (azacitidine and JAK 1 inhibitor)	Salvage	-1	Dead	543	1	17.83983573	Dead-Disease	0	75	90	0	0	22.1	6.2	1.8	0	19	33	1.8	0.84	NA	25.5	8.1	46,XY,t(4;12)(q12;p13)[10]/46,XY[10]	706	91.4	42/100 (42%) interphase cells scored were positive for  ETV6 rearrangement.  Metaphase FISH showed part of the ETV6 signal (red) on  the long arm of chromosome 4.  Based on the breakpoint, ETV6/CHIC2 fusion  is predicted, consistent with AML	25	partial CD7, CD13, CD33, CD38, CD34, CD58, CD117, CD123,  HLA-DR positive	6.6	118	negative	0	negative	RUNX1 (p.R166*; 41.5%)	NA	NA	DNMT3A (p.R882H; MAF 49%)|IDH1 (p.R132S; MAF 48%)|RUNX1 (p.R166*; MAF 50%)|SRSF2 (p.P95H; MAF 50%)	1	17.83983573	4
BA2644R	2280	BA2644D	Waves1+2	no	no	no	no	Male	Male	White	NA	White	3	NA	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus Crenolanib|IDAC	3	Consolidation|Induction|Allogeneic - Child	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Child	-1	Alive	306	0	10.05338809	Alive	NA	26.3	12	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[11]	NA	NA	Normal	69	NA	NA	9.28	negative	0	negative	NA	NA	NA	BCOR (p.Tyr354*; MAF 72.2%)|DNMT3A (p.Phe755Ser; MAF 38.6%)|DNMT3A (p.Thr835Met; MAF 47%)|IDH1 (p.Arg132Cys; MAF 2.9%)	0	10.05338809	4
BA2011R	2280	BA2011D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NA	White	3	NA	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	1	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus Crenolanib|IDAC	3	Consolidation|Induction|Allogeneic - Child	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Child	-1	Alive	306	0	10.05338809	Alive	NA	26.3	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[11]	NA	NA	Normal	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	BCOR (p.Tyr354*; MAF 72.2%)|DNMT3A (p.Phe755Ser; MAF 38.6%)|DNMT3A (p.Thr835Met; MAF 47%)|IDH1 (p.Arg132Cys; MAF 2.9%)	0	10.05338809	4
BA2217R	2538	BA2217D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	bi	NA	47	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	HiDAC	Consolidation	116	Alive	214	0	7.030800821	Alive	0	83	82	3.4	0	23.1	3.4	0	1.6	23	11	3.5	0.95	M1	31.1	10.2	46,XY[20]	290	88.9	NA	24	CD7, CD13, CD33, CD34, CD38, partial CD56,  CD58, dim CD64, CD117, CD123, HLA-DR, and cMPO	6.5	18.71	negative	0	negative	NA	NA	NA	CEBPA (p.I68fs; MAF 50%)|CEBPA (p.K313_V314insK; MAF 50%)|EZH2 (p.S519P; MAF 51%)|NRAS (p.G13D, MAF 3%)|WT1 (p.M392fs*10; MAF 13%)|WT1 (p.R458*; MAF 23%)	0	7.030800821	2
BA2454R	2234	BA2454D	Waves1+2	yes	yes	yes	yes	Male	Male	White	NA	White	2	NA	NA	73	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Supportive/Palliative Care	NA	NA	NA	Standard Chemotherapy	Decitabine	Supportive/Palliative Care	-1	Dead	31	1	1.018480493	Dead-Unknown	NA	83	59	NA	NA	NA	NA	NA	NA	21	23	NA	NA	NA	NA	NA	46,XY[20]	NA	NA	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[195],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	22	NA	NA	24.23	negative	0	negative	RUNX1 (p.S322*; 51.4%)	ASXL1 (p.R693*; 50.0%)	NA	NA	1	1.018480493	2
BA2776R	2431	BA2776D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	61	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	n	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Supportive/Palliative Care	1	Hydroxyurea	1	Supportive/Palliative Care	NA	NA	NA	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	-1	Dead	316	1	10.38193018	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M1	NA	NA	46,XX[20]	NA	NA	Normal	NA	CD13, CD33, CD38, CD56, CD58, CD117, CD123 and dim MPO positive	NA	NA	positive	9	positive	NA	NA	NA	FLT3-ITD (30 bp insertion; MAF 70%)|NPM1 (p.W288fs*12; MAF 45%)	1	10.38193018	3
BA2218R	2282	BA2218D	Waves1+2	yes	yes	yes	yes	Female	Female	White	HISPANIC	HispNative	6	NA	NA	39	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	40	0	Relapse|Post-Chemotherapy	Relapse	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	4	7+3 (Cytarabine, Idarubicin)|HiDAC|ME (Etoposide, Mitoxantrone)|Decitabine	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	39	Standard Chemotherapy	Decitabine	Salvage	69	Dead	433	1	14.22587269	Dead-Unknown	NA	NA	91	NA	NA	9	NA	NA	NA	21	34	3.8	0.49	NA	29.3	9.9	NA	NA	93.6	NA	66	NA	5.8	73	negative	0	positive	NA	NA	NA	NA	1	14.22587269	3
BA2135R	2547	BA2135D	Waves1+2	yes	yes	yes	yes	Female	Female	NA	NA	HispNative	6	NA	NA	73	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Supportive/Palliative Care	NA	NA	NA	Standard Chemotherapy	Decitabine	Supportive/Palliative Care	-1	Alive	122	0	4.008213552	Alive	NA	71	3	1	NA	68	8	11	NA	11	23	2.9	0.51	NA	24.9	7.8	46,XX,del(1)(p22),der(15)t(15;?)(q15;?),-17,+mar[19]/46,XX[1]	NA	110.7	Loss of RARA gene at 17q21 is detected in 69% of cells Gain of MLL gene at 11q23 is detected in 8% of cells.	95	blasts 55% of all events; they are positive for cd34, hla-dr, cd117, cd13, cd33, and negative for cd11b, cd14, cd64, tdt and mpo	4.8	63.4	negative	0	negative	NA	ASXL1 (p.G646Wfs*12; 32.6%)	NA	NA	0	4.008213552	2
BA2914R	2508	BA2914D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	NA	38	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	38	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	106	Alive	1586	0	52.10677618	Alive	NA	47	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M4	NA	NA	46,XX[20]	NA	NA	Normal	NA	CD117, dimCD4,  heterogeneous CD13, CD33, dimCD64 and  MPO positive  (Myeloid Blast Population) | heterogeneous CD13, bright CD33, dimCD4,  dimCD14, bright CD64 positive  (Monocytes/promonocytes Population)	NA	46.27	negative	0	positive	NA	NA	NA	DNMT3A (p.R882H; MAF 46%)|IDH1 (p.R132H; MAF 25%)|KRAS (p.Q61L; MAF 10%)|NPM1 (p.W288fs*12; MAF 51%)|NRAS (p.G13D; MAF 24%)	0	52.10677618	4
BA2500R	2120	BA2500D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	PML-RARA	59	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	59	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide, Idarubicin	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	ATRA, Arsenic Trioxide, Idarubicin	Induction	-1	Alive	28	0	0.919917864	Alive	0.9	90	90	1.7	44	8.6	0	6	1.5	110	255	2.4	0.86	M3	19.8	6.7	46,XX,t(15;17)(q22;q21)[20]	NA	88.4	86/100 cells (86%) had the 1r/1g/2f dual fusion signal pattern consistent  with PML/RARA fusion and with t(15;17) as seen on metaphase analysis.	30	CD13, CD33, CD58, CD64, CD117, CD123, MPO	5.4	47.35	negative	0	negative	NA	NA	NA	ASXL1 (p.M1050V; MAF 51%)|FLT3-ITD (MAF 46%)	0	0.919917864	3
BA2830R	2268	BA2830D	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1	NA	CBFB-MYH11	72	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	74	0	Relapse	Relapse	Peripheral Blood	y	y	y	y	y	y	1	Targeted Therapy - Kinase Inhibitor(s)	1	Dasatinib	1	Experimental	NA	NA	NA	Targeted Therapy - Kinase Inhibitor(s)	Dasatinib	Experimental	16	Alive	808	0	26.54620123	Alive	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	NA	0	26.54620123	2
BA2406R	2143	BA2406D	Waves1+2	yes	yes	yes	no	Male	Male	White	NA	White	6	NA	NA	64	FALSE	FALSE	FALSE	FALSE	FALSE	y	Hodgkin Lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	64	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	Dead	80	1	2.628336756	Dead-Unknown	NA	17	NA	NA	NA	NA	5	NA	NA	NA	NA	NA	NA	NA	NA	NA	42,XY,-3,-7,der(12)t(12;?)(q24.3;?)-17,der(17)t(17;?)(p13;?),-21,der(22)t(22;?)(p11.2:?)[10]/46,XY[10]	NA	NA	NA	43	NOT DETECTED for the MLL partial tandem duplication (PTD). NOT DETECTED for the FLT3 Internal Tandem Duplication (ITD)-Signal Ratio (SR). NOT DETECTED for the FLT3 TKD Mutation. Pathogenic alterations are DETECTED in the DNMT3A, NF1 and TP53 genes.  (Bone Marrow Immunophenotyping) | positive for CD34, CD117, HLA-DR, CD13, and CD33, negative for monocytic markers CD11b, CD14 and CD64, negative for specific B and T cell markers. (Bone Marrow Immunophenotyping)	NA	2.2	negative	0	negative	NA	NA	TP53 (p.E204*; 52.3%)	DNMT3A (c.2635_2651delAACATGAGCCGCTTGGC; p.N879Efs*36c.2656C>T; pQ886*MAF 43%, 36% )|NF1 (c.2192_2199delTCTTGCCC; p.L731Qfs*3  MAF 38%)|TP53 (c.610G>T;p.E204*MAF 51%)	1	2.628336756	4
BA3108R	2673	BA3108D	Waves3+4	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	72	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	4	Vidaza, BI836858 (anti-CD33)|Azacitidine|Enasidenib|Incyte trial (azacitidine and JAK 1 inhibitor)	3	Salvage|Induction|Maintenance	Refractory	Standard Chemotherapy	185	Targeted Therapy - Other	Enasidenib	Salvage	28	Alive	1640	0	53.88090349	Alive	0	47	0	0	0.9	74.3	0	13.3	0	15	8	2.9	0.51	M2	29.1	9.4	48,XX,+8,+8,add(9)(q22)[1]/50,idem,+15,+18[5]/46,XX[14] (Six of twenty metaphase cells analyzed comprised two related hyperdiploid clones.)	85	101.7	Results were consistent with tetrasomy 8 (RUNX1T1/CEP8) and trisomy 15 (PML) in approximately 50% of cells scored.  All other probe results were within normal limits with no evidence for rearrangements or deletions.	57	CD13, CD33, CD34, CD38, moderate-dim  CD45, and CD117+	5.7	1.62	negative	0	negative	NA	NA	NA	IDH2 (p.R140Q; MAF 43%)|U2AF1 (p.Q157P; MAF 17%)	0	53.88090349	1
BA2924R	2475	BA2924D	Both	no	no	no	no	Male	Male	White	NA	White	6	NA	NA	66	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	67	0	Relapse|Post-Chemotherapy	Relapse	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	23	Standard Chemotherapy	HiDAC	Consolidation	63	Alive	300	0	9.856262834	Alive	NA	NA	8	1	NA	14	19	46	NA	15	22	4.3	0.88	NA	38.3	12.5	NA	NA	97.2	NA	165	NA	6.2	9	negative	0	positive	NA	NA	NA	NA	0	9.856262834	4
BA2303R	2570	BA2303D	Both	no	no	no	no	Female	Female	NA	NA	White	3	NA	NA	39	FALSE	FALSE	FALSE	FALSE	FALSE	y	Cervical Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	39	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC + Midostaurin|Fludarabine, TBI	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, TBI	Allogeneic - Sibling	-1	Alive	296	0	9.724845996	Alive	NA	70	80	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX[20]	NA	NA	NA	NA	Large pop. of promonocytes/monoblasts representing approx 57% of total leukocytes and increased atypicalCD117 pos, partial CD34 pos myeloblasts (partial CD7 pos) representing approx 6% of leukocytes consistent w/AMLw/monocytic differentiation.	NA	190	positive	5.666666667	positive	NA	NA	NA	DNMT3A (p.Arg882His; MAF 41.8%)|FLT3 (p.Tyr572Cys; MAF 1.2%)|FLT3 (p.Val581_Arg595dup; MAF 22%)|FLT3-ITD|NPM1 (p.Trp288fs; MAF 21.2%)	0	9.724845996	4
BA2160R	2216	BA2160D	Both	no	no	no	no	Male	Male	NA	NA	White	3	NA	NA	74	FALSE	FALSE	FALSE	FALSE	FALSE	y	Bladder Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	74	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction|Supportive/Palliative Care	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	Dead	58	1	1.905544148	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX[20]	NA	NA	Normal	NA	Large population of CD117pos, CD34 neg, HLA-DR neg myeloblasts, representing approx 68% of leukocytes, consistent w/ residual/recurrent AML.	NA	NA	negative	0	positive	NA	NA	NA	NA	1	1.905544148	4
BA2040R	2085	BA2040D	Both	no	no	no	no	Male	Male	Black	NA	Black	6	NA	NA	50	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	51	249	Post-Chemotherapy	Remission	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	HiDAC|3+7 (Cytarabine, Daunorubicin)	2	Consolidation|Induction	Refractory	Standard Chemotherapy	20	Standard Chemotherapy	HiDAC	Consolidation	182	Alive	424	0	13.9301848	Alive	NA	1	NA	NA	NA	NA	6	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[20]	NA	NA	RUNX1/RUNX1T1 fusion negative (Cytogenetics)	94	Positive for CD34, CD117, HLADR, CD13 AND CD33.  (Bone Marrow Immunphenotyping)	NA	6.6	negative	0	negative	NA	NA	NA	NA	0	13.9301848	4
BA2590R	2131	BA2590D	Both	no	no	no	no	Male	Male	NA	NA	HispNative	5	NA	NA	55	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Midostaurin|Fludarabine, Cyclophosphamide, Thiotepa, TBI|7+3 (Cytarabine, Idarubicin) plus Enasidenib	3	Induction|Double Umbilical Cord Blood Transplant (DUCBT)|Maintenance	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Midostaurin	Maintenance	44	Dead	282	1	9.264887064	Dead-Disease	0	88.5	64	0	NA	25	4	7	NA	34	36	3.3	NA	NA	31.3	10.9	46,XY[19]	NA	NA	Normal	54	Negative (CD19, CD22, Cyt CD3, CD7, CD56, CD11b, CD13, CD14, CD34, CD64, CD117, TdT) | Positive (CD38, Cyt CD79a, CD15, CD33, MPO) | Dim (CD45, HLA-DR)	7.4	24.9	positive	1	positive	NA	NA	NA	FLT3 (c.1811_1812insl8; p.E604_P605insYDLKWE; MAF 32%)|IDH1 (c.395G>A; p.R132H; 44%)|NPM1 (c.863_864insTCTG; p.W288fs; MAF 42%)|SRSF2 (c.284_307del; p.P95_R102del; MAF 45%)	1	9.264887064	3
BA3195R	2827	BA3195D	Waves3+4	yes	yes	yes	yes	Male	Male	NA	NA	NA	5	NA	NA	77	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	n	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	77	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other	4	Venetoclax, Idasanutlin|anti-CD123, Decitabine|Enasidenib|cd47mAb	3	Salvage|Induction|Experimental	Refractory	Targeted Therapy - Kinase Inhibitor(s)	-1	Targeted Therapy - Kinase Inhibitor(s)	Enasidenib	Salvage	-1	Alive	322	0	10.57905544	Alive	0	90	92	0	NA	4	1	3	NA	17	22	3.8	NA	NA	24.7	7.4	46,XY[19]	NA	NA	Normal	72	Positive (CD38, CD15, CD34, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD11b, CD13, CD14, CD33, CD64, TdT) | Dim Positive (CD45, CD117)	6.4	224.2	negative	0	negative	RUNX1 (p.L98Pfs*40; 52.3%)|RUNX1 (p.N434Kfs*166; 32.4%)	NA	NA	DNMT3A (c.2644C>T; p.R882C; MAF 47%)|IDH2 (c.419G>A; p.R140Q; MAF 48%)|JAK2 (c.1849G>T; p.V617F; MAF 50%)|RUNX1 (c.1289_1290insTGCC; p.P430fs; MAF 17%)|RUNX1 (c.1301 1302insA; p.N434Â£s; MAF 21%)|RUNX1 (c.292_293insC; p.L98fs; MAF 45%)|SRSF2 (c.284C>A; p.P95H; MAF 48%)	0	10.57905544	2
BA2516R	2500	BA2516D	Both	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1	NA	NA	70	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	70	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	Imatinib|Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Salvage|Induction|Experimental|Re-induction	Refractory	Standard Chemotherapy	61	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	Dead	362	1	11.89322382	Dead-Disease	0	NA	15	0	16.2	16.2	8.1	6.3	4.5	20	45	4.6	1.5	NA	31.5	9.8	46,XY[20]	851	92.6	Normal	14	NA	7.6	92.55	negative	0	negative	NA	ASXL1 (p.E635Dfs*22; 42.9%)	NA	BCOR (p.S1024; MAF 5%)|NRAS (p.G13D; MAF 34%)|PTPN11 (p.G60V; MAF 3%)|SRSF2 (p.P95H; MAF 40%)	1	11.89322382	1
BA2353R	2268	BA2353D	Both	no	no	no	no	Female	Female	White	NON-HISPANIC	White	1	NA	CBFB-MYH11	72	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	74	33	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	1	Targeted Therapy - Kinase Inhibitor(s)	1	Dasatinib	1	Experimental	NA	NA	NA	Targeted Therapy - Kinase Inhibitor(s)	Dasatinib	Experimental	16	Alive	808	0	26.54620123	Alive	2.6	90	74	0	0	6	2.6	2.6	0	12	22	2.7	0.69	NA	19.5	6.5	46,XX,inv(16)(p13q22)[18]/46,XX[2]	807	86.7	CBFB:  79/100 cells (79%) reflecting CBFB rearrangement and the inverted chromosome 16 observed in the metaphase karyotype.	9	CD13, CD33, CD34, variable CD38, CD117,  CD123, and HLA-DR +.	5.8	34.76	negative	0	negative	NA	NA	NA	KIT (p.D816H; MAF 44%)	0	26.54620123	2
BA3036R	2372	BA3036D	Both	no	no	no	no	Female	Female	Black	NA	Black	2	NA	NA	43	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	43	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	Alive	35	0	1.149897331	Alive	NA	NA	48	NA	NA	NA	NA	NA	NA	30	21	NA	NA	NA	NA	NA	46,XX[20]	NA	NA	nucish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	27	NA	NA	41.91	positive	0.492537313	negative	NA	NA	NA	FLT3-D835	0	1.149897331	4
BA2971R	2086	BA2971D	Both	no	no	no	no	Male	Male	White	NON-HISPANIC	White	6	NA	NA	57	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	57	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|HiDAC|3+7 (Cytarabine, Daunorubicin)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)	Allogeneic - Matched Unrelated Donor	13	Alive	307	0	10.0862423	Alive	NA	20	NA	NA	NA	NA	3	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[20]	NA	NA	NA	49	THESE ARE POSITIVE FOR CD34, CD117, HLADR, CD13, AND CD33. (Bone Marrow Immunophenotyping)	NA	19.3	negative	0	negative	RUNX1 (p.D198N; 47.6%)|RUNX1 (p.P113L; 42.7%)	NA	NA	DNMT3A (c.2644C>T; p.R882C MAF 47%)|JAK2 (c.1849G>T; p.V617F MAF 91%)|RUNX1 (c.338C>T; p.P113L  MAF 42% c.592G>A; p.D198N MAF 46%)|SETBP1 (c.883G>A; p.V1295M MAF 47%)|SRSF2 (c.284C>A; p.P95H MAF 47%)	0	10.0862423	4
BA3410R	2695	BA3410D	Waves3+4	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	NA	8	NA	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Supportive/Palliative Care	2	7+3 (Cytarabine, Idarubicin)|Decitabine	2	Induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	8	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	67	Dead	250	1	8.213552361	Dead-Disease	NA	NA	5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	43-48,XY,add(2)(q11.2),add(3)(p13),add(3)(q29),del(5)(q15q33),der(7)add(7)(p11.2)add(7)(q22),?hsr(8)(q24),+10,+11, add(12)(p11.2),-13,add(14)(p13),add(15)(p12),add(15)(p13),-16,?hsr(16)(q22),-17,-20,+21,add(21)(q22),idic(21)(q22),-22, add(22)(p12),+mar1-5[cp22]/87-88,idem[cp2]	NA	NA	NA	79	NA	NA	1.9	negative	0	negative	NA	NA	TP53 (p.R248Q; 58.8%)	NA	1	8.213552361	1
BA3118R	2709	BA3118D	Waves3+4	yes	yes	yes	yes	Female	Female	Asian	NA	NA	2	NA	CBFB-MYH11	45	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid sarcoma	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid sarcoma	45	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	92	Alive	279	0	9.166324435	Alive	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX[20]	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	MYH11 (CBFB-MYH11 fusion)|NRAS (G12D)	0	9.166324435	2
BA3206R	2668	BA3206D	Waves3+4	yes	yes	yes	yes	Female	Female	White	HISPANIC	NA	1	NA	RUNX1-RUNX1T1	35	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	35	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine, Venetoclax	4	Consolidation|Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine, Venetoclax	Salvage	165	Dead	1220	1	40.08213552	Dead-Disease	0	60	10	0	0.9	88.7	0.9	9.5	0	34	12	3	0.8	M2	22	7.8	45,X,-X,t(8;21)(q22;q22)[20]	334	93.2	RUNX1T1(8q21.3)/RUNX1(21q22):   64% of cells had an atypical 1r/2g/1f  signal pattern, a fusion pattern consistent with t(8;21) as seen on metaphase analysis.  | All twenty metaphase cells examined were abnormal, with monosomy X and  t(8;21).	34	CD13, dim CD19, dim CD33, CD34, CD38, CD56, CD58, CD117, dim CD123, HLA-DR and MPO+	7	4.73	negative	0	negative	NA	NA	NA	FLT3-ITD (MAF 5%)	1	40.08213552	2
BA3202R	2153	NA	Waves3+4	no	no	no	no	Female	Female	Black	NON-HISPANIC	NA	6	NA	NA	45	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	47	148	Post-Chemotherapy	Remission	Bone Marrow Aspirate	y	n	n	y	n	n	1	Standard Chemotherapy	4	HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)|3+7 (Cytarabine, Daunorubicin)|Cyclophosphamide, Etoposide, Cytarabine	4	Consolidation|Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	25	Standard Chemotherapy	CLAG (Cladribine, Cytarabine, Filgrastim)	Salvage	23	Alive	465	0	15.27720739	Alive	NA	2	NA	NA	NA	NA	9	NA	NA	NA	NA	NA	NA	NA	NA	NA	45,XX,-7[4]/46,sl,+mar[2]/46,XX[14]	NA	NA	NA	64	POSITIVE FOR CD34, CD117, HLADR, CD33 AND CD13. (Bone Marrow Immunophenotype)	NA	2.1	negative	0	negative	NA	NA	NA	NA	0	15.27720739	1
BA3217R	2624	BA3217D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NA	NA	5	NA	NA	60	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)	2	Allogeneic - Sibling|Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Sibling	-1	Alive	293	0	9.626283368	Alive	NA	95	70	NA	NA	27	1	2	NA	37	32	3.2	NA	NA	29.2	9.9	46,XY[20]	NA	NA	Normal	48	Positive (CD38, CD33, CD34, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD13, CD14, CD15, CD117, TdT) | Dim (CD11b, CD45, CD64)	6	25.5	positive	0.960784314	negative	NA	NA	NA	FLT3-ITD (ITD, c.1769_1770ins42; p.Y589_F590insl4 (MAF 38%))|IDH2 (c.419G>A; p.R140Q (MAF 48%))|STAG2 (c.3034delC; p.R1012fs (MAF 92%))	0	9.626283368	4
BA3405R	2701	BA3405D	Waves3+4	yes	yes	yes	no	Male	Male	NA	NA	NA	3	NA	NA	67	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Cytarabine	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	-1	Alive	177	0	5.815195072	Alive	NA	35	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M4	NA	NA	NA	NA	NA	NA	NA	NA	NA	35.04	negative	0	negative	RUNX1 (p.D198G; 94.2%)	ASXL1 (p.G646Wfs*12; 30.1%)	NA	NA	0	5.815195072	4
BA3306R	2811	BA3306D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NA	NA	5	NA	NA	26	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	26	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Cyclophosphamide, Thiotepa, TBI	3	Consolidation|Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Alive	289	0	9.49486653	Alive	0	89.5	88	0	NA	7	2	3	NA	10	21	3	NA	NA	23.1	7.6	NA	NA	NA	Normal	19	Dim Positive (CD13, MPO) | Dim Partial positive (CD34) | Variable partial positive (CD117)	5.2	138.2	positive	19	positive	NA	NA	NA	FLT3-ITD (ITD, c.l815_1816ins30; p.F605_P606insl0 (MAF 49%))|IDH1 (c.395G>A; p.R132H (MAF 45%))|NPM1 (c.863_864insTCTG; p.W288fs (MAF 43%))	0	9.49486653	3
BA3371R	2809	BA3371D	Waves3+4	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	NA	8	NA	NA	21	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	21	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	4	HiDAC|7+3 (Cytarabine, Idarubicin)|Unknown|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	2	Bone Marrow Transplant	Unknown	Allogeneic - Matched Unrelated Donor	-1	Dead	678	1	22.275154	Dead-Disease	NA	13	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX[20]	NA	NA	Negative for RUNX1/RUNX1T1, KMT2A (MLL), CBFB	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	NA	1	22.275154	1
BA3413R	2666	BA3413D	Waves3+4	yes	yes	yes	no	Female	Female	White	NA	NA	3	bi	NA	31	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	31	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine|CLAG (Cladribine, Cytarabine, Filgrastim)|7+3 (Cytarabine, Idarubicin, Dexamethasone)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	-1	Alive	153	0	5.026694045	Alive	NA	80	69	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX,del(9)(q13q22)[5]/46,sl,del(11)(q13q23)[14]  /46,sdl,t(2;4;7)(q33;q21;p15),add(8)(p11.2)[2]	NA	NA	NA	18	NA	NA	11.23	negative	0	negative	NA	NA	NA	CEBPA (p.Ala111fs; MAF 44.5%)|CEBPA (p.Ser319_Asp320del; MAF 32.9%)|CSF3R (p.Thr618Ile; MAF 1.6%)|GATA2 (p.Arg330Gln; MAF 46%)	0	5.026694045	2
BA3411R	2615	BA3411D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	48	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	48	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	-1	Alive	351	0	11.53182752	Alive	0	25	7	0	2.6	47	9.6	36.5	0	NA	NA	NA	NA	M4	19.5	6.7	47,XX,+8,del(8)(q11.2q22)[20]	NA	89.4	CEP 8:  73/100 cells (73%) had three signals, consistent with the extra chromosome 8 in the metaphase karyotype	21	CD13, CD33, CD34, CD38, CD56, CD58, variable CD64, CD71, CD117, dim CD123, HLA-DR, MPO  (Myeloid Blasts) | CD11b, CD13, CD15, CD33, CD56, CD64, HLA-DR (Abnormal Monocytes)	NA	4.8	negative	0	negative	NA	ASXL1 (p.L823*; 45.9%)	NA	ASXL1 (p.L823; MAF 47%)	0	11.53182752	2
BA3133R	2747	BA3133D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	61	FALSE	FALSE	TRUE	FALSE	FALSE	y	Skin cancer	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Vidaza	1	Induction	Unknown	Standard Chemotherapy	-1	Standard Chemotherapy	Vidaza	Induction	-1	Dead	51	1	1.675564682	Dead-Disease	0	25	26	0	11.5	9.7	7.1	43.4	0.1	23	33	3.6	0.8	M2	22	7	45,XY,del(5)(q13q33),-7,add(8)(q24.3),add(9)(q34),add(10)(q23),del(17)(p13)  ,add(18)(q23)[3]/47-49,sl,+2-4mar[cp12]/44,sl,-2,add(3)(p21),t(6;11)(p22;q1  4),-add(8)(q24.3),add(8)(p22),-9,add(9)(q33),-10,-13,add(21)(q21),+2mar[8]	855	116.4	TP53 (17p13.1):  83% of cells were missing a signal for TP53, consistent with the 17p deletion seen on metaphase analysis.  | RUNX1 (21q22):  15.5% of cells were missing a signal for RUNX1.  No  evidence for RUNX1/RUNX1T1 fusion.  | MECOM (3q26.2):  33% of cells had six (6) signals for MECOM. On available  metaphases, the extra MECOM signals hybridized to the small marker  chromosomes.  No evidence for MECOM/RPN1 fusion.	166	CD13, CD33, CD34, CD38, CD58, CD71, CD117,  CD123, HLA-DR +	6.7	19.22	negative	0	negative	RUNX1 (p.X170_splice; 26.1%)	NA	TP53 (p.Q167*; 91.3%)	BCOR (p.Q1658H; MAF 100%)|RUNX1 (Splice Site; MAF 17%)|SF3B1 (p.K666M; MAF 47%)|SRSF2 (p.R180G; MAF 54%)|TP53 (p.Q167; MAF 65%)	1	1.675564682	1
BA3164R	2194	BA3164D	Waves3+4	no	no	no	no	Female	Female	Multiracial	HISPANIC	NA	1	NA	NA	46	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	124	Relapse|Post-Chemotherapy|Post-Transplant	Relapse	Peripheral Blood	y	y	y	y	y	y	4	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	7	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Methotrexate	6	Allogeneic - Sibling|Consolidation|Induction|Experimental|CNS|Re-induction	Complete Response i	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Dasatinib	Experimental	-1	Dead	360	1	11.8275154	Dead-Disease	0	85	50	0	0	7.1	4.4	41.6	0.4	25	56	3.7	1	NA	31.9	10.5	46,XX,t(10;16)(q22;q24)[10]/46,X,t(X;1)(q23;q44),t(10;16)(q22;q24)[3]/46,X,t(X;13)(p21;q14),t(3;22)(q13.2;p11.1),t(5;6)(q31;q24),add(9)(q13),t(10;16)(q22;q24)[2]/46,sl,der(1)t(1;2)(p32;q32)t(1;15)(q23;q24),der(2)t(1;2)(p32;q32),der(15)t(1;15)(q23;q24)[2]/46,sl,der(1)t(1;2)(p13;q11.2),-2, (der(3)t(3;5)(q12;p15),del(6)(q13q23),+22[2]/46,XX[1])	1199	93	Normal	63	partial CD7, CD13, CD33, partial CD34, CD38,  CD58, CD71, partial CD117, CD123, and HLA-DR +	6.6	23.68	positive	11.5	positive	NA	NA	NA	DNMT3A (p.R882H; MAF 43%)|FLT3-ITD (Internal tandem duplication (~75 bp; in-frame); MAF 79%)|JAK3 (p.H529R; MAF 50%)|NPM1 (p.W288fs*12; MAF 36%)	1	11.8275154	3
BA3451R	2780	BA3451D	Waves3+4	yes	yes	yes	yes	Female	Female	White	UNKNOWN	NA	1	NA	NA	47	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	95	Alive	1181	0	38.80082136	Alive	0	85	70	0.4	0.4	27.1	63.8	5.3	0.1	14	15	2.8	1.39	M5	19.8	6.5	46,XX[20]	355	97.5	Normal	48	CD4, CD11b, CD13, CD33, variable CD14, CD38,  dim CD56, CD58, bright CD64, dim CD123, HLA-DR, and partial MPO +	7.7	58.66	negative	0	positive	NA	NA	NA	KRAS (p.G13D; MAF 36%)|NPM1 (p.W288fs*12; MAF 44%)|TET2 (p.Q897*; MAF 39%)	0	38.80082136	4
BA3286R	2645	BA3286D	Waves3+4	yes	yes	yes	yes	Female	Female	Declined	NON-HISPANIC	NA	1	NA	NA	45	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	45	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	7+3 (Cytarabine, Daunorubicin) plus Sorafenib|HIDAC + Sorafenib|7+3 (Cytarabine, Idarubicin) plus Sorafenib	3	Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HIDAC + Sorafenib	Consolidation	-1	Alive	104	0	3.416837782	Alive	0	85	70	0	2.6	6	25.6	4.3	0.1	110	114	3.8	0.8	M1	23.3	7.4	46,XX[20]	2504	104	Normal	59	dimCD7, dimCD13, CD33, CD34, CD38, variable CD64, dimCD117, CD123, HLA-DR, and MPO positive	6.4	185.9	positive	0.298701299	negative	NA	NA	NA	FLT3-ITD (123 bp insertion; MAF 50%)	0	3.416837782	4
BA3212R	2727	BA3212D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	0	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	0	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Cytarabine, Daunorubicin, and Etoposide|Busulfan, Cyclophosphamide|Etoposide, Cytarabine	5	Consolidation|Induction|Intensification|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Re-induction	4	Dead	855	1	28.09034908	Dead-Disease	0	NA	82	0	NA	23.1	63.1	5.8	0.6	55	179	3.2	0.26	M0	15.5	5.6	46,XX,der(1)t(1;9)(p36.1;q22),t(5;17)(p13;q21),der(5;9)(p10;p10),+8[12]/47,  sl,+20[7]64~69<3n>,XXX,+1,der(1)t(1;9)(p36.1;q22)x2,+5,t(5;17)(p13;q21)x2,+  6,-9,-11,+21[cp3]	8707	85.2	EGR-1/ D5S23, D5S721: 175/200 cells had a 1 red/ 2 green signal  pattern, indicating a deleted 5q. Five cells had a 2 red/ 4 green signal pattern consistent with the  two normal chromosomes 5 and the two derivative chromosomes (5;9),  resulting in loss of 5q, present in the near-triploid clone. | RUNX1T1/ RUNX1: 155/200 cells had a 3 chromosome 8 signals,  consistent with the trisomy 8 observed in the metaphase karyotype.  Four cells had 4 chromosome 21 signals (in addition to trisomy 8),  consistent with the tetrasomy 21 observed in the near-triploid clone. No evid for RUNX1T1/RUNX1 fusion. | ETV6/ RUNX1:   5/200 cells (2.5%) had a 4 red/ 3 green signal pattern,  consistent with the near-triploid clone with trisomy 8 and tetrasomy 21.  There was no evidence for ETV6/ RUNX1 fusion.	28	CD4, CD7, partial CD13, CD33, CD71, partial CD117, CD123 and dim HLA-DR-positive	5.7	133.39	negative	0	negative	NA	NA	NA	NRAS (p.G12D; MAF 29%)|NRAS (p.Q61K; MAF 6%)	1	28.09034908	1
BA3103R	2790	BA3103D	Waves3+4	yes	yes	yes	no	Female	Female	White	NA	NA	2	NA	CBFB-MYH11	49	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	49	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	-1	Alive	225	0	7.392197125	Alive	NA	58	44	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX,inv(16)(p13.1q22)[18]/46,XX[2]	NA	NA	NA	32	NA	NA	57.75	negative	0	negative	NA	NA	NA	KIT|KRAS|MYH11 (CBFB-MYH11 fusion)	0	7.392197125	2
BA3271R	2792	BA3271D	Waves3+4	yes	yes	yes	yes	Female	Female	White	HISPANIC	NA	1	NA	NA	62	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Unknown	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	Dead	23	1	0.755646817	Dead-Disease	0	81	43	7.5	NA	20.6	16.8	8.4	0.8	21	33	2.3	2.79	M5	26.5	8.6	46,XX[20]	487	106.4	Normal	73	dim CD4, dim CD7, CD13, CD33, CD38, CD58, CD117, CD123, HLA-DR, and dim partial MPO (Myeloid Blast Population) | CD4, CD11b, CD13, dim CD14, dim CD15, CD16, CD33, CD38, CD58, CD63, CD123, HLA-DR  (Promonocyte/Monocyte Blast Population)	6.5	28.53	positive	0.666666667	positive	NA	NA	NA	FLT3-ITD (ITD; MAF 45%)|IDH2 (p.R140Q; MAF 38%)|NPM1 (p.W288fs*12; MAF 41%)	1	0.755646817	4
BA3152R	2758	BA3152D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	74	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	74	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Supportive/Palliative Care	NA	NA	NA	Standard Chemotherapy	Azacitidine	Supportive/Palliative Care	3	Dead	5	1	0.164271047	Dead-Disease	0	42	4	0	9.1	3.8	44.7	38.6	0.5	27	23	2.3	1.64	M5	23.8	7.7	43~44,XY,der(5)t(5;15)(q22;q11.2),add(6)(p23),-15,-16,-17,add(18)(q21),add(  19)(q13.1),-21,+mar1,+mar2[cp20]	387	93.3	Approximately 95% of cells had abnormal signal patterns consistent with the metaphase karyotype and reflecting deleted 5q, monosomy 16, monosomy 17, and monosomy 21.	93	partial CD11b, CD13, partial CD14, CD33, CD34, partial CD64, CD117, HLA-DR and dim MPO (+)	6	29.15	negative	0	negative	NA	NA	TP53 (p.Y220C; 90.9%)	TP53 (p.Y220C;  MAF 91%)	1	0.164271047	4
BA3095R	2626	BA3095D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	27	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	27	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	7	Ruxolitinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Busulfan, Cyclophosphamide|Ibrutinib	5	Consolidation|Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Ruxolitinib	Maintenance	-1	Alive	1512	0	49.67556468	Alive	0	61	82	0	0	11.5	0.9	1.8	1.9	17	33	3.5	0.64	M1	20.5	7.1	47,XX,+8[19]/46,XX[1]	440	96.2	RUNX1T1 (8q21.3):   93% of cells had three signals for RUNX1T1 (8q21.3)  consistent with trisomy 8 as seen on metaphase analysis.	53	dim CD7, CD13, CD33, dimCD34, dimCD64, dim CD117, CD123, and dim HLA-DR+	5.9	24.3	positive	0.818181818	negative	NA	NA	NA	FLT3-ITD (MAF 50% )	0	49.67556468	3
BA3192R	2475	BA3192D	Waves3+4	no	no	no	no	Male	Male	White	NA	NA	6	NA	NA	66	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	67	80	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	23	Standard Chemotherapy	HiDAC	Consolidation	63	Alive	300	0	9.856262834	Alive	NA	90	NA	NA	NA	NA	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	49,XY,+4,+8,+14[9]/49,sl,del(4)(q21q31.1)[11]	NA	NA	NA	41	POSITIVE FOR CD117, HLA-DR, CD13, CD33, CD14 AND MPO AND NEGATIVE FOR CD34, CD11B, CD64, CD10 AND TDT. (Bone Marrow Immunophenotype)	NA	13	positive	NA	positive	NA	NA	NA	DNMT3A (c.2645G>A; p.R882H MAF 42%)|FLT3-ITD|KIT (c.2447A>T; p.D816V MAF 81%)|NPM1 ((NPM1) c.860_863dupTCTG; p.W288Cfs*12  MAF 51%)|SETBP1 (c.3209C>T; p.P1070L MAF 46%)|TET2 (c.3638T>G; p.V1213G MAF 87%)	0	9.856262834	3
BA3251R	2815	BA3251D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NA	NA	5	NA	NA	75	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	75	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Venetoclax (ABT-199), Azacitidine	1	Induction	Unknown	Standard Chemotherapy	4	Standard Chemotherapy	Venetoclax (ABT-199), Azacitidine	Induction	4	Dead	14	1	0.459958932	Dead-Disease	0	80.5	60	0	NA	16	22	1	NA	61	75	3.7	NA	NA	33.7	11.1	46,XX[20]	NA	NA	Normal	35	Positive (CD38, CD13, CD33, CD117, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD11b, CD14, CD15, CD34, CD64, TdT, Glyc A) | DIM (CD45, CD71)	6.5	142.8	positive	0.5625	negative	NA	NA	NA	FLT3-ITD (c.1829_1830ins51; p.N609_L610ins17; MAF 19%)|IDH2 (c.419G>A; p.R140Q; MAF 48%)|RUNX1 (c.1041G>A; p.M347I; MAF 50%)	1	0.459958932	4
BA3362R	2655	BA3362D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	72	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Unknown	Standard Chemotherapy	-1	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	-1	Dead	24	1	0.788501027	Dead-Disease	0	85	75	0	0	14.8	7.8	1.7	0.5	31	63	3.4	0.89	M5	23.7	7.7	46,XX,der(1)t(1;1)(p36.3;q21),t(8;16)(p11.2;p13.3),add(15)(q24)[20]	4853	96.7	In 95/100 cells (95%), three  signals for chromosome 1q25 were observed, and only two signals for 1p36  were observed, consistent with gain of 1q by der(1)t(1;1)	144	CD4, CD11b, partial CD13, CD33, CD56, bright CD64, partial CD117, CD123, HLA-DR and partial MPO-positive	6.6	95.49	negative	0	negative	NA	NA	TP53 (p.R175H; 55.0%)	FLT3 (p.D835E; MAF 42%)|TP53 (p.R175H; MAF 43%)	1	0.788501027	4
BA3400R	2292	BA3400D	Waves3+4	no	no	no	no	Female	Female	Unknown	NA	NA	2	NA	NA	52	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	54	616	Relapse	Relapse	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	-1	Dead	633	1	20.79671458	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M1	NA	NA	46,XX[20]	NA	NA	nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	NA	NA	NA	NA	negative	0	positive	NA	NA	NA	NA	1	20.79671458	3
BA3135R	2733	BA3135D	Waves3+4	yes	yes	yes	yes	Male	Male	Black	NA	NA	8	NA	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	7	Alive	48	0	1.577002053	Alive	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M1	NA	NA	NA	NA	NA	NA	NA	dim CD56 | dim CD15 | dim CD123	NA	NA	positive	0.315789474	positive	NA	NA	NA	FLT3-ITD	0	1.577002053	2
BA3408R	2689	BA3408D	Waves3+4	yes	yes	yes	no	Female	Female	White	NA	NA	8	NA	NA	64	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	64	1	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	4	Ruxolitinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Salvage|Induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	-1	Supportive/Palliative Care	Ruxolitinib	Salvage	6	Dead	269	1	8.837782341	Dead-Treatment	NA	30	NA	NA	NA	62	NA	30	NA	10	18	4.5	NA	NA	NA	6.9	46,XX,der(2)del(2)(p23)inv(2)(p22q31),add(3)(p?14),der(12)add(12)(p11.2)t(3;12)(p?13;q?15)[12]/46,idem,der(7)t(7;11)(q11.2;q13)[7]/46,XX[1]	NA	NA	NA	71	NA	NA	1.8	negative	0	negative	NA	ASXL1 (p.G646Wfs*12; 12.8%)	NA	KMT2A	1	8.837782341	1
BA3187R	2823	BA3187D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NA	NA	8	NA	CBFB-MYH11	76	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	78	0	Relapse	Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Salvage	81	Alive	901	0	29.60164271	Alive	NA	10	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M4	42.5	14.6	46,XY,inv(16)(p13.1q22.1) [16]/46,idem,del(7)(q32)[ 4]	NA	97.7	POSITIVE for CBFB gene locus rearrangement (separated by chromosome 16 inversion)	47	NA	NA	13.3	negative	0	negative	NA	NA	NA	NA	0	29.60164271	2
BA3098R	2630	BA3098D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NA	NA	3	NA	CBFB-MYH11	44	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	44	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)	Allogeneic - Matched Unrelated Donor	-1	Alive	119	0	3.909650924	Alive	NA	74.8	83	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY,der(7)t(7;11)(q22;q13), inv(16)(p13.1q22)[15]/46,XY[5]	NA	NA	7cen (D7Z1), 7q31 (D7S486): deletion present | 11q23 (KMT2A; also known as MLL): gain present | 16q22 (CBFB): rearrangement present	23	NA	NA	102.09	negative	0	negative	NA	NA	NA	KIT (p.Tyr418_Arg420delinsArgTrpGly; MAF 10%)	0	3.909650924	2
BA3435R	2613	BA3435D	Waves3+4	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	79	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	79	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	Decitabine|Azacitidine, BI 836858 (anti-CD33)	2	Salvage|Induction	Refractory	Standard Chemotherapy	50	Standard Chemotherapy	Decitabine	Salvage	37	Dead	135	1	4.435318275	Dead-Disease	0	85	49	0	0	42.4	0.8	6.8	0.1	20	20	3.6	1.6	M1	26.7	9	47,XY,+8[18]/46,XY[2]	NA	89	CEP8 and RUNX1T1 (8q21.3): ~90% of cells had an extra signal for chromosome 8 probes, consistent with trisomy 8, as seen on metaphase analysis.	97	partial CD13, partial CD33, CD34, CD117, CD123, partial HLA-DR, and partial MPO	7.3	20.17	positive	0.111111111	negative	RUNX1 (p.T246Hfs*15; 25.0%)	ASXL1 (p.G646Wfs*12; 30.2%)	NA	FLT3-ITD (MAF 16%)|IDH1 (p.R132C; MAF 46%)|JAK2 (p.V617F; MAF 12%)|RUNX1 (p.T246fs*15; MAF 50%)|U2AF1 (p.Q157P; MAF 48%)	1	4.435318275	1
BA3261R	2633	BA3261D	Waves3+4	yes	yes	yes	yes	Male	Female	White	NON-HISPANIC	NA	1	bi	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Dead	289	1	9.49486653	Dead-Treatment	0	40	25	0	0	27	0	46	0	30	14	3.9	0.84	M2	22.8	8.1	45,X,-Y,del(11)(q12)[20]	NA	98.3	95/100 cells (95%) had a single signal, consistent with the deleted 11q in the metaphase karyotype. There was no evidence for MLL rearrangement.	35	CD7, partial CD13, dim CD33, CD34, CD28, CD58, CD71, CD117, HLA-DR and MPO	6.9	4.17	negative	0	negative	NA	ASXL1 (p.A752Lfs*20; 43.9%)	NA	ASXL1 (p.A752fs*20; MAF 46%)|CEBPA (D105Vfs*64; MAF 45%)|CEBPA (H236Rfs*78; MAF 35%)|EP300 (p.R1627W ; MAF 46%)|IDH2 (p.R140Q, MAF 50%)|KMT2D (p.P647Q; MAF 43%)	1	9.49486653	2
BA3203R	2767	BA3203D	Waves3+4	yes	yes	yes	yes	Male	Male	Unknown	HISPANIC	NA	6	NA	NA	62	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine|HiDAC|3+7 (Cytarabine, Daunorubicin)	3	Allogeneic - Sibling|Consolidation|Induction	Refractory	Standard Chemotherapy	7	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	6	Dead	310	1	10.18480493	Dead-Disease	NA	35	39	1	NA	36	2	9	NA	83	69	2.8	0.99	NA	NA	7	NA	NA	102.9	The translocations commonly seen in AML are not detected. 3 copies of RUNX1T1 gene at 8q22 are detected in 56% of cells. Loss of RUNX1 and RARA genes at 21q22 and 17q21 are detected in about 58% of cells Gain of MLL gene at 11q23 are detected in 82% of cells. (Cytogenetics)	50	THESE ARE POSITIVE FOR HLA-DR, CD117, CD34, CD33 AND CD13. POSITIVE FOR HLA-DR, CD117, CD34, CD33 AND CD13. (Bone Marrow Immunnophenotype)	NA	44.8	negative	0	negative	NA	NA	TP53 (p.P153Afs*28; 75.8%)	NA	1	10.18480493	4
BA3174R	2652	BA3174D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	8	NA	NA	61	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	61	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	4	Vidaza|7+3 (Cytarabine, Idarubicin)|Cytarabine, OXi4503|Velcade	3	Salvage|Induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Velcade	Salvage	41	Dead	283	1	9.297741273	Dead-Disease	NA	14	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	26	9.2	46,XY,del(5)(q13q33)[1]/4 7,idem,+21[14]/46,idem,id ic(21)(p12)[cp4]/47,idem, +21,idic(21)[1]	NA	81.5	POSITIVE for chromosome 5q copy number loss	34	NA	NA	6.5	negative	0	negative	RUNX1 (p.R107H; 59.2%)	ASXL1 (p.E635Rfs*15; 24.3%)	NA	NA	1	9.297741273	4
BA3317R	2366	BA3317D	Waves3+4	no	no	no	no	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	60	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	62	769	Post-Chemotherapy|Relapse	Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)	3	Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	167	Standard Chemotherapy	Azacitidine	Salvage	6	Dead	870	1	28.58316222	Dead-Disease	0	80	45	1.8	0	49.6	0	3.5	0.9	31	20	3	0.85	M4	26.2	9.3	46,XY,t(3;4)(p21;q21)[20]	261	99.6	Normal	44	CD13, CD34, dim CD33, CD38, CD58, CD71, CD117, CD123, partial TdT, and partial MPO+	6.1	3.42	negative	0	positive	NA	NA	NA	FLT3 (p.N841T; MAF 43%)|NPM1 (p.W288fs*12; MAF 41%)|SF3B1 (p.K666Q; MAF 48%)|WT1 (p.Y395fs*51; MAF 44%)	1	28.58316222	2
BA3299R	2608	BA3299D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	6	NA	NA	47	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Busulfan, Fludarabine|HiDAC|3+7 (Cytarabine, Daunorubicin)	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Fludarabine	Allogeneic - Sibling	11	Alive	263	0	8.640657084	Alive	NA	70	NA	2.3	NA	18.3	72.7	6.2	NA	17	17	3.1	0.62	NA	NA	9.5	46,XX[20]	NA	97.7	An apparently NORMAL KARYOTYPE was observed in all 20 mitotic cells analyzed. Specifically, there was no significant numerical chromosomal abnormality and no clonal structural aberration of any chromosome detectable within the limits of resolution.  (Cytogenetics)	237	positive for CD117, HLADR, CD33, CD11b, CD64 and MPO (partial).  (Bone Marrow Immunophenotyping)	NA	66.7	negative	0	positive	NA	NA	NA	NA	0	8.640657084	4
BA3221R	2645	BA3221D	Waves3+4	no	no	no	no	Female	Female	Declined	NON-HISPANIC	NA	1	NA	NA	45	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	45	29	Post-Chemotherapy	Remission	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	3	7+3 (Cytarabine, Daunorubicin) plus Sorafenib|HIDAC + Sorafenib|7+3 (Cytarabine, Idarubicin) plus Sorafenib	3	Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HIDAC + Sorafenib	Consolidation	-1	Alive	104	0	3.416837782	Alive	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M1	NA	NA	46,XX[20]	NA	NA	Normal	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	CRLF2 (p.P224L; MAF 49%)|FLT3-ITD (MAF 2%)|KMT2D (p.R863P; MAF 48%)|PTPN11 (p.A72V; MAF 6%)|SETBP1 (p.P1134T, MAF 51%)	0	3.416837782	4
BA3347R	2708	BA3347D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NA	NA	5	NA	NA	68	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Venetoclax (ABT-199), Azacitidine	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Venetoclax (ABT-199), Azacitidine	Induction	-1	Alive	233	0	7.655030801	Alive	0	85	30	3	NA	35	21	11	NA	16	15	2.8	NA	M5	32.4	10.3	46,XX[20]	NA	NA	Normal	131	Neagtive (CD10, CD19, CD16, CD14, CD34, CD117) | Bright Positive (CD64)	5.2	22	negative	0	positive	NA	NA	NA	DNMT3A (c.2311T>C; p.R771X; MAF 40%)|NPM1 (c.863_864insTCTG; p.W288fs; MAF 38%)|TET2 (c.2827C>T; p.Q943X; MAF 80%)	0	7.655030801	4
BA3235R	2194	BA3235D	Waves3+4	no	no	no	no	Female	Female	Multiracial	HISPANIC	NA	1	NA	NA	46	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	168	Residual Disease|Post-Chemotherapy|Post-Transplant	Residual	Peripheral Blood	y	y	y	y	y	y	4	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	7	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Methotrexate	6	Allogeneic - Sibling|Consolidation|Induction|Experimental|CNS|Re-induction	Complete Response i	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Dasatinib	Experimental	-1	Dead	360	1	11.8275154	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX,t(10;16)(q22;q24)[cp12]/46,sl,t(1;4)(q41;q33),t(7;9)(p15;q32)[5]/46,sl,t(X;1)(q23;q44)[2]/46,sl,der(1)t(1;2)(p32;q32)t(1;15)(q23;q24),der(2)t(1;2)(p32;q32),der(15)t(1;15)(q23;q24)[1]	NA	NA	NA	NA	NA	NA	NA	positive	15.66666667	positive	NA	NA	NA	FLT3-ITD (ITD; MAF 60%)	1	11.8275154	4
BA3126R	2686	BA3126D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	KMT2A_re	66	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	66	2	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	Alive	1580	0	51.90965092	Alive	0	61	NA	0	1.5	3.6	87.8	7.1	0.2	22	39	1.7	1.52	M5	24.4	7.8	46,XY[20]	607	87.8	MLL: 86% of cells had a split signal pattern consistent with MLL rearrangement.	14	CD11b, CD13, CD14, CD33, bright CD64, HLA-DR and partial MPO-positive	5	67.35	negative	0	negative	NA	NA	NA	FLT3 (p.D835Y; MAF 35%)	0	51.90965092	4
BA3380R	2766	BA3380D	Waves3+4	yes	yes	yes	yes	Male	Male	NA	HISPANIC	NA	7	NA	NA	21	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	23	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Alive	520	0	17.08418891	Alive	NA	NA	96	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Normal	NA	NA	NA	NA	NA	NA	55	positive	5.666666667	negative	NA	NA	NA	NA	0	17.08418891	4
BA3089R	2219	BA3089D	Waves3+4	no	no	no	no	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	67	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	68	429	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	5	AG-120|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC	5	Consolidation|Salvage|Induction|Experimental|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	-1	Dead	864	1	28.38603696	Dead-Other	0	75	68	1.7	0	17.4	0.9	12.2	0	21	22	3.4	0.9	M4	40.6	13.6	46,XY[20]	NA	95.8	Normal	91	CD7, CD13, CD33, CD38, CD58, CD117, CD123, partial MPO+	6.4	20.31	negative	0	positive	NA	NA	NA	DNMT3A (p.R882H; MAF 46%)|FLT3 (p.V592D; MAF 39%)|IDH1 (p.R132H, MAF 39%)|IDH2 (p.R140Q; MAF 39%)|NPM1 (p.W288fs*12; MAF 41%)|NRAS (p.Q61P; MAF 40%)|SETBP1 (p.K459E; MAF 40%)	1	28.38603696	4
BA3109R	2835	BA3109D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NA	NA	2	NA	NA	56	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	63	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	4	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine, Trametinib	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine, Trametinib	Salvage	-1	Alive	2929	0	96.22997947	Alive	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX,der(22)t(1;22)(q12;p11.2)[1]/46,XX[19]	NA	NA	NA	NA	NA	NA	NA	negative	0	positive	RUNX1 (p.S100Lfs*38; 45.6%)	NA	NA	NA	0	96.22997947	4
BA3114R	2631	BA3114D	Waves3+4	no	no	no	no	Female	Female	White	NON-HISPANIC	NA	8	mono	NA	75	FALSE	FALSE	TRUE	FALSE	FALSE	y	Endometrial cancer|Lobular carcinoma in situ	y	n	n	n	y	y	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	75	0	Post-Chemotherapy	Remission	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	1	Induction	Unknown	Standard Chemotherapy	4	Standard Chemotherapy	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Induction	4	Dead	93	1	3.055441478	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX[20]	NA	NA	Normal (Clonal aberrations were not identified in metaphase cells examined by conventional cytogenetic techniques* or for any loci examined by FISH methods.)	NA	NA	NA	NA	negative	0	positive	NA	NA	NA	CEBPA (biallelic)|NPM1|PTPN11|TET2	1	3.055441478	4
BA3418R	2824	BA3418D	Waves3+4	yes	yes	yes	yes	Male	Male	Asian	NON-HISPANIC	NA	8	NA	GATA2-MECOM	72	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	7	Dead	24	1	0.788501027	Dead-Disease	NA	50	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	29.3	10.3	45-46,X,-Y,t(3;3)(q21;q26 .2),del(4)(q12),-5,del(6) (q21),del(9)(q22),del(11) (p11.2),ins(15;5)(q12;p15 .2p15.2),add(16)(q22),-17,-20,-21,-22,+mar1-5[c p18]/ 46,XY[2]	NA	85.5	NA	40	NA	NA	2.2	negative	0	negative	NA	NA	NA	NA	1	0.788501027	1
BA3245R	2829	BA3245D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NA	NA	5	NA	NA	62	FALSE	FALSE	TRUE	FALSE	FALSE	y	Fallopian Tube Cancer	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	62	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Targeted Therapy - Kinase Inhibitor(s)	1	Decitabine	1	Supportive/Palliative Care	NA	NA	NA	Targeted Therapy - Kinase Inhibitor(s)	Decitabine	Supportive/Palliative Care	-1	Alive	53	0	1.741273101	Alive	0	50.5	53	0	NA	12	3	25	NA	19	19	2.2	NA	NA	NA	8	47,XX,psu dic(5;7)(q13;p10),r(7)(p12q11.2),+8,der(12)del(12)(p11.2p13)add(12)(q24.1)[2]/ 44,sl,add(3)(q12),-r(7)(p12q11.2),-8,-der(12)del(12)(p11.2p13)add(12)(q24.1),idic(22)(p11.2), +der(?)(7qter- > 7q11.2::?- > cen- > ?::12q11- > 12qter)[16]/ 45,sdl1,+der(?)(7qter- > 7q11.2::?- > cen- > ?::12q11- > 12qter)[2]	NA	NA	5p15.2/ 5q31 (EGR1) (ABNORMAL - Loss of 5q31 sequences) | 7 centromere/ 7q31 (ABNORMAL - Loss of 7q31 sequences, see interpretation) | 8 centromere/ 20q12 (ABNORMAL - Gain of chromosome 8 centromere, Normal 20q12) | RUNX1 (21q22.12)/ RUNX1T1(8q22) (Negative rearrangement, ABNORMAL - Gain of 8q22 sequences)	30	Negative (CD19, CD22, CD56, CD14, CD15, CD64, MPO) | Positive (CD38, CD7, CD13, CD33, CD34, HLA-DR) | Dim (CD11b, CD45, CD117)	NA	18	negative	0	negative	NA	NA	TP53 (p.L257Q; 84.5%)	IDH2 (c.419G>A; p.R140Q; MAF 5%)|NRAS (c.!82A>T; p.Q61L; MAF 26%)|TP53 (c.770T>A; p.L257Q; MAF 92%)	0	1.741273101	1
BA3085R	2785	BA3085D	Waves3+4	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	NA	1	NA	RUNX1-RUNX1T1	14	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	14	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Intrathecal	3	ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Cytarabine	2	Induction|Intensification	Complete Response	Standard Chemotherapy	17	Standard Chemotherapy	HiDAC	Intensification	9	Alive	1523	0	50.03696099	Alive	0	NA	60	0	3.5	24.3	6.1	15.7	0	21	26	3.7	0.78	NA	18.5	6.4	45,X,-X,t(8;21)(q22;q22)[20]	NA	93.9	RUNX1T1/RUNX1:  92/100 cells (92%) had a 1red/ 1 green/ 2 yellow fusion signal pattern, reflecting RUNX1T1/RUNX1fusion	80	dim CD13, dim CD19, CD33, CD34, CD38, CD58, CD117,  CD123, HLA-DR and MPO	7.5	13.58	negative	0	negative	NA	NA	NA	NRAS (p.G12D; MAF 6%)	0	50.03696099	3
BA3128R	2596	BA3128D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	8	NA	NA	33	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	33	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	4	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|CECA (Cyclophosphamide, Etoposide, Carboplatin, Cytosine)|Cytarabine, OXi4503	3	Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	Cytarabine, OXi4503	Salvage	-1	Alive	255	0	8.377823409	Alive	NA	NA	18	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	23.6	8.4	Normal	NA	NA	Normal	59	NA	NA	5.8	positive	NA	negative	NA	NA	NA	NA	0	8.377823409	4
BA3423R	2605	BA3423D	Waves3+4	yes	yes	yes	yes	Female	Female	NA	HISPANIC	NA	6	NA	NA	49	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	50	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Unknown	Standard Chemotherapy	28	Standard Chemotherapy	HiDAC	Consolidation	114	Alive	345	0	11.33470226	Alive	NA	90	96	NA	NA	2	1	2	NA	43	32	3.7	0.67	NA	NA	8.7	NA	NA	84.8	NA	78	Positive for CD34, CD117, HLADR, CD33 and CD13.  (Bone Marrow Immunophentyping)	NA	19	negative	0	positive	NA	NA	NA	FLT3-TKD	0	11.33470226	3
BA3173R	2784	BA3173D	Waves3+4	yes	yes	yes	no	Female	Female	Black	NA	NA	6	NA	RUNX1-RUNX1T1	45	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	46	0	Residual Disease	Residual	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	Salvage	4	Dead	457	1	15.01437372	Dead-Unknown	NA	NA	97	NA	NA	3	NA	NA	NA	151	37	3.5	0.49	NA	22.5	7.7	46,XX,t(8;21)(q22;q22)[15]/46-47,sl,+6,add(13)(p11.2),add(15)(q26),-16,+19,+22[cp5]	NA	88.9	NA	23	NA	6.5	9.3	positive	0.075268817	positive	NA	NA	NA	NA	1	15.01437372	2
BA3171R	2719	BA3171D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	55	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	9	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Dead	402	1	13.2073922	Dead-Treatment	0	60	NA	0	6.8	19.7	20.5	15.4	1.5	NA	NA	NA	NA	M4	29.8	9.6	43,XY,dic(5;12)(q11.2;p13),der(7)t(7;13)(q11.2;q12),i(8)(q10),+9,dup(11)(q2  3q23),-13,-15,-16,der(17)t(15;17)(q22;q23),-21,+mar[20]/46,XY[5]	NA	101.4	RUNX1T1/RUNX1:  86/100 cells (86%) reflecting the isochromosome 8q and the monosomy 21.  No evidence for RUNX1T1/RUNX1fusion | EGR-1/ D5S23, D5S721:  89/100 cells (89%) consistent with missing 5q in the dicentric 5;12 | PML/RARA:  Signal patterns were within normal limits with no evidence for  PML/RARA fusion.  One metaphase cell shows the PML (15q22) signal on the derivative 17, consistent with the metaphase karyotype | BCR/ABL/ASS:  72/100 cells (72%) consistent the trisomy 9 in the metaphase karyotype.  No evidence  for BCR/ABL fusion.  | D7S486/ CEP 7:  79/100 cells (79%) consistent with missing 7q in the derivative 7 | DEK/NUP:  79/100 cells (79%) reflecting the trisomy 9 in the metaphase karyotype.  No evidence for  DEK/NUP fusion. | MLL:  61/100 cells (61%) had three intact MLL signals. One metaphase cell  shows two signals on the duplicated 11q.  There was no evidence for MLL rearrangement.	21	CD11c, CD13, CD33, CD34, CD38, CD56, CD64, CD117, HLA-DR; negative TdT, CD19 and CD10 (from bmbx 5/3/17)	NA	17.99	negative	0	negative	NA	NA	TP53 (p.X125_splice; 75.0%)	KRAS (p.G12D; MAF 35%)|TP53 (Splice site (5' splice site mutation in intron 4); MAF 69%)	1	13.2073922	1
BA3277R	2818	BA3277D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	5	NA	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Venetoclax (ABT-199), Azacitidine	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Venetoclax (ABT-199), Azacitidine	Induction	-1	Alive	211	0	6.932238193	Alive	0	66.5	37	2	NA	24	6	31	NA	23	25	2.6	NA	M4	26.3	8.1	46,XY[20]	NA	NA	Normal	101	positive (CD38 dim, CD33 dim, CD45 dim, CD117 var, MPO var) | negative (CD10, CD19, CD20, CD22, CD23, Surf Kappa, Surf Lambda, FMC7, CD3, CD5, CD7, CD56, CD13, CD14, CD15, CD34) | PP (CD11b VAR, CD64 VAR, HLA-DR VAR)	6	8.6	negative	0	positive	NA	NA	NA	IDH2 (c. 419G>A; p.R140Q; MAF 47%)|NPM1 (C.863_864insTCTG; p.W288fs; MAF 34%)|SRSF2 (c. 284C>A; p.P95H; MAF 47%)	0	6.932238193	4
BA3210R	2644	BA3210D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NA	NA	2	NA	NA	74	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	75	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	3+7 (Cytarabine, Daunorubicin)	Induction	-1	Alive	305	0	10.02053388	Alive	NA	65	30	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	47,XX,+8,del(9)(q13q22),t(12;22)(p13;q13)[12]/46,XX[8]	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	RUNX1 (p.L429Pfs*171; 82.9%)	ASXL1 (p.G646Wfs*12; 36.4%)	NA	BCORL1 (K632fs*33)|CSF3R (T6181)|ETV6 (MN1-ETV6 fusion)|IDH2 (R140Q)|IDH2 (p.Arg140Gln)|PHF6|PTPN11 (E69K)|RUNX1 (L429fs*171)	0	10.02053388	1
BA3157R	2614	BA3157D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	60	FALSE	FALSE	FALSE	FALSE	FALSE	y	Basal Cell Carcinoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	HiDAC|3+7 (Cytarabine, Daunorubicin)|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	Alive	1425	0	46.81724846	Alive	0	87	83	0	0	13.4	0.8	8.3	0.3	125	74	2.3	0.79	M1	26.3	9.2	46,XY,del(9)(q13q22)[20]	823	89.5	Normal	146	CD13, CD33, variable CD34, CD38, CD58, CD117,  CD123, HLA-DR, variable MPO	6.1	23.32	negative	0	positive	NA	NA	NA	NPM1 (p.W288fs*12; MAF 41%)|NRAS (p.G13D; MAF 41%)|SF3B1 (p.T663I; MAF 50%)	0	46.81724846	3
BA3433R	2681	BA3433D	Waves3+4	yes	yes	yes	yes	Male	Male	NA	NA	NA	5	NA	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin) plus Midostaurin	2	Allogeneic - Sibling|Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Sibling	-1	Alive	215	0	7.063655031	Alive	0	92	96	0	NA	3	0	1	NA	30	16	3.3	NA	M0	24.8	8.5	46,XY[20]	NA	NA	Normal	51	negative (CD19, CD22, CD7, CD11b, CD13, CD14, CD15, CD34, CD64, HLA-DR) | Dim (CD38, CD45) | Positive (CD56, CD33, CD117, MPO)	6.5	52.1	negative	0	positive	NA	NA	NA	FLT3 (c.1818_1819ins26; p.P606_R607insCREYEYDLKWEFP; MAF 7%)|NPM1 (c.863_864insTCTG; p.W288fs; MAF 45%)|TET2 (C.3379C>t; p.Q1127X; MAF 44%)	0	7.063655031	3
BA3322R	2009	BA3322D	Waves3+4	no	no	no	no	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	62	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	63	487	Post-Chemotherapy	Remission	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	3	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Induction|Re-induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	Azacitidine	Re-induction	-1	Dead	581	1	19.08829569	Dead-Unknown	1.1	2	NA	0.4	0.7	55.7	4.3	37.8	1.1	31	18	3.5	NA	M1	36.6	12.2	46,XY[20)	NA	90.4	NA	240	CD5, CD19, CD20 and dim surface kappa light chain +	7.4	2.8	negative	0	negative	RUNX1 (p.E223*; MAF 1%)	ASXL1 (p.S1028*; MAF 14%)	NA	ASXL1 (p.S1028*; MAF 14%)|BCOR (p.Y1350*; MAF 6%)|FBXW7 (p.T15_G16insP; MAF 49%)|FLT3|RUNX1 (p.E223*; MAF 1%)	1	19.08829569	4
BA3374R	2617	BA3374D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	KMT2A_re	21	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	21	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Intrathecal	6	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Venetoclax (ABT-199), Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Methotrexate	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	4	Standard Chemotherapy	Venetoclax (ABT-199), Azacitidine	Salvage	26	Dead	316	1	10.38193018	Dead-Disease	0	91	90	0	0	27.3	0	2.7	0	70	152	2.2	1.35	M5	19.9	6.8	47~49,XY,+8[cp13]/46,XY[7]	2767	96.6	RUNX1T1/CEP8: 140/200 cells (70%) reflect the trisomy 8 in the metaphase karyotype; 20 cells (10%) reflect extra centromere signals only. It is possible the G-banded cell with two small markers reflects a small clone containing extra copies of a derivative chromosome 8. | MLL: 88/100 cells (88%) had a variant. A green signal appears on the short arm of a chromosome 10 with a red/small green signal retained on the chromosome 11q. It is unclear whether the material translocated disrupts MLL.	54	CD4, partial CD11b, CD13, CD33, dim CD22, CD34, variable CD56, variable CD64, CD117, HLA-DR, dim PAX5+	5.5	55.69	negative	0	negative	NA	NA	NA	KRAS (p.G13R; MAF 37%)|U2AF1 (p.S34F; MAF 39%)	1	10.38193018	4
BA3450R	2627	BA3450D	Waves3+4	yes	yes	yes	no	Female	Female	White	NA	NA	7	NA	NA	68	FALSE	FALSE	FALSE	FALSE	FALSE	y	Breast Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	22	1	0.722792608	Dead-Unknown	NA	74	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46~47,XX,add(3)(p13),del(5)(q13q33),der(14)t(14;17)(q32;q11.2),del(16)(q22),-17,-22,+2~4mar[cp19]/46,XX[1]	NA	NA	NA	NA	positive for CD13, CD33, CD34, CD38, partial HLA-DR, CD117, and a minor population is also positive for MPO	NA	NA	negative	0	negative	NA	NA	TP53	JAK2|TP53	1	0.722792608	1
BA3167R	2704	BA3167D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	2	NA	MLLT3-KMT2A	38	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	38	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	-1	Alive	162	0	5.32238193	Alive	NA	94	55	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY,t(9;11)(p22;q23),inv(9)(p11q12)	NA	NA	NA	NA	NA	NA	25.29	negative	0	negative	NA	NA	NA	BCOR (D1006fs*16)|FLT3-D835|MLL (MLL-MLLT3 (AF9) Fusion)	0	5.32238193	4
BA3269R	2622	BA3269D	Waves3+4	yes	yes	yes	no	Female	Female	White	NA	NA	5	NA	NA	66	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	AG-221|Azacitidine	1	Supportive/Palliative Care	NA	NA	NA	Standard Chemotherapy	Azacitidine	Supportive/Palliative Care	6	Dead	61	1	2.004106776	Dead-Disease	0	75	86	0	NA	10	2	2	NA	14	28	2.4	NA	M0	24.3	7.7	46,XX[19]	NA	NA	Normal	66	negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD14, CD15, CD34, CD64 TdT) | positive (CD38, CD13, CD33, CD117, MPO, HLA-DR) | dim (CD11b, CD45)	6.2	70.1	negative	0	positive	NA	NA	NA	DNMT3A (c.1903C>G; p.R635G (COSM144550) MAF 44%)|IDH2 (c.419G>A; p.R140Q (COSM41590) MAF 44%)|NPM1 (c.863_864insTCTG; p.W288fs (COSM158604) MAF 37%)	1	2.004106776	4
BA3110R	2713	BA3110D	Waves3+4	yes	yes	yes	yes	Male	Male	NA	HISPANIC	NA	2	NA	NA	51	FALSE	unknown	unknown	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Unknown	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Unknown	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	121	1	3.975359343	Dead-Unknown	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[20]	NA	NA	Normal	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	NA	1	3.975359343	2
BA3156R	2702	BA3156D	Waves3+4	yes	yes	yes	no	Male	Male	NA	NA	NA	8	NA	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute erythroid leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute erythroid leukaemia	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	Dead	50	1	1.642710472	Dead-Disease	NA	25	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M6	NA	NA	45,XY,del(7)(p13),-9[7]/4 5-47,idem,+13,-15,add(19) (p13.3),+20[cp11]/ 46,XY[2]	NA	NA	POSITIVE for ABL1 gene locus copy number loss | POSITIVE for PML gene locus copy number loss	NA	NA	NA	NA	negative	0	negative	NA	NA	TP53 (p.R273C; 67.5%)	NA	1	1.642710472	1
BA3226R	2734	BA3226D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	75	FALSE	FALSE	FALSE	FALSE	FALSE	y	Breast Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	75	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	37	1	1.215605749	Dead-Disease	0	73	79	0	0	11.4	1.8	7.9	0.4	42	41	2.8	0.66	M2	22.9	7.5	46,XX[20]	NA	97.9	Normal	45	dim CD11b, CD13, CD33, partial CD34, partial CD38, dim CD45, partial CD64, CD58, partial CD117, CD123 and partial MPO positive	6.9	88.2	positive	0.960784314	positive	NA	NA	NA	FLT3-ITD (MAF 44%)	1	1.215605749	3
BA3421R	2659	BA3421D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NA	NA	5	NA	NA	52	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	52	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	7+3 (Cytarabine, Idarubicin) plus Midostaurin|Midostaurin|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Maintenance	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Midostaurin	Maintenance	13	Alive	181	0	5.94661191	Alive	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Normal/Negative Rearrangement	NA	NA	NA	NA	positive	0.724137931	positive	NA	NA	NA	DNMT3A (MAF 47%)|FLT3-ITD (2 on separate alleles: p.E604_F605insYDLKWE, MAF 19%; p.L601_K602ins18, MAF 9%)|NPM1 (MAF 44%)	0	5.94661191	4
BA3232R	2714	BA3232D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	36	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	36	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	4	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Other	6	Azacitidine, Sorafenib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Busulfan, Cyclophosphamide|Cytarabine, Methotrexate	5	Allogeneic - Sibling|Induction|Experimental|Re-induction|Maintenance	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Other	SY-1425 (Tamibarotene) plus Daratumumab	Experimental	28	Dead	370	1	12.15605749	Dead-Disease	0	30	40	0	9.6	13.9	0.9	36.5	0.1	14	25	3.5	0.77	M4	13.3	4.6	46,XX[20]	NA	100	Normal	58	dim CD7, partial CD11b, variable CD13, CD33, CD64,  CD117, dim CD123, dim HLA-DR and partial MPO positive	6.6	59.05	positive	0.265822785	positive	NA	NA	NA	BCOR (p.V89D; MAF 54%)|DNMT3A (p.R882H; MAF 51%)|FLT3-ITD (MAF 15%)|NPM1 (p.W288fs*12; MAF 48%)|NRAS (p.G12S; MAF 20%)	1	12.15605749	4
BA3289R	2677	BA3289D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NA	NA	5	NA	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	7+3 (Cytarabine, Idarubicin)|Midostaurin|Fludarabine, Cyclophosphamide, Thiotepa, TBI	3	Induction|Double Umbilical Cord Blood Transplant (DUCBT)|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Alive	177	0	5.815195072	Alive	NA	65	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M0	NA	NA	NA	NA	NA	Normal	179	NA	NA	111.5	positive	0.587301587	negative	NA	NA	NA	DNMT3A|FLT3-ITD|TET2	0	5.815195072	4
BA3430R	2728	BA3430D	Waves3+4	yes	yes	yes	no	Female	Female	White	NA	NA	5	NA	MLLT3-KMT2A	60	FALSE	FALSE	FALSE	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	60	1	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	1	1	0.032854209	Dead-Disease	NA	90	87	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	positive for CD11b, CD13, CD14, CD15, CD33, CD38, CD45, CD64, HLA-DR and MPO	NA	166.8	negative	0	negative	NA	NA	NA	NA	1	0.032854209	4
BA3145R	2523	BA3145D	Waves3+4	no	no	no	no	Male	Male	White	NON-HISPANIC	NA	2	NA	DEK-NUP214	74	FALSE	FALSE	FALSE	FALSE	FALSE	y	Prostate Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	77	979	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	3	Crenolanib|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Azacitidine, Pracinostat	2	Induction|Maintenance	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Other	Crenolanib	Maintenance	433	Dead	1003	1	32.95277207	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	47,XY,t(6;9)(p23;q34),+8[13]/48,idem,+13[4]/46,XY[3]	NA	NA	DEK-NUP214 fusion; MAF unavailable (DEK-NUP214 fusion; MAF unavailable) | nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[198], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[17/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	NA	NA	NA	NA	positive	NA	negative	NA	ASXL1 (p.G645Vfs*58; 10.5%)	NA	DNMT3A (F827fs*4)|FLT3-ITD	1	32.95277207	4
BA3399R	2643	BA3399D	Waves3+4	no	no	no	no	Male	Male	White	NA	NA	5	NA	NA	57	FALSE	FALSE	FALSE	TRUE	FALSE	y	Rectal Cancer	y	y	n	n	y	n	n	n	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	unknown	NonAML	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	unknown	57	1	NA	NA	Bone Marrow Aspirate	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Alive	78	0	2.562628337	Alive	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	47,XY,+21[19]	NA	NA	NA	NA	positive for CD11b, CD13, CD33, CD34, CD38, dim CD45, CD117 and HLA-DR with aberrant expression of CD56	NA	NA	negative	NA	negative	NA	ASXL1 (p.E865*; 39.7%)	NA	NA	0	2.562628337	4
BA3449R	2609	BA3449D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	8	NA	GATA2-MECOM	55	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	55	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	Vidaza|Decitabine	2	Salvage|Supportive/Palliative Care	NA	NA	NA	Standard Chemotherapy	Decitabine	Salvage	-1	Dead	1	1	0.032854209	Dead-Disease	NA	80	67	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	30.1	10.4	49,XY,dup(1)(p22.1p32.1), inv(3)(q21.3q26.2),+8,+12 ,+21[20]	NA	83.7	POSITIVE for RUNX1T1 and RUNX1 copy number gains	31	NA	NA	43.7	negative	0	negative	RUNX1 (p.R76Pfs*62; 66.7%)	NA	NA	NA	1	0.032854209	1
BA3384R	2736	BA3384D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	KMT2A_re	39	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	39	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	4	DLI|Standard Chemotherapy|Bone Marrow Transplant|Other	7	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Radiation|Busulfan, Cyclophosphamide	5	Consolidation|Unknown|Induction|Maintenance|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Alive	1512	0	49.67556468	Alive	0	>90	90	0	0	9.7	28.3	0	0	NA	NA	2.4	0.57	M4	20.5	6.7	47,XX,del(11)(q23),+21[20]	540	109.6	MLL:  97/100 cells (97%) had a 0 red/ 1 green/ 1 yellow signal pattern,  partially deleting the MLL region of 11q23 and consistent with the deleted 11q in the metaphase karyotype. | RUNX1T1/RUNX1:  95/100 cells (95%) had a 2 red/ 3 green signal pattern, consistent with the trisomy 21 in the metaphase karyotype. There was no evidence for RUNX1T1/RUNX1fusion.	12	partial CD11b, dim CD13, CD33, partial CD34, variable CD64, CD117, CD123, HLA-DR+	NA	173.2	negative	0	negative	RUNX1 (p.P49T; MAF 69%)	NA	NA	MLL (Possible subclone with partial tandem duplication)|RUNX1 (p.P49T; MAF 69%)	0	49.67556468	4
BA3427R	2807	BA3427D	Waves3+4	yes	yes	yes	no	Male	Male	Unknown	UNKNOWN	NA	1	NA	NA	67	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	117	1	3.843942505	Dead-Disease	1.7	20	7	0	0	80	7	10.4	0	26	17	3.5	0.87	NA	29.3	10	45,XY,-4,-5,del(6)(p24),add(7)(q21),der(9)t(9;14)(q12;q11.2),-14,-21,+22,ad  d(22)(p11.2)x2,+2mar[20]	251	96.1	EGR1/5p:   77% of cells were missing a signal for both probes, consistent  with monosomy, as seen on metaphase analysis.  | D7S486 (7q31):  73% of cells were missing a signal for D7S486 (7q31),  consistent deletion and with the add(7) seen on metaphase analysis. | NUP214 (9q34):   64% of cells were missing a signal for NUP214 (9q34), consistent with deletion due to the der(9) seen on metaphase analysis.  (Also, deletion of 9q34 was observed using the ABL+ASS probe set on a parallel study, GL17-02579.)  | RUNX1 (21q22):   55% of cells had four signals for RUNX1 (21q22); another  28% of cells had three signals.  One of the four signals was on what  appeared to be a larger submetacentric chromosome, possibly the larger of  the two marker chromosomes observed on metaphase analysis.	18	CD13, CD33, variable CD34, CD117, partial HLA-DR	7	1.88	negative	0	negative	NA	NA	TP53 (p.H179N; 16.9%)|TP53 (p.I195Mfs*13; 9.9%)|TP53 (p.I195Yfs*14; 11.4%)	TP53 (p.H179N; MAF 63%)|TP53 (p.I195fs*52; MAF 39%)	1	3.843942505	4
BA3163R	2638	BA3163D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	MLLT3-KMT2A	43	FALSE	FALSE	FALSE	FALSE	FALSE	y	Breast Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	43	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	Azacitidine|Mitoxantrone	2	Induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Mitoxantrone	Supportive/Palliative Care	0	Dead	62	1	2.036960986	Dead-Disease	0	80	55	0.9	2.5	8.5	61	25.4	0.3	198	685	2.7	1.18	M5	34.2	11.4	46,XX,t(9;11)(p22;q23)[15]/47,idem,+8[2]/46,XX[3]	5919	99.1	MLL:  57/100 cells (57%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting MLL (11q23) rearrangement, consistent with the 9;11  translocation observed in the metaphase karyotype. | RUNX1T1/RUNX1:  6/200 cells (3%) had a 3 red/ 2 green signal pattern,  reflecting an extra RUNX1T1 (8q21.3) signal, consistent with the trisomy 8  clone observed in the metaphase karyotype. | CEP 8:  5/200 cells (2.5%) had three signals, reflecting an extra  chromosome 8 centromere signal, consistent with the trisomy 8 clone observed in the metaphase karyotype.	120	dim CD4, CD11b, CD13, partial CD14, CD33,  CD38, variable CD56, CD58, CD64, dim CD71, dim CD123, and HLA-DR+	5	91.72	negative	0	negative	NA	NA	NA	DNMT3A (Splice site mutation (invariant splice donor at end of exon 14; likely pathogenic); MAF 20%)	1	2.036960986	4
BA3158R	2646	BA3158D	Waves3+4	yes	yes	yes	yes	Male	Male	NA	NA	NA	3	NA	RUNX1-RUNX1T1	68	FALSE	FALSE	FALSE	FALSE	FALSE	y	Non-Hodgkins Lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	68	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Unknown	0	0	0	NA	NA	90.8	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY,t(8;21)(q22;q22)[8]46,sl,del(9)(q13q22)[4]/47,sdl,+21[2]/47,sl,+21[4]/46,XY[2]	NA	NA	This analysis showed evidence of t(8;21)(q22;q22) (RUNX1T1-RUNX1 translocation) in 196/200 (98.0 percent) cells scored. Of these cells, 20/200 (10.0 percent) showed the translocation accompanied by an additional copy of the RUNX1 locus.	NA	NA	NA	27.1	negative	0	negative	NA	NA	NA	NA	0	0	2
BA3436R	2755	BA3436D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	mono	NA	23	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	23	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|FLAG-IDA, Gemtuzumab|Busulfan, Cyclophosphamide	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Alive	1510	0	49.60985626	Alive	0.9	80	NA	0	0	11.6	0	10.7	0.3	17	7	3	0.68	M1	26.7	8.9	46,XX[8]	145	90.8	Normal	54	CD13, CD33, partial CD34, CD38, CD58, dim CD71, CD117,  CD123, and cMPO+	6.9	29.58	negative	0	positive	NA	NA	NA	CEBPA (p.A199fs*114; MAF 50%)|EZH2 (p.R288*; MAF46%)|GATA2 (p.A372T; MAF 31%)|NPM1 (p.W288fs*12; MAF 50%)	0	49.60985626	3
BA3154R	2768	BA3154D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NA	NA	7	NA	NA	29	FALSE	FALSE	FALSE	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	n	n	ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE	Mixed phenotype acute leukaemia, B/myeloid, NOS	Adverse	ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE	Mixed phenotype acute leukaemia, B/myeloid, NOS	29	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	256	1	8.410677618	Dead-Other	NA	95	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	30~35<1n>,XX,+1,+2,+6,+10,+11,+12,+18,+19,+21,+22[cp6]/46XX[20]	NA	NA	Negative for 9;22 and MLL	NA	positive for dim CD2 (aberrant), CD11b (aberrant), CD13, CD33, CD34, CD38, CD117, HLA-DR, and dim nTdT (aberrant)	NA	NA	negative	0	negative	NA	NA	TP53 (p.V122Dfs*26; 87.5%)	CREBBP|NF1|TP53	1	8.410677618	2
BA3162R	2740	BA3162D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NA	NA	2	NA	CBFB-MYH11	20	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	20	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	-1	Alive	99	0	3.252566735	Alive	NA	50	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY,inv(16)(p13.1q22)[20]	NA	NA	Evidence of a CBFB [inv(16)] gene rearrangement in 98% of the cells.	16	CD2(-), CD4(-), CD5(-), CD7(-), CD8(-),CD10(-), CD11b(dim +), CD13(dim +),CD14(dim +), CD15(dim+CD16(-), CD20(-), CD22(-), CD25(dim +), CD33(dim +), CD34(+), CD38(+), CD36(subset +), CD56(-), CD64(subset +), CD79a +)(-), CD123(dim +), MPO(dim +), TdT(-), and surface kappa lambda light chain(-).,	NA	68.59	negative	0	positive	NA	NA	NA	KIT (Y418_R420>RW; MAF 10.2%)|NRAS (G12s; MAF45.4%)	0	3.252566735	2
BA3352R	2699	BA3352D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NA	NA	2	NA	NA	73	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	Dead	22	1	0.722792608	Dead-Disease	NA	90	94	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[20]	NA	NA	Normal	NA	CD34(-), CD13(predominantly -), CD33(+), CD38(partial +), CD45(dim +), CD56(variably +), CD64(partial dim +), CD117(+),HLA-DR(-), MPO(+), TdT(-), other myeloid and lymphoid antigens(predominantly -).	NA	64.4	positive	1.222222222	positive	NA	NA	NA	NA	1	0.722792608	3
BA3084R	2694	BA3084D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	KMT2A_re	22	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	22	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone) + Midostaurin|Busulfan, Cyclophosphamide	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Dead	328	1	10.7761807	Dead-Disease	0	92	91	0.9	0	9.8	1.8	0	0.1	22	35	2.5	0.71	M4	27.8	9.5	46,XY,t(10;11)(p13;q23)[20]	1186	102.2	MLL: 88% of cells had a 1g/0r/2f signal pattern, where the lone green signal was small and the green component suggesting a disruption of MLL (11q23) within the green portion of  the probe.  This result is consistent with MLL rearrangement and with the t(10;11) seen on metaphase analysis.	95	Immunophenotype 1(15% WBCs): dim CD4, variable CD13, CD33, bright  CD34, CD58, CD64, CD117, CD123, variable MPO  | Immunophenotype 2 (79% WBCs): dim CD4, CD11b, variable CD13, CD33, CD38, CD58, CD64, CD117, CD123	7	82.99	negative	0	negative	NA	NA	NA	FLT3-D835 (MAF: 31%)|KRAS (p.G12D; MAF 4%)	1	10.7761807	4
BA3149R	2597	BA3149D	Waves3+4	yes	yes	yes	no	Female	Female	White	NA	NA	5	NA	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	Azacitidine, BI 836858 (anti-CD33)	1	Supportive/Palliative Care	NA	NA	NA	Standard Chemotherapy	Azacitidine, BI 836858 (anti-CD33)	Supportive/Palliative Care	6	Dead	27	1	0.887063655	Dead-Disease	NA	85	54	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Normal	NA	positive for CD13, CD33, CD34, dim CD45, CD38, CD117, HLA-DR and MPO	NA	9.4	negative	0	negative	RUNX1 (p.M267Ifs*44; 77.6%)	ASXL1 (p.E635Rfs*15; 16.4%)	NA	NA	1	0.887063655	4
BA3169R	2662	BA3169D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NA	NA	5	NA	KMT2A_re	88	FALSE	FALSE	FALSE	FALSE	FALSE	y	Uterine Sarcoma	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	88	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	5	1	0.164271047	Dead-Disease	NA	80	24	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	47,XX,+8[4]/47,sl,add(10)(q22)[10]/89~94,sdlx2[cp3]/55,sl,+X,+6,+8,+ 8,+9,+13,+21,+22[2]/46,XX[1]	NA	NA	MLL (KMT2A) rearrangement in 94% of 200 cells | gain of 8q22 sequence in 94% of 200 cells	NA	positive for CD11b, dim CD7, CD13, CD14, CD33, CD38, CD15, CD45, CD56, CD64 and HLA-DR	NA	23.4	negative	0	positive	NA	NA	NA	NA	1	0.164271047	4
BA3180R	2770	BA3180D	Waves3+4	yes	yes	yes	no	Male	Male	White	NA	NA	5	NA	NA	27	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	27	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, Thiotepa, TBI|7+3 (Cytarabine, Idarubicin) plus Azacitidine	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Alive	116	0	3.811088296	Alive	NA	NA	60	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	positive	0.886792453	positive	NA	NA	NA	FLT3-ITD|IDH2	0	3.811088296	3
BA3255R	2725	BA3255D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	55	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	7+3 (Cytarabine, Idarubicin)|HiDAC + Midostaurin|Decitabine, Sorafenib |Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine, Sorafenib	Salvage	61	Dead	272	1	8.936344969	Dead-Disease	0	90	80	0	2.6	9.6	22.6	5.2	0.4	21	25	3	0.9	M0	22.3	7.4	46,XY[20]	1037	85.8	Normal	234	dim partial CD4, dim partial CD7, dim CD11b, CD13, CD33,  partial CD34, CD38, CD58, dim CD71, CD117, CD123 and HLA-DR+	7.7	118.21	positive	3	positive	NA	NA	NA	DNMT3A (Splice site (start of intron 18; likely pathogenic); MAF 47%)|FLT3-ITD (p.E598delinsDYVDFREYE; MAF 60%)|NPM1 (p.W290fs*10; MAF 45%)|WT1 (p.D464N; MAF 46%)	1	8.936344969	4
BA3438R	2834	BA3438D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	KMT2A_re	53	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)	2	Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	5+2 (Cytarabine, Idarubicin)	Re-induction	4	Dead	65	1	2.135523614	Dead-Disease	3.5	95	NA	1.7	NA	69.8	0.9	15.5	4.5	30	24	3.3	0.87	M1	25.1	8.4	47,XY,der(5)t(5;17)(q12;q12),+8,+15,der(15)t(11;15)(q22;q24)dup(11)(q25q22)  ,del(16)(q22q24),-17,der(20;21)(p10;q10),+mar[16]/46,idem,der(10)t(10;11)(q  25;q23)t(5;11)(q12;q25),-mar[3]/46,XY[1]	399	88.4	EGR1:  90% of cells were missing a signal for EGR1 (5q31), consistent with  the der(5) seen on metaphase analysis.  | MLL (11q23):   97% of cells had two normal intact signals and a many other  intact signals per cells, suggesting amplification.  (On available metaphase  cells, there was clustering of amplified fused signals on two chromosomes:  in the first clone, amplified signals clustered on the der(15) and on the  marker chromosome; in the second clone, amplified signals clustered on the  der(15) and on the der(10).) | CBFB (16q22):   94% of cells were missing a signal for CBFB, consistent  with del(16q) as seen on metaphase. | RUNX1/RUNX1T1+CEP8: 92% of cells had three signals for chromosome 8 probes (CEP8 and RUNX1T1) and only one signal for RUNX1 (21q22), consistent with trisomy 8. Results with the RUNX1 probe on chromosome 21 suggest that the interpretation of the chrom results as der(20;21) may be more complicated.	23	CD4, dim CD20, dim CD11b, CD13, CD33, CD34, CD38, CD58,  variable CD64, partial dim CD117, MPO	6.8	3.81	negative	0	negative	NA	NA	TP53 (p.R248Q; 80.3%)	MLL |TP53 (p.R248Q; MAF 82%)	1	2.135523614	4
BA3345R	2775	BA3345D	Waves3+4	yes	yes	yes	yes	Female	Female	Black	NON-HISPANIC	NA	8	NA	NA	59	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	59	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	4	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	4	Alive	57	0	1.872689938	Alive	NA	3	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5	21.7	7.4	47,XX,+8[20]	NA	87.2	POSITIVE for RUNX1T1 copy number gain	51	NA	NA	3.7	negative	0	negative	RUNX1 (p.S100F; 39.6%)	NA	NA	NA	0	1.872689938	4
BA3403R	2617	BA3403D	Waves3+4	no	no	no	no	Male	Male	White	NON-HISPANIC	NA	1	NA	KMT2A_re	21	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	22	99	Relapse|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Intrathecal	6	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Venetoclax (ABT-199), Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Methotrexate	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	4	Standard Chemotherapy	Venetoclax (ABT-199), Azacitidine	Salvage	26	Dead	316	1	10.38193018	Dead-Disease	0	95	95	0	0	4.5	6.3	0	0	31	75	3.1	0.8	M5	30	9.9	49,XY,+8,+mar1,+mar1[cp13]/49,idem,del(6)(q13q21)[8]	1612	92.9	RUNX1T1/CEP8:  95/100 cells (95%) had an abnormal 3 red/ 3 aqua signal  pattern, reflecting the trisomy 8 in the metaphase karyotype and previously  observed. There was no evidence for RUNX1T1/RUNX1 fusion. | MLL:  93/100 cells (93%) had a variant abnormal 0 red/ 1 green/ 1 yellow  (red/small green)/ 1 yellow (red/green) signal pattern, reflecting MLL rearrangement and previously observed. | MECOM/RPN1:  84/100 cells (84%) had an abnormal 5-6 red/ 2 green signal  pattern, reflecting extra copies of MECOM (3q26.2) and gain of 3q.  Metaphase FISH shows the extra signals to be on the two markers. There was  no evidence for MECOM/RPN1 fusion.	42	CD4, CD11b, CD13, variable CD14, CD15, CD33, CD34, variable CD38, CD56, CD58, CD64, variable CD117, and HLA-DR	5.8	60.51	negative	0	negative	NA	NA	NA	KRAS (p.G13R; MAF 52%)|U2AF1 (p.S34F; MAF 49%)	1	10.38193018	4
BA3431R	2647	BA3431D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NA	NA	7	NA	NA	45	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	45	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Alive	68	0	2.234086242	Alive	NA	69	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46[XX]	NA	NA	NA	NA	positive for CD11b, CD11c, CD14, CD64, CD33, CD38, HLA-DR and partial for CD13, CD15, cMPO	NA	NA	negative	0	positive	NA	NA	NA	FLT3-TKD (MAF 1%)|NPM1 (MAF 39%)|PTPN11 (likely pathogenic)	0	2.234086242	4
BA3181R	2667	BA3181D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	8	NA	NA	60	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid sarcoma	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid sarcoma	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin, Dexamethasone)	2	Allogeneic - Sibling|Induction	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Sibling	-1	Alive	212	0	6.965092402	Alive	NA	7	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5	NA	NA	46,XX[20]	NA	NA	Normal	NA	NA	NA	NA	negative	0	negative	NA	ASXL1 (p.R634Kfs*24; 38.6%)	NA	NA	0	6.965092402	4
BA3341R	2628	BA3341D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NA	NA	2	NA	NA	62	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Targeted Therapy - Other	1	Enasidenib	1	Induction	Refractory	Targeted Therapy - Other	-1	Targeted Therapy - Other	Enasidenib	Induction	-1	Alive	52	0	1.708418891	Alive	NA	48	26	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX,del(7)(q22q32)[cp4]/46,XX[16]	NA	NA	Evidence of deletion of the BCR (22q11.2) gene in 7% of the cells examined.	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	DNMT3A|IDH2 (p.172Arg>Lys)|KMT2A	0	1.708418891	4
BA3191R	2700	BA3191D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	CBFB-MYH11	46	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	46	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	5	5+2 (Cytarabine, Idarubicin)|Azacitidine|Gemtuzumab|MiDAC|Decitabine	5	Consolidation|Salvage|Induction|Re-induction|Maintenance	Refractory	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Gemtuzumab	Salvage	-1	Dead	546	1	17.93839836	Dead-Disease	1.7	36	28	1.7	2.5	21.8	34.5	21.8	0	24	16	3.1	0.88	M4	37.4	12.7	NA	593	82.9	Positive for CBFB rearrangement. (96/100 cells (96%) reflected a loss of the distal green portion of one break-apart signal. Presence of an  inverted chromosome 16 was confirmed.  In addition, metaphase FISH showed a  normal chromosome 16 with a yellow (red/green) signal in the long arm and the inverted chromosome 16 with the proximal red signal in the short arm and the green signal missing.)	42	CD13, dim CD33, CD34, CD38, CD117, CD123, HLA-DR  and dim MPO+. (Blast Immunophenotype) | CD11b, CD13, dim CD14, CD33, CD38, CD64,  HLA-DR, dim CD117, CD123 and dim MPO+ (Monocytic Immunophenotype)	6.3	47.64	negative	0	negative	NA	NA	NA	GATA2 (p.T356A; MAF 41%)|NRAS (p.Q61K; MAF 41%)	1	17.93839836	2
BA3197R	2738	BA3197D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	47	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	10	1	0.328542094	Dead-Disease	0	NA	95	0	0	1.7	0	0	0.1	190	80	3.4	0.83	M1	30.2	10.3	NA	730	93.5	PML/RARA: Negative	22	partial CD13, CD33, CD38, partial CD56, CD58, CD117,  CD123, and MPO positive	6.5	134.63	positive	0.785714286	positive	NA	NA	NA	FLT3-ITD (p.F605delinsTGSSDNEYFYVDFREYEYDLKWEF; MAF 46%)|IDH1 (p.R132G; MAF 47%)|NOTCH1 (p.E1555V; MAF 51%)|NPM1 (p.W288fs*12; MAF 50%)	1	0.328542094	3
BA3448R	2752	BA3448D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	KMT2A_re	27	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	27	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)	Allogeneic - Sibling	-1	Alive	1455	0	47.80287474	Alive	0	90	85	0	0	30.2	0	0	0	23	16	2.2	0.81	M0	25.5	8.3	46,XX,t(6;11)(q27;q23)[25]	496	91.1	MLL:  92/100 cells (92%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting MLL rearrangement and consistent with the 6;11  translocation observed in a companion bone marrow G-banded chromosome  study. One metaphase cell showed the 6;11 rearrangement.	16	CD13 , CD33 , partial CD34 , CD38 , CD58 , CD64 , CD71 , CD117 , CD123 and HLA-DR positive	5.5	22.95	negative	0	negative	NA	NA	NA	KRAS (p.G12D; MAF 16%)|MLL (PTD)	0	47.80287474	4
BA3453R	2764	BA3453D	Waves3+4	yes	yes	yes	no	Female	Female	White	NA	NA	5	NA	NA	76	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	76	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Targeted Therapy - Kinase Inhibitor(s)	1	Decitabine	1	Supportive/Palliative Care	NA	NA	NA	Targeted Therapy - Kinase Inhibitor(s)	Decitabine	Supportive/Palliative Care	9	Alive	19	0	0.624229979	Alive	NA	90	85	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX[20]	NA	NA	NA	NA	A large blastic population, positive for CD13, CD15, CD33, CD38, dim CD45, dim CD64, CD117, HLA-DR, and MPO	NA	44.4	negative	0	positive	NA	NA	NA	NA	0	0.624229979	4
BA3406R	2796	BA3406D	Waves3+4	yes	yes	yes	yes	Male	Male	NA	NA	NA	3	NA	NA	33	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	33	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	UNKNOWN	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	Alive	30	0	0.985626283	Alive	NA	69	28	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46, XY[20]	NA	NA	Normal	70	NA	NA	4.52	positive	0.492537313	negative	NA	NA	NA	BCOR (p.G1n1626; MAF 62.2%)|FLT3-ITD (p.Glu598_Tyr599ins9)|WT1 (p.Arg370fs; MAF 27.7%)	0	0.985626283	4
BA3308R	2772	BA3308D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	78	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	n	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	78	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	4	AG-221|Imatinib|Midostaurin|Interferon	3	Salvage|Maintenance|Supportive/Palliative Care	NA	NA	NA	Targeted Therapy - Kinase Inhibitor(s)	AG-221	Salvage	191	Dead	319	1	10.48049281	Dead-Disease	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	47,XY,del(6)(q13),+8[8]/47,idem,-8,+13[2]/46,XY,del(13)(q14q22),del(20)(q11.2)[6]/46,XY[4]	NA	NA	RUNX1T1:  22/200 cells (11%) had a 3 red/ 2 green signal  pattern, reflecting an extra RUNX1T1 (8q21.3) signal, consistent with the  trisomy 8 clone observed in the metaphase karyotype | RUNX1: 18/200 cells (9%) had a 2  red/ 3 green signal pattern, reflecting an extra RUNX1 (21q22) signal.  The  extra chromosome 21 material was not apparent in the G-banded karyotype.  There was no evidence for RUNX1T1/RUNX1 fusion. | CEP8:  29/200 (14.5%) cells  scored with the CEP 8 probe had three signals, consistent with trisomy 8.  | D20S108/20p subtel:  6/200 cells (3%) had a 1 red/ 2 green signal pattern,  consistent with the deleted 20q in the metaphase karyotype.	NA	NA	NA	NA	negative	0	negative	RUNX1 (p.R162S; 84.5%)	ASXL1 (p.G646Wfs*12; 34.3%)	TP53 (p.X187_splice; 9.3%)	IDH2 (p.R140Q; MAF 45%)|KRAS (p.Q61R; MAF 5%)|NOTCH1 (p.P2412L; MAF 57%)|RUNX1 (p.R162S; MAF 74%)|SRSF2 (p.P95H; MAF 54%)|TP53 (Splice site; MAF 9%)	1	10.48049281	2
BA3186R	2743	BA3186D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	68	TRUE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	70	0	Relapse|Post-Chemotherapy|Post-Transplant	Relapse	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	3	Fludarabine, Melphalan|Azacitidine|MiDAC	3	Symptom Control|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	NA	NA	NA	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Dead	980	1	32.19712526	Dead-Disease	0	79	56	0	0	14.6	4.5	8.2	2.6	31	58	2.9	0.69	NA	33.5	11.8	45,XY,add(3)(p22),-7,t(8;22)(q11.2;q11.2),add(11)(q23),-13,-15,-16,  der(17)t(7;17)(q11.2;p11.2),+3mar[cp3]/44~46,sl+der(8)t(8;21)(q11.2;q11.2),  -18[cp15]/44,sl,-add(3)(p22),+10,+13,+15,-18,-3mar[2]	3293	92.5	MLL:  97/100 cells (97%) had the variant abnormal 0 red/ 1 green/1 yellow  signal pattern, reflecting MLL (11q23) rearrangement and previously  observed.  | TP53/CEP 17:  99/100 cells (99%) had a 1 red/ 2 green signal pattern,  reflecting TP53 deletion, previously observed and consistent with the  derivative 17 in the metaphase karyotype. | RUNX1T1/RUNX1:  93/100 cells (93%) had a 2-3 red/ 3-4 green signal pattern,  reflecting an extra copies of RUNX1T1 and RUNX1.  There was no evidence for  RUNX1T1/RUNX1 fusion.  | CBFB:  96/100 cells (96%) had a single intact signal, reflecting CBFB  (16q22) loss and consistent with the monosomy 16 in the metaphase  karyotype.  | D7S486/ CEP 7:  99/100 cells (99%) had a 2 red/ 1 green signal pattern,  indicating loss of a chromosome 7 centromere signal with 7q material  attached to the derivative 17 in the metaphase karyotype.  | CEP 8:  66/100 cells (66%) had three signals, consistent with the clone  having an extra copy of the derivative 8.	28	dim CD4, dim CD7, dim CD33, CD34, dim CD56, CD58, dim  CD123, CD117 and HLA-DR positive	NA	49.48	negative	0	negative	NA	NA	TP53 (p.R248W; 71.9%)	JAK2 (p.V617F; MAF 88%)|SF3B1 (p.G740V; MAF 41%)|TET2 (p.E692fs*8; MAF 40%)|TP53 (p.R248W; MAF 78%)	1	32.19712526	1
BA3334R	2640	BA3334D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NA	NA	2	NA	NA	76	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	76	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Targeted Therapy - Other	1	Entospletinib	1	Experimental	NA	NA	NA	Targeted Therapy - Other	Entospletinib	Experimental	-1	Alive	47	0	1.544147844	Alive	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Normal	NA	NA	NA	NA	negative	0	negative	NA	ASXL1 (p.C687Yfs*30; 45.2%)	NA	ASXL1|FLT3 (N841K)|SRSF2|STAG2	0	1.544147844	4
BA3447R	2669	BA3447D	Waves3+4	yes	yes	yes	no	Male	Male	White	NA	NA	7	NA	NA	67	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	249	1	8.180698152	Dead-Disease	NA	82	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M1	NA	NA	46XY	NA	NA	NA	NA	positive for CD13, CD33, CD34, CD38, CD117, HLA-DR, cytoplasmic myeloperoxidase (subset), and TdT (subset)	NA	NA	negative	0	negative	NA	NA	NA	FLT3-ITD|NRAS|U2AF1	1	8.180698152	4
BA3116R	2810	BA3116D	Waves3+4	yes	yes	yes	no	Female	Female	White	NA	NA	5	NA	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	Azacitidine, BI 836858 (anti-CD33)	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine, BI 836858 (anti-CD33)	Induction	-1	Alive	83	0	2.726899384	Alive	NA	40	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	ASXL1|TET2	0	2.726899384	4
BA3280R	2648	BA3280D	Waves3+4	yes	yes	yes	no	Male	Male	White	NA	NA	5	N/A	NA	51	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	-1	Alive	82	0	2.694045175	Alive	NA	80	85	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[20]	NA	NA	NA	NA	positive for CD117, CD13, CD33, and HLA-DR. Roughly half of the blasts were positive for CD34, roughly half of the blasts showed aberrant dim expression of CD7, and roughly half of the cells showed aberrant dim expression of CD19.	NA	NA	positive	0.136363636	positive	NA	NA	NA	ASXL1|CEBPA|FLT3-ITD|NPM1|NRAS|PTPN11|STAG2	0	2.694045175	2
BA3185R	2769	BA3185D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NA	NA	5	NA	NA	75	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	75	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Entospletinib, Azacitidine|Entospletinib	2	Induction|Re-induction	Refractory	Targeted Therapy - Kinase Inhibitor(s)	-1	Standard Chemotherapy	Entospletinib, Azacitidine	Re-induction	-1	Alive	75	0	2.464065708	Alive	NA	90	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	47,XY,+13[20]/47,XY,+8[1]	NA	NA	Low level gain of chromosome 8 sequences (trisomy). Loss of 21q22 sequences (monosomy)	NA	CD13, CD33, HLA-DR, and CD34	NA	NA	negative	0	negative	RUNX1 (p.H105Afs*33; 41.2%)|RUNX1 (p.T104R; 53.3%)	ASXL1 (p.G646Wfs*12; 33.3%)	NA	ASXL1|RUNX1|SRSF2|TET2	0	2.464065708	2
BA3094R	2660	BA3094D	Waves3+4	yes	yes	yes	yes	Male	Male	White	UNKNOWN	NA	1	NA	KMT2A_re	23	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	23	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Alive	1386	0	45.53593429	Alive	0	95	85	0	0	12.4	0.9	1.8	0	68	83	2.8	0.78	M5	25.5	8.6	46,XY,der(10)t(10;11)(p13;q23),der(11)t(10;11)(p13;q23)inv(11)(q13q23)[20]	2144	87.9	MLL:  60% of cells had a split signal pattern consistent with MLL rearrangement. On available metaphase cells, there was a distal signal on chromosome 10p and the proximal signal was close to the chromosome 11 centromere, consistent with t(10;11) and inv(11), as seen on chromosome analysis.	56	CD4, variable CD13, CD33, CD38, variable CD56, CD58,  CD64, dim CD71, dim CD117, dim CD123 and HLA-DR+	7.7	98.29	negative	0	negative	NA	NA	NA	NRAS (p.G12A; MAF 4%)|NRAS (p.Q61H; MAF 30%)	0	45.53593429	4
BA3318R	2593	BA3318D	Waves3+4	yes	yes	yes	yes	Female	Female	NA	NA	NA	2	NA	NA	83	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	83	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Alive	13	0	0.427104723	Alive	NA	80	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX,-15,+dic(1;15)(p11;p11)[10]/47,idem,+11[10]	NA	NA	67.5% of cells had an extra copy of MLL(11q23)	78	NA	NA	14.17	negative	0	negative	NA	NA	NA	IDH2 (p.172Arg>Lys)	0	0.427104723	4
BA3216R	2632	BA3216D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NA	NA	5	mono	NA	73	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	16	1	0.525667351	Dead-Disease	NA	85	79	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	44	NA	NA	123.2	positive	0.428571429	negative	NA	NA	NA	FLT3-ITD (suspicious for D835 as well)	1	0.525667351	4
BA3332R	2748	BA3332D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	7	NA	NA	26	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	26	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin	1	Induction	Complete Response	Standard Chemotherapy	8	Standard Chemotherapy	7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin	Induction	8	Alive	720	0	23.6550308	Alive	NA	41	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX	NA	NA	Normal	NA	CD117(+) myeloid precursors comprise 26% of total events and are positive for dim CD7, CD13, CD33, CD38, CD117, HLA-DR, and cyMPO.  They are negative for CD34.  	NA	NA	negative	0	positive	NA	NA	NA	NA	0	23.6550308	4
BA3214R	2820	BA3214D	Waves3+4	yes	yes	yes	yes	Female	Female	NA	NA	NA	7	NA	NA	NA	unknown	unknown	unknown	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Unknown	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Unknown	51	0	Unknown	Unknown	Bone Marrow Aspirate	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Unknown	0	0	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	NA	0	0	1
BA3099R	2224	BA3099D	Waves3+4	no	no	no	no	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	52	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	53	383	Post-Chemotherapy|Relapse	Relapse	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	5	MiDAC|Idarubicin and Cytarabine|FLAG-IDA plus Midostaurin|Azacitidine, Midostaurin, Ponatinib|7+3 (Cytarabine, Idarubicin) plus Dasatinib	4	Consolidation|Salvage|Induction|Maintenance	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Idarubicin and Cytarabine	Salvage	3	Dead	559	1	18.36550308	Dead-Disease	0	NA	78	0	0	14.9	7	10.5	0	40	99	2.3	0.43	M5	25.6	8.5	46,X,t(X;7)(q21;q32)[20]	NA	94.1	Normal	5	variable CD7, CD13, CD33, partial CD34, CD38, CD58,  CD117, CD123 and HLA-DR  (Immunophenotypic shift is noted from the prior leukemic blast  population.)	5.5	7.66	positive	13.28571429	positive	NA	NA	NA	DNMT3A (p.R882C; MAF 46%)|FLT3-ITD (MAF ~90%)|NPM1 (p.W288fs*12; MAF 44%)	1	18.36550308	4
BA3141R	2831	BA3141D	Waves3+4	yes	yes	yes	yes	Female	Female	NA	NA	NA	3	NA	NA	NA	unknown	unknown	unknown	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NA	0	Unknown	Unknown	Bone Marrow Aspirate	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Unknown	0	0	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	21.7	negative	0	negative	NA	NA	NA	NA	0	0	3
BA3373R	2680	BA3373D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	GATA2-MECOM	67	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	n	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	49	1	1.609856263	Dead-Unknown	0	70	88	2.6	0.9	14.8	0	3.5	0	21	24	3.2	0.81	M1	26.9	9.1	45,XX,t(3;3)(q21;q26),del(5)(q22q35),-7[20]	643	88.5	EGR-1/ D5S23, D5S721:  96/100 cells (96%) had a 1 red/ 2 green signal  pattern, reflecting a deleted 5q, consistent with the metaphase karyotype. | D7S522/ CEP 7:  98/100 cells (98%) had a 1 red/ 1 green signal pattern,  reflecting monosomy 7, consistent with the metaphase karyotype. | MECOM/ RPN1:  97/100 cells (97%) had a 1 red/ 1 green/ 2 yellow signal  pattern, reflecting MECOM/RPN1 fusion, consistent with the 3;3  translocation in the metaphase karyotype.	85	dim CD5, CD7,  partial CD11b, CD13, CD33, CD34, variable  CD38, variable CD56, CD58,  dim CD71, CD117, dim CD123, dim HLA-DR and MPO+	6.3	44.52	negative	0	negative	NA	NA	NA	DNMT3A (p.R882H; MAF 48%)|NRAS (p.Q61R; MAF 29%)|PTPN11 (p.E69K; MAF 9%)	1	1.609856263	1
BA3319R	2707	BA3319D	Waves3+4	yes	yes	yes	yes	Male	Male	Pacific Islander	NON-HISPANIC	NA	1	NA	CBFB-MYH11	22	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	22	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	106	Alive	1409	0	46.29158111	Alive	0	61	12	2.7	0	16.1	72.3	2.7	0.2	63	28	2.3	0.87	M4	24.1	8.2	46,XY,inv(16)(p13;q22)[20]	482	94.5	CBFB:   39% of cells had a 1r/1g/1f split signal pattern consistent with CBFB disruption and inv916), as seen on metaphase analysis.	50	Myeloid blast immunophenotype: CD13, CD33, CD34, CD38, CD58, CD117,  CD123, dim HLA-DR and MPO+  | Monocytic blast immunophenotype: CD11b, CD13, CD14, partial CD16, CD33,  dim CD34, CD38, CD58, CD64, CD117, dim CD123, HLA-DR and MPO+	7.3	99.89	negative	0	negative	NA	NA	NA	KIT (p.D816Y; MAF 6%)|NRAS (p.Q61H; MAF 32%)	0	46.29158111	2
BA3328R	2741	BA3328D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan|HiDAC|7+3 (Cytarabine, Idarubicin) plus Midostaurin	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Dead	167	1	5.486652977	Dead-Treatment	0	95	86	0	32	13	0	6	0.8	15	25	3.5	0.98	M1	25.2	8.5	46,XX[15]	563	93	Normal	60	dim CD13, CD33, CD38, partial CD56, CD58, CD64, dim CD117, CD123 and MPO+	7.4	59.23	positive	0.754385965	positive	NA	NA	NA	DNMT3A (p.R326L; MAF 47%)|FLT3-ITD (MAF 43%; mutant allelic ratio 0.74)|IDH2 (p.R140Q; MAF 47%)|NPM1 (p.W288fs*12; MAF 48%)	1	5.486652977	4
BA3339R	2742	BA3339D	Waves3+4	yes	yes	yes	yes	Female	Female	NA	NA	NA	3	NA	NA	NA	unknown	unknown	unknown	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	31	0	Unknown	Unknown	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Unknown	0	0	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	NA	0	0	4
BA3240R	2711	BA3240D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	BCR-ABL1	79	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	79	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Vyxeos (Daunorubicin, Cytarabine - liposomal)	1	Induction	Unknown	Standard Chemotherapy	-1	Standard Chemotherapy	Vyxeos (Daunorubicin, Cytarabine - liposomal)	Induction	-1	Dead	20	1	0.657084189	Dead-Disease	0	90	NA	0	0	2.9	1.5	1.4	0.1	25	29	2.9	1.02	M1	19.9	6.2	51~52,XX,+2,+6,add(7)(q31),+8,+9,+10,+15[cp14]/50~52,idem,del(19)(q11.2)[cp  5]/46,XX[1]	483	108.2	BCR/ABL/ASS: 72/100 cells had a variant abnormal fusion reflecting a single BCR/ABL fusion. The Philadelphia rearrangement was not visible in the metaphase karyotype  and is, thus, likely a cryptic rearrangement involving at least three chromosomes.    (Twenty-one cells (21%) had three signals for ASS and ABL with  no fusion signal.) | RUNX1T1:  89/100 cells (89%) had three signals, consistent with the trisomy  8 in the metaphase karyotype.  There was no evidence for RUNX1T1/RUNX1  fusion.  In addition, 80% of cells had three chromosome 8 centromere  signals, also consistent with trisomy 8. | DEK/NUP21:  96/100 cells (96%) had three signals for both probes,  consistent with trisomies 6 and 9 in the metaphase karyotype.  There was no evidence for DEK/NUP21 fusion | PML:  41/100 cells (41%) had three signals, consistent with the trisomy 15  in the metaphase karyotype.  Fifty-two cells (52%) had four PML signals –  the chromosomal context of the fourth signal was not apparent in the  metaphase karyotype.  There was no evidence for PML/RARA fusion.	126	CD13, variable CD34, CD38, dim CD58, CD117, CD123, HLA-DR and dim MPO+	6.1	130.45	negative	0	negative	NA	NA	NA	DNMT3A (p.R882C; MAF 64%)|FLT3 (p.D835H; MAF 5%)|IDH1 (p.R132L; MAF 54%)	1	0.657084189	3
BA3142R	2612	BA3142D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	54	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	54	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Other	3	7+3 (Cytarabine, Idarubicin)|Decitabine, MGB453|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Other	Decitabine, MGB453	Salvage	56	Dead	214	1	7.030800821	Dead-Disease	0	NA	65	1.8	0.9	41.7	1.7	14.8	0	71	50	3.7	1.13	M1	22.6	8.1	43,XY,add(5)(q11.2),add(9)(q12),add(10)(p11.2),-12,idic(12)(p11.2),t(14;14)  (q31;q32),-16,-17,add(17)(q21),add(19)(p13),-20,add(21)(p11.2),+mar[19]/46,  XY[1]	185	89.7	NA	23	CD13, dim CD33, CD34, CD38, CD117, dim CD123,  HLA-DR positive	7.6	8.94	negative	0	negative	NA	NA	TP53 (p.V216M; 78.5%)	TP53 (p.V216M; MAF 57%)	1	7.030800821	1
BA3333R	2746	BA3333D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NA	NA	5	NA	NA	NA	FALSE	FALSE	TRUE	FALSE	FALSE	y	Prostate Cancer	n	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NA	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	2	1	0.065708419	Dead-Disease	NA	93	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[20]	NA	NA	Normal	NA	NA	NA	NA	negative	0	positive	NA	NA	NA	FLT3-TKD (I836del; VAF 8%)|GATA2 (T358A;16%)|NPM1 (W288Cfs*12; VAF 46%)|SRSF2 (P95L; VAF 41%)|TET2 (A1344E; VAF 52%)|TET2 (R1440Tfs*38; VAF 47%)	1	0.065708419	4
BA3381R	2754	BA3381D	Waves3+4	yes	yes	yes	yes	Male	Male	Black	NON-HISPANIC	NA	1	NA	NA	51	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	HiDAC + Midostaurin|Fludarabine, TBI|Azacitidine|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Decitabine, Venetoclax	5	Consolidation|Induction|Allogeneic - Child|Maintenance|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine, Venetoclax	Re-induction	-1	Dead	486	1	15.96714579	Dead-Treatment	4.3	14	NA	0.9	6.1	7	25.2	52.2	0.6	19	34	3.4	1.36	M4	19.7	6.3	46,XY[20]	1116	106.5	Normal	17	CD13, CD33, CD34, CD38, CD58, dim CD71, CD117, dim CD123  and HLA-DR+	7.5	80.58	negative	0	negative	RUNX1 (p.F259Sfs*338; 18.3%)	ASXL1 (p.G646Wfs*12; 32.0%)	NA	ASXL1 (p.S1236A; MAF 51% )|CBL (p.R420Q, MAF 3%)|CBL (p.Y368_C372delinsP; MAF 9%)|DNMT3A (p.E616*; MAF 50%)|FLT3 (p.D835V; MAF 37%)|FLT3-ITD (Allelic Ratio = .03)|SF3B1 (p.K666N; MAF 47%)	1	15.96714579	4
BA3290R	2753	BA3290D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	66	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	67	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	2	Induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	Dead	232	1	7.622176591	Dead-Disease	0.9	17	22	7.1	8	38	7.1	22.1	0.3	43	30	2.9	1.04	M2	25	8.3	46,XY,del(12)(p11.2)[9]/46,XY[11]	287	94.7	Normal	16	dim partial CD7, CD13, CD33, CD34, dim CD38, CD58,  CD117, dim CD123, HLA-DR and partial TdT+	5.6	6.21	negative	0	negative	RUNX1 (p.D198N; MAF 6%)	ASXL1 (p.G646Wfs*12; 36.6%)	NA	RUNX1 (p.D198N; MAF 6%)|SF3B1 (p.K666N; MAF 45%)|SRSF2 (p.P95H; MAF 46%)	1	7.622176591	4
BA3207R	2641	BA3207D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	65	FALSE	FALSE	FALSE	FALSE	FALSE	y	Melanoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	y	y	y	y	y	y	2	Standard Chemotherapy|Intrathecal	2	7+3 (Cytarabine, Idarubicin)|Methotrexate	1	Induction	Complete Response	Standard Chemotherapy	-1	Intrathecal	Methotrexate	Induction	6	Dead	21	1	0.689938398	Dead-Disease	0	90	96	0	0	3.6	92.8	0.9	0.4	15	60	2.2	6.73	M4	19.7	6.6	46,XY[20]	2285	90.4	Normal	18	CD11b, variable CD14, CD15, CD33, CD38, variable CD56,  CD58, CD64, CD123, HLA-DR, variable MPO	5.9	89.55	negative	0	negative	RUNX1 (p.F396Vfs*204; 55.4%)	ASXL1 (p.G646Wfs*12; 35.0%)	NA	IDH1 (p.R132H; MAF 46%)|MLL (Partial tandem duplication )|NRAS (p.Q61R; MAF 45%)|RUNX1 (p.F396fs*204; MAF 46%)|SRSF2 (p.P95L; MAF 28%)	1	0.689938398	4
BA3296R	2684	BA3296D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	18	FALSE	FALSE	FALSE	FALSE	FALSE	y	B lymphoblastic leukaemia/lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid sarcoma	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid sarcoma	18	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy|Post-Transplant	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Other	3	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|Radiation	2	Re-induction|Allogeneic - Matched Unrelated Donor	NA	NA	NA	Bone Marrow Transplant	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)	Allogeneic - Matched Unrelated Donor	-1	Dead	336	1	11.03901437	Dead-Treatment	0.6	0.5	0	0.4	NA	15.6	6.3	75.6	0	32	27	4.6	0.78	NA	44	15.5	46,XY[20]	NA	89.4	MLL (11q23):   88% of cells had a 0r1g1f split signal pattern consistent with rearrangement|9p21: 76% of cells were missing both signals for 9p21, consistent with homozygous deletion of 9p21|ETV6 (12p13): 68% of cells had an extra signal for ETV6 (Solid Tissue/Skin)	291	CD43, CD68, CD163 (weak) and lysozyme positive (Solid Tissue/Skin)	7.5	13.67	negative	0	negative	NA	NA	NA	EP300 (p.P318A (possible germline polymorphism); MAF 41%)|FAM5C (p.R353C (possible germline polymorphism); MAF 44%)|NOTCH2 (p.E366V; MAF 65%)|PHF6 (p.T12fs*23 (5 bp insertion with frame-shift); MAF 40%)|PTPN11 (p.D61V (confirmed somatic); MAF 39%) (Solid Tissue/Skin)	1	11.03901437	4
BA3305R	2634	BA3305D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NA	NA	5	NA	NA	84	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	84	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Venetoclax (ABT-199), Azacitidine	1	Induction	Complete Response	Standard Chemotherapy	344	Standard Chemotherapy	Venetoclax (ABT-199), Azacitidine	Induction	344	Dead	394	1	12.94455852	Dead-Disease	NA	90	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	47,XY,+8[12]/47,XY,+15[8]/46,XY[5]	NA	NA	Gain of 8q22 and 15q22 sequences	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	IDH2 (R140Q; VAF 51%)|NRAS (Q61K; VAF 27%)|SMC1A (E687*; VAF 64%)|SMC1A (R807H; VAF 13%)|SRSF2 (P95R; VAF 38%)	1	12.94455852	4
BA3434R	2651	BA3434D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	78	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	78	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Lenalidomide|Azacitidine	2	Experimental|Supportive/Palliative Care	NA	NA	NA	Standard Chemotherapy	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Experimental	0	Dead	79	1	2.595482546	Dead-Disease	NA	35	23	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M2	NA	NA	46,XX,del(9)(q22q22)[20]	NA	NA	With the TP53 probe set, 7/200 cells (3.5%) were missing a TP53  signal, within normal limits, but also this patient's previous abnormal  pattern.  	NA	CD13, CD33, CD34, CD38, CD58, CD117, HLA-DR, partial  MPO	NA	NA	negative	0	negative	RUNX1 (p.T196Dfs*17; 40.6%)|RUNX1 (p.X20_splice; 49.2%)	NA	NA	DNMT3A (p.A644fs*7; MAF 37%)|ETV6 (p.L205fs*12; MAF 30%)|IKZF1 (p.N159S; MAF 35%)|NRAS (p.Q61H; MAF 31%)|RUNX1 (c.58+2T>C, Donor-splice-site mutation in intron 1; MAF 46%)|RUNX1 (p.T196fs*17; MAF 46%)|SF3B1 (p.K700E; MAF 51%)	1	2.595482546	1
BA3189R	2676	BA3189D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	20	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	20	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	4	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	5	Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|7+3 (Cytarabine, Daunorubicin) plus Midostaurin|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Induction|Re-induction|Maintenance	Refractory	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Maintenance	317	Alive	1356	0	44.55030801	Alive	0	80	75	0.9	NA	11.3	0	11.3	0.1	16	17	2.5	0.77	M2	24.6	8.3	46,XY,del(2)(q11.2q21)[3]	NA	98.4	Normal	102	CD13, CD33, CD34, CD38, CD58, dim CD64, CD117,  variable MPO	7	34.16	positive	1	negative	NA	NA	NA	FLT3-ITD (p.E608delinsDPVDFREYEYDLKWEFPRE; p.E598delinsDLSYVDFREYE;  ratio: ~1.0; Two visible FLT3 ITD insertions, one  of ~ 10 amino acids (predominating, with a high mutant allele ratio) and  one of ~18 amino acids (smaller sub-clone).)	0	44.55030801	4
BA3264R	2603	BA3264D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	PML-RARA	41	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	41	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	ATRA, Arsenic Trioxide, Idarubicin|ATRA, Arsenic Trioxide	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	26	Standard Chemotherapy	ATRA, Arsenic Trioxide	Consolidation	200	Alive	1253	0	41.16632444	Alive	0	72	86	0	NA	14.3	4.4	2.7	0.1	87	65	4.1	0.84	M3	36.5	13.5	46,XY,t(15;17)(q24;q21)[20]	588	81.5	PML/RARA (92% of  cells had the dual fusion signal pattern consistent with PML/RARA fusion and t(15;17).)	55	partial CD11b, CD13, CD33, CD34, CD38, CD58, variable  CD64, CD117, CD123, partial HLA-DR and bright MPO	7.8	39.57	positive	1.127659574	negative	NA	NA	NA	FLT3-ITD (Mutant Allele Ratio:  0.85)	0	41.16632444	3
BA3329R	2715	BA3329D	Waves3+4	yes	yes	yes	yes	Male	Male	NA	HISPANIC	NA	5	mono	NA	77	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	77	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	Venetoclax (ABT-199), Azacitidine|Azacitidine	2	Induction|Maintenance	Refractory	Standard Chemotherapy	36	Standard Chemotherapy	Venetoclax (ABT-199), Azacitidine	Induction	36	Dead	113	1	3.712525667	Dead-Disease	NA	22	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY,inv(4)(p14q21)[9]/47,sl,+8[2]/46,XY[10] 	NA	NA	Gain of chromosome 8 (trisomy)	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	CEBPA (P189dup; VAF 30%)|ETV6 (N228S; VAF 52%)|SRSF2 (P95R; VAF 18%)|STAG2 (VAF 34%)|TET2 (Q745*; VAF 23%)	1	3.712525667	1
BA3417R	2600	BA3417D	Waves3+4	yes	yes	yes	yes	Female	Female	NA	NA	NA	3	NA	BCR-ABL1	NA	unknown	unknown	unknown	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Unknown	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Unknown	50	0	Unknown	Unknown	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Unknown	0	0	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	NA	0	0	1
BA3367R	2730	BA3367D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NA	NA	3	NA	NA	NA	unknown	unknown	unknown	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Unknown	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Unknown	34	0	Unknown	Unknown	Bone Marrow Aspirate	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Unknown	0	0	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	NA	0	0	4
BA3225R	2658	BA3225D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	UNKNOWN	Standard Chemotherapy	4	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	4	Dead	16	1	0.525667351	Dead-Disease	NA	85	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5	NA	NA	NA	NA	NA	Normal	NA	Monocytic blast immunophenotype (75%):  CD11b, CD13, CD14, CD33, CD38, CD58, CD64, dim CD117, CD123, and dim HLA-DR+. | Myeloid blast immunophenotype (13%): dim CD13, CD33, CD38, CD58 dim CD117, dim CD123 and MPO+.           | Monoclonal plasma cell population immunophenotype (approximately10% involvement): CD138 and kappa+.	NA	NA	negative	0	positive	NA	NA	NA	GNA13 (p.T365S; MAF 46%)|NPM1 (p.W288fs*12; MAF 43%)|PHF6 (c.730-2A>G, Acceptor-splice-site mutation in intron 6; MAF 89%)|TET2 (c.3594+1G>T, Donor-splice-site mutation in intron 3; MAF 46%)|TET2 (p.D1242fs*11; MAF 42%)	1	0.525667351	4
BA3183R	2798	BA3183D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	64	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	64	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	Fludarabine, Melphalan|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	4	Consolidation|Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Dead	337	1	11.07186858	Dead-Treatment	0	51	65	0.9	NA	12.3	3.5	15.8	0.1	20	13	2.6	1.2	NA	24.4	8.2	46,XY[20]	NA	103	Normal	46	CD13, CD33, CD38, CD58, CD117, CD123, partial MPO+	6.5	15.38	negative	0	positive	NA	NA	NA	ATM (p.H1136R; MAF 45%)|DNMT3A (p.R882H; MAF 46%)|IDH1 (p.R132H; MAF 27%)|IDH2 (p.D314V (Low allele frequency, subclonal), MAF 2%)|IDH2 (p.R140Q; MAF 18%)|KRAS (p.G12A; MAF 3%)|NPM1 (p.W288fs*12; MAF 49%)|U2AF1 (p.D208E; MAF 46%)	1	11.07186858	4
BA3222R	2617	BA3222D	Waves3+4	no	no	no	no	Male	Male	White	NON-HISPANIC	NA	1	NA	KMT2A_re	21	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	22	267	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Intrathecal	6	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Venetoclax (ABT-199), Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Methotrexate	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	4	Standard Chemotherapy	Venetoclax (ABT-199), Azacitidine	Salvage	26	Dead	316	1	10.38193018	Dead-Disease	0	43	0	1.7	NA	13.3	13.3	70	0	41	26	3.5	0.9	M5	25.4	8.5	49,XY,del(4)(q21),add(6)(q27),-17,add(19)(p13.3),+mar1X2,+mar2,+mar3 [cp13]/49,XY,add(4)(q21),-6,+8,+mar1X2,+mar4[cp6]/46,XY[1]	229	85.2	51% had an abnormal signal pattern, reflecting the trisomy 8 in the metaphase karyotype and previously observed.  There was no evidence for RUNX1T1/RUNX1 fusion.  | 61% had a variant abnormal signal pattern, reflecting MLL rearrangement and previously observed.  | 72% had an abnormal signal pattern, reflecting extra copies of MECOM (3q26.2) and gain of 3q, previously observed.  Metaphase FISH shows the extra signals to be on  two markers.  There was no evidence for MECOM/RPN1 fusion.	57	dim CD4, CD13, CD33, CD34, dim CD56, CD64, HLA-DR+	5.7	0.6	negative	0	negative	NA	NA	NA	KRAS (p.G13R; MAF 24%)|U2AF1 (p.S34F; MAF 24%)	1	10.38193018	4
BA3139R	2618	BA3139D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	30	TRUE	FALSE	TRUE	FALSE	FALSE	y	Dyskeratosis congenita	y	n	y	y	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Unknown	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	31	504	Post-Chemotherapy|Post-Transplant|Relapse	Relapse	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine|Fludarabine, Cytarabine	4	Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Fludarabine, Cytarabine	Re-induction	5	Dead	475	1	15.60574949	Dead-Disease	0	87	NA	0	NA	10.4	3.5	1.7	0.4	23	29	3.3	0.77	NA	23.8	8	40~42,X,-Y,dic(5;12)(q13;p11.2),del(7)(q22q36),add(9)(q31),add(13)(q22),ins(?;14)(?;q11.2),-15,add(15)(p11.2),del(16)(q11.1),-17,-18,add(19)(q13.4),-20,der(21)t(3;21)(q22.3;q13),+mar[cp12]/40~41,sl,add(2)(q31)[cp7]/46,XY[1]	532	102.1	84.5% of cells were missing a signal for EGR1, consistent with 5q deletion, and as seen previously.	36	NA	6.2	19.23	negative	0	negative	NA	NA	TP53 (p.M340Cfs*5; 41.0%)|TP53 (p.R273H; 47.8%)	BCL6 (p.C475R; VAF 6%)|TP53 (p.M340fs*5; MAF 42%)|TP53 (p.R273H; MAF 47%)	1	15.60574949	2
BA3397R	2674	BA3397D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	79	FALSE	FALSE	FALSE	FALSE	FALSE	y	Prostate Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	79	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	54	1	1.77412731	Dead-Disease	0	60	74	0	NA	10.7	22.9	9	0.4	22	27	2.2	1.36	M2	27.9	9.2	44,XY,-3,-5,dic(10;12)(q26;p13),add(11)(p15),-17,+mar[20]	219	97.9	ETV6 (12p13): 93.5% of cells were missing a signal for ETV6, consistent with 12p deletion resulting from dic(10;12).  | CEP17: 98.5% of cells were missing a signal for CEP17, consistent with monosomy 17.  | PML/RARA: 189/200 cells (94.5%) were missing a signal for RARA (17q21.2).	92	CD13, CD33, CD34, variable CD38, CD117, CD123, HLA-DR, partial MPO	6.3	13.72	negative	0	negative	NA	NA	TP53 (p.L194R; 86.6%)	TP53 (p.L194R; MAF 80%)	1	1.77412731	1
BA3311R	2720	BA3311D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	74	FALSE	FALSE	TRUE	FALSE	FALSE	y	Prostate Cancer	y	y	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	74	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Induction	Unknown	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine	Induction	6	Dead	24	1	0.788501027	Dead-Disease	NA	21	8	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M2	NA	NA	48,XY,+11,+13[17]/46,XY[3]	NA	NA	MLL (11q23):  161/200 cells (80.5%) had three intact signals for MLL, consistent with the trisomy 11 seen on metaphase analysis.	NA	CD13, CD33, CD34, variable CD38, partial CD64, CD117, dim CD123, HLA-DR, partial TdT.	NA	NA	negative	0	negative	NA	NA	NA	CBLB (p.V581M; MAF 52%)|DNMT3A (p.V877fs*4; MAF 40%)|MLL (Partial tandem duplication (exon 9/exon 3) )|NRAS (p.G12D; MAF 14%)|U2AF1 (p.S34F; MAF 43%)|WT1 (p.R353fs*15; MAF 26%)|WT1 (p.S364*; MAF 25%)	1	0.788501027	4
BA3422R	2636	BA3422D	Waves3+4	yes	yes	yes	yes	Female	Female	Black	NA	NA	5	NA	NA	72	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Venetoclax (ABT-199), Azacitidine	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Venetoclax (ABT-199), Azacitidine	Induction	-1	Alive	521	0	17.11704312	Alive	NA	97	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX[20]	NA	NA	Normal	NA	NA	NA	NA	negative	0	positive	NA	NA	NA	GATA2 (A372T; VAF 48%)|NPM1 (W288Cfs*12; VAF 39%)|TET2 ( E843*; VAF 47%)|TET2 (T1726Lfs*19; VAF 51%)	0	17.11704312	3
BA3228R	2717	BA3228D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	68	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	69	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	Azacitidine|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Cytarabine, Midostaurin	3	Induction|Re-induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	11	Standard Chemotherapy	Cytarabine, Midostaurin	Re-induction	-1	Alive	494	0	16.22997947	Alive	2.1	NA	NA	0	NA	6.2	29.4	3.4	1.1	NA	NA	NA	0.99	NA	24.8	7.8	46,XX,i(14)(q10)[8]/46,XX[12]	1036	91.5	IGH (14q32) breakapart probe set, as listed  below.  4/200 interphase cells had three intact signals, but one abnormal  metaphase was found, which had an IGH signal on either end of the  i(14)(q10).	482	NA	NA	105.01	positive	NA	negative	RUNX1 (p.R320*; 49.8%)	NA	NA	NA	0	16.22997947	4
BA3213R	2817	BA3213D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NA	NA	5	NA	CBFB-MYH11	50	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	50	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin) plus Gemtuzumab Ozogamicin	1	Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin) plus Gemtuzumab Ozogamicin	Induction	7	Alive	536	0	17.60985626	Alive	NA	73	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY,inv(16)(p13.1q22)[18]/47,sl,+9[2]	NA	NA	Positive for a CBFB rearrangement	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	CBL (L399V; VAF 50%)|KIT (N587_R588ins16; VAF 34%)	0	17.60985626	2
BA3270R	2814	BA3270D	Waves3+4	yes	yes	yes	yes	Female	Female	White	DECLINED	NA	1	NA	NA	47	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	HiDAC	Consolidation	100	Alive	432	0	14.19301848	Alive	0	18	9	0	NA	13.3	16.8	46	0.6	16	23	2.7	0.7	NA	23.4	7.4	46,XX[20	470	98.7	Normal	189	NA	6.1	65.11	negative	0	positive	NA	NA	NA	DNMT3A (p.R882C; MAF 46%)|NPM1 (p.W288fs*12; MAF 48%)|NRAS (p.G12D; MAF 46%)	0	14.19301848	4
BA3415R	2825	BA3415D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	79	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	79	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	14	1	0.459958932	Dead-Disease	0	65	15	0	NA	25.2	0.9	24.3	1.7	NA	NA	NA	NA	M2	23.9	8.3	49~50,XX,+X,-3,del(5)(q13q33),der(7)t(3;7)(q11.2;q21),+8,-9,  del(17)(p11.2),+18,+21,der(21)t(9;21)(q22;q22)X2,+22,+1~2mar[cp20]	NA	92.6	EGR-1/ D5S23, D5S721:  97/100 cells (97%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the metaphase karyotype.  | CEP 8:  179/200 cells (89.5%) had three signals, consistent with the trisomy 8 in the metaphase karyotype.  | RUNX1T1/RUNX1:  92/100 cells (92%) had a 3 red/ 3 green signal pattern, reflecting the extra copies of chromosome 8 and chromosome 21 in the metaphase karyotype.  There was no evidence for RUNX1T1/RUNX1 fusion.  | BCR/ABL:  95/100 cells (95%) had a 3 red/ 2-3 green signal pattern, reflecting the extra copies of chromosome 9q and chromosome 22 in the metaphase karyotype.  There was no evidence for BCR/ABL fusion. | DEK/NUP214:  184/200 cells (92%) had a 3 red/ 2 green signal pattern, reflecting an extra copy of NUP214 (9q34),consistent with the extra chromosome 9q material in the metaphase karyotype.  There was no evidence for DEK/NUP214 fusion.  | TP53/CEP 17:  93/100 cells (93%) had a 1 red/ 2 green signal pattern, reflecting TP53 deletion and consistent with the deleted chromosome 17 short arm in the metaphase karyotype.	31	partial CD7, CD13, CD33, CD34, CD38, CD56,  CD117, HLA-DR, MPO	NA	11.5	negative	0	negative	NA	NA	TP53 (p.R196*; 89.6%)	CBL (p.L209V; MAF 92%)|FLT3 (p.L198F; MAF 52%)|TP53 (p.R196*; MAF 80%)	1	0.459958932	1
BA3324R	2625	BA3324D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	60	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	Decitabine, MGB453|7+3 (Cytarabine, Idarubicin) plus Sorafenib	2	Induction|Re-induction	Complete Response	Standard Chemotherapy	15	Standard Chemotherapy	Decitabine, MGB453	Re-induction	84	Dead	200	1	6.570841889	Dead-Disease	0	85	72	0.9	NA	14.6	32.8	4.3	0.1	12	37	2.5	1.2	M1	27.5	9.1	46,XY,del(5)(q13q34),add(7)(q11.2),+11,add(12)(p13),-16, add(17)(p11.2)[cp17]/46,idem,add(4)(q35)[4]	1498	107.4	EGR-1/ D5S23, D5S721:  193/200 cells (96.5%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the metaphase karyotype.  | D7S522/ CEP 7:  191/200 cells (95.5%) had a 1 red/ 2 green signal pattern, indicating deleted 7q, consistent with the metaphase karyotype.  | MLL:  150/200 cells (75%) had three intact signals, consistent with the trisomy 11 in the metaphase karyotype. An additional 18 cells (9%) had four intact MLL signals.  There was no evidence for MLL rearrangement.  | CBFB:  195/200 cells (97.5%) had a single intact signal, consistent with the monosomy 16 in the metaphase karyotype.  There was no evidence for CBFB rearrangement.	133	variable CD4, dim CD7, dim CD11b, CD13, variable CD14, variable CD15, CD33, variable CD34, CD38, dim CD56, partial CD64, CD117, HLA-DR, MPO positive.	7.1	62.69	negative	0	negative	NA	NA	TP53 (p.L194R; 88.3%)	PTPN11 (p.S502P; MAF 34%)|TP53 (p.L194R; MAF 87%)	1	6.570841889	1
BA3194R	2757	BA3194D	Waves3+4	yes	yes	yes	no	Male	Male	NA	NA	NA	3	mono	NA	NA	unknown	unknown	unknown	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NA	9	Unknown	Unknown	Peripheral Blood	y	y	n	y	y	n	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Unknown	0	0	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	16.24	negative	0	negative	NA	NA	NA	NA	0	0	2
BA3335R	2602	BA3335D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NA	NA	5	NA	NA	56	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	56	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Venetoclax (ABT-199), Azacitidine	1	Induction	Refractory	Standard Chemotherapy	30	Standard Chemotherapy	Venetoclax (ABT-199), Azacitidine	Induction	30	Alive	514	0	16.88706366	Alive	NA	80	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XX[22]	NA	NA	Normal	NA	NA	NA	NA	positive	NA	positive	NA	NA	NA	DNMT3A (P38SRfs*22; VAF 22%)|FLT3-ITD|GATA2 (T354_T355 insF; VAF 15%)	0	16.88706366	3
BA3199R	2724	BA3199D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NA	NA	5	mono	NA	69	FALSE	FALSE	FALSE	FALSE	FALSE	y	Prostate Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	7	Dead	156	1	5.125256674	Dead-Disease	NA	94	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[19] 	NA	NA	Normal	NA	NA	NA	NA	negative	0	negative	RUNX1 (p.X269_splice; 48.1%)	ASXL1 (p.K618_A619ins*; 43.5%)	NA	ASXL1 (A619*; VAF 47%)|CEBPA (H24Afs*84; VAF 44%)|CEBPA (R165Afs*153; VAF 48%)|RUNX1 (VAF 45%)|SRSF2 (P95H; VAF 53%)|TET2 (S1486*; VAF 48%)	1	5.125256674	2
BA3326R	2797	BA3326D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NA	NA	5	NA	NA	63	FALSE	FALSE	FALSE	FALSE	FALSE	y	Prostate Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Venetoclax (ABT-199), Azacitidine	1	Induction	Refractory	Standard Chemotherapy	29	Standard Chemotherapy	Venetoclax (ABT-199), Azacitidine	Induction	29	Dead	52	1	1.708418891	Dead-Disease	NA	59	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	47,XY,+6[4]/49,sl,+6,+22[2]/49,sl,+4,+8,i(8)(q10)x2[5]/47,XY,+r[2]/46,XY[7]	NA	NA	Gain of 8q22, 8 centromere and 16q22 sequences	NA	NA	NA	NA	negative	0	negative	NA	ASXL1 (p.G646Wfs*12; 36.6%)	NA	ASXL1 (G64Wfs*12; VAF 39%)|NRAS (Q61K; VAF 33%)|TET2 (Q892*; VAF 49%)	1	1.708418891	4
BA3285R	2618	BA3285D	Waves3+4	no	no	no	no	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	30	FALSE	FALSE	TRUE	FALSE	FALSE	y	Dyskeratosis congenita	y	n	y	y	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Unknown	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	31	573	Post-Chemotherapy|Post-Transplant|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine|Fludarabine, Cytarabine	4	Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Fludarabine, Cytarabine	Re-induction	5	Dead	475	1	15.60574949	Dead-Disease	1.8	NA	NA	1.8	NA	14.7	8.3	0	0	65	64	2.2	0.77	NA	22.9	7.5	39~41,X,-Y,dic(5;12)(q13;p11.2),del(7)(q22q36),add(9)(q31),add(13)(q22),ins(?;14)(?;q11.2),-15,add(15)(p11.2),del(16)(q11.1),-17,-18.add(19)(q13.4),-20,der(21)t(3;21)(q22.3;q13)[cp16]/46,XY[5]	NA	90.5	84.5% of cells were missing a signal for EGR1, consistent with 5q deletion, and as seen previously.	9	NA	5.2	10.63	negative	0	negative	NA	NA	TP53 (p.M340Cfs*5; 50.0%)|TP53 (p.R273H; 42.2%)	NA	1	15.60574949	2
BA3297R	2657	BA3297D	Waves3+4	yes	yes	yes	yes	Female	Female	Asian	NON-HISPANIC	NA	1	NA	NA	46	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	46	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	102	Alive	1159	0	38.07802875	Alive	0	81	84	0	NA	12.1	16.1	8.9	0.2	45	29	2.9	0.41	M2	30	9.9	46,XX[20]	NA	95.2	Normal	220	dim CD13, CD33, CD38, CD117 and MPO+	7.4	61.13	negative	0	positive	NA	NA	NA	IDH2 (p.R140Q; VAF 46%)|NPM1 (p.W288fs*12; VAF 40%)	0	38.07802875	4
BA3227R	2650	BA3227D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	70	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	70	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	4	MIDAC, Midostaurin|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Methotrexate|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Allogeneic - Sibling|Consolidation|Induction	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	-1	Alive	1188	0	39.03080082	Alive	0	95	96	0	NA	2.7	0	0	0.2	163	68	3.1	0.78	M1	16.8	5.6	46,XX[20]	469	106.3	Normal	45	dim CD13, CD33, CD38, CD117, and MPO +	7.6	159.73	positive	0.149425287	positive	NA	NA	NA	ATM (p.K1454N; VAF 49%)|BCL6 (p.A321V; VAF 49%)|FLT3-ITD (Allelic ratio: 0.32)|IDH2 (p.R140Q; VAF 49%)|NOTCH2 (p.P2377L; VAF 48%)|NPM1 (p.W288fs*12; VAF 69%)|NRAS (p.A59T; VAS 3%)	0	39.03080082	3
BA3394R	2653	BA3394D	Waves3+4	yes	yes	yes	yes	Male	Male	NA	NA	NA	3	NA	NA	NA	unknown	unknown	unknown	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Unknown	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Unknown	NA	0	Unknown	Unknown	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Unknown	0	0	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	12	negative	0	negative	NA	NA	NA	NA	0	0	1
BA3412R	2833	BA3412D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	74	FALSE	FALSE	FALSE	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	74	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Vidaza, BI836858 (anti-CD33)	1	Induction	Refractory	Standard Chemotherapy	90	Standard Chemotherapy	Vidaza, BI836858 (anti-CD33)	Induction	90	Dead	149	1	4.895277207	Dead-Disease	NA	81	85	NA	NA	NA	NA	NA	NA	13	23	2.5	1.1	M5	19.7	6.3	46,XX,t(8;16)(p11.2;p13.3)[19] /46,XX[1]	1017	102.6	Normal	111	dim CD4, dim CD11b, CD15, bright CD33, CD38, variable CD56, bright CD64, partial CD117, HLA-DR, MPO, and dim TdT+	5.4	43.06	negative	0	negative	NA	NA	NA	KMT2D (p.R1918C; VAF 50%)|PTPN11 (p.S502P; VAF 41%)	1	4.895277207	4
BA3293R	2685	BA3293D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	53	TRUE	FALSE	FALSE	FALSE	FALSE	y	Cervical Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	55	0	Relapse|Post-Chemotherapy|Post-Transplant	Relapse	Leukapheresis	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	-1	Dead	835	1	27.43326489	Dead-Disease	NA	NA	90	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M4	27.2	8.8	46,XX[20]	NA	97.5	NA	34	variable CD11b, CD13, CD33, dim CD123, partial HLA-DR, dim/partial MPO	NA	43.57	positive	11.5	positive	NA	NA	NA	NA	1	27.43326489	3
BA3250R	2718	BA3250D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	CBFB-MYH11	58	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	58	2	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	UNKNOWN	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	Dead	22	1	0.722792608	Dead-Disease	NA	82	63	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M4	22	7.4	46,XY,inv(16)(p13q22)[20]	NA	98.7	CBFB/MYH11:  165/200 cells (82.5%) had the abnormal 1 red/ 1 green/ 2 yellow signal pattern, reflecting CBFB/MYH11 fusion and consistent with the inverted chromosome 16 observed in the metaphase karyotype.	29	Myeloid blasts: CD13, CD33, CD34,  CD117, HLA-DR+ | Promonocytic/ monocytic population (56%): variable CD13, variable CD14, partial CD16, CD33, CD64, HLA-DR+	NA	26.58	negative	0	negative	NA	NA	NA	CARD11 (p.N191S; VAF 45%)|KRAS (p.G12V; VAF 4%)	1	0.722792608	2
BA3177R	2793	BA3177D	Waves3+4	yes	yes	yes	yes	Male	Male	Unknown	UNKNOWN	NA	1	NA	CBFB-MYH11	66	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	1	1	0.032854209	Dead-Disease	0	NA	82	0.9	NA	17.4	7.8	1.7	0	76	125	2.8	2.11	NA	15.8	5.6	NA	3316	94.6	NA	57	partial CD1a, CD13, variable CD14, CD33, CD34, CD38, dim CD117, HLA-DR and cMPO	5.5	310.71	negative	0	negative	NA	NA	NA	NA	1	0.032854209	2
BA3315R	2812	BA3315D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	57	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	57	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	3	Salvage|Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Salvage	0	Dead	127	1	4.1724846	Dead-Disease	0	83	12	0.9	NA	69.9	0.9	8.8	7.1	72	49	3.2	0.9	M1	21.5	6.9	69~82<3n>,X,-X,+4,+8,+8,+8,+8,+8,+8,-9,+10,-12,-15,-17,+18,+20,+21,+22,+1~2mar[cp13]/47~48,X,-X,+4,+6,+8,+8,-9,-16,-17,+mar[cp3]/92,XXXX[2]/46,XX[2]	1498	89.2	BCR/ABL: 38% of cells had three signals for BCR and another 18% of cells had three signals for BCR and for ABL/ASS.  | PML/RARA: 6% of cells had three signals for both probes.	32	MPO, CD33, CD43, CD45, and CD117 positive	6.1	3.65	negative	0	negative	NA	NA	TP53 (p.V143M; 44.0%)	BCL6 (p.R459C; VAF 44%)|IDH2 (p.R172K; VAF 14%)|NRAS (p.Q61K; VAF 12%)|TP53 (p.V143M; VAF 32%)	1	4.1724846	1
BA3182R	2804	BA3182D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	CBFB-MYH11	30	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	30	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Intrathecal	4	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA, Gemtuzumab|Methotrexate	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	38	Alive	1076	0	35.35112936	Alive	NA	80	75	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M2	17.5	5.7	46,XY,del(7)(q32q36),inv(16)(p13.1q22)[20]	NA	100.6	CBFB/MYH11: 90% of cells had a 1r1g2f dual-fusion signal pattern consistent with CBFB/MYH11 fusion and inv(16).	14	Myeloid blast immunophenotype: CD13, CD33, CD34, CD117, HLA-DR, MPO positive | Aberrant monocytoid population with variable CD14, CD15, and CD64 expression	NA	41.42	negative	0	negative	NA	NA	NA	No clinically significant variants identified	0	35.35112936	2
BA3260R	2806	BA3260D	Waves3+4	no	no	no	no	Male	Male	White	NA	NA	5	NA	NA	72	FALSE	FALSE	FALSE	TRUE	FALSE	n	NA	n	n	y	y	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Refractory cytopenia with multilineage dysplasia	NonAML	MYELODYSPLASTIC SYNDROMES	Refractory cytopenia with multilineage dysplasia	72	0	NA	NA	Bone Marrow Aspirate	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	308	1	10.11909651	Dead-Disease	NA	2	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XY[20]	NA	NA	Normal	NA	NA	NA	NA	negative	0	negative	NA	ASXL1 (p.G646Wfs*12; 36.2%)	NA	ASXL1 (G646Wfs*12; VAF 41%)|BRAF (G469A; VAF 50%)|ETV6 (VAF 48%)|KRAS (Y64N; VAF 10%)|SRSF2 (P95H; VAF 45%)	1	10.11909651	4
BA3369R	2621	BA3369D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	CBFB-MYH11	73	FALSE	FALSE	FALSE	FALSE	FALSE	y	Melanoma	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	10	1	0.328542094	Dead-Unknown	NA	NA	80	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M4	27.5	9	46,XY,inv(16)(p13.1q22)[cp20]	NA	102.6	CBFB/MYH11: 93/100 cells (93%) had the abnormal 1 red/ 1 green/ 2 yellow signal pattern, reflecting CBFB/MYH11 fusion, consistent with the metaphase karyotype and the diagnosis of AML.	96	Myeloid blasts: CD13, CD33, CD34, dimCD38, CD117, dim HLA-DR, and MPO. | Promonocytes/monocytes: dimCD4, CD11b, bright CD13, variable CD14, bright CD33, CD64, variable HLA-DR positive	NA	21.23	negative	0	negative	NA	NA	NA	EP300 (p.S1033L; VAF 50%)|FLT3-TKD (p.D835V; VAF 26%)|KRAS (p.G12V; VAF 19%)|WT1 (p.T225M; VAF 50%)	1	0.328542094	2
BA3078R	2737	BA3078D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	68	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	y	y	y	y	y	y	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	1	Induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	7+3 (Cytarabine, Idarubicin)	Induction	6	Dead	24	1	0.788501027	Dead-Disease	NA	74	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M0	19.9	6.8	46,XY[20]	NA	102.1	Normal	64	dimCD2, partial CD7, dimCD13, CD34, CD38, CD117, HLA-DR	NA	38.83	negative	0	negative	NA	NA	NA	NA	1	0.788501027	2
BA3386R	2654	BA3386D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	y	y	y	y	y	y	4	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	5	Fludarabine, Melphalan|Gilteritinib or Placebo|MIDAC, Midostaurin|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Methotrexate	5	Consolidation|Induction|CNS|Maintenance|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Gilteritinib or Placebo	Maintenance	734	Alive	1046	0	34.36550308	Alive	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M1	27.9	9.2	46,XX[20]	NA	87.2	NA	135	dim CD7, partial CD11b, dim CD13, variable CD25, CD33, partial CD34, CD117, HLA-DR, and MPO positive	NA	40.36	positive	32.33333333	positive	NA	NA	NA	DNMT3A (p.G543C; VAF 49%)|FLT3-ITD (VAF 76%; VAR 13.3)|NPM1 (p.W288fs*12; VAF 45%)	0	34.36550308	3
BA3445R	2786	BA3445D	Waves3+4	yes	yes	yes	yes	Male	Male	NA	NA	NA	3	NA	NA	NA	unknown	unknown	unknown	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Unknown	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Unknown	NA	0	Unknown	Unknown	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Unknown	0	0	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	NA	0	0	4
BA3452R	2835	BA3452D	Waves3+4	no	no	no	no	Female	Female	White	NA	NA	2	NA	NA	56	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	64	455	Relapse	Relapse	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	4	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine, Trametinib	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine, Trametinib	Salvage	-1	Alive	2929	0	96.22997947	Alive	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	46,XXder(22)t(1;22)(q12;p11.2)[1]/46,XX[19]	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	RUNX1 (p.S100Lfs*38; 47.8%)	NA	NA	NA	0	96.22997947	2
BA3176R	2765	BA3176D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	53	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	HiDAC|Vyxeos (Daunorubicin, Cytarabine - liposomal)|MEC (Cytarabine, Etoposide, Mitoxantrone) plus Midostaurin	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	4	Standard Chemotherapy	MEC (Cytarabine, Etoposide, Mitoxantrone) plus Midostaurin	Salvage	-1	Dead	326	1	10.71047228	Dead-Disease	0	34	0	0.5	NA	46.5	2.7	50.3	0	10	11	3.3	0.63	M2	23.4	8.2	47,XX,+4[3]/46,XX[17]	NA	104.9	Normal	40	dim CD7, CD13, CD33, CD38, CD117 and HLA-DR+	7	1.87	negative	0	positive	NA	NA	NA	DNMT3A (p.N879D; VAF 37%)|NPM1 (p.W288fs*12; VAF 28%)|PTPN11 (p.A461T; VAF 3%)|RAD21 (p.E534*; VAF 4%)|SMC1A (p.R496H; VAF 31%)	1	10.71047228	4
BA3258R	2739	BA3258D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	66	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|HiDAC, Mitoxantrone, CPI-613|Methotrexate	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Alive	1130	0	37.12525667	Alive	0.2	90	NA	0	NA	8.1	85.9	4	0.1	30	25	2.8	1.17	M5	30.8	10.1	46,XX[20]	363	86.8	Normal	130	partial CD7 and CD9, CD11b, dim CD13, CD14, CD15, CD33, CD38, partial CD56, CD64, HLA-DR+	6.1	145.55	negative	0	positive	NA	NA	NA	DNMT3A (p.N797D; VAF 46%)|IDH2 (p.R140Q; VAF 46%)|NPM1 (p.W288fs*12; VAF 46%)|NRAS (p.Q61P; VAF 47%)	0	37.12525667	4
BA3295R	2763	BA3295D	Waves3+4	yes	yes	yes	yes	Male	Male	White	UNKNOWN	NA	1	NA	CBFB-MYH11	63	FALSE	FALSE	FALSE	FALSE	FALSE	y	Prostate Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin) plus Gemtuzumab Ozogamicin|HiDAC|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|FLAG-Ida-Mylotarg	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Alive	953	0	31.3100616	Alive	0.8	57	70	2.5	NA	20.9	46.7	8.3	0.1	90	90	3.2	1.66	M2	21	7.1	46,XY,inv(16)(p13.1q22)[20]	627	105.5	CBFB/MYH11: 91% of cells had the 1r1g2f dual-fusion signal pattern consistent with CBFB/MYH11 fusion and inv(16).	27	Myeloid blast population, about 25%: CD13, CD33, CD34, CD117, HLA-DR and MPO.   | Atypical monocyte population, about 20%: dim CD4, partial CD9, bright CD11b, CD13, CD14, CD33, CD64, HLA-DR and MPO	6.4	50.68	negative	0	negative	NA	NA	NA	NOTCH1 (p.V1739M; VAF 48%)|NRAS (p.Q61K; VAF 45%)	0	31.3100616	2
BA3283R	2723	BA3283D	Waves3+4	yes	yes	yes	yes	Male	Male	NA	NA	NA	3	NA	CBFB-MYH11	NA	unknown	unknown	unknown	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	NA	0	Unknown	Unknown	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Unknown	0	0	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	NA	0	0	2
BA3390R	2744	BA3390D	Waves3+4	yes	yes	yes	yes	Male	Male	NA	NA	NA	3	NA	NA	NA	unknown	unknown	unknown	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NA	0	Unknown	Unknown	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Unknown	0	0	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	negative	0	positive	NA	NA	NA	NA	0	0	4
BA3275R	2639	BA3275D	Waves3+4	yes	yes	yes	yes	Male	Male	NA	NA	NA	3	NA	NA	NA	unknown	unknown	unknown	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Unknown	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Unknown	NA	0	Unknown	Unknown	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Unknown	0	0	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	positive	0.388888889	negative	NA	NA	NA	NA	0	0	4
BA3136R	2649	BA3136D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	KMT2A_re	47	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	133	Alive	529	0	17.3798768	Alive	0	95	60	0	NA	18.5	0	3.4	0.2	100	142	2.2	0.92	M5	23.7	8.2	46,XY,t(10;11)(p12;q23)[8]/45,sl,-Y[12]	3738	100.9	86/100 cells (86%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting MLL (11q23) rearrangement and consistent with the 10;11 translocation observed in the metaphase karyotype.	32	dim CD4, CD9, CD11b, CD15, CD33, CD38, partial CD56, CD64, partial CD117, and partial HLA-DR+	6.7	12.35	negative	0	negative	NA	NA	NA	FLT3 (p.I836del; VAF 3% (in frame deletion in the tyrosine kinase domain))|MLL (Partial tandem duplication (exon 11/3 breakpoint) )	0	17.3798768	4
BA3190R	2726	BA3190D	Waves3+4	yes	yes	yes	yes	Male	Male	NA	NA	NA	3	NA	NA	NA	unknown	unknown	unknown	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Unknown	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Unknown	NA	0	Unknown	Unknown	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Unknown	0	0	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	NA	ASXL1 (p.G646Wfs*12; 26.8%)	NA	NA	0	0	1
BA3234R	2688	BA3234D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	75	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	75	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Induction	UNKNOWN	Standard Chemotherapy	8	Standard Chemotherapy	Azacitidine	Induction	8	Dead	91	1	2.98973306	Dead-Disease	0	80	NA	0	NA	4.4	77.4	11.3	0.1	52	29	2.4	2.78	M5	31.4	10.1	46,XY[20]	747	99.1	Normal	39	Monocytic population (about 80%) : dim CD4, dim CD9, CD11b, partial CD13,  partial CD14, CD15, subset CD16, CD33, CD38, CD56, CD64, and HLA-DR. | Myeloid blasts phenotype (8%): CD33, CD56, CD117, HLA-DR, and MPO	5.9	84.29	negative	0	positive	NA	NA	NA	NPM1 (p.W288fs*12; VAF 24%)|SRSF2 (p.P95R; VAF 48%)|TET2 (p.R506*; VAF 95%)	1	2.98973306	4
BA3087R	2693	BA3087D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	31	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	31	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	Fludarabine, Melphalan|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine	4	Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Alive	1073	0	35.25256674	Alive	0	90	NA	0.9	NA	26.1	1.7	0.9	0.9	13	10	3.8	0.97	M1	24.8	8.6	46,XY,del(5)(q13q33),t(10;11)(p13;q21)[15]/46,XY[5]	165	98	93% of cells were missing a signal for both 5q probes (EGR1, 5q31; and 5q33) but had two signals for 5p, consistent with 5q deletion.	196	partial CD7, CD13, CD33, CD34, dim CD38, CD56, CD117, HLA-DR, partial MPO, and dim TDT.	7.1	17.92	negative	0	negative	NA	ASXL1 (p.D821Efs*15; 26.7%)|ASXL1 (p.D821Wfs*6; 20.1%)	NA	ASXL1 (p.D821fs*12; VAF 28%)|CREBBP (p.N970fs*21; VAF 8%)|JAK1 (p.T114A; VAF 49%)|KMT2D (p.R598H; VAF 49%)|WT1 (p.S165fs*35; VAF 45%)	0	35.25256674	2
BA3454R	2679	BA3454D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	82	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	82	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	14	1	0.459958932	Dead-Disease	0	50	50	0	NA	11	5	35	0.3	22	35	3.2	0.8	M2	29.4	9.4	46,XX[20]	574	98	Normal	71	CD13, CD33, CD117, and MPO	5.9	87.73	positive	0.960784314	positive	NA	NA	NA	DNMT3A (p.R882C; VAF 48%)|FLT3-ITD (VAF 44%; Allelic ratio 0.77)|NPM1 (p.W288fs*12; VAF 48%)	1	0.459958932	4
BA3302R	2805	BA3302D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	65	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	5	7+3 (Cytarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|Pexidartinib|Azacitidine, BI 836858 (anti-CD33)|Ruxolitinib, Venetoclax	2	Induction|Experimental|Re-Induction	Refractory	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Ruxolitinib, Venetoclax	Experimental	69	Dead	541	1	17.77412731	Dead-Disease	1.7	80	80	0	NA	12.9	1.7	7.8	1.4	41	47	3.5	1.4	M1	26.9	8.5	46,XY[20]	1042	95.4	Normal	29	partial CD10, CD13, CD33, CD34, subset CD79a, CD117, HLA-DR, partial MPO, and TDT+	6.3	32.75	negative	0	negative	RUNX1 (p.D198N; 47.7%)	NA	NA	CBL (p.V363_Q365del; VAF 31%)|RUNX1 (p.D198N; VAF 50%)|SF3B1 (p.K666N; VAF 51%)	1	17.77412731	2
BA3117R	2629	BA3117D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	bi	NA	35	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	35	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Fludarabine, Cyclophosphamide, TBI	4	Haploidentical - Parent|Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	Fludarabine, Cyclophosphamide, TBI	Haploidentical - Parent	-1	Alive	1064	0	34.95687885	Alive	0	85	53	0	NA	40.4	0	10.5	2.9	29	15	4.4	0.9	M1	23.3	7.6	47,XY,del(9)(q13q22),+10[3]/46,XY[17]	199	98.7	NA	18	CD7, CD33, CD34, CD38, CD117, HLA-DR, and MPO positive	7.4	4.18	negative	0	negative	RUNX1 (p.R166Q; VAF 6%)	NA	NA	CEBPA (p.A111fs*56; 35% (likely underestimate VAF))|CEBPA (p.D322delinsETQQKVLELTSDND; VAF 37% (likely underestimate VAF))|GATA2 (p.P304H; VAF 32%)|RUNX1 (p.R166Q; VAF 6%)	0	34.95687885	2
BA3083R	2692	BA3083D	Waves3+4	yes	yes	yes	yes	Female	Female	NA	NA	NA	3	NA	NA	NA	unknown	unknown	unknown	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	57	0	Unknown	Unknown	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Unknown	0	0	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	positive	5.666666667	positive	NA	NA	NA	NA	0	0	4
BA3266R	2672	BA3266D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	83	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	83	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	28	1	0.919917864	Dead-Disease	0.9	75	52	0	NA	9.4	14.5	27.3	0.2	19	24	2.7	0.77	M2	20.5	6.5	46,XX[20]	333	95.8	NA	273	dim CD4, CD7, partial CD9, CD13, CD25, CD33, partial CD34, CD38, CD117, CD123, HLA-DR and MPO-positive	7	44.85	positive	0.587301587	positive	NA	NA	NA	BRAF (p.S87N; VAF 52%)|DNMT3A (p.R882C; VAF 47%)|FLT3-ITD (Allelic ratio: 0.464; VAF 31.7%)|IDH1 (p.R132H; VAF 32%)|IDH2 (p.R140Q; VAF 3%)|NPM1 (p.W288fs*12; VAF 42%)	1	0.919917864	4
BA3175R	2783	BA3175D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	62	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	248	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	5	Decitabine, anti-PD1, anti-TIM3|7+3 (Cytarabine, Idarubicin)|JNJ-40346527 (CSF1R inhibitor)|Mitoxantrone|FLAG, Midostaurin	3	Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Mitoxantrone	Salvage	0	Dead	373	1	12.25462012	Dead-Disease	0.9	25	NA	0	NA	6.8	58.1	16.2	0.1	55	53	3.5	1	NA	27.2	9.5	46,XY,t(1;3)(p36;q21)[2]/46,sl,-1,+der(1)t(1;3)(p36;q21)[15]/46,sl,add(3)(q12)[2]/46,sl,-1,+t(1;3)(p36;q21),-3[1]	NA	83.4	MECOM/RPN1:  171/200 cells (85.5%) had a 2 red/ 3 green signal pattern,  reflecting an extra RPN1 (3q21.3) signal, consistent with RPN1 disruption  due to the 1;3 translocation observed in the metaphase karyotype.  There  was no evidence for MECOM/RPN1 fusion.	20	CD7, CD13, CD33, CD34, CD117, and HLA-DR positive	7.1	39.59	positive	0.234567901	negative	RUNX1 (p.D198N; 44.9%)	NA	NA	BCL2 (p.A32G; VAF 48%)|FLT3-ITD (p.N609delinsIIPCPEYDLKWEFPREN; VAF 19%, allelic ratio 0.24)|GATA2 (p.S201fs*1; VAF 13%)|NPM1 (p.H30Q; VAF 3%)|NRAS (p.G12D; VAF 72%)|RUNX1 (p.D198N; VAF 44%)|WT1 (p.R380fs*5; VAF 45%)|WT1 (p.V371fs*14; VAF 22%)|ZRSR2 (p.P350R; VAF 5%)	1	12.25462012	4
BA3268R	2773	BA3268D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	73	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	2	Azacitidine, Ivosidenib|Ivosidenib	2	Induction|Maintenance	Complete Response	Standard Chemotherapy	324	Targeted Therapy - Other	Ivosidenib	Maintenance	-1	Alive	1028	0	33.77412731	Alive	0	92	90	0	NA	17.7	1	0	9.6	23	39	2.7	0.85	M1	25.5	8.3	46,X,-X,add(5)(q23),del(7)(q22),add(11)(p13),add(21)(q22),+mar1[9]/47,sl,add(3)(q28),+5,-add(5)(q23),+mar2[3]/46,XX[1]	615	97.3	D7S486/ CEP 7:  93/100 cells (90%) had a 1 red/ 2 green signal pattern, consistent with the deleted 7q observed in the metaphase karyotype.  | RUNX1T1/RUNX1:  10/200 cells (5%) had a 2 red/ 3 green signal pattern, suggesting low level presence of an extra copy of RUNX1 (21q22).  There was no evidence for RUNX1T1/RUNX1 fusion.  | EGR-1/ D5S23, D5S721: While this probe set showed a normal numeric signal pattern in interphase cells, metaphase FISH showed an EGR-1 (5q) signal on the add(11p) and a 5q33 signal on the add(21q).  (The G-banded chromosomes were not of adequate band length/morphology to establish specific breakpoints.  Therefore, it is possible that some or all of the apparently missing 5q material is actually accounted for on other chromosomes.  This probe set will not be useful for monitoring the abnormal 5q.)	48	CD7, dim CD13, CD33, CD34, CD38, CD117, partial HLA-DR, and partial MPO	5.8	11.49	negative	0	negative	NA	NA	NA	DNMT3A (Splice site; VAF 46%)|IDH1 (p.R132S; VAF 44%)|STAG2 (p.F437fs*11; VAf 48%)	0	33.77412731	3
BA3229R	2619	BA3229D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	56	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	56	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	5	HAM (Cytarabine, Mitoxantrone)|Azacitidine|Vyxeos (Daunorubicin, Cytarabine - liposomal)|MBG453 (TIM-3 inhibitor)|Decitabine, Ruxolitinib	4	Salvage|Induction|Maintenance|Re-induction	Refractory	Standard Chemotherapy	5	Standard Chemotherapy	Decitabine, Ruxolitinib	Salvage	-1	Dead	164	1	5.388090349	Dead-Disease	2.5	NA	35	2.5	NA	3.4	12.6	41.2	0.9	17	27	3.3	1.31	NA	29.1	8.7	49,XY,+10,+13,+21[6]/51,idem,+9,+15[14]	363	105.8	Chromosome 9:  With all chromosome 9 probes (ABL, ASS and NUP214) ~20% of cells had three signals, consistent with trisomy 9.  | PML (15q24): 17% of cells had three signals, consistent with trisomy 15.  | RUNX1 (21q22):  69% of cells had three signals, consistent with trisomy 21.	112	partial CD11b, CD13, partial CD25, CD33, CD34, CD38, partial CD56, CD117 and HLA-DR positive	7.2	85.46	negative	0	negative	RUNX1 (p.S322*; 49.8%)	ASXL1 (p.G646Wfs*12; 37.6%)	NA	ASXL1 (p.G646fs*12; VAF 36%)|BRAF (p.G469R; VAF 36%)|CREBBP (p.F1703fs*33; VAF 12%)|CSF3R (p.T618I; VAF 5%)|EZH2 (p.F672L; VAF 73%)|FLT3 (p.V491L; VAF 53%)|NRAS (p.G12D; VAF 10%)|RUNX1 (p.G199E; VAF 7%)|RUNX1 (p.S322*; VAF 52%)	1	5.388090349	4
BA3353R	2696	BA3353D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	71	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	Venetoclax (ABT-199), Azacitidine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	2	Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	103	Bone Marrow Transplant	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	-1	Dead	972	1	31.93429158	Dead-Other	1	98	44.8	3.8	NA	39.4	1	7.7	0.4	44	22	3.4	0.7	M1	30	9.5	46,XX,del(5)(q13q33)[14]/46,XX[6]	NA	107.5	5q:  96% of cells were missing a signal for EGR1 (5q31) and 5q33, consistent with deletion, as seen on metaphase analysis.	100	CD7, CD13, CD33, dim CD38, CD117, HLA-DR and variable MPO +	6.4	4.92	negative	0	negative	NA	NA	NA	DNMT3A (p.R749H; VAF 42%)|ETV6 (p.R378Q; VAF 52%)|JAK2 (p.V617F; VAF 3%)|KMT2D (Partial tandem duplications (exon 9/exon3))|STAT3 (p.D661Y; VAF 38%)	1	31.93429158	3
BA3312R	2703	BA3312D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	bi	NA	43	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	43	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	132	Dead	472	1	15.50718686	Dead-Disease	0	70	68	1.7	NA	14.8	5.2	9.6	0.1	25	24	2.9	0.84	M2	16.5	5.5	46,XY,t(2;12)(p13;q13)[20]	1024	102.5	Normal	21	CD13, CD33, variable CD34, CD117, and HLA-DR positive (CD7, dim CD15, and MPO expression was noted on the prior flow cytometric analysis and was not tested in the current assay)	7	79.15	negative	0	negative	NA	NA	NA	CEBPA (p.G36fs*122; VAF 45%)|CEBPA (p.Q311_Q312linsRKAKQRNVETQ; VAF 45%)|DNMT3A (p.R19P; VAF 48%)|EZH2 (p.K30fs*17 (loss of function); VAF 65%)|GATA2 (p.R362Q; VAF 47%)|NRAS (p.G13D; VAF 43%)	1	15.50718686	2
BA3119R	2778	BA3119D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	61	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	101	Alive	784	0	25.75770021	Alive	0.8	90	65	0	NA	30.2	3.1	6.2	5.3	21	13	3.4	0.5	M1	31.3	10.8	46,XX[20]	NA	95.7	Normal	104	CD33, CD38, CD117, MPO positive	7.7	4.68	negative	0	positive	NA	NA	NA	ASXL1 (p.L1395V; VAF 50%)|IDH1 (p.R132H; VAF 45%)|KMT2D (p.R3167W; VAF 48%)|NPM1 (p.W288fs*12; VAF 48%)	0	25.75770021	3
BA3138R	2619	BA3138D	Waves3+4	no	no	no	no	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	56	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	56	48	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	5	HAM (Cytarabine, Mitoxantrone)|Azacitidine|Vyxeos (Daunorubicin, Cytarabine - liposomal)|MBG453 (TIM-3 inhibitor)|Decitabine, Ruxolitinib	4	Salvage|Induction|Maintenance|Re-induction	Refractory	Standard Chemotherapy	5	Standard Chemotherapy	Decitabine, Ruxolitinib	Salvage	-1	Dead	164	1	5.388090349	Dead-Disease	1.7	NA	NA	0.3	NA	14.3	16	67.7	NA	20	21	3.6	1.1	NA	27.9	8.6	49,XY,+10,+13,+21[1]/51,sl,+9,+15[1]/49,sl,+8,-10[12]/46,XY[6]	201	106.9	Chromosome 9:  With all chromosome 9 probes (ABL, ASS and NUP214) ~20% of cells had three signals, consistent with trisomy 9.  | PML (15q24): 17% of cells had three signals, consistent with trisomy 15.  | RUNX1 (21q22):  69% of cells had three signals, consistent with trisomy 21.	31	NA	7.1	16.7	negative	0	negative	RUNX1 (p.S322*; 17.2%)	ASXL1 (p.G646Wfs*12; 31.3%)	NA	NA	1	5.388090349	4
BA3219R	2731	BA3219D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	73	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	y	y	y	y	y	y	1	Standard Chemotherapy	1	Cytarabine	1	Induction	Refractory	Standard Chemotherapy	1	Standard Chemotherapy	Cytarabine	Induction	1	Dead	4	1	0.131416838	Dead-Disease	0.4	90	NA	0.4	NA	13.9	80	1.8	0.1	130	186	2.1	6.6	M5	17.8	6	46,XY[15]	1072	89.4	Normal	35	dim CD9, CD11b, variable CD13, partial CD14, dim CD15, dim CD16, CD33, CD38, dim CD56, CD64, CD123, and HLA-DR	6.3	104.23	negative	0	positive	NA	NA	NA	CCND1 (p.R245W; VAF 48%)|DNMT3A (p.P633R; VAF 46%)|NPM1 (p.W288fs*12; VAF 46%)|NRAS (p.G13D; VAF 6%)|PTPN11 (p.T73I; VAF 33%)|TET2 (p.N926fs*28; VAF 16%)	1	0.131416838	4
BA3388R	2619	BA3388D	Waves3+4	no	no	no	no	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	56	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	56	55	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	5	HAM (Cytarabine, Mitoxantrone)|Azacitidine|Vyxeos (Daunorubicin, Cytarabine - liposomal)|MBG453 (TIM-3 inhibitor)|Decitabine, Ruxolitinib	4	Salvage|Induction|Maintenance|Re-induction	Refractory	Standard Chemotherapy	5	Standard Chemotherapy	Decitabine, Ruxolitinib	Salvage	-1	Dead	164	1	5.388090349	Dead-Disease	2.6	NA	NA	0	NA	2.6	10.4	40.9	2.5	20	23	3.5	1.3	NA	29.9	9	49,XY,+10,+13,+21[1]/51,sl,+9,+15[1]/49,sl,+8,-10[12]/46,XY[6]	254	110.3	Chromosome 9:  With all chromosome 9 probes (ABL, ASS and NUP214) ~20% of cells had three signals, consistent with trisomy 9.  | PML (15q24): 17% of cells had three signals, consistent with trisomy 15.  | RUNX1 (21q22):  69% of cells had three signals, consistent with trisomy 21.	43	NA	7.3	23.94	negative	0	negative	RUNX1 (p.S322*; 17.2%)	ASXL1 (p.G646Wfs*12; 37.2%)	NA	NA	1	5.388090349	1
BA3357R	2788	BA3357D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	mono	NA	75	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	75	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	4	Gilteritinib (ASP2215)|Venetoclax (ABT-199), Azacitidine|Gilteritinib, Decitabine|PIM kinase inhibitor	3	Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Targeted Therapy - Other	PIM kinase inhibitor	Salvage	21	Dead	583	1	19.15400411	Dead-Disease	0	48	NA	2.6	NA	15	4.4	25.7	1.3	22	13	3.4	1.15	M2	25.7	8.7	47,XY,+21[2]/46,XY[18]	190	86.5	RUNX1 (21q22): 19/200 cells (9.5%) had three signals for RUNX1, consistent with trisomy 21.	16	dimCD7, dimCD11b, dimCD13, CD33, varibleCD34, CD38, CD117, partial HLA-DR, and MPO positive	6.1	10.15	positive	0.162790698	negative	NA	NA	NA	CEBPA (p.R300_D301delinsQY; VAF 85%)|FLT3-ITD (VAF 15%; allelic ratio 0.18)|GATA2 (p.G320S; VAF 30%)|NOTCH1 (p.A929D; VAF 52%)|RAD21 (p.E447fs*19; VAF 3%)|RAD21 (p.N462fs*1; VAF 3%)	1	19.15400411	2
BA3351R	2623	BA3351D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	PML-RARA	72	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	ATRA, Arsenic Trioxide	Induction	-1	Alive	927	0	30.45585216	Alive	0	95	NA	0.9	NA	52.3	0	3.8	0.4	45	44	3.4	0.67	M3	20.4	7.2	46,XX,t(15;17)(q22;q21)[20]	506	94	positive for PML/RARA fusion	93	CD7, CD11b, CD13, CD15, CD16, CD33, CD38, CD56, CD64, CD117, CD123, and MPO positive	6.5	5.6	positive	0.03092784	negative	NA	NA	NA	FLT3-ITD (allelic ratio 0.03; VAF 3.09%)|NRAS (p.A146T; VAF 19%)	0	30.45585216	3
BA3208R	2620	BA3208D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	70	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	70	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Ruxolitinib, Vyxeos (Daunorubicin, Cytarabine - liposomal)	1	Induction	Refractory	Standard Chemotherapy	43	Standard Chemotherapy	Ruxolitinib, Vyxeos (Daunorubicin, Cytarabine - liposomal)	Induction	43	Dead	84	1	2.759753593	Dead-Disease	0	85	78	0.9	NA	19.3	0	0	1.2	30	34	3.5	0.81	M1	28.1	9.5	46,XX[18]	623	110.6	Normal	57	variable CD11b, CD13, CD33, CD34, variable CD38, dim variable cCD79a, CD117, HLA-DR, cMPO, and cTdT positive	6.7	27.26	negative	0	negative	NA	NA	NA	DNMT3A (p.R882H; VAF 47%)|FLT3-ITD (allelic ratio 0.03; VAF 3%)|KMT2A (PTD, exon 9/3 break)|TET2 (p.H578fs*2; VAF 36%)|TET2 (p.Y1345fs*14; VAF 27%)|WT1 (p.D367_V374delinsWS; VAF 3%)|WT1 (p.R370fs*6; VAF 5%)|WT1 (p.R380fs*5; VAF 2%)|WT1 (p.R380fs*5; VAF 47%)|WT1 (p.T377fs*73; VAF 23%)|ZRSR2 (p.R452C; VAF 48%)	1	2.759753593	4
BA3310R	2716	BA3310D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	82	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	82	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Dead	17	1	0.558521561	Dead-Disease	0	90	70	0	NA	1.7	0	16.7	0.2	11	38	1.9	0.7	M1	25.7	7.8	46,XY[20]	421	88.6	Normal	23	dim CD13, CD33, CD117 and MPO	6.4	44.35	negative	0	positive	NA	NA	NA	CBL (p.G838V; VAF 48%)|CREBBP (p.N1615S; VAF 48%)|FLT3 (p.D839G; VAF 6%)|FLT3 (p.N676K; VAF 2%)|FLT3-ITD (Allelic ratio 0.01)|IDH2 (p.R140Q; VAF 46%)|KIT (p.D816V; VAF 4%)|KMT2D (p.F4579S; VAF 49%)|NPM1 (p.W288fs*12; VAF 46%)|SRSF2 (p.P95_R102del; VAF 45%)	1	0.558521561	2
BA3200R	2665	BA3200D	Waves3+4	yes	yes	yes	yes	Female	Female	Asian	NON-HISPANIC	NA	1	NA	NA	76	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	76	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	2	SY-1425 (Tamibarotene) plus Azacitidine|Ruxolitinib, Venetoclax	2	Salvage|Induction	Complete Response i	Targeted Therapy - Other	357	Standard Chemotherapy	Ruxolitinib, Venetoclax	Salvage	37	Dead	425	1	13.96303901	Dead-Disease	NA	NA	predominant	NA	NA	NA	NA	NA	0.1	NA	NA	NA	0.56	M1	21.8	7.3	46,XX[8]	411	97.3	Normal	10	CD33, CD38, CD56, CD117, and cMPO positive	NA	97.67	negative	0	positive	NA	NA	NA	NPM1 (p.W288fs*12; VAF 50%)|PHF6 (p.R274*; VAF 45%)|PRDM1 (p.P467L; VAF 48%)|TET2 (p.H1382R; VAF 50%)|TET2 (p.K1720*; VAF 48%)	1	13.96303901	3
BA3325R	2782	BA3325D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	56	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	57	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	6	7+3 (Cytarabine, Idarubicin)|Gilteritinib (ASP2215)|Venetoclax (ABT-199), Azacitidine|CSF1R inhibitor|IMGN779 (Immunogen Trial)|Decitabine	4	Salvage|Induction|Experimental|Re-induction	Refractory	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Gilteritinib (ASP2215)	Experimental	-1	Dead	568	1	18.66119097	Dead-Disease	0	NA	NA	1	NA	22	2	17	27.3	20	52	2.6	0.5	NA	19.9	6	46,XY[20]	1243	94.8	NA	11	NA	5.8	26.1	negative	0	negative	NA	NA	NA	NA	1	18.66119097	4
BA3146R	2776	BA3146D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	42	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	42	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	HIDAC + Gemtuzumab Ozogamicin|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Sibling	-1	Dead	140	1	4.599589322	Dead-Treatment	0	70	NA	1	NA	22	30	5	0	NA	NA	NA	0.95	M2	23.6	8	46,XY[20]	1811	98.7	Normal	18	CD7, CD13, CD25, CD33, partial CD34, CD117, dim CD123, HLA-DR, and MPO.	NA	22.79	positive	0.176470588	positive	NA	NA	NA	DNMT3A (p.R882H; VAF 45%)|FLT3-ITD (allelic ratio 0.85; VAF 45.9%)|NPM1 (p.W288fs*12; VAF 69%)	1	4.599589322	4
BA3211R	2697	BA3211D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	69	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	69	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	4	Gilteritinib (ASP2215)|Azacitidine|RVD (Bortezomib, Dexamethasone, Lenalidomide)|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin	3	Salvage|Induction|Maintenance	Refractory	Standard Chemotherapy	6	Targeted Therapy - Other	Gilteritinib (ASP2215)	Salvage	-1	Dead	76	1	2.496919918	Dead-Disease	0	90	78	0	NA	35	31	7	0	12	8	2	0.87	M0	21.6	7.4	46,XY,del(20)(q11.2)[cp20]	198	87.8	CEP 3:  16/100 cells (16%) had three signals, reflecting trisomy 3.	15	CD43+ and dim CD45+ with dim CD13, dim CD33, dim CD38, partial CD11b, variable HLA-DR, and partial, dim CD117	4.9	5.79	positive	0.176470588	negative	RUNX1 (p.R346Pfs*254; 37.7%)|RUNX1 (p.X269_splice; 43.5%)	NA	NA	FLT3-ITD (allelic ratio 0.84; VAF 45.7%)|KMT2A (PTD (exon 11/exon 3))|RUNX1 (splice site; VAF 43%)|U2AF1 (p.S34F; VAF 44%)	1	2.496919918	4
BA3237R	2760	BA3237D	Waves3+4	yes	yes	yes	yes	Male	Male	NA	NA	NA	3	NA	NA	NA	unknown	unknown	unknown	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	76	0	Unknown	Unknown	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Unknown	0	0	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	NA	ASXL1 (p.C594Mfs*25; 38.2%)	NA	NA	0	0	4
BA3130R	2610	BA3130D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	61	FALSE	FALSE	TRUE	FALSE	FALSE	n	NA	y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Sibling	-1	Dead	110	1	3.613963039	Dead-Treatment	0	20	20	0	NA	20.5	55.4	15.2	0.1	160	228	2.1	2.11	M2	22.3	7.6	48,XY,+7,+mar[4]/46,XY[16]	NA	99.1	Chromosome 7: 44% of cells had three signals for both chromosome 7 probes, consistent with trisomy 7	23	CD4, dim CD7, CD11b, CD13, variable CD14, CD16, dim CD33, dim CD 38, dim CD56, CD64.	4.6	69.09	negative	0	negative	NA	NA	NA	BRAF (p.V600E; VAF 36%)|TET2 (p.A1355V; VAF 48%)|TET2 (p.Q803*; VAF 44%)|ZRSR2 (Splice site; VAF 92%)	1	3.613963039	4
BA3376R	2781	BA3376D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	N/A	NA	58	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	58	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	4	Gilteritinib or Placebo|HiDAC + Midostaurin|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Consolidation|Induction|Maintenance	Complete Response	Standard Chemotherapy	6	Targeted Therapy - Other	Gilteritinib or Placebo	Maintenance	-1	Alive	803	0	26.38193018	Alive	0.9	91	NA	0	NA	4.3	1.7	1.7	0.2	49	90	2.8	0.69	M1	19.7	6.5	46,XX[20]	1122	98	Normal	26	CD11b, CD13, CD33, variable CD34, CD38, CD117, CD123, and MPO positive	6.9	145	positive	1.040816327	positive	NA	NA	NA	CEBPA (p.G242S; VAF 47%)|FLT3-ITD (allelic ratio 1.03; VAF 51%)|NPM1 (p.W290fs*10; VAF 49%)|SYNE1 (p.A2715G; VAF 50%)	0	26.38193018	3
BA3137R	2759	BA3137D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	NA	CBFB-MYH11	39	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	39	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	7	Ruxolitinib|7+3 (Cytarabine, Idarubicin) plus Gemtuzumab Ozogamicin|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Venetoclax (ABT-199), Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|HIDAC + Gemtuzumab Ozogamicin|Busulfan, Cyclophosphamide	6	Consolidation|Salvage|Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Ruxolitinib	Maintenance	-1	Dead	751	1	24.67351129	Dead-Other	3.4	36	28	5.2	NA	19.8	38.8	6.9	0	NA	NA	NA	1.17	M4	22.1	7.6	46,XY,inv(16)(p13.1q22)[20]	415	90.2	NA	13	CD13, CD33, CD34, CD38, CD117, HLA-DR, MPO  (the monocytic cells show an aberrant immunophenotype: CD11b, CD13, variable CD14, variable CD15, CD33, CD64, HLA-DR positive)	NA	20.76	negative	0	negative	NA	NA	NA	CUX1 (p.V88I; VAF 50%)|NRAS (p.G13D; VAF 6%)|NRAS (p.Q61H ((different allele from p.Q61K); VAF 3%)|NRAS (p.Q61K (different allele from p.Q61H); VAF 18%)|PTPN11 (p.G60R; VAF 3%)|USH2A (p.R2557T; VAF 48%)	1	24.67351129	2
BA3300R	2595	BA3300D	Waves3+4	yes	yes	yes	yes	Male	Male	Declined	UNKNOWN	NA	1	NA	NA	0	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE	Mixed phenotype acute leukaemia, T/myeloid, NOS	Intermediate	ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE	Mixed phenotype acute leukaemia, T/myeloid, NOS	0	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	5	Cytarabine|Cytarabine, Mitoxantrone, Gemtuzumab ozogamicin|Cytarabine, Daunorubicin, and Etoposide|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide	3	Induction|Intensification|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	28	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Dead	314	1	10.31622177	Dead-Disease	0	90	92	0.9	NA	13	3.5	2.6	0.1	NA	NA	NA	0.21	NA	NA	6	46,XY,t(3;12)(q29;p13),ins(12;?)(p13;?)[20]	NA	75.1	ETV6 is disrupted by the insertion of unidentified material within the locus.  Any fusion partners with the ETV6 rearrangements were not identified in this study.	90	cCD3, CD7, CD11b, dim CD13, CD33, CD34, CD56, C117, MPO	NA	95.48	negative	0	negative	NA	NA	NA	FAT4 (p.S2691L; VAF 50%)	1	10.31622177	2
BA3375R	2749	BA3375D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	63	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	63	1	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Dead	171	1	5.618069815	Dead-Treatment	0.8	95	85	0.8	NA	9.2	2.3	4.6	0.3	NA	NA	NA	0.64	M1	26.9	8.8	NA	476	94.1	Normal	30	dim CD13, CD33, CD117 and MPO-positive	NA	62.54	positive	0.754385965	positive	NA	NA	NA	CHD2 (p.P1353L; VAF 50%)|CHEK2 (p.T410fs*15; VAF 51%)|FLT3 (p.N676K; VAF 4%)|FLT3-ITD (p.F594delinsLPSDNEYFYVDF (33-nucleotide internal tandem duplication); allelic ratio 0.85; VAF 46%)|IDH1 (p.R132S; VAF 47%)|KMT2A (p.F798L; VAF 49%)|NPM1 (p.W288fs*12; VAF 48%)|PLCG2 (p.Y206F; VAF 50%)	1	5.618069815	3
BA3249R	2774	BA3249D	Waves3+4	yes	yes	yes	yes	Female	Female	NA	NA	NA	3	NA	KMT2A_re	NA	unknown	unknown	unknown	FALSE	FALSE	n	NA	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myeloid leukaemia, NOS	28	0	Unknown	Unknown	Peripheral Blood	y	y	y	y	y	y	0	NA	0	NA	0	NA	NA	NA	NA	NONE	NONE	NONE	NA	Unknown	0	0	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	negative	0	negative	NA	NA	NA	NA	0	0	4
BA3385R	2594	BA3385D	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	50	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	50	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	HiDAC|7+3 (Cytarabine, Daunorubicin) plus Crenolanib|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	-1	Dead	264	1	8.673511294	Dead-Disease	0	88	NA	0	NA	23.5	48.7	9.5	0.1	20	14	2.9	0.65	M4	20.5	6.8	46,XX[20]	409	97.2	Normal	29	Myeloid blasts immunophenotype:  CD7, partial CD13, CD33, partial CD34, CD117, HLA-DR and MPO | Monoblasts immunophenotype: dim CD4, CD11b, partial CD13, CD14, CD15, bright CD33, CD64, HLA-DR	6.9	31.8	positive	0.492537313	positive	NA	NA	NA	DNMT3A (p.S714C; VAF 43%)|FLT3-ITD (p.E596delinsQVTGSSDNEYFYVDFRE (48-nucleotide internal tandem duplication); VAR 0.79; VAF 44%)|NPM1 (p.W288fs*12; VAF 44%)|WT1 (p.S381fs*4; VAF 43%)	1	8.673511294	4
BA3242R	2805	BA3242D	Waves3+4	no	no	no	no	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	65	FALSE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	66	316	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	5	7+3 (Cytarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|Pexidartinib|Azacitidine, BI 836858 (anti-CD33)|Ruxolitinib, Venetoclax	2	Induction|Experimental	Refractory	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Ruxolitinib, Venetoclax	Experimental	69	Dead	541	1	17.77412731	Dead-Disease	0.3	46	23	0.3	NA	43.8	21.3	21.7	3.9	12	22	3.9	0.94	M1	23.8	7.8	46,XY[20]	530	105.3	Normal	14	partial CD10, CD34, CD13, CD117, and HLA-DR	5.8	10.24	negative	0	negative	RUNX1 (p.D198N; 47.3%)	NA	NA	ATG2B (p.L1989V; VAF 51%)|CBL (p.V363_Q365del; VAF 34%)|FLT3-ITD (Allelic Ratio: ~0.013)|MED12 (p.N1049T; VAF 97%)|RTEL1 (p.S925Y; VAF 50%)|RUNX1 (p.D198N; VAF 47%)|SF3B1 (p.K666N; VAF 47%)|SH2B3 (p.S488Y; VAF 49%)	1	17.77412731	2
BA3446R	2739	BA3446D	Waves3+4	no	no	no	no	Female	Female	White	NON-HISPANIC	NA	1	NA	NA	66	TRUE	FALSE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	67	366	Relapse|Post-Chemotherapy	Relapse	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	5	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|HiDAC, Mitoxantrone, CPI-613|Methotrexate	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	-1	Alive	1130	0	37.12525667	Alive	0	26	NA	0	NA	7.9	21.1	22.8	0.1	35	39	2.7	0.66	M5	33.8	10.6	46,XX,del(14)(q21q31)[20]	775	90.1	Normal	14	Myeloid blasts: CD13, CD33, CD38, CD117, HLA-DR. | Blasts with monocytic features: CD11b, dim CD13, CD15, CD33, CD38, CD64, HLA-DR	5.7	39.23	negative	0	positive	NA	NA	NA	BCOR (p.E1093K; VAF 48%)|DNMT3A (p.N797D; VAF 46%)|FAT4 (p.D1836N; VAF 41%)|IDH2 (p.R140Q; VAF 47%)|KMT2D (p.P647T; VAF 67%)|NPM1 (p.W288fs*12; VAF 43%)|NRAS (p.Q61P; VAF 46%)|RBBP6 (p.P1416A; VAF 51%)	0	37.12525667	4
BA3416R	2607	BA3416D	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	NA	1	mono	NA	54	FALSE	TRUE	FALSE	FALSE	FALSE	n	NA	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	54	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	1	Induction	Refractory	Standard Chemotherapy	3	Standard Chemotherapy	FLAG (Fludarabine, High-dose Cytarabine, G-CSF)	Induction	3	Dead	24	1	0.788501027	Dead-Disease	0	92	85	0	NA	33.3	2.6	0	0	NA	NA	NA	1.75	M1	23.9	7.8	46,XY[20]	528	89.5	RUNX1:  17/200 (8.5%) interphase cells had three RUNX1 (21q22) signals. There was no evidence for RUNX1T1/RUNX1 fusion.	8	Partial immunophenotype: CD33, cCD79a, CD117, HLA-DR, and cMPO	NA	4.67	negative	0	negative	NA	NA	NA	CBL (p.Q490E; VAF 52%)|CEBPA (p.K304_T318dup; VAF at least 70%)|CHD2 (p.R1354K; VAF 49%)|DOCK8 (p.E766K; VAF 46%)|FAT1 (p.E38K; VAF 49%)|GATA2 (p.R307L; VAF 41%)|RUNX1 (p.I366_G367dup; VAF 46%)	1	0.788501027	2
BA3123R	2611	BA3123D	Waves3+4	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	NA	1	NA	NA	69	FALSE	FALSE	FALSE	FALSE	FALSE	y	Prostate Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	4	Busulfan, Fludarabine|Venetoclax (ABT-199), Azacitidine|7+3 (Cytarabine, Daunorubicin) plus Glasdegib/placebo|MiDAC plus Glasdegib/placebo	4	Consolidation|Salvage|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Venetoclax (ABT-199), Azacitidine	Salvage	149	Dead	468	1	15.37577002	Dead-Disease	0	60	NA	0	NA	24.3	2.9	11.4	0	31	22	4.2	0.55	M2	33.3	10.9	46,XY[20]	256	109.2	NA	21	variable CD5, CD7, CD11b (partial), CD13, CD33 (dim), CD34, CD38 (dim), CD117, and HLA-DR	7.1	9.32	negative	0	negative	NA	ASXL1 (p.T514Nfs*15; 34.3%)	NA	ASXL1 (p.T514fs*15; VAF 37%)|BLM (p.N936D; VAF 50%)|CSF3R (p.R311C; VAF 50%)|KMT2A (p.D2911N; VAF 50%)|MSH2 (p.V437M; VAF 41%)|PCLO (p.D2885N; VAF 47%)|PRPF40B (p.P751S; VAF 51%)|SRSF2 (p.P95H; VAF 37%)|TCF3 (p.H344R; VAF 49%)|TET2 (p.Q1030*; VAF 43%)|TET2 (p.R1359L; VAF 40%)	1	15.37577002	4
